#### Kliiniline küsimus nr 28

Kas perekeskne neonataalne ravi võrreldes selle mittekasutamisega parandab enneaegsete vastsündinute ravitulemusi ja perede psühhosotsiaalset toimetulekut ning kiindumussuhte tekkimist lapsega vs mitte?

- sünnijärgne nahk-naha kontakt koos nCPAP ravi alustamisega
- nahk-naha kontakt vaginaalse sünnituse ja keisrilõike korral (kestus)
- känguruhooldus
- NIDCAP
- perepalat
- analüüside ja uuringute sagedus, ajastamine ning valutustamine

**Tulemusnäitajad:** lapse peamised tulemusnäitajad, mõju pere psühhosotsiaalsele toimetulekule (vanemate ja/või õdede-vendade stress) ja lähedussuhtele lapsega

#### Ravijuhendid

Kokkuvõte ravijuhendis leiduvast

Care of extremely premature infants A guideline for the care of children born before 28 full weeks of pregnancy have passed. The Swedish National Board of Helth and Welfare. Published <u>www.socialstyrelsen.se,September</u> 2014

Rootsi ravijuhendis esitatud soovitused käsitlevad erakordselt väikese gestatsioonivanusega (enne 28. rasedusnädalat sündinud) enneaegsete vastsündinute eest hoolitsemist ja ravi, samuti soovitusi paremaks neonataalse abi korraldamiseks. Tegemis hea kvaliteediga ravijuhendiga.

Rootsi ravijuhendis esitatud soovitused põhinevad 2014. aastani publitseeritud teaduskirjandusel ja Rootsi rahvuslikust kvaliteediregistrist ja rahvuslikust EXPRESS uuringust saadud andmetel (s.o. uuring erakordselt väikese gestatsioonivanusega enneaegsete kohta, koos järelkontrolliga, uuringus oli 1011 last, kes olid sündinud enne 27. rasedusnädalat, aastatel 2004-2007, Rootsis).

Rootsi riikliku tervise- ja heaoluameti hinnang/ The Swedish National Board of Health and Welfare's assessment

#### Lapse stabilisatsioon vahetult peale sündi

• lapsel peab olema võimalus olla oma vanemate lähedal enne, kui ta viiakse neonatoloogia osakonda.

The assessment is based on systematic charting, WHO recommendations, guidelines from a European consensus panel of neonatologists and consensus between the chairpersons of the expert groups.

Last tuleks alati stabiliseerida vanemate lähedal. Kui on võimalik, siis peale lapse seisundi stabiliseerimist, lubada emal last kallistada lühikese aja jooksul, tagades vajadusel hingamisabi. Sõltuvalt kohalikest oludest, lapsevanem võiks aidata last kaaluda, panna kuvöösi, võiks lapse viimisel neonatoloogia osakonda kaasas olla.

#### Valu

Valul võivad olla negatiivsed lühi- ja pikaajalised tagajärjed sensitiivses närvisüsteemi kiire kasvu- ja differentseerumiseperioodis ebaküpsele enneaegsele lapsele. Valulikke protseduure tuleks püüda minimeerida ja valu ravida. Kaasaegne neonataalne valu ravi on

[Type text]

balansseeritud, mitmepalgeline strateegia: vajalik on regulaarne valu hindamine, individuaalse käitumise toetamine (mittefarmakoloogiline ravi) ja vajadusel farmakoloogiline ravi.

#### <u>Valu hindamine</u>

• Valu diagnostikaks peaks valu hindama valideeritud instrumentidega (mis on kohandatud vastavalt lapse vanusele, küpsusastmele ja valu tüübile) nii suures ulatuses, kui võimlik.

The assessment is based on Swedish guidelines from the Swedish Child Pain Society and guidelines drawn up by an international consensus group.

Rahvusvahelised ja riiklikud ravijuhendid soovitavad, et kõik vastsündinutega tegelevad osakonnad, peavad omama toimimisviise, mis sisaldavad struktureeritud valu hindamise mudelit. See mudel on fundamentaalne objektiivse valu hindamiseks, vajalik adekvaatse ja ohutu ravi tegemiseks. Kasutatakse erinevaid vaatlusskaalasid. Lisa 2 näitab valu hinnangu instrumente, mida sageli kasutatakse ja soovitatakse kaasaegses neonataalses abis.

## <u>Appendix 2.</u> Examples of pain assessment instruments

Pain assessmer		Reference	Dimensions	Emphasis	Validated for gestational ag
ALPS-Neo	Astrid Lindgren and Lund children's hospitals pain and stress assessment scale for preterm and sick newborn infants	[185]	Behaviour: facial expression, level of consciousness, activity and tone in extremities. Physiological: breathing	Continuous	< 42 weeks, cared for at a neonatal unit directly after the birth
ALPS 1	Astrid Lindgren children's hospital pain assessment scale for term neonates		Behaviour: facial expression, level of consciousness, activity and tone in extremities Physiological: breathing	Continuous	Full-term until one month old
BIIP	Behavioural Indicators of Infant Pain	[186]	Behaviour: facial expression, hand activity, sleep	Procedure	23-32 weeks
COMFORT- neo		[187]	Behaviour: facial expression, level of consciousness, movement and tone in extremities, crying	Continuous	24-43 weeks
EDIN	E'chelle Douleur Inconfort Nouveanne	[188]	Behaviour: facial expression, body movements, quality of sleep, contact, consolability	Continuous	34-37 weeks
NFCS	Neonatal Facial Coding System	[189, 190]	Behaviour: facial expression	Procedure and Continuous	
NIPS	Newborn Infant Pain Scale	[191]	Behaviour: facial expression, breathing patterns, extremity movements, level of consciousness, crying	Procedure	
N-PASS	Neonatal Pain, Agitation, and Sedation Scale	[192]	Behaviour: crying, level of consciousness, facial expression, extremity tone Physiological: heart rate, breathing rate, blood pressure, oxygen saturation		23-40 weeks
PIPP PIPP-R	Premature Infant Pain Profile Premature Infant Pain Profile- Revised	[193][194]	Behaviour: facial expression Physiological: heart rate, oxygen saturation Context: gestational age, level of consciousness	Procedure	24-48 weeks

#### Mittefarmakoloogiline valuravi

• Valulike vahelesegamiste arv tuleb minimeerida

• Erakordselt väikese gestatsioonivanusega enneaegsetele tuleks alati tagada mittefarmakoloogiline, individualiseeritud hoolitsus valu ja stressi vähendamiseks, mis võib sisaldada järgnevat:

o läbimõeldud ja optimeeritud ümbritsev keskkond, näiteks vaikus (minimiseerida häirivad visuaalsed ja auditoorsed mõjud, vähendada otsest tugevat valgust);

o vanemate osalemine;

o hoolduses nahk-naha kontakti ja toetava koosolemise kasutamine;

o kindlustama, et laps oleks enne protseduure söönud, kuiv ja soe;

o lapsel peaks olema mugav asend;

o lapsel peaks olema võimalus midagi imeda (lutt, käsi või sõrm – enda või lapsevanema oma).

The assessment is based on Swedish guidelines from the Swedish Child Pain Society and guidelines drawn up by an international consensus group.

#### Farmakoloogiline valuravi

• Igal osakonnal peaks olema hästi korraldatud ja teada protseduurid, millal ja millist farmakoloogilist valuravi kasutada, mis sobivad ka akuutsetes situatsioonides.

• Situatsioonid, kus protseduurid peaks valutustama:

o protseduuri valu, k.a. intubatsioon

o postnataalne ja postoperatiive valu

o pideva valu ja stressi ravi respiraatorravi-, operatsiooniaegse valu korral

• Farmakoloogilist ravi peaks andma sobival ajal enne valulikku protseduuri ja alati toetama mittefarmakoloogiliste võtetega.

• The assessment is based on Swedish guidelines from Swedish Child Pain Society and guidelines drawn up by an international consensus group.

• Nõrk ja keskmine valu; suukaudselt anda vastsündinutele valuvaigistava toimega magusaid lahuseid (kontsentreeritud glükoos või sahharoos) (Stevens et al 2013).

#### HOOLDAMINE

Kõrge kvaliteediga põetamine peaks olema individualiseeritud, toetama arengut ja olema perekeskne.

## Hoolitsus/ravi erakordselt väikese enneaegse eest peaks olema patsiendi ja perekeskne:

- o individualiseeritud
- o arengut toetav
- o perele hoolitsuse pakkumine
- o integreeritud ravi pakkumine
- o aktiivne vanemate kaasamine ja informeerimine.

The assessment is based on systematic charting and consensus between the chairpersons of the expert groups.

Patsiendi ja perekesksus tähendab, et hoolitsus ja ravi ei ole limiteeritud ning ainult haigusele orienteeritud, vaid laiendatud, katmaks lapse, vanemate ja õdede-vendade teisi vajadusi.

Patsiendi- ja perekeskne ravi hõlmab järgmist:

• Perele hoolitsuse pakkumine s.t. vanemaid ja lapsi ei lahutata/eraldata, vanematele peaks pakutama võimalust jääda vastsündinute osakonda ka ööseks.

• Emasid, kellel endal on meditsiinilised vajadused, peaks niipalju kui võimalik integreerima vastsündinu eest hoolitsemisse vastsündinute osakonnas.

• Perekonna individuaalseid vajadusi peaks respekteerima niipalju kui võimalik.

• Vanemate tunnetega peaks arvestama ja neid märkama. Vanematele peaks pakutama psühhosotsiaalset tuge, lähedussuhte toetamist lapsega, mis sisaldab ka lapse eest põetamise toetamist.

• Vanemaid peaks julgustama võtma enda peale vastutus lapse eest hoolitsemisel. Lapse arengut soodustab, kui vanem veedab lapse juures võimalikult palju aega ning osaleb varakult ettevõtmistes, mis on fokusseeritud vanemate ja lapse omavahelistesse suhetesse, koostoimesse.

• Kogu informatsiooni lapse kohta jagatakse vanemaga, kui ei ole juriidilisi takistusi teabe avalikustamiseks.

• Hõlbustama koostööd vanemate ja personali vahel.

Patsiendi ja perekesksus on võti edukakas kiindumuseks ja analüütiliseks protsessiks ema ja lapse vahel. Analüütiline protsess on otsustav aju arengus ja lapse võimes stressiga toime tulla, mis omakorda mõjutab lapse üldist arengut ja tervist tulevikus.

#### Arengut-toetav hooldus

Arengut toetav ravi baseerub osaliselt meditsiinilisel ravil, aga ka sotsioloogilisel- ja käitumisteadusel. See baseerub kompetentsil aru saada lapse käitumisest, et toetada lapse autoregulatsiooni (närvisüsteemi, erksust, koostoimimist ümbritsevaga), samuti on kasu vanematele ja hooldavale personalile koostoimimisest lapsega.

Enneaegsele vastsündinule peaks pakkuma individuaalselt kohandatud, arengut toetavat ravi/hoolitsust, millel on positiivsed lühiaegsed toimed, suurendab lapse heaolu neonataalses perioodis, isegi kui pikaaegsetel mõjudel on nõrgem teaduslik tugi.

Erinevad sekkumisprogrammid, mida võib kasutada väga väikeste enneaegste laste eest hoolitsemisel, näiteks:

**NIDCAP** - (newborn individualised developmental care and assessment programme) vastsündinu individualiseeritud arenguline ravi/hoolitsus ja hindamisprogramm, mida rakendatakse kogu hoolitsusperioodi ajal, mille läbiviimist alustatakse peale sündi, mis on oluline neurobioloogilise arengu perspektiivis [NIDCAP Federation International, 2014]. Põhiliseks on lapse reageerimisvõime ja stiimulitega toime tuleku võimekuse individualne hindamine ja selle toetamine. Lisaks on oluline tähelepanu pöörata lapse asendile, kohanemisele ümbritseva keskkonnaga ja spetsiifiliste hooldusvõtete läbiviimise ajastatusele.

NIDCAP rakendamisel on mõned teaduslikud kinnitused positiivsetest lühiaegsetest toimetest tõsisele bronhopulmonaalsele düsplaasiale, nekrootilise enterokoliidi esinemissageduse vähenemisele ja perekondade olukorra parandamisele. Uuringud näitasid ka positiivseid kaugtoimeid lapse käitumisele ja motoorsetele oskustele [Symington et al. Cochrane Database Syst Rev 2006, Wallin et al. 2009]. Teiste uuringute järgi NIDCAP-1 on positiivne mõju aju küpsusele ja kognitiivsele arengule [Als et al. 2012, Als et al. 2004] ning lühemale hoolitsus ajale [Peters et al. 2009].

<u>Modifitseeritud NIDCAP</u>, sama eesmärk, aga ei sisalda kõiki vaatluselemente, sama teoreetiline baas: **MITP** (mother infant transaction programme) ja **IBAIP** (infant behavioural assessment and intervention programme). MITP vähendab vanemate

stressitaset lapse esimesel eluaastal, on kasulik toime lapse kognitiivsele arengule 5.a.v. [Kaaresen et al. 2008, Olafsen et al. 2008]. IBAIP parandab lapse motoorset arengut, eriti sünnikaaluga alla 1500g, 5.a. järelkontrollil oli neil lastel parem kognitsioon (tulemuslikkuse IQ), samuti võime koordineerida visuaalseid muljeid ja liigutuste mustreid (visual-motor integration) [Koldewijn et al. 2013, Van Hus et al 2013].

Sageli kasutatakse nahk-naha kontakti meetodit 24 tundi päevas e. känguruhooldust (KH). Meetod baseerub otsesel nahakontaktil vanemaga või lähedase pereliikmega. Teaduslik toetus selle meetodi positiivsetele toimetel on sagedamini uuritud madala sissetulekuga maades [Conde-Agudelo et al. Cochrane Database Syst Rev 2011, Moore et al. Cochrane Database Syst Rev 2012, Nyqvist et al. 2010]. Uuringutega on leitud, et NNK meetodit e. KH kasutamisel esineb madalam suremus, vähem tõsiseid infektsioone, parem temperatuuri regulatsioon ja lühemad raviajad vastsündinutel. Meetod on ka valu leevendava toimega [Cochrane Database Syst Rev, Ridell et al. 2011, Akcan et al. 2009, Cignacco et al. 2007] ja positiivse toimega lapse kasvule, ema rahulolule ja kiindumussuhtele lapsega haiglast väljakirjutamisel [Kramer et al. 2008], emal on parem piima produktsioon ja lapse eest hoolitsemise käitumine [Renfrew et al. 2010]. Pikemal imetamisperioodil on ka positiivne toime lapse kognitiivsele arengule [Kramer et al, 2008].

#### Süstemaatilised ülevaated

Kokkuvõte süstemaatilistest ülevaadetest, randomiseeritud uuringutest, prospektiivsetest uuringutest

Nahk-naha kontakt (NNK), känguruhooldus (KH), perekeskne ravi

-Perekeskse neonataalse ravi kohta, mis parandab enneaegsete vastsündinute ravitulemusi ja perede psühhosotsiaalset toimetulekut ning kiindumussuhte tekkimist lapsega, oli vastavalt otsingukriteerimitele kättesaadavad 1 ülevaate artikkel 2015a., 7 süstemaatilist ülevaadet/metaanalüüsi (avaldatud viimase 5 aasta jooksul – (2014, 2014a,b, 2014, 2012, 2010, 2010, 2012), lisaks 2 randomiseeritud uuringut (2006, 2014), 2 prospektiivset vaatlusuuringut (2010, 2013), 1 soovitustega artikkel känguruhoolduse kohta (2010) I Euroopa konverentsilt ja VII Rahvusvaheliselt Töötoalt.

- NIDCAP – 1 süstemaatiline ülevaade/meta-analüüs aastast 2013,

-perekeskse ravi kohta intensiivravi osakonnas 2 RCT uuringut 2013, 2015

-**perepalat** - 1 prospektiivne kõrge kvaliteediga quasi-eksperimentaalne kohort uuring 2014.a.

-Valu, protseduuride, valutustamise kohta avaldatud viimase 5 aasta jooksul süstemaatilisi ülevaateid 5 - (2011, 2012, 2013, 2013, 2014), 4 RCT uuringut (2012, 2012, 2013, 2015).

Perekonna kaasamine on võtmeks realiseerida potentsiaal	1. Review article
kauakestvateks positiivseteks mõjudeks kõikide vastsündinute	Recommendations
füüsilisele, kognitiivsele ja psühhosotsiaalsele arengule, k.a.	for involving the
nendele, kes on ravil neonataalses intensiivravi osakonnas	family in develop-
(NICU). Perekeskne arenguline ravi (ingl.k. family-centered	mental care of the
developmental care (FCDC)) tunnustab perekonda, kui NICU	NICU baby
meeskonna olulist liiget. Perekonnad on integreeritud	
otustamisprotsessidesse ja on kaastöötajad lapse eest hoolitsemisel.	Craig JW, Glick C,
Perekeskse arengulise ravi standardiseeritud põhimõtete	Phillips R, Hall SL,
kasutamisega NICU-s luuakse tugev ja toetav alus, suurendamaks	Smith J, Browne J
perekonna eluaegset suhet oma lapsega ning tagatakse lapse	
optimaalne füüsiline, kognitiivne ja psühhosotsiaalne areng. Tehtud	Journal of

<ul> <li>eest hooliisejate rolli NICU-s. Soovitused toetavad ka NICU 35, S5–S8;</li> <li>personali osalemist perekeskese arengulises ravis ja thttasi luuakse NICU strateegiad/eeskirjad/teguisemsiviisid, mis toetavad perekeskset ravi. Perekeskse ravi soovitused on tehtud kõikide laste põhivajadusi-, hospidaliseeritud laste erivajadusi arvestades ning arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püšiv negativne mõju, mis lapse haigusega võib vanema-lapse suhtele mõjuda.</li> <li>Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskse ravi (2012).</li> <li>Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetanine c) NICU tegutsemisviisid.</li> <li>1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s</li> <li>-Lapse eraldamisel emast on tugev negativne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse siunituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikses sümikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast cemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015. Singer jt. 2007).</li> <li>-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsindinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui graskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituma vaimse tervise küsimustega nagu depression, post-traumatiline stress, angistus ja teised stressist põhjustatud seisuodi võivad kahjustada ebasoodsalt v</li></ul>			
personali osalemist perekeskses arengulises ravis ja ühtlasi luuakse NICU strateegial/eeskirjad/tegutsemisviisid, mis toetavad perekeskset ravi. Perekeskse ravi soovitused on tehtuk köikide laste pohivajadusi-, hospidaliseeritud laste erivajadusi arvestades ning arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel maast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikses sümikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli pudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) komineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed fagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 201			(2015)
NICU strateegiad/eeskirjad/tegusemisviisid, mis toetavad perekeskset ravi. Perekeskse ravi soovitused on tehtul kõikide laste põhivajadusi-, hospidaliseeritud laste erivajadusi arvestades ning arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvalitecti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. <u>1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, sanuti psühhosotsiaalsele heaolule ja aju arengule, sämas enneagse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enanus ajast eemal oma vanematest ja neil on kõrge risk pikaaegsteteks arengulisteks ja käitumisproblecmideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsindinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui, raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Melher jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, poost-traumatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikee (Pierrehumbert jt., 2003) ja kognitiivsetele funk	5	35, S5–S8;	
perekeskset ravi. Perekeskse ravi soovitused on tehtud kõikide laste põhivajadusi-, hospidaliseeritud laste erivajadusi arvestades ming arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püsiv negativne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsenisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündiu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veeda henamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskieid" (Cho jt. 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise kläsimustega nagu depression, post-traumatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierehumbert jt., 2003) ja koguitiisvetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). E	personali osalemist perekeskses arengulises ravis ja ühtlasi luuakse		
põhivajadusi-, hospidaliseeritud laste erivajadusi arvestades ning arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on criti tösine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituma vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengude (Ishirzik 2013, Huhala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikses sünnikaaluga	NICU strateegiad/eeskirjad/tegutsemisviisid, mis toetavad		
arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakomas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vainse tervise käsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishiraki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele,	perekeskset ravi. Perekeskse ravi soovitused on tehtud kõikide laste		
arvestades ka perekondade vajadusi, kes peavad kriisiga toime tulema, kui laps on ravil intensiivravi osakomas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vainse tervise käsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishiraki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele,	põhivajadusi-, hospidaliseeritud laste erivajadusi arvestades ning		
tulema, kui laps on ravil intensiivravi osakonnas. Primaarne vajadus on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikses sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig ji 2015, Singer ji 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusanu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengue (Ishizki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese stimikaaluga vaststindinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 20			
on minimiseerida püsiv negatiivne mõju, mis lapse haigusega võib vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. I. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja nei on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi närgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma bebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundi võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagäärjed lapse sutsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Erakdamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vaststindinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Häiget enneaegsete laste vanem	1 5 1 5		
vanema-lapse suhetele mõjuda. Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Birecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	-		
Ameerika Pediaatrite Akadeemia ja paljud teised organisatsioonid toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. <u>Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsindinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegste laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmi			
toetavad perekeskset ravi (2012). Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kaljustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, Discala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	1 5		
Üks võimalus NICU meeskondadele on arendada ja laiendada perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. <u>1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s</u> -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegste laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundi võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegset laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
perekeskse ravi praktikaid läbi kvaliteeti parandavate algatuste rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsüudinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
rakendamise, milledest peamised on: a) vanemate toetamine b) personali toetamine c) NICU tegutsemisviisid. 1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaanu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtal, Korja jt. 2012), käitumuslikke (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vaststindinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegset laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	•		
personali toetamine c) NICU tegutsemisviisid. 1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s -Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegset laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
<ul> <li>1. Toetades vanemaid kui oma laste eest hooldajaid NICU-s</li> <li>-Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007).</li> <li>-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vainse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004).</li> <li>Eraldamine võib muuta enneaegste last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisel ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005).</li> <li>Haigete enneaegste laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>			
<ul> <li>-Lapse eraldamisel emast on tugev negatiivne mõju lapse füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007).</li> <li>-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse subet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslike (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004).</li> <li>Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisel ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005).</li> <li>Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>			
füsioloogilisele stabiilsusele, samuti psühhosotsiaalsele heaolule ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
ja aju arengule, samas enneaegse sünnituse mõju või haige vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
vastsündinu hospitaliseerimine mõjutab oluliselt ka vanemaid ja peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	<b>U</b>		
<ul> <li>peresid. Omavaheline eraldamine on eriti tõsine väga väikese sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007).</li> <li>-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004).</li> <li>Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005).</li> <li>Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>			
sünnikaaluga enneaegste (VLBW) ja nende perede puhul, kuna EA laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamissele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegset laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	· · · · ·		
laps veedab enamus ajast eemal oma vanematest ja neil on kõrge risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
risk pikaaegseteks arengulisteks ja käitumisprobleemideks (Craig jt. 2015, Singer jt. 2007). -Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
<ul> <li>(Craig jt. 2015, Singer jt. 2007).</li> <li>-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004).</li> <li>Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005).</li> <li>Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>	• • • •		
-Enneaegsete laste vanematel on sageli puudus toetusest ja võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
<ul> <li>võimalustest tegeleda lapse kasvatamisega intensiivravi perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008).</li> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004).</li> <li>Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005).</li> <li>Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>			
perioodil, mis põhjustab sageli väärarusaamu oma vastsündinu käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
käitumuslikes märguannetes (Melnyk jt. 2006) ja isegi märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
märgistades oma lapsi, kui "raskeid" (Cho jt., 2008). -Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
<ul> <li>-Vanemate eraldamine oma beebist NICU-s (Mehler jt., 2011) kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis</li> </ul>			
kombineerituna vaimse tervise küsimustega nagu depression, post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
post-traumaatiline stress, ängistus ja teised stressist põhjustatud seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	-		
seisundid võivad kahjustada ebasoodsalt vanema-lapse suhet, millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
millel on negatiivsed tagajärjed lapse sotsiaalsele ja emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
emotsionaalsele arengule (Ishizaki 2013, Huhtala, Korja jt. 2012), käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
käitumuslikele (Pierrehumbert jt., 2003) ja kognitiivsetele funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
funktsioonidele (Brecht, Shaw jt. 2012, Bernard-Bonnin 2004). Eraldamine võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles riskiga kuritarvitamisele ja väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
<b>Eraldamine</b> võib muuta enneaegset last, eriti väga väikese sünnikaaluga vastsündinut, olles <b>riskiga kuritarvitamisele ja</b> <b>väärkohtlemisele, mis võib järgneda peale kojukirjutamist</b> (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
sünnikaaluga vastsündinut, olles <b>riskiga kuritarvitamisele ja</b> <b>väärkohtlemisele, mis võib järgneda peale kojukirjutamist</b> (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
väärkohtlemisele, mis võib järgneda peale kojukirjutamist (Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	8 , 8		
(Huhtala, Korja jt. 2012, DiScala et al 2000, Hoffmann 2005). Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis	-		
Haigete enneaegsete laste vanemad peavad arenema ja säilitama asjakohased arusaamised oma lapse vajadustest, et olla valmis			
asjakohased arusaamised oma lapse vajadustest, et olla valmis			
1	koduseks lapse eest hoolitsemiseks (Craig 2015, Lee jt. 2012).		
-Uuringutes (O'Brieni jt. Kanadas, 2013, Ortenstrand jt. 2010a.			
Rootsis), kus perekonnad olid täielikult integreeritud NICU			
meeskonda ja aktiivselt hoolitsesid oma lapse eest, näitasid	•		
positiivseid toimeid nii vanematele kui lastele. Emadel esines	positiivseid toimeid nii vanematele kui lastele. Emadel esines		

vähem stressi ja tundsid ennast rohkem teadlikemana ja enesekindlamana, lastel paranes kaaluiive ja väljakirjutamisel esines kõrgem ainult rinnagatoitmine O`Brieni uuringus. Haiglasoleku aeg oli lühem Ortenstrandi uuringus. Phillips jt. 2012a. leidsid, et toetades emasid NICU-s vastama oma lapse käitumisele, püüdes toetada kiindumussuhet, esines märkimisväärselt sagedamini rinnagatoitmist 8 nädalat pärast sündi.

-Erinevad uuringud on näidanud seost vastsündinu stressi ja aju struktuuri muutuste vahel (Smith jt., 2011). Smith jt. uuringute andmetel selgus et, kui vastsündinu oli NICU-s avatud/kaitsmata suurenevale arvule stressoritele, esines lapse aju struktuuris ja kindlaks funktsioonis regionaalne kahjustus, mis tehti magnetresonantstomograafias (MRI-s), esines samuti ebanormaalsusi käitumises neuroloogilismotoorses käitumuslikul läbivaatusel. Kui vanematele näidata, kuidas ära tunda lapse käitumuslikke, sotsiaalseid ja füüsilisi märguandeid, siis vanemad toetavad lapse arengulist ja füüsilist edasiminekut, mis edaspidi kajastub muutustes aju struktuuris.

-Milgrom jt. 2010 leidsid, et kui vanemad osalesid 10-sessioonilises koolitusprogrammis, kuidas vähendada nende EA laste stressirikkaid kogemusi, oli hiljem MRI uuringul nähtav nende laste ajude paranenud tserebraalne valgeaine mikrostruktuurne areng.

-Scher jt. 2009a. uuringu andmetel, kus enneaegsed olid **emaga** nahk-naha kontaktis 8 nädalat, esines lastel kiirem aju funktsiooni küpsemine hinnatuna elektroentsefalogrammiga, võõreldes lastega, kes ei saanud sellist kontakti.

-Milgromi uuring jt. edasine 2013a. hindas laiendatud vahelesegamise mõju kasutades täiustatud programmi (Mother-Infant Transaction Program, nim. PremieStart) beebidele ja emadele, kelle laps oli sündinud alla 30 rasedusnädala. Emad pidid selles treeningus ära tundma ja minimiseerima stressi vastuseid oma lastel. Osalenud emad oli enam sensitiivsed oma laste suhtes ja sobilikult tundlikud lapse stressi käitumisele. Nende lastel esines hiljem vähem stressikäitumist ajalise lapse- ja 6 kuu korrigeeritud vanuses. Tulemustest järeldus, et positiivne vahelesegamine võib anda varast kasu kognitiivsele ja prelingvistilisele arengule.

-White-Traut jt. 2015a. näitasid, et kui emad said informatsiooni, kuidas anda oma beebidele lihtsaid, arengule vastavaid ("Hospital multisensoorseid stiimuleid programmi to Home Transition-Optimizing Premature Infant's Environment program") raames - siis nende lastel oli parem kaaluiive haiglasoleku ajal, olid vähem haiged 6-nädalat peale NICU-st koju kirjutamist.

Kokkuvõtte: erinevad uuringud kindlustavad tugeva baasi erinevateks sekkumisteks, millel on potentsiaali vähendada keskkonna stressorite ebasoodasat mõju NICU-s olles, vähendavad arenguliseks võimalust halvaks tulemuseks lapsel. stressi vähendamine parandab vanemate vaimset tervist, mis omakorda võib parandada lapse ja vanema omavahelisi suhteid.

Soovitused vanematele kui oma lapse eest hooldajate toetuseks

#### A. Vanemaid peaks kaasama oluliste osalejatena partnerina lapse tervendamisel NICU ravi- ja hoolitsemis meeskonnas.

a) Vanemad peaksid kasutama "hands-on" e. "käed lapse küljes hoolitsust", mis sisaldab varast, sagedast ja kauakestvat nahk-naha kontakti kui on meditsiiniliselt asjakohane, koos juhendamisega ja toetusega NICU personali poolt (Cleveland 2008).,

b) osalema meditsiinilistel visiitidel, õendusabi aruannetel (AAP 2012, Voos jt., 2012),

c) peaks olema ligipääes meditsiiniandmetele

**B.** Vanemaid ja pereliikmeid peaks toetama rakendama arenguliselt vastavat hoolitsust lastele, et nad oleksid kompetentsed hooldajad ja neuroprotektiivsed toetajad oma lastele (Melnyk jt., 2006, Cho jt., 2008, Altimier jt., 2013) s.t.:

a) andma mugavuse ja turvalisuse oma lapsele järjekindla kohalolekuga b) aru saama käitumuslikust kommunikatsioonist lapsega

c) andma toetava asendi ja hooldamise beebile, s.t. toetavat suukaudset toitmise kogemust, nahk-naha kontakti, lapse puudutamist

d) tegema koostööd NICU personaliga, et minimiseerida lapse stressi ja valu arenguliselt ootamatus NICU keskkonnas

e) kaitsma lapse und, saades aru une tähtsusest tervenemisele, kasvamisele ja aju arengulse

f) optimeerima lapse toitmist rinnapiimaga ja imetamisega igal võimalikul juhul

g) kaitsma lapse nahka ja paljusid funktsioone

2. Personali osalemine perekeskses arengulises ravis

Juhtkonna panustamine kogu tervishoiusüsteemi interdistsiplinaarsesse ravi/hoolitsemise mudelisse on oluline edukaks perekeskse arengulise ravi rakendamiseks, k.a. administratsioon, arstide ja medõdede meeskond ja kogu haigla ülejäänud personal, kes annab toetust ja teenindab beebisid ja perekondi NICU-s.

**Personali osalemine:** arvestada vanemate kultuurilis eripärasid, vajalikud on kirjalikud infomaterjalid vanematele. Kui vanemad saavad lapsega olla: õpetada käte hügieeni, personali rolle ja aparatuuri tööpõhimõtteid. Oluline on keskenduda lapse ja vanema suhtlemisele, rõhutades vanemate kohaloleku vajadust lühi- ja kaugtoimetele lapse arengus. Personalile õpetada perekeskse ravi printsiipe ja rakendamist. Personali suhtlemine vanemate ja peredega peaks olema regulaarne, arusaadav, personaalne, pidev.

3. NICU tegutsemisviisid toetamaks perekeskset arengulist ravi. NICU poliitika, tegutsemisviisid, protseduurid peavad toetama vanemate osalemist kui osa inetrdistsiplinaarsest meeskonnast.

Kasutades integreeritud, neuroprotektiivset, perekeskset arengulise ravi mudelit, spetsiaalse koolitusega vastsündinu terapeudid peavad tegema individualiseeritud raviprotseduure NICU-s (Barbosa 2013). Professionaalse koolitusega meeskonda vanema-lapse arenguliseks toetuseks peaks kuuluma spetsiaalselt treenitud õed, arstid, psühholoogid, koos vastsündinu terapeutidega s.t. tööterapeudid,

füsioterapeudid ja kõnekeele patoloogid (Craig jt. 2015, Ludwig	
2013, Sturdivant 2013, Barbosa 2013).	
Soovitused: a) vanemate ööpäevaringne ligipääs lapse juurde ning	
info kättesaadavus, b) töökorraldus soodustab vanemate osalemist	
tugisüsteemis, k.a. lapse õed-vennad, vanavanemad c) vanemate	
toetamise alustamine, kui on kahtlus lapse võimalikule ravile NICU-	
s (antenataalne konsultatsioon). d) tagada optimaalne peretoetus	
NICU-s: materiaalsed ressursid – näit. Peretuba, peresalong,	
magamistuba, pesemisruum, köök, jne., kus harjutada	
5 7 11 5 7 7	
psühhosotsiaalne toetus iga professionaalse meeskonna liikme poolt	
f) vastastikune toetus erinevate laste vanemate vahel g) lapse surma	
korral interdistsiplinaarne toetus; h) kojuminekueelne ettevalmistus,	
jne.	
Sissejuhatus Känguruhooldus (KH) juurutati 1978a. Bogotas,	2. Kangaroo mother
Kolumbias, pediaatri Edgar Rey poolt. KH ema ja lapsega oli	care to reduce
esialgselt mõeldud kasutada madala sissetulekuga maades	morbidity and
inkubaatorite puuduse-, kõrge hospitaalinfektsioonide	mortality in low
esinemissageduse ja lastest loobumise tõttu. KH kasutati	birthweight infants
alternatiivina konventsionaalsele väikese sünnikaaluga vastsündinute	(Review)
eest hoolitsemisele.	
KMC- ingl.k. kangaroo mother care – känguruhooldust (KH)	Conde-Agudelo A,
originaalis defineeritakse kui (1) <u>nahk-naha kontakti ema</u>	Díaz-Rossello JL
•	Diaz-Rosseno JL
(NNK) ja vastsündinu vahel, mis on KH peamine komponent.	The Cochrane
Laps pannakse vertikaalasendis alasti (või mähkmega) ema	
rindkerele rindade vahele, ema riiete alla või kaetakse tekiga,	Database Syst Review
<u>rätikuga, jms. Kaks teist komponenti on</u> (2) sage imetamine ja	2014
ainult või valdavalt rinnaga toitmine ning (3) võimalusel varane	
koju kirjutamine haiglast järelkontrolliga. NNK rakendatakse	
lapsele nii kaua kui ema ja laps seda taluvad. Ema võib NNK	
läbiviimist asendada teiste pereliikmetega, eriti lapse isaga.	
Maailmas on kasutusele võetud erinevad modifikatsioonid	
känguruhooldusest, näiteks: täielik rinnapiimaga või mitte täielik	
rinnapiimaga toitmine, rinnaga või sondiga toitmine, täielikult või	
osaliselt lapse alasti olek NNK olles, pidev nahk-naha kontakt	
kestusega ≥20 tunni päevas; vahelduv nahk-naha kontakt –	
lühikesed episoodid 1 või paar korda päevas, päevade arv	
variaabelne, kestus erinev; varane koju kirjutamine või mitte.	
-2014a. hea kvaliteediga süstemaatilissee ülevaatesse/meta-	
analüüsi hõlmati 18 randomiseeritud kontrolluuringut, 2751	
väikese sünnikaaluga last (LBW<2500g, lapsed sõltumata	
gestatsioonivanusest).	
16 uuringut hindas känguruhooldust-(KH) ingl.k. (KMC) LBW	
lastel peale stabiliseerimist (Ali 2009; Blaymore Bier 1996; Boo	
2007; Cattaneo 1998; Charpak 1997; Eka Pratiwi 2009; Gathwala	
2008;Ghavane 2012; Kadam 2005;Neu 2010; Ramanathan 2001;	
Roberts 2000; Rojas 2003; Sloan 1994; Suman 2008; Whitelaw	
1988), <b>1 hindas KH enne stabiliseerimist</b> (Worku 2005) ja 1	
võrdles varajast känguruhooldust (alustatud esimese 24 tunni	
jooksul peale sündi) (Nagai 2010), hilisema KH alustamisega (24	
Jooksui peare sunui (Nagai 2010), imisema Kii austaimisega (24	

tundi peale sündi) suhteliselt stabiilsetel väikese sünnikaaluga enneaegsetel. 13 uuringut hindas vahelduvat KH (lühikesed episoodid 1 või paar korda päevas, päevade arv variaabelne) ja 5 pidevat KH (≥20 tunni päevas). <u>Väljakirjutamisel või 40- 41.nädalal korrigeeritud vanuses, KH oli seotud suremuse riski</u> (RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
episoodid 1 või paar korda päevas, päevade arv variaabelne) ja 5 pidevat KH ( $\geq 20$ tunni päevas). Väljakirjutamisel või 40- 41.nädalal korrigeeritud vanuses, KH oli seotud suremuse riski (RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
pidevat KH (≥20 tunni päevas). Väljakirjutamisel või 40- 41.nädalal korrigeeritud vanuses, KH oli seotud suremuse riski (RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
pidevat KH (≥20 tunni päevas). Väljakirjutamisel või 40- 41.nädalal korrigeeritud vanuses, KH oli seotud suremuse riski (RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
<b>41.nädalal korrigeeritud vanuses, KH oli seotud suremuse riski</b> (RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), <b>nosokomiaalse infektsiooni/sepsise</b> (RR 0.45, 95% CI 0.27 to 0.76), <b>hüpotermia</b> (RR 0.34, 95% CI 0.17 to 0.67), <b>ja haiglasoleku aja</b> (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) <b>vähenemisega. Hiliseimal järelkontrollil, KH oli seotud</b> <b>vähenenud nii suremuse riski</b> (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) <b>kui ka tõsise infektsiooni /sepsise esinemisega</b> (RR 0.56, 95% CI 0.40 to 0.78). <b>Leiti, et KH suurendas mõningaid</b>
(RR 0.60, 95% CI 0.39 to 0.92; 8 uuringut, 1736 last), nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
nosokomiaalse infektsiooni/sepsise (RR 0.45, 95% CI 0.27 to 0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
0.76), hüpotermia (RR 0.34, 95% CI 0.17 to 0.67), ja haiglasoleku aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
aja (tüüpiline keskmine erinevus 2.2 päeva, 95% CI 0.6 to 3.7) vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
vähenemisega. Hiliseimal järelkontrollil, KH oli seotud vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
vähenenud nii suremuse riski (RR 0.67, 95% CI 0.48 to 0.95; 11 uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
uuringus, 2167 last) kui ka tõsise infektsiooni /sepsise esinemisega (RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
(RR 0.56, 95% CI 0.40 to 0.78). Leiti, et KH suurendas mõningaid
lapse kasvuparameetreid (kaal, pea ümbermõõt, pikkus),
rinnaga toitmist ja ema-lapse kiindumust. Ei esinenud
märkimisväärseid erinevusi KH laste ja kontrollgrupi laste
vahel psühhomotoorses arengus ja neurosensoorses kahjustuses
1.a. vanuselt korrigeeritud vanuses. Tõendid sellest ülevaatest
toetavad KH kasutamist väikese sünnikaaluga lastel
alternatiivina konventsionaalsele neonataalsele hooldusele
peamiselt piiratud ressurssidega seadmete korral. Edasine
<b>5</b> / <b>1 5</b>
efektiivsusesse, pikaaegsetesse psühhomotoorse arengu
tagajärgedesse, hoolduskuludesse varase pideva KH alustamisse
ebastabiilsetel või suhteliselt stabiilsetel LBW lastel.
-Soovitused praktikasse: Kuigi käesolevad tõendid on peamiselt
limiteeritud KH kasutamisega madala/keskmise sissetulekuga
maades, on siiski uusi tõendeid, et KH võib parandada rinnaga
toitmise kestust kõrge sissetulekuga maades.
Alagruppide analüüs soovitas mõlemat: pidevat ja vahelduvat
känguruhooldust, mis mõlemad on kasulikud stabiilsetele LBW
lastele. Kuna kontrollgrupp uuringutes, mis hindasid pidevat
KH, olid inkubaatorites või soojenduslampide all, KH
potentsiaalne kasulik toime haigestumisele ja suremusele LBW
I 8 /
konventsionaalne neonataalne abi ei ole kättesaadav. Tänaseni,
varast pidevat KH mittestabiilsetele või suhteliselt stabiilsetele
LBW lastele ei saa soovitada, mille tõendid baseeruvad 2-le
väikesele uuringule.
I osa 2014. avaldatud kvalitatiivses süstemaatilises 3.a Parental
ülevaateartikklis, metauuringus, tehti metaandmete analüüs experiences of
vanemate kogemuste kohta lapsega nahk-naha kontakti korral. providing skin-to-
29 kvalitatiivses uuringus (avaldatud 2013a. detsembrini) oli skin care to their
käsitletud 401 ema ja 94 isa kogemusi, neist 18 uuringut enneaegsete newborn infant*Part
lastega (k.a. VLBW, LBWI), 2 ajalistega ja 8 ei olnud <b>1: A qualitative</b>
gestatsioonivanus välja toodud. 2 teemat, mis seoses nahk-naha systematic review
kontaktiga esile kerkisid – taastav kogemus ja energiat kulutav
kogemus. Anderzen-Carlsson A,

emotsionaalseid kannatusi leevendavad-, rikastavad kogemused, õppimiskogemused, oma rolli leidmine, enesehinnagu paranemine, kontrolli saavutamine, toetava keskkonna loomine). Lapsevanema teadmine, et teeb head lapsele (s.o. tähtis lapsele, vanematel pereks saamise tunne, kiindumuse-, lähedussuhte teke lapsega). <b>Energiat kulutav kogemus:</b> ümbritsev keskkond takistuseks lapsega suhtlemisel, füüsiline ja emotsionaalne koormus, soovide ja nõudmiste lahknevus, ebakindlus, teistele haiget tegemise tunne oma lapse probleemidega.	Int J Qualitative Stud Health Well-being <b>2014</b> , 9: 24906 REVIEW ARTICLE
See ülevaade lisas teaduslikku ja süstemaatilisi teadmisi vanemate kogemuste kohta NNK-i korral oma lapsega. Vajalikud on edaspidised uuringud isade kogemuste kohta. Tõenduspõhisest perspektiivist lähtudes süstemaatiline ülevaade näitas, et emad ja isad, kes teevad NNK-i lapsega, kogevad seda kui taastavat aga samas ka energiat kulutava kogemusena. II osa 2014. avaldatud ülevaateartikklis, metauuringus, tehti	3.b Parental
kvalitatiivne metasüntees vanemate kogemuste kohta lapsega nahk-naha kontakti korral. 29 kvalitatiivses uuringus 9 riigist, oli käsitletud 401 ema ja 94 isa kogemusi, neist 18 uuringut enneaegsete lastega (k.a. VLBW, LBWI), 2 ajalistega ja 8 ei olnud gestatsioonivanus välja toodud. Interpreteerides ja sünteesides tulemusi ülevaates olevatest analüüsidest: tekkis teoreetiline mudel " <i>Becoming a parent under</i>	experiences of providing skin-to- skin care to their newborn infant*Part 2: A qualitative meta- synthesis
<i>unfamiliar circumstances" – Lapsevanemaks saamine võõras olukorras.</i> Vanematele NNK-i pakkudes, tundub see olevat taastav, positiivne kogemus, kuid ka energiat kulutav kogemus. Toetav ümbritsev keskkond hõlbustab taastavat, positiivset kogemust, samal ajal kui takistused ümbritsevas keskkonnas teevad NNK-i läbiviimise energiat kulutavaks kogemuseks. NNK-i kogedes positiivse protsessina, soodustab see vanemate enesehinnangu kasvamist ja vanemad on valmis võtma täielikku vastutust oma lapse eest.	Anderzen-Carlsson A, CaravalhoLampy Z, & Eriksson M. Int J Qualitative Stud Health Well-being 2014, 9: 24906 REVIEW ARTICLE
Tulemused näitavad, et NNK-i saab interpreteerida mitte ainult kui perest-koosnevat ja tähtsat tervishoiualast sekkumist, vaid ka "tegelikult lapsevanemaks saamise protsessina". Protsess – "lapsevanemaks saamine" – spetsiifilises situatsioonis on mõjutatud väliste faktorite poolt 3 erineval tasandil: perekond ja sõbrad, kogukond ja ühiskond üldiselt. Vanemate kirjeldused NNK-i pakkumisest on sarnased sellele, mida varem on kirjeldatud kui loomulikku protsessi emaks või isaks saamisel.	
Tervishoiutöötajad peaksid soodustama igati nahk-naha kontakti läbiviimist, kui planeeritakse uusi neonatoloogia osakondi, on oluline, et NNK-i lubatakse teha mõlemal vanemal, nii emal kui isal oma lapsega, luua selleks head tingimused: privaatsus, füüsiline komfort, toetav suhtumine - see kõik aitab kaasa eriolukorras lapsevanemaks saamisel. Känguruhooldus/Nahk-naha kontakt	4. Effects of
Sissejuhatus KH kasutatakse laialdaselt arenenud ja arengumaades vanematele ja nende väikese sünnikaaluga lastele, rakendatakse pidevat NNK-i ja	Kangaroo Mother Care on maternal mood and interaction

vahelduv NNK-i (Nyqvist et al., 2010). Pidevat NNK-i kasutatakse arengumaades, tavaliselt kuid samuti ka mõnedes kõrgtehnoloogilistes intensiivraviosakondades (Blomqvist & Nyqvist, 2010; Nyqvist et al., 2010). Pidevat NNK-i rakendatakse ema ja lapse vahel alates sünnist, vähemalt 40 nädalani, ideaaljuhul imetamisega, haiglast väljakirjutamisega, kui laps on meditsiiniliselt stabiilne ja hoolika järelkontrolliga (Cattaneo, Davanzo, Uxa, & Tamburlini, 1998; Nyqvist et al., 2010).

Vahelduvat NNK-i kasutatakse Läänemaades kiindumussuhte soodustamiseks vanema ja lapse vahel, NNK-i rakendatakse lühemate perioodidena päeva jooksul, erinevatel arvul päevadel (Nyqvist et al., 2010).

KH korral laps pannakse NNK-i emaga või isaga või hoolitsejaga, lapse pea on pööratud küljele, hingamisteed peavad olema vabad, et vältida hingamisteede obstruktsiooni (Nyqvist et al., 2010). Kehatemperatuuri säilitamiseks võib laps kanda mütsi, sokke või mähet ja pannakse hoolitseja riiete alla või kaetakse rätikuga (Cattaneo et al., 1998; Nyqvist et al., 2010). Elastse riidega võib siduda asendi säilitamiseks KH tegija külge. (Nyqvist et al., 2010). KH teostajale peaks pakkuma adekvaatset toetust ja informatsiooni, personalile õpetusi ja treeninguid KH kohta (Cattaneo et al., 1998; Nyqvist et al., 2010). Tervishoiuasutuses peaks olema protokollid ja juhised känguruhooldusest/nahk-naha kontaktist (Cattaneo et al., 1998; Nyqvist et al., 2010).

Känguruhoolduse positiivsed toimed: positiivne toime lapse füsioloogilistele parameetritele. kognitiivne parem areng. infektsioonide esinemissageduse vähenemine, positiivne toime temperatuurile, kaaluiibele, unele, kisale. südame ia hingamissagedusele, energia kulutamisele ja oksügenisatsioonile (Dodd, 2005; Hall, & Kirsten, 2008; Ludington-Hoe, 2011; Tessier, Cristo, Nadeau, & Schneider, 2011). Positiivsed psühholoogilised toimed lastele ja peredele, ema-lapse suhetele, ema meeleolule ja tunnetega toimetulekule (Charpak et al., 2005; Tallandini & Scalembra, 2006: Tessier et al., 2011).

-2014a. süstemaatilises ülevaates sünteesiti ja hinnati 13 randomiseeritud ja randomiseerimata kontrolluuringu teadustulemusi känguruhoolduse mõjudest vanema–enneaegse lapse suhtlemismustritele ja/või ema meeleolule. Uuringutes enneaegsed ja LBW lapsed (terved või mitte) gestatsioonivanusega  $\leq 37$  nädala ja nende hooldajad (ema ja isa) – bioloogilised vanemad või mitte. Uuriti kas KH kasutamine vähendab kahjulikke psühholoogilisi mõjusid enneaegsest sünnitusest, leevendades ema negatiivset meeleolu ja/või edendades positiivsemaid koostoimeid enneaegse lapse ja vanemate vahel.

KH positiivsed tulemused esinesid 7 uuringus 9-st (Ahn et al., 2010; Feldman et al., 2002; Feldman et al., 2003; Gathwala et al., 2008; Neu&Robinson, 2010; Tallandini & Scalembra, 2006; Tessier et al., 1998), sisaldades rohkem positiivseid koostoimeid vanemate (enamus emad) ja nende enneaegsete laste vahel: rohkem puudutusi ja positiivset mõju, parem kohanemine lapse

patterns between parents and their preterm, low birth weight infants: A Systemic review

Athanasopoulou E., Fox JRE

Infant Mental Health Journal, Vol.35(3), **2014** 

käitumisega, tõusnud tundlikkus ja vähem piiravat käitumist.	
Eelised esinesid ka 6. kuu vanuselt (Feldman et al., 2002; Feldman	
et al., 2003; Neu&Robinson, 2010).	
Samuti on võimalik, et KH aitab kaasa vanema-lapse	
lähedussuhte ja kiindumuse tekkeks, kuna võimaldab vanemal	
rohkem aega veeta oma lapsega, vastupidiselt traditsioonilisele	
hooldusele, kui laps on inkubaatoris, vähendades varase lapse emast	
eraldamise negatiivset mõju.	
5 uuringus KH rakendamisel esines ema emotsionaalse heaolu	
paranemine, mis väljendus vähema stressi ja depressiooni	
esinemisega, mis oli tingitud enneaegset sünnitusest, emadel	
esines suurem kompetentsustunne lapsega tegelusel (De Macedo	
et al., 2007; Feldman et al., 2002; Lai et al., 2006; Tallandini &	
Scalembra, 2006; Tessier et al., 1998).	
Vastupidiselt 4 uuringus ei leitud erinevusi KH ja	
kontrollgrupiga (Ahn et al., 2010; Miles et al., 2006; Roberts et al.,	
2000; Whitelaw et al., 1988).	
Uuringud olid heterogeensed oma disaini, osalejate omaduste ja	
KMC rakendamise kestuse suhtes.	
<u>Uuringutest leiti tõendeid, et soovitada KH-st positiivsete</u>	
toimete tõttu, kuid ei saa teha mingeid kindlaid järeldusi.	
Eelkõige leiti, et KH võib parandada negatiivset ema meeleolu	
(stressi ja depressiooni) ja soodustada positiivselt vanema-lapse	
omavahelist suhtlemist.	
2012.a. süstemaatilises ülevaates analüüsiti 34 randomiseeritud	5. Early skin-to-skin
i gyrgaa, gugtymaatmgyg uityaattg anaiuusiti JT TanuviiiisCCIItuu	<b>5.</b> Early Skiii-10-Skiii
	e
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti	contact for mothers
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema-	contact for mothers and their healthy
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed	contact for mothers and their healthy newborn infants
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni <37 nädala), kes olid varases nahk-	contact for mothers and their healthy
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni <37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja	contact for mothers and their healthy newborn infants (Review)
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni <37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.	contactformothersandtheirhealthynewborninfants(Review)Moore ER, Anderson
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni <37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega. Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:	contact for mothers and their healthy newborn infants (Review) Moore ER, Anderson GC, Bergman N,
kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni <37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega. <u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u> (a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või	contact for mothers and their healthy newborn infants (Review) Moore ER, Anderson
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts,</li> </ul>	contact for mothers and their healthy newborn infants (Review) Moore ER, Anderson GC, Bergman N, Dowswell T
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)Moore ER, AndersonGC, Bergman N,Dowswell TTheCochrane
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas</li> </ul>	contact for mothersand their healthynewborn infants(Review)Moore ER, AndersonGC, Bergman N,Dowswell TTheCochrane
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)infantsMooreER, AndersonGC, BergmanN,DowswellTTheCochraneDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)infantsMooreER, AndersonGC, BergmanN,DowswellTTheCochraneDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahknaha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahknaha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)infantsMooreER, AndersonGC, BergmanN,DowswellTTheCochraneDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (ema- lapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk- naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele: <ul> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> </ul> </li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,DowswellTTheCochraneDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> <li>Uuringute üldine metodoloogiline kvaliteet oli segatud, esines kõrge heterogeensus mõnedes tulemustes. Metodoloogiliste piirangute</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)infantsMooreER, AndersonGC, BergmanN,DowswellTTheCochraneDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele: <ul> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> <li>Uuringute üldine metodoloogiline kvaliteet oli segatud, esines kõrge heterogeensus mõnedes tulemustes. Metodoloogiliste piirangute tõttu uuringu üldine kvaliteet on keskmine.</li> </ul> </li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)Moore ER, AndersonGC, Bergman N,Dowswell TTheCochraneDatabase Syst Review
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahknaha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele: <ul> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> <li>Uuringute üldine metodoloogiline kvaliteet oli segatud, esines kõrge heterogeensus mõnedes tulemustes. Metodoloogiliste piirangute tõttu uuringu üldine kvaliteet on keskmine.</li> </ul> </li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele.</li> <li>vai laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> <li>Uuringute üldine metodoloogiline kvaliteet oli segatud, esines kõrge heterogeensus mõnedes tulemustes. Metodoloogiliste piirangute tõttu uuringu üldine kvaliteet on keskmine.</li> <li>Tulemused</li> </ul>	contactformothersandtheirhealthynewborninfants(Review)(Review)MooreER, AndersonGC, BergmanN,Dowswell TTheCochraneDatabaseDatabaseSystReview
<ul> <li>kontrolluuringut, mis võrdlesid varast nahk-naha kontakti tavalise haigla hooldusega. Uuringusse hõlmati 2177 osalejat (emalapse paari) emad ja terved ajalised või enneaegsed lapsed (getstatsioonivanusega 34 kuni &lt;37 nädala), kes olid varases nahk-naha kontaktis, mis algas alla 24 tunni peale sündi ja kontrollgrupp tavalise hooldusega.</li> <li><u>Varase NNK-i alakategooriad ajalistele ja hilisenneaegstele:</u></li> <li>(a) NNK sünnil – laps pannakse kõhuli asendis ema rindkerele või kõhule esimesel eluminutil. Laps kuivatatakse, pähe pannakse müts, kaetakse eelsoojendatud rätikuga. NNK kestab vähemalt esimese elutunni lõpuni või esimese eduka imetamiseni.</li> <li>(b) Väga varane NNK – umbes 30-40 minutil peale sündi, paljas laps pannakse kõhuli asendis ema rindkerele.</li> <li>(c) Varane NNK – algus ükskõik, mis ajal esimese 24 elutunni jooksul. Paljas laps, mähkmega või ilma ja mütsiga, pannakse kõhuli asendis ema rindkerele, rindade vahele. Emal avatud pluus või kittel või laps pannakse riiete alla. Kõige tähtsam, et ema ja laps oleks vahetus kontaktis ventraalselt, last hoitakse kuiva ja soojana.</li> <li>Uuringute üldine metodoloogiline kvaliteet oli segatud, esines kõrge heterogeensus mõnedes tulemustes. Metodoloogiliste piirangute tõttu uuringu üldine kvaliteet on keskmine.</li> </ul>	contact for mothersand their healthynewborn infants(Review)Moore ER, AndersonGC, Bergman N,Dowswell TThe CochraneDatabase Syst Review

korral pikem imetamisperiood (7 uuringuuts; 324 osalejat) ((MD)	
42.55 päeva, 95% CI - 1.69 to 86.79) aga tulemused ei olnud	
statistiliselt päris märkimisväärsed (P = 0.06). Hilisenneaegsetel	
lastel oli parem kardiorespiratoorne stabiilsus varase NNK-i	
korral (üks uuring; 31 osalejat) (MD 2.88, 95% CI 0.53 to 5.23).	
Veresuhkur 75 kuni 90 minutit peala sündi oli märkimisväärselt	
kõrgem NNK-i grupis (2 uuringut, 94 last) (MD 10.56 mg/dL, 95%	
CI 8.40 to 12.72).	
Kokkuvõte	
Piirangud metodoloogilise kvaliteedi osas, varieeruvus rakendamisel	
ja tulemustes.	
NNK-i rakendamine on kasulik rinnaga toitmise õnnestumisele,	
kestusele ja kardiorespiratoorsele stabiilsusele, vähendab	
vastsündinu kisa, ei ole negatiivseid lühi- ega kaugtagajärgi.	
Soovitatavad edasised uuringud.	
2010a. metaanalüüsi eesmärgks oli uurida, kas NNK mõjutab	6. Meta-analysis of
vastsündinu kehatemperatuuri, südamesagedust ja hapniku	physiological effects
saturatsiooni.	of skin-to-skin
Tulemused	contact for
Metaanalüüsi hõlmati 23 uuringut (18 uuringut kõrge sissetulekuga	newborns and
maades), 15 uuringut enneaegsete (gestatsioonivanuses 26-36	mothers
nädalat, 326 last), 8 uuringut ajaliste vastsündinute (190 last) kohta.	
Metaanalüüsis esinesid tõendid kehatemperatuuri tõusust (weighted	Mori R, Khanna R,
mean difference [WMD] 0.22°C, P< 0.001) ja hapniku saturatsiooni	Debbie P, Nakayama
langusest (WMD -0.60%; P = 0.01) nahk-naha kontakti ajal,	Τ
võrreldes enne nahk-naha kontakti. Keha temperatuuri tõus oli enam	
ilmne halva varustusega kohtades (WMD, 0.61°C, P<0.001)	Pediatrics
võrreldes hea varustusega kohtades (WMD 0.20°C, P< 0.001).	International (2010)
Mõlemad, positiivne mõju keha temperatuurile ja negatiivne mõju	52, 161–170 doi:
saturatsioonile olid enam väljendunud külmas keskkonnas võrreldes	10.1111
soojema temperatuuriga keskkondades (WMD 0.18°C, P< 0.001;	
WMD -0.82%, $P = 0.02$ ).	
Metaanalüüsist järeldus, et kehatemperatuur tõusis 0.22°C, ei	
esinenud muutusi südamesageduses ja statistiliselt, mitte kliiniliselt,	
<b>e e</b>	
märkimisväärne saturatsiooni langus 0.60% NNK-i ajal. Soovitused kliinilisse praktikasse	
Arvestades kõiki KH ja/või NNK-i mõjusid madalama	
sissetulekuga maades, siis NNK-i võib propageerida stabiilsetele madala sünnikaaluga ja normaalse sünnikaaluga	
vastsündinutele. Enneaegsed, kellel esineb enneaegse apnoe, ei	
tohiks rakendada NNK-i ilma adekvaatse saturatsiooni ja	
respiratoorse monitooringuta. Keskkonna mõju on oluline,	
sellele peab pöörama tähelepanu.	
NNK on efektiivne viis soojendada vastsündinuid, eriti kui	
ressursid on piiratud ja keskkond on suhteliselt külm.	
Adekvaatne saturatsiooni ja respiratoorse staatuse monitooring	
kogu hoolduse ajal on vajalik maades, kus sissetulek on	
suhteliselt kõrge.	
2010a. süstemaatilisesse ülevaatesse metaanalüüsiks oli	7. 'Kangaroo mother
hõlmatud 15 uuringut enneaegsete (sünnikaaluga <2000 g)	care' to prevent
	L .

suremuse ja/või haigestumise tulemuste kohta, 9 randomiseeritud	neonatal
uuringut ja 6 vaatlusuuringut keskmise või madala sissetulekuga	deaths due to
maades. <u>Uuringute kvaliteet hinnati keskmiseks või kõrgeks.</u>	preterm birth
Esimene publitseeritud metaanalüüs, kõrge tõenduspõhisusega, mis	complications
näitas, et esimesel elunädalal rakendatud känguruhooldus vähendas	
märkimisväärselt neonataalset suremust (3 RCT - RR 0.49, 95%, CI	Systematic review/
0.29–0.82; 3 vaatlusuuringut RR 0.68, 95% CI 0.58–0.79))	metaanalysis
enneaegsete (sünnikaaluga <2000 g) hulgas haiglas, võrreldes	
tavapärase hooldusega (inkubaator). Samuti esines märkimisväärne	Lawn JL, Mwansa-
haigestumise vähenemine tõsistesse infektsioonidesse (5 RCT - RR	Kambafwile J,
0.34, 95% CI 0.17–0.65) (sepsis, nekrootiline enterokoliit, raske	Bernardo LH,
pneumoonia).	Fernando CB,
KOKKUVÕTE:	Cousens S
-Känguruhooldus vähendab oluliselt neonataalset suremust	
enneaegsete (sünnikaaluga <2000 g) hulgas haiglas ja on väga	International Journal
efektiivne tõsise haigetumise (eriti infektsioonidesse)	of Epidemiology
vähendamisel.	<b>2010</b> ;39:i144–i154
-Tõendid on piisavad, et soovitada rutiinselt KH-t kõikidele	doi:10.1093/ije/dyq031
<2000g enneaegsetel niipea, kui nende seisund on stabiilne.	J. J
2012a. esimene süstemaatiline ülevaade, kus uuriti enneaegse	8. The effects of
sünni mõju ema-lapse omavahelisele suhtlemisele ja	preterm birth on
kiindumussuhtele lapse 2 esimese eluaasta jooksul. Ülevaates oli	nother_infant
29 uuringut: 3 uuringut ema kiindumuse kohta, 18 uuringut	interaction
ema-enneaegse lapse suhtlemise kohta ja 8 uuringut enneaegse	and attachment
lapse kiindumuse kohta, mis hinnati ka metaanalüüsiga.	during the infant's
Tulemused	first two years
Uuringud ema-enneaegse lapse suhtlemise kohta näitasid, et esinesid	÷
erinevused emade käitumises suhtlemisel enneaegse (emad rohkem	Systematic Review
kontrollivad, aktiivsemad, sirgjoonelisemad) ja ajalise lapsega, eriti	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
6.esimesel elukuul. Enneaegsete emad räägivad ja vaatavad rohkem	Korja R, Latva R &
oma last, võrreldes ajaliste laste emadega, aga samas nad	Lehtonen L.
puudutavad ja naeratavad vähem oma lapsele esimesel 3-1 elukuul,	Lentonen L.
vähem esineb näoga emotsioonide peegeldamist, imiteerimist.	Acta Obstetricia et
Erinevused enneaegse lapse suhtlemiskäitumises esinesid peale	Gynecologica
	Scandinavica, <b>2012</b> ;
sündi 61 elukuul, lapse suhtlemisvõimes esines käitumuslik ja emotsionaalne defitsiit (näit. Lapsed passiivsemad, vähem aega	91;164-173
ärkvelolekus, madalam tähelepanu kvaliteet, mängu ja motoorsed	91,104-175
oskused, jne.) ja erinevused ema suhtlemisstiilides (5 uuringut 18st	
näitasid võrdset või isegi kõrgema kvaliteediga ema-lapse suhtlemist	
enneaegsete grupis võrreldes ajaliste laste grupiga).	
Uuringud ema ja lapse kiindumussuhte/lähedussuhte kohta näitasid,	
et enneaegsed lapsed ja nende emad ei ole kõrgema riskiga	
ebakindlaks/mitteturvaliseks kiindumuseks võrreldes ajaliste	
vastsündinute ja nende emadega.	
Kokkuvõte, kliinilised järeldused	
-Ema ja enneaegse lapse suhe on keeruline ja mõned	
käitumismustrid prognoosivad suuremat psühholoogilist riski	
kui teised. Kliinilises kontekstis on oluline toetada lähedast ema-	
lapse kontakti, vähendada ema stressi ja varast ema-lapse	
eraldatust igal võimalikul viisil haiglasoleku ajal, samuti koju	

kirjutamisel.	
-Lapse vaimse tervise huvides, varased sekkumised, mis	
soodustavad enneaegse emotsionaalset ja sotsiaalset arengut	
peaksid olema tavapärases kasutuses.	
2013a. prospektiivne vaatlusuuring enneaegsetel lastel (GV 24-	9. Safety and
33näd., 96 last, sünnikaal 510-1972g, postnataalne vanus 0-55p,	Effectiveness of skin-
keskmine nahk-naha kontakti kestus 71.39 (±34.36minutit, 17	to-skin Contact in the
last_intubeeritud, 49 nCPAP, 92 lapsel tsentraalne veeni	NICU to Support
kateeter) kinnitas, et nahk-naha kontakti rakendamine NICU-s	Neuro-development
on ohutu ja efektiivne isegi ventileeritud enneaegsetele lastele.	in Vulnerable
NNK-i ajal suurenes oluliselt hapniku saturatsioon hapniku vajaduse	Preterm Infants.
langusega, südamesageduse langusega stabiilsemaks, vererõhk ja	
transkutanne CO2 osarõhk eriti ei varieerunud, vähenes	Carabasse A, Kracher
transitoorselt keskmine aksillaarne temperatuur.	S, Hausser M, Lnaglet
Apnoesid/bradükardiaid ei esinenud 122 NNK-i episoodil (87%),	C, Escande B, Donato
vähese vahelesegamise vajadus esines 19 korral (13%), mille korral	L, Astruc D, Kuhn P.
NNK-i ei pidanud lõpetama. Need andmed võivad kaasa aidata varasemale ja pikemaaegsele	JPerinatol Neonat
nahk-naha kontakti kasutamisele, mis võib parandada NICU-s ravi	Nurs, <b>2013</b> ; 27;3, 255-
vajavate laste neuroloogilist arengut. Registreerides füsioloogilisi	262
andmeid enne, NNK ajal ja peale NNK-i, kindlustab andmed, mis on	202
vajalikud NNK-i julgemaks ja kindlamaks kasutamiseks praktikas.	
Kasutada originaalset känguruhooldus meetodit, koos pideva	10. State of the art
nahk-naha kontaktiga, ükskõik, kus see on võimalik, on soovitav	and
rakendada kõrg-tehnoloogilises keskkonnas, kuigi teduslik	recommendations
hindamine peaks jätkuma.	
IIIIIUAIIIIIIE DEAKSTALKUIIIA.	Kangaroo mother
	Kangaroo mother care: application in a
Soovitused	care: application in a
	e
<u>Soovitused</u> <u>1. NNK alustamine:</u>	care: application in a high-tech
<u>Soovitused</u> <u>1. NNK alustamine:</u> - <u>pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või	care: application in a high-tech
Soovitused <u>1. NNK alustamine:</u> - <u>pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad	care: application in a high-tech environment.
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC,
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.:</u> lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N,
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist:</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U,
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li><u>Kerged adaptatsiooniprobleemid sünnijärgselt</u>: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>CPAP-ga laps</u>: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S,
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás-
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>pidev NNK sünnist:</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG,
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV 28-31näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A-
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u> <ul> <li><u>pidev NNK sünnist:</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV 227näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on</li> </ul> </li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M
<ul> <li><u>Soovitused</u></li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>-Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M COMMITTEE
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui võimalik, ilma põhjendatud piiranguteta (isa või asendaja võib olla</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV 27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui võimalik, ilma põhjendatud piiranguteta (isa või asendaja võib olla kui esmane hooldaja lapsele);</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M COMMITTEE REPORT
<ul> <li>Soovitused</li> <li><u>1. NNK alustamine:</u></li> <li><u>-pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>-Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui võimalik, ilma põhjendatud piiranguteta (isa või asendaja võib olla kui esmane hooldaja lapsele);</li> <li>Kui ema ei saa intensiivravi osakonda peale sünnitust, lapse võib</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M COMMITTEE REPORT Acta Pædiatrica 2010
<ul> <li>Soovitused</li> <li><u>I. NNK alustamine:</u></li> <li><u>pidev NNK sünnist;</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui võimalik, ilma põhjendatud piiranguteta (isa või asendaja võib olla kui esmane hooldaja lapsele);</li> <li>Kui ema ei saa intensiivravi osakonda peale sünnitust, lapse võib transportida ema juurde isaga nahk-naha kontaktis olles (saadab</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M COMMITTEE REPORT
<ul> <li>Soovitused</li> <li><u>NNK alustamine:</u></li> <li><u>pidev NNK sünnist:</u> erandid – lapse meditsiiniline seisund või vanemad ei ole kättesaadavad</li> <li><u>Gestatsioonivanus (GV) ≥32näd.</u>: lapse esmase seisundi hindamine sünnitustoas ema rindkerel, kui võimalik;</li> <li>Kerged adaptatsiooniprobleemid sünnijärgselt: kohe peale esmast stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li>CPAP-ga laps: peale stabilisatsiooni transport ema juurde NNK-ks koos monitoriga ja jälgimisega (CPAP/ventilaatorravi ei ole takistuseks NNK-le)</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV 28-31näd.</u>: NNK kohe peale esmast seisundi hindamist/ stabilisatsiooni, kui lapse seisund ja hooldus võimaldab;</li> <li><u>-GV &lt;27näd.</u>: NNK esimesel elunädalal: baseerub individuaalsel meditsiinilisel hinnangul</li> <li><u>-Keisrilõige:</u> NNK – laps panna lühikeseks ajaks ema rindkerele operatsioonitoas, võimalusel jätkata post-op jälgimisel. Kui ema on transporditud intensiivravi osakonda, rakendada NNK-i nii palju kui võimalik, ilma põhjendatud piiranguteta (isa või asendaja võib olla kui esmane hooldaja lapsele);</li> <li>Kui ema ei saa intensiivravi osakonda peale sünnitust, lapse võib</li> </ul>	care: application in a high-tech environment. Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A, Charpak N, Davanzo R, Ewald U, Ludington-Hoe S, Mendoza S, Pallás- Allonso C, Peláez JG, Sizun J, Widström A- M COMMITTEE REPORT Acta Pædiatrica 2010

<ul> <li>2. NNK transpordi ajal 3. Vanemate kohalolu ja rolli toetamine</li> <li>2010a. Prospektiivne uuring, kus osales 22 erakordselt väikest</li> <li>2. NNK transpordi ajal 3. Vanemate kohalolu ja rolli toetamine</li> <li>2010a. Prospektiivne uuring, kus osales 22 erakordselt väikest</li> <li>2. Status and the s</li></ul>
ast, uuriti kas suudavad säilitada normotemia NNK-i ajal ja kas esines negatiivseid mõjusid. 10 lapsel oli nabakateeter, 8 perifeerne 70i perkutaanne veenitee, 1 mehhaanilisel ventilatsioonil, teistel mCPAP. 16 lapsel emaga NNK, 5-l isaga, 1-l vanema õega. Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed enneaegsed GV <28 rasedusnädala suudavad säilitada adekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuse hingamissagedus, südamesagedus või hapniku saturatsioontolerate skin-to-skin contact during the first weeks of life00 <t< th=""></t<>
esines negatiivseid mõjusid. 10 lapsel oli nabakateeter, 8 perifeerne või perkutaanne veenitee, 1 mehhaanilisel ventilatsioonil, teistel MCPAP. 16 lapsel emaga NNK, 5-l isaga, 1-l vanema õega. <u>Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed</u> <u>enneaegsed GV &lt;28 rasedusnädala suudavad säilitada</u> <u>idekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuse</u> <u>hingamissagedus, südamesagedus või hapniku saturatsioon</u> <u>nahk-naha kontakti ajal ja peale seda oma vanematega (ema.</u> <i>Contact during the first</i> <i>veeks of life</i> Maastrup R., Greisen G Acta Paediatrica <b>2010</b> ;99;1145-1149
<ul> <li>või perkutaanne veenitee, 1 mehhaanilisel ventilatsioonil, teistel nCPAP. 16 lapsel emaga NNK, 5-l isaga, 1-l vanema õega.</li> <li>Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed emaeagsed GV &lt;28 rasedusnädala suudavad säilitada adekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuse hingamissagedus, südamesagedus või hapniku saturatsioon)</li> <li>Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed on takti ajal ja peale seda oma vanematega (ema.)</li> </ul>
<ul> <li>või perkutaanne veenitee, 1 mehhaanilisel ventilatsioonil, teistel nCPAP. 16 lapsel emaga NNK, 5-l isaga, 1-l vanema õega.</li> <li>Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed emaeagsed GV &lt;28 rasedusnädala suudavad säilitada adekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuse hingamissagedus, südamesagedus või hapniku saturatsioon)</li> <li>Kokkuvõte: Kliiniliselt stabiilised erakordselt väikesed on takti ajal ja peale seda oma vanematega (ema.)</li> </ul>
MCPAP. 16 lapsel emaga NNK, 5-l isaga, 1-l vanema õega.weeks of lifeKokkuvõte:Kliiniliselt stabiilised erakordselt väikesedMaastrup R.,enneaegsedGV <28 rasedusnädala suudavad säilitada
Kokkuvõte:KliiniliseltstabiilisederakordseltväikesedMaastrup R.,enneaegsedGV<28
enneaegsed GV <28 rasedusnädala suudavad säilitada adekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuse hingamissagedus, südamesagedus või hapniku saturatsioon) nahk-naha kontakti ajal ja peale seda oma vanematega (ema,
ndekvaatse nahatemperatuuri ja adekvaatse füüsilise stabiilsuseActa Paediatricahingamissagedus, südamesagedus või hapniku saturatsioon)Acta Paediatricaahk-naha kontakti ajal ja peale seda oma vanematega (ema,Content of the sector o
hingamissagedus, südamesagedus või hapniku saturatsioon) nahk-naha kontakti ajal ja peale seda oma vanematega (ema,
nahk-naha kontakti ajal ja peale seda oma vanematega (ema,
so) Kadzmina NNK i Izactua uuningua ali UVmin
sa). Keskmine NNK-i kestus uuringus oli 98min.
<b>2014a. randomiseeritud kontrolluuring</b> , kus osales 100 stabiilses <b>12. Effect of early</b>
eisundis last n=100, GV 34-40n., sünnikaal >1800g. Võrreldi skin-to-skin contact
varase nahk-naha kontaktigrupi lapsi (varane NNK I 24 tunni <b>following normal</b>
ooksul, alates 30min 1 tund peale sündi, soovitati teha delivery on incidence
niinimumajaga 60-minutiliste sessioonidega niipalju kui võimalik, of hypothermia in
ärgmised 24 t konventsionaalne hooldus) ja konventsionaalse <b>neonates more than</b>
nooldusega (riietatud lapsed ema juures 48 tunni jooksul). Mõõdeti 1800 g: randomized
aste kehatemperatuuri ja südamesagedust. <b>control trial</b>
<b>Fulemused:</b> Mõlemas grupis 50 last. NNK grupis keskmiselt (s.d.)
6.98t (0.28) NNK-i kestus I 24t jooksul. Keskmine temperatuur Nimbalkar SM, Patel
närkimisväärselt kõrge NNK grupis igal mõõdetud ajal I 48 t VK, Patel DV,
ooksul (P<0.05 for all). NNK-i grupis ainult 2 lapsel kerge Nimbalkar AS, Sethi
nüpotermia (4%) ja ühel neist 2 hüpotermia episoodi I 3 tunni A, Phatak
ooksul. Relatiivne risk hüpotermia tekkeks kontrollgrupis võrreldes
NNK-i grupiga oli 8.00 (95% CI 1.94–32.99). A Journal of
Kokkuvõte: Vastsündinud nahk-naha kontakti grupis Perinatology (2014)3-
aavutasid kiire temperatuuri kontrolli võrreldes 364–368
kontrollgrupiga. Varane NNK esimese 24 tunni jooksul peale
sündi vähendab hüpotermiat esimese 48 elutunni jooksul.
Varast nahk-naha kontakti peab agressiivselt soovitama
nilisenneaegsetele ja ajalistele lastele.
2006a. randomiseeritud kontrolluuring neurofüsioloogiline 13.Neurophysiologic
ieonataalse une organiseerituse hindamine Assessment of
elektoentsefalograafia/polüsomnograafiaga enneaegsetel lastel <b>Neonatal Sleep</b>
<32rasedusnädalat sündinud enneaegsed), 14 last NNK-i grupis, 14 Preliminary Results
controllgrupis. of a Randomized,
NNK ema või isaga, näitas, et NNK-i võib kasutada Controlled Trial of
enneaegsetele magamisel parema ja organiseerituma une Skin Contact With
aamiseks (esines märkimisväärselt vähem erutusi, vähem Preterm Infants
kiireid silmaliigutusi ja aktiivset und, vähem ebamäärast und,
suurenes vaikse une periood – need on muudatused une Susan M. Ludington-
organistasioonis, mis võivad soodustada aju küpsemist). NNK-i Hoe,, Mark WJ,
<b>organistasioonis, mis võivad soodustada aju küpsemist).</b> NNK-i Hoe, , Mark WJ, Ijal esines kardiorespiratoorne ja hapniku saturatsiooni stabiilsus. Morgan K, Lewis T, Lapsele on oluline ema südamelöökide kuulmine, ema rindkere Gutman J, Wilson,

we have to see a locat	DED11752000
rahustavad last.	PED117,5, <b>2006</b>
See uuring näitab, et NNK on mittefarmakoloogiline sekkumine	
ravisse, mis mõjutab une organiseeritust.	
Vanemate kaasamine neonataalsesse intensiivraviosakonda	
vastsündinu eest hoolitsemisse on väga soovitatav, rohkem tuleks	
kaasta vanemaid. Kuna paranenud une kasulikud mõjud on	
olulised neuroloogilises (aju) arengus, mis on subtiilsed ja	
järkjärgulised, peab NNK-i postnataalselt praktiseerima	
rohkem, pikemate perioodidena.	
2013a. süstemaatilisse ülevaatesse/metaanalüüsi oli kaasatud 11	14. NIDCAP: A
randomiseeritud kontrolluuringut esmaste tulemuste kohta, ja 7	Systematic Review
uuringut kaugtulemuste kohta (otsing 2012a. veebruarini), 627	and Meta-analyses of
vastsündinut. Uuringute kvaliteet varieerus, kuid 2 olid kõrge	Randomized
kvaliteediga. Uuriti NIDCAP efektiivsust meditsiinilistele ja	Controlled Trials
neuroloogilise arengu kaugtulemustele, kas parandab tulemusi	Controlled Trials
	Obleson A Jacobs SE
enneaegsetel lastel võrreldes standardhooldusega. Süstemaatilises ülevaates, milles uuriti 627 enneaegset	Ohlsson A, Jacobs SE
······································	
vastündinut, ei leitud ühtegi tõendit, et NIDCAP parandab	PEDIATRICs
neuroloogilisearengu kaugtulemusi või lühiajalisi meditsiinilisi	131;3; <b>2013</b>
tulemusi, ei saa soovitada NIDCAP praegusel kujul enneaegsete	
standardhooldusessse. NIDCAP-i on kulukas rakendada ja	
säilitada, vajab arenguspetsialiste, regulaarsust, abipersonali.	
Sissejuhatus	15. Randomized
Enneaegsete laste elulemuse tõusuga seoses püsivad kõrged riskid	controlled trial of
pikaaegseteks negatiivseteks neuroloogise arengu- ja	Family Nurture
käitumishäireteks, nagu tähelepanu defitsiit [Johnson et al 2011],	Intervention in the
kognitiivsed häired [Peterson et al 2000, Baron et al 2012],	NICU: assessments of
depressioon ja psühhootilised häired [Nosarti et al 2012] ja autismi	length of stay,
spektri häired [Pinto-Martin et al 2011].	feasibility and safety
FNI - family nurture intervention - Perekesksed	
sekkumised/perepoolne lapse eest hoolitsemine/perekeskne ravi	Welch MG, Hofer
s.t. stimuleerida ema ja tema enneaegse lapse vahelist sidet nii vara	MA, Stark RI,
kui võimalik ning rakendada abikaasa ja teiste pereliikmete toetust.	Andrews HF, Austin J,
Perekesksed sekkumised soodustavad tundmuslikku	Glickstein SB, Ludwig
suhtlemist/lähedussidet, emotsionaalset sidet ema ja lapse vahel.	RJ
Rakendatakse rahustavaid sessioone (calming sessions), kui laps	Myers MM and the
on NICU-s ja kuvöösis, mis aktiveerivad ema ja last vastastikku	FIN trial Group
füüsilistes, sensoorsetes ja emotsionaalsetes kogemustes.	BMC Dedictrice 2012
Nendeks on ema ja lapse lõhnaga vastastikune puuvillase	BMC Pediatrics <b>2013</b> ,
riideeseme vahetus, pikemaaegne lapse puudutamine (üks käsi	13:148
jalgadel, teine kõhul), häälega rahustamine, silmside kontakt.	
Hiljem, kui laps on stabiilne, rakendada NNK-i (vähemalt 4x	
nädalas), lisaks võimalikult palju kaasta ema igapäevasesse lapse	
hooldamisse.	
Randomiseeritud kontrollitud ühekeskuseline,	
paralleelgruppidega uuring, tõenduspõhiste perekesksete	
sekkumiste mõjust haiglasoleku ajale, rakedatavusest, ohutusest	
NICU-s. Enneaegsete laste (GV 26-34n.) pered n=150	
randomiseeriti 2 gruppi:, FNI=78, standardhooldus (standard care)	
SC=72. FNI grupis eriväljaõppega spetsialisti poolt soodustati ema-	

lapse suhtlemist spetsiifiliste rahustavate tegelustega (rahustav puudutus ja lapsega rääkimine, NNK vähemalt 4x nädalas, lapse eest hoolitsemine – toitmine, mähkemete vahetamine, vannitamine). <b>Tulemused: Perekesksed sekkumised/tegelused/perekeskne ravi enneaegse lapse eest hoolitsemisel (GV 26-34n.)</b> – <u>ei esinenud</u> märkimisväärset mõju esmastele lühiajalistele tagajärgedele, haiglasoleku ajale, s.t. positiivne toime, FNI võib rakendada ohutult ja on teostatav IV astme intensiivravi osakonnas. FNI ei tõstnud meditsiinilisi riske: ei tõusnud sepsise, nekrootilise enterokoliidi, krampide, retinopaatia esinemine, ei esinenud hapniku vajaduse tõusu, ravimite suurenenud vajadust. Suurenenud puudutuste ja lõhnavate riiete vahetamisega ei kaasnenud infektsioonide esinemissageduse tõusu.	
Enneaegsetel lastel on kõrge risk ebasoodsateks neuroloogilise arengu ja käitumishäirete tekkeks. Perekeskne sekkumine/perekeskne ravi (FNI) – s.o. uus sekkumise viis, mis on loodud vastukaaluks ema-enneaegse lapse lahutamisest tingitud kahjulikele toimetele NICU-s. Soodustades emotsionaalset sidet ja taastades klassikalised adaptatiivsed rutiinsed tingimused ema-lapse vahel – nim. rahustavaks tsükliks (calming cycle), s.o. teatud kindlate rahustavate võtete kasutamine, ema ja enneaegse lapse vahelise sideme ja suhtlemise soodustamiseks (Welch jt. 1988, Welch, Hofer, Brunelli, Stark jt. 2012). Varasemalt perekesksest (FNI) sekkumistest on randomiseeritud kontrolluuringud läbi viidud aastatel 2008-2012 (Welch jt. 2013, 2014, 2015).	16. Family Nurture Intervention in the Neonatal Intensive Care Unit improves social-relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized controlled trial Welch MG, Morgan
2015.a. randomiseeritud longitudinaalses järelkontrolli uuringus hinnati FNI toimet – perekesksete lapse eest hoolitsemise võtete kasutamist NICU-s neuroloogilis-käitumuslikele tulemustele, korrigeeritud 18. kuu vanuses enneaegsetele lastele. 2 gruppi, FNI grupp=45, standard hooldus n=31. FNI parandas märkimisväärselt Bayley-III testi tulemusi	RF, Austin J, Hane AA, Stark RI, Hofer MA, Garland M, Glickstein SB, Brunelli SA Ludwig
<b>kognitiivse skooringu osas</b> (p = .039), (Bayley III test on valideeritud lapse arengu hindamine 1k42k. vanuses: kognitiivne areng, kõne areng, motoorika areng) ja <b>keeleoskuse skooringu osas</b> (p = .008) lastel, kelle skooring oli üle 85 (üle 85-100 on norm, ei esine arengus mahajäämust). <b>FNI lastel oli vähem tähelepanu</b> probleeme (p < .02), vähem autistlikke iseloomujooni (p < .02). Perekesksete lapse eest hoolitsemise võtete kasutamine (FNI) NICU-s, näitas märkimisväärset paranemist neuroloogilises arengus, sotsiaalses empaatiavõimes/ mõistmises/suhtlemises ja tähelepanuga- ning käitumisega seotud probleemides emneaegsetel lastel. Perekeskne ravi, mis soodustab emotsionaalset vastastikust mõju ema ja lapse vahel NICU-s, võib olla võtmeks, et muuta arengulist trajektoori enneaegsetel lastel.	Journal of Child Psychology and Psychiatry <b>2015</b> Mar 11. doi: 10.1111/ jcpp.12405
2014a. longitudinaalsesprospektiivsesquasi-eksperimentaalseskohortuuringus(teostatudaastatel2008-2012)võrreldimeditsiinilisijaneuroloogiliskäitumuslikketulemusikojukirjutamiselenneaegsetelsünnikaaluga<1500g.	17. Single-Family Room Care and Neurobehavioral and Medical Outcomes in

seoseid NICU avatud palatitega (open-bay) vs ühe peretubadega	Preterm Infants
disaini ja meditsiiniliste ja neuroloogiliskäitumuslike tulemuste	
vahel kojukirjutamisel enneaegsetel peale NICU muutmist ühe	
peretubadega NICU-ks. Kaasati 151 EA last avatud ruumiga NICU-s	
ja 252 EA last peale muutmist peretubadega palatitega NICU-ks.	Miller R, Bigsby R,
Tulemused: statistiliselt märkimisväärsed tulemused (kõik Ps <.05)	Laptook A,
näitasid, et lapsed ühe peretubadega NICU-s kaalusid rohkem koju	Salisbury A, Taub M,
kirjutamisel, neil oli kiirem kaalutõus, vajasid vähem meditsiinilisi	Lagasse LL, F.
protseduure, neil oli madalam gestatsioonivanus täieliku enteraalse	Padbury JF.
toitmise saavutamisel ja vähem sepsist, näitasid paremat	Pediatrics
tähelepanuvõimet, vähem psühholoogilist stressi, vähem lihaspinget,	<b>2014;</b> 134:754–760
vähem letargiat ja vähem valu. NICU erinevused laste kaalus	
väljakirjutamisel olid seotud arengulise toetusega; erinevused	
meditsiinilistes protseduurides olid seotud suurenenud ema	
kaasamisega. NICU erinevused tähelepanus olid vahendatud	
suurenenud arengulisest toetusest. Erinevused stressis ja valus olid	
seotud ema kaasamisega. Õed teatasid positiivsemast töö	
keskkonnast ja suhtumisest ühe peretubadega NICU-s.	
Meetmed ema kaasamiseks: ema kohalolek, rinnast/pudelist	
toitmine, NNK, ema hooldus lapse eest (toitmine, vannitamine,	
mähkmete vahetamine).	
Järeldused: Ühe peretubadega NICU on seotud paranenud	
neuroloogiliskäitumuslike ja meditsiiniliste tulemustega	
enneaegsetel lastel, mis on seotud suurenenud arengulise	
8	
toetusega ja emade kaasamisega. 2014a. avaldatud süstemaatilisse ülevaatesse nahk-naha kontakti	18. Skin-to-skin care
mõjust valuvaigistamiseks protseduuridest tingitud valu korral	
vastsündinutele oli kaasatud üldiselt 19 tugevat uuringut,	in neonates (Review)
randomiseeritud kontrolluuringud või osaliselt randomiseeritud	
uuringud, topeltpimedad või ühekordselt pimedad uuringud.	_
Laste arv n=1594: enneaegsed (15 uuringut) gestatsioonivanuses	
<37 nädala ja ajalised vastsündinud GV≥37-42nädalat (4 uuringut),	Inglis D, Streiner D,
kellele rakendati NNK-i valuliku protseduuri ajal. 15 uuringus	Zee R
n=744 valuliku protseduurina oli – kannatorge, 1 uuringus	
veenipunktsioon ja kannatorge n=50, 2-s intramuskulaarne süst, 1-s	
uuringus vaktsineerimised n=80.	Database Syst
Autorid järeldasid, et NNK on efektiivne mõõdetuna mõlema	Review, 2014
valu indikaatori: füsioloogilise (südamesagedus,	
hingamissagedsus, hapniku saturatsioon, regionaalne	
infrapunaspektroskoopia) ja käitumusliku indikaatori (kuuldav	
kasutada ühekordse valuliku protseduuri nagu kannatorke	
naha kontakti, samal ajal kui füsioloogilised indikaatorid üldiselt ei	
olnud mõjutatud erinevate tingimuste korral. Kuigi känguruhooldus	
on efektiivne, kasu suurus ei pruugi olla suur.	
2013a. avaldatud süstemaatilisse ülevaatesse analgeesiaks	19. Sucrose for
kasutatava sahharoosi mõjust, doosist ja ohutusest protseduurist	analgesia in newborn
kisa sekundites, kisa proportsioon protseduuriga, näo grimassid, keha liigutused) <b>muutustega ja nahk-naha kontakti on ohutu</b> <b>kasutada ühekordse valuliku protseduuri nagu kannatorke</b> <b>korral.</b> Puhtalt käitumuslikud indikaatorid kaldusid eelistama nahk- naha kontakti, samal ajal kui füsioloogilised indikaatorid üldiselt ei	

	• • • • • •
olid randomiseeritud kontrolluuringud – uuringute kvaliteet oli	painful procedures
üldiselt kõrge. Uuringutes oli kokku 4730 last, 27 uuringut ainult	
enneaegsete, 29 uuringut ajaliste ja 1 uuring enneaegsete ja	Stevens B, Yamada J,
ajaliste laste kohta.	Lee GY, Ohlsson A
Valulikud protseduurid: kannatorge, veenipunktsioon, enneaegsete	
retinopaatia uuringul silmade läbivaatus, subkutaanne- ja	The Cochrane
intramuskulaarne süst, põie kateteriseerimine, nasogastraalsondi	Database Syst
paigaldus, ümberlõikus.	Review, 2013
Tulemusi uuringutes hinnati erinevate valu indikaatoritega	
nagu: füsioloogilised indikaatorid (südamesagedus,	
hingamissagedus, perifeerses veres hapniku saturatsioon - SpO2,	
transkutaanne hapniku ja süsinikdioksiidi sisaldus (gaasivahetus	
mõõdetuna transkutaanselt - TcpO2, TcpCO2), kortisooli tase),	
individuaalsed käitumuslikud indikaatorid (kisa kestus, kisa	
proportsioon ajas, näo liigutsed/grimassid), valideeritud liitvalu	
skaala skoorid (sisaldades kombinatsioone käitumuslikest,	
füsioloogilistest, kontekstuaalsetest näitajatest) või nende	
kombinatsioonid ja valu korral kasutatava sahharoosi toimest	
psühhomotoorse arengu kaugtulemustele.	
Tulemused Tulemusi mõnedest uuringutest sai kombineerida	
metaanalüüsis. Ennneaegse lapse valu hindamise skaala (PIPP-	
Premature Infant Pain Profile scores) väärtuste võrdlusel peale	
kannatorget - sahharoosi saanute grupis olid märkimisväärselt	
madalamad PIPP väärtused 30sek. (weighted mean difference	
(WMD) -1.76; 95%CI -2.54 to - 0.97; 4 uuringut; 264 vastsündinut]	
ja 60sek. pärast (WMD-2.05; 95%CI -3.08 to -1.02; 3 uuringut; 195	
vastsündinut). Enneaegsete retinopaatia (ROP) uuringul - silmade	
läbivaatus – sahharoos ei vähendanud märkimisväärselt PIPP	
väärtusi (WMD -0.65; 95% CI -1.88 to 0.59; 3 uuringut; 82	
vastsündinut). Ei esinenud erinevusi ebasoodsates kaugtulemustes	
sahharoosi ja kontrollgrupi vahel. Sahharoos vähendas	
märkimisväärselt kogu kisa kestust (WMD -39 seconds; 95% CI -44	
to -34; 2 uuringut; 88 vastsündinnut), aga ei vähendanud esimese	
kisa kestust kannatorke ajal (WMD -9 seconds; 95% CI -20 to 2; 3	
uuringut; 192 vastsündinut). Hapniku saturatsioon (%) oli	
märkimisväärselt madalam lastel, kellele anti sahharoosi ROP	
uuringu ajal võrreldes kontrollgrupiga (WMD -2.6; 95% CI -4.9 to -	
0.2; 2 uuringut; 62 vastsündinut). Individuaalsete uuringute	
tulemused, mida ei saanud kasutada metaanalüüsis, toetasid neid	
tulemusi. Sahharoosi toime pikaaegsele psühhomotoorsele arengule	
ei ole teada.	
<u>Autorid järeldasid</u> :	
-Sahharoos on ohutu ja efektiivne protseduurist tingitud valu	
leevendamiseks ühekordse valuliku protseduuri korral ja	
vähemal määral korduvate kannatorgete korral.	
-Sahharoosi efektiivset optimaalset doosi ei olnud võimalik	
kindlaks määrata, kuna uuringutes esinesid selle kohta	
vastuolud (optimaalne doos ajalistele ja enneaegsetele ei ole veel	
täpselt teada).	
-Sahharoos vähendab protseduuri valu minimaalse või	

Körvaltoimeteta. Väikesed doosid 24% sahharoosi (0.01-0.02g) on efektiivsed väga väikese sünnikaaluga enneaegsetele, samas kui suuremad loosid (0.24-0.50g, 2ml 12%-50%) vähendavad kisa kestust ujalistel vastsündinutel (small doses of 24% sucrose (0.01 to 0.02 t) are efficacious in very-low birthweight infants while larger doses 0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi tonsensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, nõie kateteriseerimisel, nasogastraalsondi paigaldusel tospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24% ahharoosi), mida manustada 2 minutit enne ühekordset
<ul> <li>väga väikese sünnikaaluga enneaegsetele, samas kui suuremad loosid (0.24-0.50g, 2ml 12%-50%) vähendavad kisa kestust ujalistel vastsündinutel (small doses of 24% sucrose (0.01 to 0.02 e) are efficacious in very-low birthweight infants while larger doses 0.24 to 0.50 g) reduce the proportion of time crying in term infants)</li> <li>See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006).</li> <li>Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, reenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, oõie kateteriseerimisel, nasogastraalsondi paigaldusel loospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta rastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest.</li> <li>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%</li> </ul>
<ul> <li>koosid (0.24-0.50g, 2ml 12%-50%) vähendavad kisa kestust ijalistel vastsündinutel (small doses of 24% sucrose (0.01 to 0.02 a) are efficacious in very-low birthweight infants while larger doses 0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006).</li> <li>Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, reenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel loospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> umust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%</li> </ul>
<ul> <li>koosid (0.24-0.50g, 2ml 12%-50%) vähendavad kisa kestust ijalistel vastsündinutel (small doses of 24% sucrose (0.01 to 0.02 a) are efficacious in very-low birthweight infants while larger doses 0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006).</li> <li>Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, reenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel loospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> umust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%</li> </ul>
njalistel vastsündinutel (small doses of 24% sucrose (0.01 to 0.02 a) are efficacious in very-low birthweight infants while larger doses (0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, reenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel cospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta rastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> umust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
are efficacious in very-low birthweight infants while larger doses 0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, nõie kateteriseerimisel, nasogastraalsondi paigaldusel nospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
0.24 to 0.50 g) reduce the proportion of time crying in term infants) See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, reenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel sospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta rastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> umust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
See tõend on integreeritud tõenduspõhisesse sahharoosi consensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel oospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u>
konsensusprotokolli, millest on tehtud juhised (Dunbar 2006, Lefrak 2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel nospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u>
2006, Sharek 2006). Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, nõie kateteriseerimisel, nasogastraalsondi paigaldusel nospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
Sahharoosi kasutatakse enneaegsete retinopaatia uuringul, veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel oospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
veenipunktsioonil, subkutaanse süsti tegemisel, ümberlõikusel, põie kateteriseerimisel, nasogastraalsondi paigaldusel pospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. <u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> <u>paseerudes</u> (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> <u>unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%</u>
põie kateteriseerimisel, nasogastraalsondi paigaldusel nospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. <u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> nmust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
ospidaliseeritud vastsündinutel, kuid siiski on vajalikud edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. <u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> <u>paseerudes</u> (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
edasised uuringud nende valulike protseduuride kohta vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. <u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> <u>vaseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater</u> 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
vastuoluliste tõendite tõttu sahharoosi valu vähendavast toimest. <u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> <u>paseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater</u> 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
<u>Käesoleva süstemaatilise ülevaate 4 uuringu metaanalüüsile</u> <u>paseerudes</u> (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
<u>baseerudes (Johntson 1999a, Stevens 1999, Gibbins 2002, Slater</u> 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> 2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u>
2010), <u>autorid soovitavad rutiinseks sahharoosi kaustamiseks</u> unnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
nnust 0.012-0.12g (0.05ml 24% sahharoosi -0.5ml 24%
<u>ahharoosi), mida manustada 2 minutit enne ühekordset</u>
<u>annatorget ja veenipunktsiooni.</u>
Kuna ülevaates on antud lai valik efektiivseid sahharoosi doose
näit. 2ml 12%-24%, 2ml 25%, 2ml 20-30%, 0.5-2ml 12%-
0%,jne.) ja uuringud on heterogeensed, on vajalik edasine
eadustöö täpsemate dooside määramiseks erinevate
estatsioonivanuste kohta.
Teised meetodid valu leevendamiseks on: tühja luti imemine ja
ahk-naha kontakt/känguruhooldus – mida kasutada
kombinatsioonis sahharoosiga valu vähendamiseks või valu
zältimiseks.
Kas korduvate sahharoosi dooside kasutamine on ohutu ja
fektiivne erakordselt väikestele, ebastabiilsetele, ventileeritavatele
või nende kombinatsioonide korral) enneaegsetele – selleks on
vajalikud edasised uuringud.
Vajalikud on teadusuuringud sahharoosi kasutamisest
combinatsioonis teiste mittefarmakoloogiliste ja farmakoloogiliste
omomatsioonis teiste mitterarmakoiooginste ja farmakoiooginste õtetega, minimaalse efektiivse sahharoosi doosi määramiseks
ihekordse valuliku protseduuri ajal ja korduvate sahharoosi dooside
tasutamise vahetust toimest (valu tugevus) ja kaugtulemustest
psühhomotoorne areng).
2013a. avaldatud süstemaatilisse ülevaatesse/metaanalüüsi 20. A systematic
iolmati 38 randomiseeritud kontrolluuringut protseduurist review and meta-
ingitud valu raviks kasutatavate magusate lahuste (v.a. analyses of
ahharoosi) efektiivsusest vastsündinutel, (3785 vastsündinut – nonsucrose sweet
jalised, enneaegsed). 35 uuringus käsitleti glükoosi mõju solutions for pain
orotseduuri valu raviks. Uuringute kvaliteet oli kõrge. Glükoosi relief in neonates.
loos varieerus 0,2-2ml 5%-50% glükoosini.
Fulemused:Kannatorge 21/38 uuringus, veenipunktsioon 11/38M Bueno, J Yamada,uuringus.3.6-punkti vähenes enneaegse vastsündinu valuskaalaD Harrison, S Khan, A

skooring kannatorke ajal uuringutes (PIPP Skoor), mis võrdlesid 1-	Ohlsson,
<b>2ml 20% - 30% glükoosi</b> vs mitte ravimisega (2 uuringut, 124	T Adams-Webber, J
vastsündinut; mean difference -3.6 [95% CI -4.6 to -2.6]; P<0.001;	Beyene, B Stevens
12=54%). Märkimisväärselt vähenes kisa kestus peale	
veenipunktsiooni 25-30% glükoosi saanud lastel võrreldes vett või mitte ravi saanud lastega.	Pain Res Manag 2013;18(3):153-161.
(3 uuringut, 130 last; risk difference -0.18 [95% CI -0.31 to -0.05];	
P=0.008, number needed to treat = 6 [95% CI 3 to 20]; I2=63%).	
Järeldused: käesolevast süstemaatilisest ülevaatest ja	
metaanalüüsist järeldub, et glükoos vähendab valu skoore ja	
kisa ühekordse kannatorke ja veenipunktsiooni korral.	
-Tulemused näitavad, et 20%-30% glükoosilahused omavad	
analgeetilist toimet ja neid võib soovitada alternatiivina	
sahharoosile protseduuri valu leevendamiseks tervetele ajalistele	
ja enneaegsetele vastsündinutele.	
2012a. avaldatud süstemaatilisse ülevaatesse oli kaasatud 20	21. Breastfeeding or
randomiseeritud kontrolluuringut või osaliselt randomiseeritud	breast milk for
uuringut – seega tõendite kvaliteet on kõrge, enneaegsed < 37	procedural pain in
nädala ja $> 37$ ajalised vastsündinud. Uuriti: rinnaga toitmine või	neonates.
rinnapiim protseduuri valu leevendamiseks vastsündinutel vs	
mitteravimine/teised võtted.	<u>Shah PS, Herbozo C,</u>
Autorid järeldasid nende uuringute tulemustest:	Aliwalas LL, Shah
-Kui võimalik, kasutada imetamist või rinnapiima andmist (suu	VS.
kaudselt (oro- või nasogastraalsondiga) protseduuri valu	<u>Cochrane Database</u>
leevendamiseks vastsündinutel ühe valuliku protseduuri korral	Syst Rev. 2012
võrreldes platseeboga, mähkimise ja voodisse panekuga, süles	<u>Byserie</u> 2012
hoidmisega, luti andmisega või mitte vahelesegamisega.	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa,	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi.	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate	
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi.</li> <li>Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete</li> </ul>	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv	
hoidmisega, luti andmisega või mitte vahelesegamisega. -Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.	22
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu</li> </ul>	22.
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel</li> </ul>	Nonpharmacological
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni</li> </ul>	Nonpharmacological management of
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud</li> </ul>	Nonpharmacological management of procedural pain in
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte</li> </ul>	Nonpharmacological management of procedural pain in infants and young
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat</li> </ul>	Nonpharmacological management of procedural pain in infants and young children:
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a.</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu</li> </ul>	Nonpharmacological management of procedural pain in infants and young children:
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsioonidele peale akuutset valulikku protseduuri (vahetult peale</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsiooni valule</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N,
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsiooni valule ('immediate pain-related regulation'). Valu reaktiivsust: mõõdeti</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N, Turcotte K, Uman LS,
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsiooni valule ('immediate pain-related regulation'). Valu reaktiivsust: mõõdeti esimese 30 seki jooksul peale valuliku stimulatsiooni lõppu.</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N, Turcotte K, Uman LS, Horton R, Osmun LD,
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsiooni valule ('immediate pain-related regulation'). Valu reaktiivsust: mõõdeti esimese 30 seki jooksul peale valuliku stimulatsiooni lõppu.</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N, Turcotte K, Uman LS, Horton R, Osmun LD, Kohut SA, Stuart JH,
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsiooni valule ('immediate pain-related regulation'). Valu reaktiivsust: mõõdeti esimese 30 seki jooksul peale valuliku stimulatsiooni lõppu.</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N, Turcotte K, Uman LS, Horton R, Osmun LD,
<ul> <li>hoidmisega, luti andmisega või mitte vahelesegamisega.</li> <li>-Glükoosi/sukroosi manustamisega olid samasugused mõjud nagu valu leevendamisel imetamisega, s.t. kui imetada ei saa, soovitav alternatiivina kasutada glükoosi või sukroosi. Rinnapiima toimet protseduuri valu leevendamisel (eriti korduvate protseduuride korral, haigetel enneaegsetel) enneaegsete populatsioonis peab uurima, kuna praegu on limiteeritud arv uuringuid, mis on hinnanud efektiivsust nende populatsioonis.</li> <li>2011a. süstemaatilises ülevaates hinnati protseduuri valu mittefarmakoloogilist ravi enneaegsetel vastsündinutel, ajalistel vastsündinutel (37n1k.), imikutel ja väikelastel – üle 1kuu kuni 36kuu vanuseni. Ülevaates oli kokku 51 randomiseeritud kontrolluuringut, n=3396, milledele kontrollgrupiks mitte ravisaanud lapsed – ülevaatel kõrge kvaliteet. Uuriti 13 erinevat tüüpi tavaliselt kasutatavaid mittefarmakoloogilisi ravivõtteid (v.a. rinnapiim, sahharoos, muusika), et määrata nende efektiivsust valu reaktsioonidele peale akuutset valulikku protseduuri (vahetult peale nõelatorget ('pain reactivity') ja vähem vahetut reaktsiooni valule ('immediate pain-related regulation'). Valu reaktiivsust: mõõdeti esimese 30 seki jooksul peale valuliku stimulatsiooni lõppu.</li> </ul>	Nonpharmacological management of procedural pain in infants and young children: An abridged Cochrane review Riddell RP, Racine N, Turcotte K, Uman LS, Horton R, Osmun LD, Kohut SA, Stuart JH, Stevens B, Lisi D.

kannatorke kohta, 10 uuringut nõelaga-süstimise kohta, 6 uuringut	2011;16(5):321-330.
veenipunktsiooni kohta, 2 uuringut NICU-s kaalumise ja 2 mähkme	
vahetuse kohta, 2 uuringut endotrahheaalse aspireerimise kohta.	
Tulemused: igat sekkumist uuringus analüüsiti eraldi vastavalt	
vanusegrupile: enneaegsed vastsündinud, ajalised ja vanemad	
imikud/väikelapsed. Suurim standardiseeritud keskmine differents	
(SMD) valu reaktiivsusele oli järgmine: mittetoitmisega seotud	
imemine (rõngasluti, mittelakteeriva nibu imemine,	
valuleevendus on maksimaalne, kui imemine algab vähemalt 3	
minutit enne valulikku protseduuri) (preterm: -0.42 [95% CI	
-0.68 to $-0.15$ ]; neonate $-1.45$ [CI $-2.34$ to $-0.57$ ]),	
känguruhooldus e. nahk-naha kontakt (preterm -1.12 [95% CI	
-2.04 to -0.21]), ja kinnimähkimine/facilitated tucking-lapse õrn	
kinnihoidmine, jalad painutatud ja kontrolli all (preterm -0.97	
[95% CI -1.63 to -0.31]). Vähem vahetu reaktsioon valule -	
suurimaks SMD oli: mittetoitmisega seotud imemine (preterm	
-0.38 [95% CI -0.59 to -0.17]; neonate -0.90 [CI -1.54 to -0.25]),	
känguruhooldus e. NNK 0.77 (95% CI -1.50 to -0.03]),	
kinnimähkimine/kinnihoidmine (preterm -0.75 [95% CI -1.14 to	
-0.36]), ja kiikumine/kinnihoidmine (neonate -0.75 [95% CI -1.20	
to -0.30]).	
Kokkuvõte: mitmetel mittefarmakoloogilistel ravivõtetel on	
piisavalt tõendeid toetamaks nende efektiivsust valuravis	
enneaegsetel ja tervetel vastsündinutel, samas ei olnud ravivõtteid,	
millel on piisavalt tõendeid toetamaks nende mõju imikutele ja	
väikelastele.	
-On piisavalt tõendeid, et soovitada protseduuri valuraviks	
mittefarmakoloogiliste ravivõtena enneaegsetele vastsündinutele	
känguruhooldust e. nahk-naha kontakti, mittetoitmisega seotud	
imemist, kinnimähkimist/kinnihoidmist.	
2013a. prospektiivse randomiseeritud kontrolluuringu	
eesmärgiks oli uurida kombineeritud mittefarmakoloogiliste	combined use of non-
võtete kasutamist enneaegsete laste une-ärkveloleku	nutritive sucking,
staadiumitele valulike protseduuride (kannatorge) ajal IIIa.	oral sucrose, and
intensiivravi osakonnas. Uuringus 100 last, gestatsioonivanus 26-	facilitated tucking on
37 nädalat.	infant behavioural
Kokkuvõte: 1. kombineeritud ravi: tühja luti imemine (1min.	states across heel-
enne protseduuri), suu kaudne sahharoos (0.2–2.0 ml 20%)	stick
sahharoosi	procedures: A
süstlaga 2 min enne nõelatorget, kogus sõltuvalt	prospective,
gestatsioonivanusest) ja facilitated tucking. s.t. lapse õrn	randomised
kinnihoidmine soojade kätega – (taktiilne ja sensoorne stiimul,	controlled trial
laps painutatud asendis, üks käsi pea peal, teine keha peal) -	
vähendasid efektiivsemalt lapse rahmeldamist ja kisa, kui	Liaw JJ, Yang L, Lee
rutiinne hooldus kannatorke ajal (kerge puudutus ja suuline	CM, Fan HC,
lohutamine)	Chang YC, Cheng LP
<u>Uuringus kasutatud 20% sahharoosi kogused gestatsioonivanuse</u>	International Journal
järgi: GV 26n28n0,2ml: GV 28,1n30n0,5ml; GV 30,1n	of Nursing Studies 50
<u>32n. – 1,0ml; GV 32,1-37n1,5ml; GV &gt;37n2,0ml.</u>	(2013) 883–894
	· · · · · · ·
2. lapsed, kes said: tühja luti imemine+suu kaudne sahharoos+ -	

hoidmine või tühja luti imemine+suu kaudne sahharoos, neil esines rohkem vaikse une staadiumi võrreldes rutiinse hooldusega 3. suu kaudne sahharoos + lapse hoidmine, esines rohkem vahepealset une-ärkveloleku staadiumi võrreldes rutiinse hooldusega 4. kannatorke ajal lapsed, kes olid külili asendis, esines rohkem vaikse une staadiumi võrreldes selili asendiga <u>Kokkuvõte:</u> 4 ravi kombinatsiooni erinevalt vähendasid erutust valuliku protseduuri ajal. Kombineeritud mitte farmakoloogiliste võtete: sahharoos-hoidmine, imemine- sahharoos ja imemine-sahharoos-hoidmine kasutamine vähendas efektiivsemalt lapse rahmeldamist või kisa võrreldes rutiinse hooldusega. <u>Kombinatsioonid:</u> imemine-sahharoos-hoidmine ja imemine- sahharoos soodustasid paremini lapse und võrreldes rutiinse hooldusega. Klinitsistid peaksid lapse une kaitsmiseks kasutama kombibatsioone imemine, sahharoos, hoidmine valulike protseduuride ajal.	
2015a. Randomiseeritud kontrolluuring mitte-farmakoloogiliste võtete kasutamisest enneaegsetel lastel valust ja stressist tingitud käitumisele. Uuringus 100 last, gestatsioonivanus 26-37 nädalat. Tagajärgedeks olid: "äratõmbamis" käitumine (grimass, jäsemete ja keha sirutus või vingerdamine) ja eneserahustav käitumine (imemine, imemise otsimine, või käte suhu panemine või haaramisliigutused, käsi suu juurde liigutus).Kokkuvõte:Kombineeritud mittefarmakoloogiliste võtete kasutamine	24. Development of atraumatic heel-stick procedures by combined treatment with non-nutritive sucking, oral sucrose, and facilitated tucking: A randomised,
imemine-sahharoos, sahharoos-hoidmine, imemine-hoidmine, - vähendasid efektiivselt lapse stressist tingitud või "äratõmbamis" käitumist. Eneserahustavat käitumist ei esinenud sagedamini või esines vähem, kui laps sai mingisugust kombineeritud mittefarmakoloogilist ravi võrreldes tavalise hooldusega lastega. <u>Kannatorge</u> võib olla atraumaatiline, kui selle tegemise ajal laps	TY, Li CC, Hua YM,
on stabiilne ja rahulik, õiges asendis ja rakendada hoidmist, sahharoosi ja imemist enne protseduuri. Neid tõendeid mittefarmakoloogilisest ravist kasutada kliinilises praktikas.2012a.Randomiseeritud intensiivravikontrollitud osakondadesmitmekeskuselises võrreldi	of Nursing Studies 52 (2015) 1288–1299 25. Oral sucrose and "facilitated tucking"
mittefarmakoloogilist ravi võtet valu leevendamiseks üksikuna või kombinatsioonis korduvate (kannatorge) verevõtmiste protseduurida ajal, enneaegsetel gestatsioonivanuses 24-32 nädalat, n=71 last. Kasutati hoidmist või suu kaudselt sahharoosi andmist. Hoidmine üksinda oli oluliselt vähem efektiivne leevendades	for repeated pain relief in preterms: a randomized controlled trial.
korduvat protseduuri valu (P, .002), kui sahharoosi <u>(0.2 mL/kg)</u> kasutamine. Hoidmine kombinatsioonis sahharoosiga omas lisaväärtust paranemisfaasis madalamate valuskooridega (P = .003) võrreldes ühe ravivõtte kasutamisega. Ei olnud olulisi erinevusi	Cignacco EL, Sellam G, Stoffel L, Gerull R, Nelle M, Anand KJ, Engberg S

vastustes valule gestatsiooniaegades.	
<u>Järeldused:</u>	Pediatrics
-Sahharoos koos ja ilma hoidmiseta omas valuvaigistavat toimet	<b>2012</b> ;129:299-308.
isegi enneaegsetel gestatsioonivanuses <32 nädala korduvate	
valulike protseduuride ajal.	
-Hoidmine üksinda ei olnud nii efektiivne ja seda ei saa	
soovitada kui mittefarmakoloogilist võtet, mis korduvate	
valulike protseduuride korral aitaks vastsündinul valust	
paraneda.	

#### Viited

Kokkuvõtte (abstract või kokkuvõtlikum info)	Viide kirjandusallikale
Stabilisation of the child directly after the birth The Swedish National Board of Health and Welfare's assessment	Care of extremely premature
<ul> <li>The care ought to be organised so that a neonatal team is on site when a child is born far too prematurely.</li> <li>o the child ought to have the option of being near his or her parents before being moved to the neonatal unit.</li> </ul>	infants A guideline for the care of children born before 28
The assessment is based on systematic charting, WHO recommendations, guidelines from a European consensus panel of neonatologists and consensus between the chairpersons of the expert groups.	full weeks of pregnancy have passed. The Swedish
<b>Treatment of pain</b> Children who are born prematurely and who are cared for at neonatal intensive care units are often exposed to pain due to their immaturity, different states of health, complications and care procedures. The pain can have negative consequences in both the short and the long term because the immature child is in a sensitive period of strong growth and differentiation of the central nervous system. Therefore, the number of painful interventions ought to be minimised and painful conditions be treated. Pain ought in the first instance to be dealt with using non- pharmacological treatment, but there are circumstances when the	National Board of Helth and Welfare. Published <u>www.socialstyrel</u> <u>sen.se,September</u> 2014
pharmacological treatment, out there are circumstances when the pharmacological treatment of pain is necessary. The majority of the medicines used are not fully tested and documented (effect, safety and dose) for extremely premature infants, so the treatment is based largely on tried and tested experience rather than scientific support. The fact that medicines lack an approved indication need not mean that the knowledge is inadequate since there is often good clinical experience of them. Extremely premature infants ought to be ensured a pain-free existence as far as possible, despite the fact that they have other physiological	

far as possible, despite the fact that they have other physiological conditions to react to and express their pain compared with full-term children. The risks of treatment with medicines (toxic effect and side effects) must be weighed against the pain the child perceives without pharmaceutical painkillers and also against the injuries that can arise due to

26

the pain. This is a difficult but very important fine line to walk and modern neonatal treatment of pain is therefore based on a balanced, multimodal strategy [Thewissen et al. 2011]. This strategy involves regular pain assessment, individualist behaviour support (non-pharmacological) treatment and, if necessary, pharmacological treatment as well.

#### Pain assessment

#### The Swedish National Board of Health and Welfare's assessment

• For pain diagnostics, pain ought to be assessed with the help of valid instruments (adapted according to age, level of maturity and type of pain) as far as possible.

The assessment is based on Swedish guidelines from the Swedish Child Pain Society and guidelines drawn up by an international consensus group.

Both international and national guidelines and procedures recommend that all units which care for newborn children must have procedures that include a structured pain assessment model [Anand 2001, Svensk Barnsmärtförening 2014]. It is fundamental for an objective pain assessment to be able to provide adequate and safe treatment of pain for these children. There is no golden rule for objective pain assessment, but different observational scales are usually used. However, it is urgent to choose valid instruments that have been designed for the child's level of maturity and type of pain, such as acute procedural pain or continuous pain and stress (for example through respirator treatment or postoperative care). Appendix 2 shows the pain assessment instruments that are often used and which are recommended in today's neonatal care.

#### Non-pharmacological treatment of pain

#### The Swedish National Board of Health and Welfare's assessment

- The number of painful interventions ought to be minimised.
- Extremely premature infants ought always to be given nonpharmacological, individualised care to reduce the perception of pain and stress. This may include
  - o thinking through and optimising the care environment, calm for example;
  - o the participation of the parents;
  - o the use of skin-to-skin care and supportive cohesion;
  - o ensuring that the child is replete, dry and warm before procedures;
  - o ensuring that the child is lying comfortably;
  - o ensuring that the child is given the option of something nonnutritive on which to suck.

The assessment is based on Swedish guidelines from the Swedish Child Pain Society and guidelines drawn up by an international consensus group.

Children who are cared for at neonatal units undergo a large number of measures that are painful to a greater or lesser extent on a daily basis. The very smallest and youngest patients are the most sensitive and can also experience nappy changing or turning over as painful. The basic principle is that the number of painful interventions should always be minimised.

There are several non-pharmacological strategies that can reduce the child's pain reaction and have a calming effect. The care environment ought to be optimised, including by minimising disruptive visual and audible impressions. An example of this is subdued direct lighting, particularly to start with when the child is especially sensitive.

The child ought to be replete, dry and warm before painful procedures. The child ought also to be assisted with something non-nutritive on which to suck, which means that the child sucks on something such as a dummy, a hand or a finger (its own or that of the parent) [Riddell et al. Cochrane Database Syst Rev 2011]. If possible, the parents ought always to be engaged in the treatment of pain, partly so that they can report the child's pain and partly because they will be able to offer supportive measures such as skin-to-skin care (HMH) or supportive cohesion [Behandling av barn i samband med smärtsamma procedure i hälso-och sjukvard – kunskapsdokument 2014].

#### Pharmacological treatment of pain

#### The Swedish National Board of Health and Welfare's assessment

- Each unit ought to have well designed pharmacological pain treatment procedures which are also suitable for acute situations. The procedures ought to cover pain in situations such as:
  - o procedural pain, including intubation
  - o postnatal and postoperative pain
  - o treatment of continuous pain and stress during respirator treatment.
- Pharmacological treatment ought to be administered in good time before painful procedures and ought always to be supplemented with non-pharmacological support.

The assessment is based on Swedish guidelines from Swedish Chid Society and guidelines drawn up by an international consensus group.

More painful intervention, such as pinpricks, the insertion of a central venous catheter or of drainage, intubation, operation and respirator treatment, usually requires pharmacological treatment of pain in addition to the non-pharmacological treatment which always constitutes the basis of the pain treatment strategy.

<u>The pharmacological treatment can include both analgesics (painkillers)</u> and sedatives (calming or soporific medicines) which have been selected on the basis of how painful the condition or measure actually is. There is clinical experience of which preparations ought to be used for extremely premature infants, but the scientific support is limited. Medicines ought to be prescribed using a conscious strategy. Each unit ought to have procedures with proposed treatments that are well-established, that are safe to use even in an emergency situation, and that are carefully documented and followed up.

For mild to moderate pain, a painkilling effect can often be achieved by administering sweet solutions (concentrated glucose or sucrose) by mouth

to newborn children [Stevens et al. Cochrane Database Syst Rev 2013]. The positive effects have also been seen in extremely premature infants, even though the scientific support is limited [Johnston et al. 1997]. Premedication ought always in principle to be given prior to intubation as well as directly after the birth or in other acute situations when there is no intravenous access. Postoperative pain and painful conditions such as necrotising enterocolitis should always be treated pharmacologically. With respirator treatment, non-pharmacological support may be sufficient if there is no other reason for the pain such as a painful condition or during postoperative care. However, treatment with medicines may be relevant as age and treatment time increase because the perceived stress of respirator treatment can then increase [Bellu et al. Cochrane Database Syst Rev 2008].

<u>Medicines ought to be administered in good time before a painful</u> <u>procedure.</u> Where there are combinations of medicines, they should be given sequentially based on time of onset, properties and effect. Preparations with a rapid time of onset and short duration of effect are considered to be ideal for a short-term and acute procedure such as intubation [Barrington 2011]. For sedation, the child ought to have stable blood pressure because this always leads to some risk of a drop in blood pressure. Sedation with benzodiazepines is not advised for extremely premature infants [Ng et al. Cochrane Database Syst Rev 2012].

<u>Medicinal substances are usually absorbed and eliminated more slowly</u> <u>in newborn children, which is much more the case in extremely premature</u> <u>infants.</u> If several medicines are used simultaneously, an effective combination of as few medicines as possible needs to be found because combinations can be risky. However, in some cases, primarily when using opioids, it can be advantageous to use combinations of several different medicines where the effects of the different preparations fortify one another, which means that the strength of the doses can be reduced and thereby also the side effects of each individual medicine. This applies to postoperative care, for example, when treatment with Paracetamol, opioids and Clonidine may be appropriate.

<u>The time to discontinue certain analgesics such as opioids ought to be</u> <u>individualised</u>. The time depends on the dose that the child has received as well as the length of time for which the treatment has lasted. First of all there ought to be a gradual reduction in the size of the dose followed by a reduction in the number of doses. Abstinence symptoms may be difficult to interpret in extremely premature infants but if symptoms do arise, the original dose should be used and the dose not continue to be reduced until the child is abstinence-free.

#### Nursing

The care of extremely premature infants concentrates on saving lives but also on promoting the child's long-term health and development. Right from the birth and onwards throughout the care period, the nursing ought to be adapted to the child's relevant level of development so that stimuli are as beneficial as possible and negative effects of stress and pain as small as possible. High quality nursing ought to be individualised, support development and be centered around the family.

#### Care centered around the patient and the family The Swedish National Board of Health and Welfare's assessment

- The care of extremely premature infants ought to be organised so that it is centered around the patient and the family. This means that the care should be:
  - o individualised
  - o support development
  - o offer family care
  - o offer integrated care
  - o actively involve and inform the parents.

## The assessment is based on systematic charting and consensus between the chairpersons of the expert groups.

Care centered around the patient and the family is an approach whereby the care is not limited to just being disease-orientated but is extended to cover other needs of the child, parents and any siblings. The UN's Children's Convention forms the basis for the child's rights as an individual and as part of the family [Cornway et al 2006, Committe on hospital care and institute for patient-and family- centered care 2012]. There are also specific policy documents for family-centered [Levin 1999, Westrup et al. 1999] and neonatal nursing [Symington et al Cochrane Database Systemic Rev 2006, Individanpassad vard av underburna barn – NIDCAP, 2006]. **Care centered around the patient and the family involves the following:** 

- Family care is offered, which means that parents and children are not separated The care ought thereby to offer accommodation for the parents to stay at the newborn's unit.
- Mothers with their own medical needs ought as far as possible to be integrated into the care with the child at the newborn unit.
- The family's individual needs being respected as far as possible.
- The parents' sensitive needs being noted. The parents ought to be offered psychosocial support and support in the bonding and the anaclytic process, which also includes nursing support (see also the chapter on nutrition).
- The parents being encouraged to take responsibility themselves for the child's nursing. The development benefits from parents being present for a lot of the time and from early interventions focusing on the interaction between the child and the parents.
- All information is shared with the parents if there is no obstacle in doing so in the Public Access to Information and Secrecy Act or Chap. 6, Sections 3 and 4 of the Parental Code.
- Facilitating the cooperation between parents and personnel.

Care centered around the patient and the family is key to successful bonding and the anaclytic process between children and parents. The anaclytic process is crucial to the development of the brain and the child's ability to handle stress, which in turn affects the child's general development and its future health. A good anaclytic process is also important so that the parents can feel secure in their parental role [Montirosso et al. 2012]. However, the short pregnancy period can make this difficult because the parents may have a natural crisis reaction and because the anaclytic process has to be developed during the neonatal care period. Extremely premature infants also give weak signals and often have behaviour that is different and more difficult to interpret compared with full-term children [Schore et al. 2001, Lubbe et al. 2012]. It is therefore essential that the units have competence to read the premature child's signals.

#### **Development-supporting nursing**

Development-supporting care is based partly on the medical treatment but also on sociology and behavioural science The basis is the competence to understand the child's behaviour, to support the child's autoregulation (of the nervous system, alertness and interaction with the surroundings, for example) as well as benefitting the parents' and the care personnel's interaction with the child. Individually-adapted, development-supporting care ought to be offered since the care gives positive short-term effects and increases the child's well-being during the neonatal care period, even though the long-term effects have weaker scientific support. Adapting the care to the individual and striving for calm surroundings increases the possibilities of undisturbed sleep and a more beneficial development for the child. The lower the lower level of maturity, the clearer the positive effects on the child's development.

There are different intervention programmes that can be used within the care of extremely premature infants. NIDCAP (newborn individualised developmental care and assessment programme) is a programme that can be carried out throughout the care period, starting directly after the birth, which is significant from a neurobiological development perspective [NIDCAP Federation International, 2014]. A key moment in NIDCAP is the individual assessment of the child's responsiveness to and capacity to handle stimuli. Other elements include the positioning of the child, adaptation of the surrounding environment as well as conduct at the time of specific care measures. There is some scientific support to show that NIDCAP has positive short-term effects on the more serious forms of bronchopulmonary dysplasia as well as reducing the incidence of necrotising enterocolitis and improving the situation for the families. The studies also showed positive long-term effects on the children's behaviour and motor skills [Symington et al. Cochrane Database Syst Rev 2006, Wallin et al. 2009]. Other studies have shown that NIDCAP has a positive impact on the maturity of the brain and on the cognitive development [Als et al. 2012, Als et al. 2004] as well as leading to shorter care periods [Peters et al. 2009].

Many neonatal units use modified NIDCAP care which works towards the same target with the same means but do not fully include all observational elements. The methods MITP (mother infant transaction programme) and IBAIP (infant behavioural assessment and intervention programme) are based on the same theoretical basis as NIDCAP. The methods are primarily intended to be used following discharge and aim to strengthen the communication between children and parents. MITP has been shown to reduce the level of stress in the parents during the child's

first year and a beneficial effect was seen on the child's cognitive development at five years of age [Kaaresen et al. 2008, Olafsen et al. 2008]. IBAIP has also been shown to improve the motor development for children with a birth weight of less than 1 500 g and, at the five-year follow-up, showed better cognition (performance IQ) as well as the ability to coordinate visual impression and movement patterns (visual-motor integration) [Koldewijn et al. 2013, Van Hus et al 2013].

One method that is often used and which ought to be offered 24 hours a day is skin-to-skin care (HMH, also called kangaroo mother care, KMC). The method is based on the fact that the child has direct skin contact with a parent or a close family member. The scientific support for the positive effects of the method is found mainly in the low income countries [Conde-Agudelo et al. Cochrane Database Syst Rev 2011, Moore et al. Cochrane Database Syst Rev 2012, Nyqvist et al. 2010]. Studies have shown that HMH contributed to lower mortality, fewer serious infections and other medical conditions, better temperature regulation as well as shortened care periods. The method has also been shown to act as a pain alleviator [Cochrane Database Syst Rev, Ridell et al. 2011, Akcan et al. 2009, Cignacco et al. 2007] and to have a positive effect on the child's growth, the mothers' satisfaction and bonding with the child following discharge [Kramer et al. 2008], the mother's milk production and the child's nursing behaviour [Renfrew et al. 2010]. In turn, a longer nursing period has a positive effect on the child's cognitive development [Kramer et al, 2008].

#### Viited

Kokkuvõtte (abstract või kokkuvõtlikum info)	Viide kirjandusallikale
<b>Family involvement</b> is a key to realize the potential for long-lasting	1. Review article
positive effects on physical, cognitive and psychosocial	Recommendations
development of all babies, including those in the neonatal intensive	for involving the
care unit (NICU). Family-centered developmental care (FCDC)	family in
recognizes the family as vital members of the NICU health-care team.	developmental
As such, families are integrated into decision-making processes and	care of the NICU
are collaborators in their baby's care. Through standardized use of	baby
FCDC principles in the NICU, a foundation is constructed to enhance	
the family's lifelong relationship with their child and optimize	Craig JW, Glick C,

NICU staff participation in FCDC and creating NICU policies that support this type of care. These recommendations are designed to meet the basic human needs of all babies, the special needs of hospitalized babies and the needs of families who are coping with the crisis of having a baby in the NICU.	Smith J, Browne J Journal of Perinatology ( <b>2015</b> ) 35, S5–S8;
BackgroundKangaroo mother care (KMC), originally defined as skin-to-skin contact between a mother and her newborn, frequent and exclusive or nearly exclusive breastfeeding, and early discharge from hospital, has been proposed as an alternative to conventional neonatal care for low birthweight (LBW) infants.Image: Conventional conv	2. Kangaroo mother care to reduce morbidity and mortality in low birthweight infants (Review)
Neonatal Group was used. This included searches in MEDLINE,IEMBASE, LILACS, POPLINE, CINAHL databases (all from inception to March 31, 2014) and the Cochrane Central Register of Controlled Trials ( <i>The Cochrane Library</i> , Issue 3, 2014) In addition, we searched the web page of the Kangaroo Foundation, conferenceI	Conde-Agudelo A, Díaz-Rossello JL The Cochrane Database Syst Review 2014

general direction of findings or the size of the treatment effect for the main outcomes.

Figure 3. Forest plot of comparison: 1 Kangaroo mother care versus conventional neonatal care, outcome: 1.1 Mortality at discharge or 40-41 weeks' postmenstrual age. Overall, KMC was associated with a statistically significant reduction in the risk of mortality at discharge or 40-41 weeks' postmenstrual age (3.2% vs 5.3%; typical RR 0.60, 95% CI 0.39 to 0.92; I2 = 0%; NNT for benefit 47, 95% CI 31 to 236).

	KIM	n	Centry	w.		Risk Ratio	Risk Ratio
Study or Subgroup			Events		Wetcht	MLH, Fixed, 95% Cl	MLH, Fixed, 95% CI
1.1.1 All studies	0.46105		4.0001.0.00	1.000	ere egal.	second is present to a restant	arrig carried EVIP M
Boo 2007	1	65	1	63	2.2%	0.97 (0.08, 15,16)	
Cattaneo 1998	i i	148	a	135	5.9%	1.91(0.19, 4.45)	
Chamak 1997	Ē	364	10	345	22.5%	1.57 (0.21, 1.55)	_ <b>_</b>
Ghavene 2012	ì	68		59	distanti di Ka	Nif estimable	-
Kadam 2005	1	44	ĩ	43	7.7%	1.02 [0.01, 15.65]	
Rojas 2003	i i	33	i	27	2.4%	1.84 (0.1%, 17.09)	
Suman 2008	i i	102	ń.	103	10.9%	1.20(0.12, 1.58)	
Worku 2005	14	61	24	61	52.9%	1.57 (0.33, 1.00)	
Subtotal (95% CD		888		818	100.0%	0.60[0.39, 0.92]	<b>—</b>
Total events	28		45				-
Heterogeneity: DhP =	1.28. df=	- 9 dP =	0.891;P*=	096			
Text for merall effects	Z = 2.23	P = 0.0	2)				
		_	•				
1.1.2 Internitient KM	C .						
Bob 2007	1	65	1	63	-12.5%	0.97 (0.08, 15.16)	
Othervanie 2012		68	0	- 68		Nirt estimable	
Kadam 2005	1	4.6	1	- 65	-12.2%	1.02 (0.07, 15.85)	
Rojas 2003	3	33	1	-27	13.6%	1.84 [0.16, 17.09]	
Suman 2008	1	102	6	103	51.7%	1.20[0.12, 1.58]	
Subtotal (95% CI)		313		306	100.0%	0.59 (0.19, 1.81)	
Total events	1		8				
Heterogeneity: DhP =				D96			
Test for two all effects	Z = 0.92	(P = 0.3)	6)				
4 C C Cardonne - Con	e-						
1.1.3 Continuous MM	_						
Cattaneo 1998	3	148	З	135	8.3%	1.91 (0.19, 4.46)	
Oharpiak 1997	8 14	264	10	246	27.2%	0.57 [0.21, 1.55]	
Worku 2005 Subtotal (95% CD	14	60 575	24	61 542	64.3% 100.0%	0.57 (0.33, 1.00) 0.60 (0.38, 0.96)	<b>_</b>
	A.B.	0.4.0	37	944	and the second second	ene (ene, ene)	-
Total events Heterogeneity: Chi*=	23			2000 B			
Textfor senal effects			and a first state of the	0.59			
TRUCTOR APPENDIX STREET,	1 - 1 I.I.	0 - 64					
1.1.4 Duration of ISM	<2 hour	siday					
Bop 2007	1	65	1	63	48.0%	0.97 (0.08, 15,16)	
Rolas 2003	ź	33	- i	- 27	52,0%	1.54 (0.1.9, 17, 09)	<b>_</b>
Subtotal (95% CI)	-	99		90	100.0%	1.32[0.22, 7.73]	
Total events	2		2				
Heterogeneith: Chi*=		:1(P =	0.780:1 <sup>-</sup> =	0%			
Testfor everall effects							
1.1.5 Duration of ISM	C betwee		15 hearn	day			
Ohavane 2012	1	68	0	- 66		Nirt estimable	
Kadam 2005	1	44	1	- 46	-16.5%	1.02 (0.07, 15,85)	
Burnen 2008	1		5	103	83.5%	0.20 (0.02, 1.68)	
Subtotal (95% CI)		215		216	100,0%	0.34[0.07, 1.64]	
Total events	3						
Heterogeneity: $Dh^{\mu} =$	the state of the s		and the second second	096			
Testifor restal effect:	Z = 1.25	(P = D.1)	R)				
1.1.6 Duration of KMR		a na sa ilaliana					
1.1.6 Duration of www Catteries 1998	- C.CH 110			4.545	D. NE	L910019.4.45	
Catianiao 15918 Challaiak 1997	1	$\frac{145}{364}$	3 10	136 345	B. 3% 27, 3%	and a figure of a could	
Utha (plais 1997) Worku 2005	10		10	340	- 27, 395 - 54, 295	0.67 (0.21, 1.56) 0.67 (0.32, 1.00)	
Subtetal (95% CD	18	575	-24	542	and a second second	0.60[0.38, 0.96]	
			1998	346	1000.000	eroalarsa'arsal	· · · · · · · · · · · · · · · · · · ·
Total events Heterogeneity: ChP =	23 1194 - 164		37 0 891:91	nse.			
		-		0.49			
Test for merall effect: Z = 1.13 (P = 0.03)							
							I

### [Type text]

— 1.1.7 Infant age ≤10 da	and set leads to the set of	C INCLUSION				
<ul> <li>1.1.7 Interacting a 10 cm</li> </ul>	ya aunuauon o	<ul> <li>FORE</li> </ul>				
Cattaneo 1998	2 148	3 135	7.2%	0.9110.19.4.46		
Chargel 1997	8 384	10 345	23.8%	1.57(0.21, 1.55)		
	1 44					
Kaidam 2005			2,3%	1.02 [0.07, 15.66]		
9uman 2009	1 100	5 103	11.5%	0.30[0.02, 1.69]		
Worku 2005	14 60	24 - 61	55,5%	1.57[0.33, 1.00]		
Subtotal (95% CI)	722	690	100.0%	0.56 [0.36, 0.88]	•	
Total events	25	43			Ŧ	
Heterogeneity: Chi*= 1.	45, df = 4 (P = 0.)	84);I*= 0%				
<ul> <li>Textifier overall effect: 2 -</li> </ul>	= 2.49 (P = 0.01)					
1.1.8 Infant age >10 day	es at initiation of	ISMC.				
Bao 2007	1 65	1 63	48,0%	0.97 (0.08, 15, 16)		
			40.030			
Ghavane 2012	I 61	0 68		Nirt estimable		
Fite) es: 2003	2 33	1 27	52. D%	1.54 [0.16, 17.09]		
Subtrial (95% CI)	166	158	100.0%	1.32[0.22, 7.73]		
Total events	3	2				
Heterogeneity: ChP = 1.						
Test for merall effect Z:	$= 0.30 \ (P = 0.76)$					
1.1.9 Lowiniddle-incon	ne countries					
Bon 2007	1 61	1 53	2,3%	0.97 (0.08, 15, 16)		
Cetterieo 1998	3 145	3 136	7.0%	1.91/0.19, 4, 451		
Chamak 1997				and a first of a could		
and a share of the state of the	8 364	10 346	23.0%	1.67 [0.21, 1.56]		
chavens 2012	1 91	0 53		NIC estimates		
Kaidam 2005	1 44	1 45	2.2%	1.02 [0.07, 15.86]		
Suman 2008	1 102	6 103	11.2%	1.20(0.12, 1.68)		
Worku 2005	14 61	24 81	54.2%	1.57(0.33, 1.00)		
Subtetal (95% CD	255	24 DI 1971		0.57 [0.37, 0.89]	<u>a</u>	
			and All the	eros (oras) ergal	<b>•</b>	
Total events	26	44				
Heterogeneity: DhP = 1/	68, df = 5 (P = 0.)	90); P <sup>a</sup> = 0.94				
Testifor negal effect 2:	= 2.46 (P = 0.01)					
1.1.10 High-income cou	ndelaar.					
			3 M.S. 1997			
Rojas 2003	1 31		1.00.0%	1.84 [0.18, 17.09]		
Subbital (95% Ct)	33	27	100,0%	1.64 [0.16, 17.09]		
Total events	1	1				
Heterogeneity: Not equil	-	-				
Testfor metall effect Z:	= 0.41 (P = 0.68)	i				
1.1.11 infant entered in						
		abilization	1 00.0%	8.57 (0.32, 1.00)		
1.1.11 infant entered in	to trial before st	abilization 24 81	1 00.0% 100.0%	0.57 (0.32, 1.00) 0.57 (0.33, 1.00)	<b>1</b>	
1.1.11 infant entered in Worku 2005 Subtotal (05% CI)	te trial before st 14 62 62	abilization 24 51 61			<b>‡</b>	
1.1.11 infant entered in Works 2005 Subtotal (05% Ct) Total events	te trial before st 14 62 62 14	abilization 24 81			=	
1.1.11 infant entered in Works 2005 Subtotal (05% Ct) Total events Historoganeity: Not eppil	te trial before st 14 62 62 14 icable	abilization 24 51 61 24			-	
1.1.11 infant entered in Works 2005 Subtotal (05% Ct) Total events	te trial before st 14 62 62 14 icable	abilization 24 51 61 24				
1.1.11 infant entered in Works 2005 Subtotal (05% Ct) Total events Historoganeity: Not eppli	te trial before st 14 62 62 14 icable	abilization 24 51 61 24				
1.1.11 infant entered in Works 2005 Subtotal (05% Ct) Total events Historoganeity: Not eppli	to trial before st 14 63 62 14 izable = 1.96 (P = 0.05)	tabilization 24 51 61 24			#	
1.1.11 infant entered in Works 2005 Subtatal (95% (1) Total events Historoganeity: Not eppli Testfor overall effect 21 1.1.12 infant entered in	to trial before st 14 62 62 14 izable = 1.96 (P = 0.05) to trial after stal	abilization 24 51 51 24 bilization	100.0%	0.57 (0.33, LOT)	*	
1.1.11 infant entered in Works 2005 Subtatal (95% Cf) Total events Historogianity: Not eppi Testifor resall effect. 2 1.1.12 infant entered in Box 2007	te trial before st 14 62 62 14 icuble = 1.96 (P = 0.05) te trial after stal 1 61	abilization 24 51 24 24 bilization 1 53	100.0%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16)		
1.1.11 infant entered in Works 2005 Subtatal (95% Cf) Total events Historogianally: Not appli Testifor restall effect 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 65 2 145	abelization 24 51 24 5 5 5 6 6 1 53 3 136	100.0% 4.7% 14.6%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4, 45)	*	
1.1.11 infant entered in Works 2005 Salitatal (95% Cf) Total events Hatarog analty: Not appli Testfor metall effect 2: 1.1.12 infant entered in Bao 2007 Cattaneo 1998 Chamak 1997	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 61 3 148 8 364	abelization 24 51 54 5 5 6 6 6 6 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7	100.0% 4.7% 14.6%	0.57 (0.33, 1.00) 0.97 (0.08, 15.16) 0.91 (0.19, 4.45) 0.67 (0.21, 1.55)		
1.1.11 infant entered in Works 2005 Subtatal (95% Cf) Total events Historogianally: Not appli Testifor restall effect 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 65 2 145	abelization 24 51 24 5 5 5 6 6 1 53 3 136	4.7% 4.8% 47.7%	0.97 (0.93, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.46) 0.67 (0.21, 1.06) Net externable		
1.1.11 infant entered in Works 2005 Salitatal (95% Cf) Total events Hatarog analty: Not appli Testfor metall effect 2: 1.1.12 infant entered in Bao 2007 Cattaneo 1998 Chamak 1997	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 61 3 148 8 364	abelization 24 51 54 5 5 6 6 6 6 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7	4.7% 4.8% 47.7%	0.57 (0.33, 1.00) 0.97 (0.08, 15.16) 0.91 (0.19, 4.45) 0.67 (0.21, 1.55)		
1.1.11 infant entered in Works 2005 Salistatal (95% Ct) Total events Heterogenally: Not appli Testfor metall effect: 2: 1.1.12 infant entered in Bob 2007 Cottaneo 1998 Charpak 1 997 Chavens 2012 Karlam 2005	te trial before st 14 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 61 3 148 6 264 6 61 1 44	abelization 24 51 54 5 5 6 6 6 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	4.7% 14.8% 47.7% 4.6%	0.97 (0.08, 15, 16) 0.97 (0.08, 15, 16) 0.91 (0.19, 4, 46) 0.07 (0.21, 1.06) Not externable 1.02 (0.07, 15, 86)		
1.1.11 infant entered in Worku 2005 Salitratai (95% Cf) Total events Heterogenally: Not appli Testifor metail effect 2: 1.1.12 infant entered in Bob 2007 Catianeo 1998 Chaptak 1997 Chaptak 1997 Chaptak 1997 Chaptak 2012 Kastam 2005 Rojas 2003	te trial before st 14 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 61 3 145 6 264 6 60 1 44 2 32	ablization 24 51 54 bilization 1 53 3 136 10 345 0 58 1 45 1 27	1000.055 4.775 14.856 47.776 4.696 5.176	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Net extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 09)		
1.1.11 infant entered in Works 2005 Salutatal (95% (1) Total events Historoganally: Not appli Testfor overall effect 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Chapak 1 997 Chavens 2012 Kadam 2005 Folge 2003 Sumar 2008	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 65 3 148 4 264 6 69 1 44 2 33 1 103	abelization 24 51 24 bilization 1 53 3 136 10 345 6 50 1 45 1 27 5 103	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
1.1.11 infant entered in Works 2005 Subtatal (95% (1) Total events Historoganally: Not appli Testfor overall effect 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Chaptek 1997 Chavens 2012 Kastan 2005 Fotas 2003 Sumar 2008 Subtatal (95% (1)	te trial before st 14 62 62 14 izable = 1.96 (P = 0.05) te trial after stal 1 65 3 148 4 264 6 69 1 44 2 33 1 103 826	abelization 24 51 24 bilization 1 53 3 136 10 345 6 50 1 45 1 27 5 103 787	1000.055 4.775 14.856 47.776 4.696 5.176	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Net extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 09)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Historogianity: Not appli Testifor restall effect: 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Charpak 1997 Charves 2012 Karlom 2006 Foi apak 1997 Subtatal (99% Ct) Total events</li> </ul>	te trial before st 14 62 62 14 icuble = 1.96 (P = 0.05) te trial after stal 1 65 3 148 4 364 5 65 1 44 2 32 1 44 2 32 1 44 4 42 3 14 4 44 2 32 1 4	abilization 24 51 54 5 5 5 6 10 345 10 345 1 45 1 27 5 103 787 21	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
1.1.11 infant entered in Works 2005 Subtatal (95% (1) Total events Historoganally: Not appli Testfor overall effect 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Chaptek 1997 Chavens 2012 Kastan 2005 Fotas 2003 Sumar 2008 Subtatal (95% (1)	te trial before st 14 62 62 14 icuble = 1.96 (P = 0.05) te trial after stal 1 65 3 148 4 364 5 65 1 44 2 32 1 44 2 32 1 44 4 42 3 14 4 44 2 32 1 4	abilization 24 51 54 5 5 5 6 10 345 10 345 1 45 1 27 5 103 787 21	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Historogianity: Not appli Testifor restall effect: 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Charpak 1997 Charves 2012 Karlom 2006 Foi apak 1997 Subtatal (99% Ct) Total events</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Historogianally: Not appli Testifor riverall effect: 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Charpas 1997 Charves 2013 Korlers 2005 Rojas 2005 Rojas 2008 Subtatal (95% Ct) Total events Historogianally: ChP = 1:	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Historogianally: Not appli Testifor riverall effect: 2: 1.1.12 infant entered in Box 2007 Cattaneo 1998 Charpas 1997 Charves 2013 Korlers 2005 Rojas 2005 Rojas 2008 Subtatal (95% Ct) Total events Historogianally: ChP = 1:	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)	TION OT THE Favours KONC Favours LONC	
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 62 14 162 14 162 14 165 165 165 165 165 165 165 165	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 izuble = 1.96 (P = 0.05) to trial after stal 1 65 3 148 8 364 6 68 1 44 2 32 1 102 826 14 22, th = 5 $\phi$ = 0.1	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect. 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpas 1997 Charves 2012 Karlers 2005 Roj as 2005 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 izuble = 1.96 (P = 0.05) to trial after stal 1 65 3 148 8 364 6 68 1 44 2 32 1 102 826 14 22, th = 5 $\phi$ = 0.1	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect: 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2005 Roj as 2003 Sumen 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 izuble = 1.96 (P = 0.05) to trial after stal 1 65 3 148 8 364 6 68 1 44 2 32 1 102 826 14 22, th = 5 $\phi$ = 0.1	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect: 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2005 Roj as 2003 Sumen 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 izuble = 1.96 (P = 0.05) to trial after stal 1 65 3 148 8 364 6 68 1 44 2 32 1 102 826 14 22, th = 5 $\phi$ = 0.1	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		
<ul> <li>1.1.11 infant entered in Works 2005 Subtatal (95% Ct) Total events Haterog analy: Not appli Testfor rvetall effect: 2: 1.1.12 infant entered in Bob 2007 Catianae 1998 Charpes 1997 Charves 2012 Kodom 2005 Roj as 2003 Sumen 2006 Roj as 2003 Sumen 2008 Subtatal (95% Ct) Total events Hotorog anally: ChP = 1:</li> </ul>	to trial before st 14 62 14 62 14 izuble = 1.96 (P = 0.05) to trial after stal 1 65 3 148 8 364 6 68 1 44 2 32 1 102 826 14 22, th = 5 $\phi$ = 0.1	abilization 24 51 54 bilization 1 53 3 136 10 345 0 50 1 45 1 27 5 103 787 21 82):P <sup>2</sup> = 09.	1000.0% 4.7% 14.6% 47.7% 4.6% 5.1% 23.2%	0.57 (0.33, 1.00) 0.97 (0.08, 15, 16) 0.91 (0.19, 4.45) 0.95 (0.21, 1.50) Not extirmable 1.02 (0.07, 15, 65) 1.54 (0.18, 17, 05) 0.20 (0.12, 1.68)		

# Figure 4. Forest plot of comparison: 1 Kangaroo mother care versus conventional neonatal care, outcome: 1.1 Mortality at latest follow up.

NHC         Count of Count of December 1 and Wingel Pit Lines. (2010)         Pit Lines. (2010)         Pit Lines. (2010)           Doc 3000**********************************	Study or Subgroup 1.4.1 All studies			Canataro			Flink Ratio	Risk Ratio
Bio 2007 C Stander 1815 C Stander 1815 C Stander 1817 C St	1.4.1 All studies					Whitght		
Calibration 1188 3 1 App 3 128 48.6 DOT [0.10, 4.45] Calibration 2020 1 2.000 (72, 1.17) Calibration 2020 1 4 00 0 44 Rev 1.007 [0.10, 4.45] Calibration 2020 1 4 00 0 44 Rev 1.007 [0.10, 4.45] Calibration 2020 1 4 04 1 45 1.45 1.007 [0.10, 4.45] The calibration 2020 1 4 04 1 45 1.45 1.45 [0.10, 15.55] Statistic differs CD 1 000 0 45 1.55 [0.10, 15.55] Calibration 2010 1 94 1 1 100 1 3 15 0 1 7.55 (1.15, 15.55] Calibration 2010 1 94 1 1 100 1 10 1 10 1 10 1 10 1 1								
Charpent 1877 11 200 16 241 3 8.8% 0.57 [0.17, 1.17] Decrement 2012 1 640 0 45 1.4% Incols 81, 17, 569 Decrement 2012 1 640 0 45 1.4% Incols 81, 17, 569 Decrement 2012 1 640 0 45 1.4% Incols 81, 17, 569 Decrement 2012 1 640 0 45 1.4% Incols 81, 17, 569 Decrement 2012 1 640 0 45 1.4% Incols 81, 17, 569 Decrement 2012 1 640 0 1 100 5 1.0 7, 15, 560 Decrement 2012 1 640 0 1 100 5 1.0 7, 15, 560 Decrement 2012 1 640 0 1 100 5 1.0 7, 15, 560 Decrement 2012 1 640 0 1 100 5 1.0 7, 15, 560 Decrement 2017 1 65 1 10, 15, 150 Decrement 2017 1 10, 150 D								
Harves 2012         B         660         0         681         Noticedemodels           Name 2013         1         44         1	tha speak: 1997		250	19	243		0.67 [0.37, 1.17]	
Cather 2185 1 44 1 44 1 44 1 48 1 48 1 402 [87, 18 48] Shar 1524 1 1 101 1 1 101 1 1 125 1 158 0000 [142, 134] Shar 1524 1 1 101 1 1 101 1 1 125 1 158 0000 [142, 134] Shar 1524 1 1 101 1 1 101 1 1 158 0000 [142, 134] Shar 1524 1 1 1 101 1 1 101 1 1 158 0000 [142, 134] Shar 1524 1 1 1 101 1 1 100 1 1 158 0000 [142, 134] Shar 1524 1 101 1 1 101 1 1 100 1 1 110 1 1 100 [142, 140] Shar 1524 1 101 1 1 101 1 1 100 1 1 100 [142, 140] Shar 1524 1 101 1 101 1 1 101 1 1 100 [142, 140] Shar 1525 1 1 1 101 1 1 101 1 1 100 [142, 140] Shar 152 1 1 101 1 1 100 [142, 140] Shar 152 1 101 1 100 [142, 140] Shar 152 1 1 100 [142, 140] Shar 153 [143, 140] Shar 154 [143, 140] Shar 154 [143, 140] Shar 154 [143, 140] Shar 154 [144, 140] Shar 140 [144, 140] Shar 140 [144, 140] Shar 14								
Table 21813 3 2 230 1 27 1.8% $(-4.4 [0, 15, 17, 20]$ Barran 2182 1 101 1 101 13 162 1 7 5 8% $(-0.66)(0.4, 2.13)$ Barran 2182 1 102 5 102 7 5.8% $(-0.65)(0.4, 2.13)$ Barran 2182 1 102 5 102 7 5.8% $(-0.25)(0.4, 2.13)$ Hereits cover all disk 2 2 - 22.2 0 - 21.2 0 Hereits cover all disk 2 - 22.0 0 Hereits cover all disk 2 - 20.2 0 - 21.2 0 Hereits cover all disk 2 - 20.2 0 - 21.2 0 Hereits cover all disk 2 - 20.2 0 - 21.2 0 Hereits cover all disk 2 - 20.2 0 - 21.2 0 Hereits cover all disk 2 - 20.2 0 - 21.0 - 20.0 0 Hereits cover all disk 2 - 20.2 0 - 21.0 0 Hereits cover all disk 2 - 20.2 0 - 21.0 0 Hereits cover all disk 2 - 20.2 0 - 21.0 0 Hereits cover all disk 2 - 20.2 0 - 2.0 0 Hereits cover all disk 2 - 20.2 0 - 2.0 0 Hereits cover all disk 2 - 20.2 0 - 2.0 0 Hereits cover all disk 2 - 20.2 0 - 2.0 0 Hereits cover all disk 2 - 2						1.4%		
$ \begin{array}{c} \text{Large 1888} & 1 & 100 & 5 & 100 & 7.3 & 0.20 [0.12, 1.9.16] \\ \text{Website 1888} & 1 & 2.23 & 2.38 & 1.38 & 0.057 [0.13, 1.00] \\ \text{Website 1888} & 1 & 2.23 & 2.38 & 1.38 & 0.057 [0.13, 0.067] \\ \text{Website 1881} & 2.22 & 2.24 & 0.057 [0.13, 0.067] \\ \text{Website 1881} & 2.22 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.27 + 0.130 \\ \text{Website 1881} & 2.2 & 2.050 \\ \text{Website 1881} & 1 & 4.4 & 1 & 4.4 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 5 & 100 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 1 & 100 & 1343 & 5.46 \\ \text{Website 1881} & 2 & 1.60 & 0.67 \\ \text{Website 1881} & 2 & 1.60 & 0.67 \\ \text{Website 1881} & 2 & 1.60 & 0.67 \\ \text{Website 1881} & 2 & 1.60 & 0.67 \\ \text{Website 1881} & 2 & 1.60 & 0.67 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 2 & 2.050 & 0.6 \\ \text{Website 1881} & 1 & 0.5 \\ \text{Website 1881} & 1 & 0.5 & 0.5 \\ \text{Website 1881} & 0.057 [0.16, 0.080] \\ \text{Website 1881} & 0 & 0.6 \\ \text{Website 1881} & 0.057 [0.16, 0.080] \\ Website 1$	7s.iso 2003		33		37	1.0%	1.64 [3.18, 17.05]	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$						1.7.6%		
Neiss 2185       14       62       24       67       3 5 3 %       0.07 [0.35, 1.00]         Obt over10       48       69       600       607 [0.35, 0.06]       0.07 [0.35, 0.06]         Weinsgemeint, C.P.T. 3.7, 0.05 IF P.C.O.K.       607 [0.35, 0.06]       0.07 [0.35, 0.06]       0.07 [0.35, 0.06]         A.2 International Minet Z = 2.27 (7 = 10.3)       4.2 International Minet Z = 2.27 (7 = 10.3)       4.2 International Minet Z = 2.27 (7 = 10.3)         A.2 International Minet Z = 2.27 (7 = 10.3)       4.20 (1.5, 0.07) [1.6, 0.57 [0.16, 0.16]       1.5 1.5 1.6 (1.5, 0.07) [1.6, 0.57 [0.16, 0.16]         Name 2010       1       6.4 0       6.4 1       1.6 1.5 1.5 1.6 (1.5, 0.07) [1.6, 0.57 [0.16, 0.57 [0								
Added (2015, CD)         SIGE         11078         SIGE (1 = 1078         SIGE (1 = 1078 <thsige (1="1078&lt;/th">         SIGE (1 = 1078</thsige>	Outica 2005		62	24	61		0.67 [0.13, 1.00]	
<pre>####################################</pre>	abiatsi (95% CI)		1068		1028	1000.0%	0.67 [0.48, 0.95]	•
A 22 Laternal left is 12 - 2.22 (P = 1.8.0) A 22 Laternal VIIIC A 23 Laternal VIIIC A 24 Laternal VIIIC A 24 Laternal VIIIC A 24 Laternal VIIIC A 25 L					~~			
4.2 Intermittical NBIC         cor 2007       1       053       1       0.1       1.1.1.5.       0.271 ([1.8.6, 15.1.6])         adam 2013       1       0.4       1       4.4       1       4.4       1         adam 2013       1       0.4       1       4.4       1       8.8       1.021 [1.8.1, 15.8]       1.0         adam 2013       1       0.0       5       1.00       4.8.8.       0.001 [1.8.1, 15.1.0]       1.0         adam 2013       1       1.00       5       1.00       4.8.8.       0.001 [1.8.1, 15.1.0]       1.0         adam works       0.00       2.00 (P = 1.8.4.0)       1.00       5.4.8.8.       0.001 [0.10, 4.4.6]         adam works       0.00 (P = 1.8.4.0)       1.0       1.2.8.8.8.       0.001 [0.10, 4.4.6]         abam 1050.       1.1       1.0       1.2.8.9.8.       0.001 [0.10, 4.4.6]         abam 1051.       1.1.8.0       1.0.2.8.18.8.       0.001 [0.10, 4.4.6]         abam 1051.       1.1.8.9.       1.0.2.8.18.8.       0.0.2.9.19.1.2.1.4.4.6]         abam 1052.       1.1.8.9.18.1.2.0.0.0.0.10.1.2.1.8.9.15.16]       0.0.10.10.2.4.6.2]       0.0.10.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.	entitar overall effect	Z = 2.220	F = 0.03	D	1.2 46			
$ \begin{array}{c} \log 2007 & 1 & 65 & 1 & 67 & 1 & 113 & 0.97T [[1.16], 15, 16] \\ \text{Reverse 2012 } & 8 & 60 & 0 & 68 & Note exist makes \\ \text{Reverse 2012 } & 8 & 60 & 0 & 68 & Note exist makes \\ \text{Reverse 2013 } & 2 & 30 & 1 & 27 & 1 & 184 & 164 [[1.16], 15, 16] \\ \text{Reverse 2013 } & 2 & 30 & 1 & 27 & 1 & 184 & 164 [[1.16], 15, 16] \\ \text{Reverse 2013 } & 2 & 30 & 1 & 27 & 1 & 184 & 164 [[1.16], 15, 16] \\ \text{Reverse 2013 } & 2 & 30 & 1 & 27 & 1 & 184 & 164 [[1.16], 15, 16] \\ \text{Reverse 2013 } & 2 & 30 & 1 & 27 & 1 & 184 & 164 [[1.16], 15, 16] \\ \text{Reverse 2016 } & 7 & 10 & \\ \text{Reverse 106 } & 7 & 10 & \\ \text{Reverse 106 } & 7 & 10 & \\ \text{Reverse 106 } & 7 & 10 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 124 & 5.46 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 1.24 & 5.46 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 1.24 & 5.46 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 3.40 & 3.41 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 3.40 & 3.41 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 3.40 & 3.41 & \\ \text{Reverse 106 } & 1 & 1 & 10 & 0 & 3.40 & 0.57 [[3.16], 4.46] & \\ \text{Reverse 106 } & 1 & 62 & 2.44 & 81 & 4.13 & 0.57 [[3.16], 6.36] & \\ \text{Reverse 106 } & 1 & 66 & 1 & 61 & 2.446 & 0.97 [[1.16], 4.46] & \\ \text{Reverse 2007 } & 1 & 66 & 1 & 61 & 2.446 & 0.97 [[1.16], 1.46 & 0.36] & \\ \text{Reverse 2013 } & 2 & 25 & 2 & 24 & 81 & 1.07 [[1.16], 1.26 & [1.16] & \\ \text{Reverse 2013 } & 2 & 25 & 2 & 24 & 81 & 1.07 [[1.16], 1.26 & [1.16] & \\ \text{Reverse 2013 } & 1 & 20 & 0 & 45 & \\ \text{Reverse 2013 } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2013 } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2014 } \text{Reverse 106 & } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2014 } \text{Reverse 106 & 0 & 0.45 & \\ \text{Reverse 2012 } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2012 } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2012 } & 1 & 60 & 0 & 45 & \\ \text{Reverse 2012 } & 1 & 100 & 0 & 136 & 5 & 60 & \\ \text{Reverse 2014 & Reverse 10 & \\ \text{Reverse 2012 } & 1 & 100 & 0 & 136 & 5 & 80 & \\ \text{Reverse 2012 } & 1 & 100 & 0 & 136 & 5 & 80 & \\ \text{Reverse 2016 & Reverse 10 & \\ \text{Reverse 1188 } & 3 & 1.40 & 3 & 126 & 1.85 & 0.071 [[3.1, 0.46]] & \\ \text{Reverse 1188 } & 3 & 1.40 & 3 & 126 & 80$				-				
The Product 2009 is $460$ to $460$ . Note out models in additionable in the set of the s			-				0.0713 88.38.38	
throws the 2012 is 600 0 E8 Net continuable share 2012 is 600 0 E8 Net continuable share 2013 1 24 1 44 1 44 5 1 8 8% 1 0.02 [18,7,18,12] (19,						1 8.135		
where 2003 2 0.00 1 22 10.0 10.10 1	tavate 2012						Not esti mable	
$ \begin{array}{c} \mbox{rma} = 2180 & 1 & 1 & 100 & 5 & 100 & 4 & 8.8 & 0.20 (0 & 12, 1.8 & 0) \\ \mbox{rmbox} = 188 & 7 & 10 \\ \mbox{rmbox} = 1080 & 0 & 2 & 389 & 9000.06 & 0.059 (0.25, 5.77) \\ \mbox{rmbox} = 1080 & 0 & 2 & 100 \\ \mbox{rmbox} = 1081 & 1 & 200 & 0 & 24.8 \\ \mbox{rmbox} = 1081 & 1 & 200 & 0 & 24.8 \\ \mbox{rmbox} = 1081 & 1 & 200 & 10 & 24.5 & 44.8 \\ \mbox{rmbox} = 1081 & 1 & 200 & 10 & 24.5 & 34.8 & 0.59 (0.27, 1.27) \\ \mbox{rmbox} = 1181 & 1 & 200 & 10 & 24.5 & 34.8 & 0.59 (0.27, 1.27) \\ \mbox{rmbox} = 1181 & 1 & 200 & 10 & 24.5 & 34.8 & 0.59 (0.27, 1.27) \\ \mbox{rmbox} = 1181 & 1 & 200 & 10 & 24.5 & 34.8 & 0.59 (0.27, 1.27) \\ \mbox} = 1281 & 11 & 200 & 10 & 24.8 & 0.67 (0.48, 15.16) \\ \mbox} = 1281 & 14 & 62 & 14 & 164 & 24.8 & 0.67 (0.48, 15.16) \\ \mbox} = 106 & 0.665 & 1 & 63 & 24.8 & 0.67 (0.48, 15.16) \\ \mbox} = 106 & 0.67 & 0.16 & 0.59 & 0.8 \\ \mbox} = 106 & 0.67 & 0.16 & 0.59 & 0.45 \\ \mbox} = 106 & 0.67 & 0.17 & 0.50 & 0.28 \\ \mbox} = 106 & 0.67 & 0.17 & 0.50 & 0.28 \\ \mbox} = 106 & 0.68 & 0.64 & 0.045 \\ \mbox} = 106 & 0.67 & 0.17 & 0.50 & 0.28 \\ \mbox} = 106 & 0.68 & 0.64 & 0.07 (0.48, 15.16) \\ \mbox} = 106 & 0.68 & 0.64 & 0.04 & 0.04 & 0.04 \\ \mbox} = 106 & 0.67 & 0.17 & 0.50 & 0.28 \\ \mbox} = 106 & 0.68 & 0.64 & 0.07 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.64 & 0.07 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.64 & 0.07 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.64 & 0.07 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.27 & 0.73 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.17 & 0.50 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.07 & 0.164 & 0.688 \\ \mbox} = 106 & 0.68 & 0.68 & 0.67 & 0.07 & 0.164 & 0.688 \\ \mbox} = 106 & 0.68 & 0.68 & 0.68 & 0.67 & 0.27 & 0.73 & 0.68 \\ \mbox} = 106 & 0.68 & 0.68 & 0.68 & 0.67 & 0.27 & 0.73 & 0.67 \\ \mbox} = 106 & 0.68 & 0$	adani 2005				45		1.02[1.07, 15.85]	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	URA 2003					1 1 1 1 1	1.64 [0.18, 17,06]	
Attends (46%)-CD       366       387       NRUMAL       Excel (0.26), 0.772         Attends (46%)-CD       7       10         CROSOPORD (1) CB = 1.14, df = 4 (P = 0.712), P = 0.35         statistic oversite affect Z = 0.50 (P = 1.40)         L3 Centifications RMC         than oversite	WIOław 1888				38	1.8.8%	1.0310.15.8.001	
theogeneity $C S P = 1.44$ , $d^2 = 0.712/P = 0.95$ within overall effect $Z = 0.600/P = 1.43$ 4.5 Centimenes NMC thanks 1583 2 1 4.40 2 128 5.4% 0.91 [0.19, 4.45] thank 1994 11 139 153 2 18.6% 0.95 [0.17, 1.17] than 1994 11 139 153 2 18.6% 0.95 [0.17, 1.17] than 1994 11 139 153 2 18.6% 0.95 [0.43, 3.10] that 2005 11 8 52 6 82 800.0% 0.57 [0.46, 0.90] that events 3 38 69 theorements for $L Z = 0.200 CP = 1.00$ 4.4 Constitue of NMC -2 hour million that 2005 1 2 23 1 22 2 4.8% 1.64 [0.19, 1.02] theorements 10 for $L Z = 0.000 CP = 0.05$ theorements 5 38 40 0 45 Not well in the 10 11, 12.66] theorements 5 1 44 1 45 1 800.0% 0.20 [0.12, 1.80] theorements 5 1 44 1 45 Not well in the 10 11, 12.68] theorements 6 1 44 1 45 Not well in the 10 11, 12.68] theorements 6 1 44 1 45 Not well in the 10 11, 12.68] theorements 1 100 0 0 18 Not well in the 10 10 0 0 0 10 10, 10, 4.45] theorements 1 10 2 0 19 0 19 20 1 2.12, 1.80] theorements 1 10 2 0 19 0 10 2.12, 1.80] theorements 1 10 2 0 19 0 2.12, 1.80] theorements 1 10 0 0 19 0 10 12, 1.30] theorements 1 10 0 0 19 0 10 12, 1.30] theorements 1 10 0 0 19 0 10 12, 1.30] theorements 1 10 0 0 19 0 10 12, 1.30] theorements 1 10 0 0 19 0 10 12, 1.30] theorements 1 10 0 0 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0		-	396		387	1080.015	0.68 [0.26, 1.77]	
estitic overall effect 2 : $0.90 (P = 1.40)$ 4.3 Constrained NMC statures 1881 1 140 2 158 18 apoint 1987 11 3310 19 343 3.2.8.5. 0.57 [0.10, 4.45] 18 apoint 1987 11 131 13 151 2 18.6.0 0.980 04.3.132] 1987 1994 11 131 13 152 2 18.6. 0.980 04.3.132] 1987 1995 11 4 62 24 81 41.3.6. 0.57 [0.14, 0.030] 1987 1995 11 4 62 24 81 41.3.6. 0.57 [0.14, 0.030] 1987 1995 11 6 65 1 63 24.8.9. 0.97 [0.88, 15.16] 1987 1997 11 6 65 1 63 24.8.9. 0.97 [0.88, 15.16] 1987 1997 11 5 2 3 5 2 38.6. 1.64 [0.14, 15.16] 1988 2007 1 6 65 1 63 24.8.9. 0.97 [0.88, 15.16] 1988 2007 1 6 65 1 63 24.8.9. 0.97 [0.88, 15.16] 1988 2012 2 323 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 2 323 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 1 2 323 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 1 2 32 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 1 2 3 23 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 1 2 3 23 1 27 3 2.8.9. 1.05 [0.82, 4.30] 1988 2012 1 2 3 20 1 202 3 1.02 [0.82, 1.02] 1980 2007 1 1 05 1 2 1 8 2.9. 1.02 [0.87, 15.85] 1980 2012 1 2 2 5 0 0 8 2 1.8.9. 4.5 Densition of HMC Deliveren 8 and 15 interminating 4.5 Densition of HMC Deliveren 8 and 15 interminating 1990 2007 1 1 102 5 10 8 2.5.9. 0.20 [0.17, 15.85] 1990 2007 0 1 2 2 0 0 2 2 0 10 00.09.1 0.20 [0.17, 15.85] 1990 2007 0 10 11 2 - 1.10 4.5 Densition of HMC 2.20 interminating 1990 1991 0 11 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 1995 1 1 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 1995 1 1 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 1995 1 1 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 1995 1 1 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 1995 1 1 1 171 173 175 2 3 2.8.9. 0.57 [0.37, 1.17] 1990 199 343 18.5.9. 0.57 [0.37, 1.57] 1990 199 343 18.5.9. 0.57 [0.37, 1.57] 1990 199 343 18.5.9. 0.57 [0.37, 1.57] 19								
4.3 Continuous RMC thanks 1358 3 1 46 2 126 5 4% 0.991 [0.19, 4.45] transition of RMC -2 beam large that defines a 235 5 4 1 1 1 2 1 1 2 1 1 2 1 1 2 1 2 8 6 1 4 1 1 3 1 5 2 2 8 6 1 4 1 1 3 1 5 2 2 8 6 1 4 1 1 3 1 5 0 2 9 4 6 1 3 1 3 0 5 7 1 3 2 1 1 2 0 1 3 0 5 7 1 3 0 5 7 1 3 2 1 1 2 0 1 3 0 5 7 1 3 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 1 5 0 5 7 1 3 1 5 0 5 7 1 3 1 5 0 5 7 1 3 1 5 0 5 7 1 3 1 5 0 5 7 1 3 1 5 0 5 7 1 3 1 5 0 5 7 1 5 0 7 1 5 0 5 7 1 5 0 7 1 5 0 5 7 1 5 0 7 1 5 0 5 7 1 5 0 7 1 5 0 5 7 1 5 0 7 1 5 0 5 7 1 5 0 7 1 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	estiar overall effect.	Z = 0.90 /	P = 1.43	D D	100			
without 1558 3 1 140 2 126 54% 0.01 [0.10, 445] any 1994 11 200 19 343 32.8% 0.057 [0.17, 1.7] any 1994 11 101 13 153 28.6% 0.990 [0.46, 2.12] with 2385 14 62 24 67 41.13, 0.057 [0.46, 0.30] Attend (255.0) 6552 682 9580.0% 6.057 [0.46, 0.30] Attend (255.0) 7 1.05 16 2 24.6% 0.07 [0.46, 0.30] Attend (255.0) 7 1.05 16 2 24.6% 0.07 [0.46, 15.16] up 2810 2 12 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 2 4 8.2% 1.057 [0.48, 15.16] up 2810 2 2 2 2 2 2 2 4 8.2% 1.057 [0.13, 1.00] Attend (956.0) 1 538 1.28 900.0% 1.188 [0.32, 4.30] witeolog order (0.17, 15.26] at events 5 4 4 kinead (956.0) 2 3 6 0 68 Noteed mable brownell effect Z = 0.25 0P = 8.80 Attend (956.0) 2 3 6 0 68 Noteed mable brownell effect Z = 0.25 0P = 8.80 Attend (956.0) 2 6 0 88 1.000 00 8.25% 0.020 [0.12, 1.88] at events 2 012 8 60 0 68 Noteed mable brownell 2 6 0 8 2 81 950.0% 6.057 [0.37, 1.69] witeolog order (0.17, 15.26] at events 2 1 2 6 0 0 88 1.057 [0.37, 1.69] witeolog order (0.17, 15.68] at events 2 1 2 6 0 0 88 1.000 00 8.25% 0.020 [0.12, 1.88] at 120 1 102 5 103 8.25% 0.057 [0.37, 1.72] at events 3 10 40 3 158 5.4% 0.01 [0.10, 4.45] brownell 696 0 682 882 950.0% 6.057 [0.37, 1.72] witeolog order (0.17, 15.68] at 120 0 19 343 3.8% 0.057 [0.33, 1.00] at events 3 38 59 at 120 0 0 8 48 1.35% 0.020 [0.44, 0.38] at 120 1 1 20 19 3 153 2.8.1% 0.057 [0.33, 1.00] at events 3 38 59 at 120 0 19 343 3.8.5% 0.057 [0.33, 1.00] at events 3 38 59 at 120 0 0 8 48 0 0 45 Noteed mable brownell 676 0.1 8.5% 0.020 [0.12, 1.68] at 120 1 950 0 19 343 3.8.5% 0.057 [0.33, 1.00] at events 3 38 59 at events 41 1 2 - 200 (P = 1.80) At events 3 3 1 4 4 1 45 1.5% 1.02 [0.10, 1.12, 1.445] at 1.3% 0.057 [0.37, 0.25] at events 1153 1 4 44 1 45 1.5% 0.057 [0.37, 0.25] at events 1153 1 4 44 1 45 1.5% 0.057 [0.37, 0.25] at eve				-				
Happed TRYF 11 250 19 342 32.8% 0.57 [0.27, 1.7] and 1994 11 101 13 152 2.8.8% 0.99 [0.46, 2.12] arks 2185 14 62 24 61 41.3% 0.57 [0.32, 1.00] arks 2185 14 62 24 61 41.3% 0.57 [0.32, 1.00] arks 2185 14 62 2.96 69 18.2 950.0% 0.57 [0.33, 1.00] arks 2007 1 66 1 63 24.8% 0.97 [0.8, 15, 16] arks 2182 2 2.08 69 = 8.80 4.4 Demation of NMC -2 beam large 50 2007 1 66 1 63 24.8% 0.97 [0.8, 15, 16] arks 2183 2 2 33 1 22 34.8% 1.64 [0.16, 15, 16] arks 2183 2 3 3 2 3 2 4 8.5 1.054 [0.15, 15, 16] arks 2183 2 3 5 2 3 8 48.13% 1.054 [0.15, 15, 16] arks 2183 2 3 5 2 3 8 48.13% 1.054 [0.15, 15, 16] arks 2183 2 3 5 2 3 2 3 4 128 900.0% 1.164 [0.16, 15, 16] arks 2183 2 3 5 2 3 2 3 4 128 900.0% 4.50 averts 5 4 theoponety C 5 P = 1.10, dF = 2 P = 0.000, P = 0.3% effor over all offert Z = 200 60 0 50 Nd Nd 1.166 [0.32, 4, 30] arks 2009 3 4 40 0 45 Nd end matche Nd events 0 2 6 0 0 50 Nd 18 Nd end matche Nd events 0 2 6 0 0 50 Nd 18 Nd end matche Nd events 0 2 6 0 0 50 Nd 18 Nd end matche As Daniel offert Z = 1.00 (0.00 Nd 1.166 [0.20, 0.20, 0.20, 0.20] arks 216 0 0 1 102 5 110 82.5% 0.020 [0.21, 2.168] arks 216 0 0 1 102 5 10 82.5% 0.027 [0.22, 1.20] ark 128 1 1 200 19 3 128 5 4% 0.91 [0.10, 4.45] ark 104 (22.5 10 10 23 23 800.0% 6.07 [0.44, 0.38] ark 104 (25.16) 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0				_			0.01.02.02.0	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$								
The 2016 $S = 0.57[0.12, 10.00]$ All events 3 38 69 the events 0.14 ( $S = 2.24$ ( $S = 3.150$ , $0.57[0.12, 10.00]$ the events 0.14 ( $S = 2.160$ , $S = 0.050$ , $P = 0.05$ , $S = 0.050$ , $P = 0.050$ ,								
Taki events 38 69 extransparticly C1P = 1.58, df = 3 ( $P = 0.05$ ); $P = 0.35$ , estroprionics of HMC -2 hearinglagy to 2007 1 665 1 60 24.8% 0.97 ([1.68, 15.16]) type 2812 2 2 23 1 27 24.8% 1.64 ([1.18, 17.16]] type 2812 2 2 25 2 2.8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 25 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 25 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 2 8 4 8.1.3% 1.051 ([3.8, 15.16]] type 2812 2 2 2 8 4 8.1.3% 1.052 ([3.8, 15.16]] type 2813 2 2 3 2 2 8 48.1.3% 1.052 ([3.8, 15.16]] type 2813 2 2 3 5 2 2 8 48.1.3% 1.052 ([3.8, 15.16]] type 2813 2 1 0.05 7 1.01 ([3.8, 15.16]] type 2813 1 10.2 5 10 8.2.5% 1.022 ([3.8, 15.8]] type 2813 1 10.2 5 10 8.2.5% 1.022 ([3.8, 15.8]] type 2813 1 10.2 5 10 8.2.5% 1.022 ([3.7, 1.17]] type 2813 1 10.2 5 10 18 23 3.8 % 0.57 [[0.37, 1.17]] type 2813 1 1 290 118 23 3.8 % 0.57 [[0.37, 1.17]] type 2813 1 1 290 118 23 3.8 % 0.57 [[0.37, 1.17]] type 2813 2 1.6 (2 2 4 61 4.1.3% 0.57 [[0.37, 1.17]] type 2813 2 1.6 (2 2 4 61 4.1.3% 0.57 [[0.37, 1.17]] type 2813 1 1.020 ([3.4, 4.5% 0.57 [[0.37, 1.17]]) type 2813 1 1.03 5 1.03 1.8 5.8 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 1.8 5.8 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 5 1.8 5.8 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 5 1.8 5.8 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 8.58 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 8.58 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 8.58 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 8.58 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.03 8.58 0.57 [[0.37, 0.38]] type 2813 1 1.03 5 1.0 8.58 0.57 [[0.37, 0.38]] type 3818 1 1.03 5 1.8 6.2 1.8 8.10 5.5 [[0.37, 0.38]] type 3818 1 1.03 5 1.8 6.2 1.8 8.10 5.5 [[0.37, 0.38]] type 3818 1 1.03 5 1.0 8.58 0.57 [[0.37, 0.38]] type 3800076 0 0 1.0 8.58 0.55 [[0.37, 0.38]] type 3800076 0 0 1.0 8.5		14		24				
$ \begin{array}{c} \label{eq:second} \label{eq:second} \end{tabular} \\ \mbox{conversite} GF(t) = 1.56, \mbox{df} = 1, \mbox{eff} = 0.050; \mbox{ff} = 0.24, \mbox{eff} = 0.057, \mbox{ff} = 0.24, \mbox{ff} = 0.057, \$		2.2	680	-00	685	1000,015	6.67 [8.46, 0.98]	•
ection over all offs at $Z = 200$ of $P = 1.040$ A.4 Densition of NMC = 2 hear milling to 2007 1 665 1 661 24.0% 0.97 (2.05, 15.16) type 2012 2 25 2 25 2 24.05 1.04 (2.05, 15.16) type 2013 2 25 2 25 2 24.05 1.05 (1.04 (2.05, 15.16) type 2014 2 25 2 25 2 2 25 4 4.05 1.05 (1.05, 15.16) the standard (0.55, 0.0) 153 128 900.0% 1.08 (0.35, 10.01 (2.05, 15.16) the standard (0.55, 0.0) 153 128 900.0% 1.08 (0.35, 10.01 (2.05, 15.16) the standard (0.55, 0.0) 153 128 900.0% 1.08 (0.35, 10.01 (2.05, 15.16) the standard (0.55, 0.0) 153 128 900.0% 1.02 (0.07, 10.46) the standard (0.55, 0.0) 10 (0.00, 10.10, 0.445) the standard (0.57, 0.20) 12 (0.00, 10.10, 0.455) the standard (0.57, 0.20) 12 (0.00, 10.10, 0.455) the standard (0.57, 0.20) 12 (0.00, 10.10, 0.57, 0.20) the standard (0.57, 0.20) 12 (0.00, 10.10, 0.57, 0.20) the standard (0.57, 0.20) 12 (0.00, 10.10, 0.557) 12 (0.10, 0.557) 12 (0.00, 10.10, 0.557			2 17 - 4		02-			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	estfor overall offect	Z = 2.08 (	P = 1.0	0				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	A di Danatikan of Mill	C all barrow						
Square 2010 2       2       22       1       22       2.6.16%       1.64 [0.16, 12.06]         With Sev 1918 10       2       2.5       2       2.6.16%       1.64 [0.16, 12.06]         Substant (05% C)       133       128       1000.0%       1.168 [0.32, 4.300]         Substant (05% C)       133       128       1000.0%       1.168 [0.32, 4.300]         Fortial events       5       4         **000000% C 16% = 0.171, dT = 210° = 0.054 (2° = 0.35)       1.60 = 0.168         A.5 Deniation of MMC between 8 and 15 hearistication       Notesci mable         Software 2000 8       6.00 158       Notesci mable         Software 2018 0       1.021 51 100 8.31%       0.2018 0.2.186         Aurear 2018 0       1.022 51 100 8.31%       0.234 [0.07, 1.42]         Aurear 1000 00% 10 101 102 103 104 104 102 103 10.04%       0.357 [0.07, 1.42]         Cold overtis       0.022 24 103 10.04%       0.057 [0.07, 1.42]         Starpast 1060 00% 01       0.062 24 10.02 10.04%       0.057 [0.07, 1.42]         Starpast 16% 10 112 2.4.453       0.01 [0.10, 4.45]       1.00 [0.01 [0.10, 4.45]         Starpast 16% 10 11 12 11 13 152 10.00%       0.057 [0.37, 1.12]       1.00         Starpast 16% 10 11 12 11 13 12 10.00%       0.007 [0.10, 10, 4.46]       1.000 <td></td> <td></td> <td></td> <td></td> <td>6.7</td> <td>24.8%</td> <td>0.97/01/01/05 15:161</td> <td></td>					6.7	24.8%	0.97/01/01/05 15:161	
$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Rejec 2003	2	22	1	22	25.5%	1.64 [3.16, 17.06]	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Whitelaw 1989	2	35		38		1.03[1.15, 8.50]	•
A:S Departidiny C B #= 0.11, df = 2 P* = 0.03, P* = 0.95         ett for overall effect Z = 0.25 0* = 0.810         A:S Departiding of HMC between 0 and 15 hears stray         bar Product 2000       8 db 0 d5         harman 2012       8 db 0 d5         harman 2013       1 d4 1 d5         harman 2016       1 d4 1 d5         harman 2016       1 d4 1 d5         harman 2017       8 db 0 d5         harman 2018       1 d4 1 d5         harman 2018       1 d4 2 d5         harman 2018       1 d5 d5         harman 10 d5       1 d5 d5			1.55	,	128	10000095	1,18 [0.32, 4,30]	
Testfor overall effect $Z = 0.25$ ( $P = 1.810$ 1.4.5 Deniation of PMC between 1 and 15 meanshipsy Bac Prateu 2012 8 60 0 58 Not excit mable Servera 2012 8 60 0 58 Not excit mable Servera 2012 8 100 0 8 0 45 Not excit mable Servera 2018 1 102 5 100 8.15% 0.20 [0.17, 15.85] Barrier 2018 1 102 5 100 8.15% 0.20 [0.17, 15.85] Barrier 2018 2 6 - Feterogeneity Chr <sup>-</sup> = 8.68, dr = 1 ( $P = 0.25$ ); $P = 0.26$ . Testfor overall effect 2 = 1.35 dP = 8.110 1.4.6 Dearthor of PMC 5.28 meanshipsy Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Charles of PMC 5.20 meanshipsy Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.01 [0.10, 4.45] Test over 16 818 3 1.40 3 138 5.4% 0.57 [0.33, 1.00] Test over 16 818 3 1.40 3 138 5.4% 0.57 [0.33, 1.00] Test over 16 818 3 1.44 1 45 1.5% 0.57 [0.37, 0.38] Test over 16 818 1 0.3 5 10 0.5% 0.57 [0.37, 0.38] Test over 18 818 1 0.3 5 10 0.5% 0.57 [0.37, 0.38] Test over 18 818 1 0.3 5 10 0.5% 0.50 [0.37, 0.38] Test over 18 818 1 0.55 [0.37, 0.38] Test over 18 818 1 0.05 [0.37, 0.38] Test over 18 0 0.55 [0.37, 0.38] Test over 18 0 0.55 [0.37, 0.38] Test over 18 0 0 0.55 [0.37, 0.38] Test	witerageneity: ChiP-	0.11,40-	2 8** = 0	2.9433 P =	0%			
Dot Profiled 2000         B         eds         D         45         Floct well modules           Nervine 2012         B         60         D         64         Floct well modules           Advental 2015         1         44         1         45         1.85%         1.02(1):17, 15, 863           Advental 2015         1         400         5         100         8.12.8         0.20(1):0.2, 12.83           Advental (95% C)         2003         261         900,0%         6.34 (0.07, 1.64)         1.65%           Advental (95% C)         2003         211         900,0%         6.34 (0.07, 1.64)         1.65%           Value 2016         Advental 300         200         8.4%         0.01 (0.10, 4.45)         1.65%           Table 0.01 (819         3         1.40         3         1.86         0.45%         0.21 (0.10, 4.45)           Table 0.01 (819         3         1.10         1.53         1.84%         0.67 (0.33, 1.00)         1.66%           Mathemat (95% C)         0.062 (0.40, 2.12)         0.67 (0.27, 1.17)         1.00         1.01         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11 <td< td=""><td>fertion overall effect</td><td>Z = 0.250</td><td>P = 11.61</td><td>D</td><td></td><td></td><td></td><td></td></td<>	fertion overall effect	Z = 0.250	P = 11.61	D				
So Product 2009         B         etc         0         45         Fact well resubles           Service 2005         1         65         0         65         Note well resubles           Schwart 2005         1         44         1         45         1.85%         1.02(10.17, 15.85)           Automation 2005         1         44         1         45         1.85%         1.02(10.17, 15.85)           Automation 2005         2         6         1.85%         1.02(10.17, 15.85)         1.85%           Schward 2005         2         6         1.85%         0.01(0.10, 4.45)         1.85%           Schward 1600         2         6         1.85%         0.01(0.10, 4.45)         1.85%           Schward 1600         2         6         1.85%         0.01(0.10, 4.45)         1.85%           Schward 1600         1.10         1.5         2.18%         0.067(0.32, 1.12)         1.10           Automation of MMC         3         1.4         1.5         2.18%         0.067(0.32, 1.12)         1.10           Schward 2005         1.8         1.8         0.8         0.67(0.27, 1.12)         1.10         1.11         1.11         1.11         1.11         1.11         1.11	4.5 Duration of RM	Chelween	1.004	15 hours	and and			
$\begin{aligned} \begin{aligned} & \text{Nervers 2012} & \text{B} & \text{S0} & \text{D} & \text{Ele softwalke} \\ & \text{Vectors 20185} & 1 & 44 & 1 & 45 & 18, \text{K} & 1.02, 10.7, 15, 86 \\ & \text{Larran 2008} & 1 & 1003 & 5 & 1003 & 0.250 [0, 0.7, 16, 86] \\ & \text{Larran 2008} & 1 & 1003 & 5 & 1003 & 0.250 [0, 0.7, 16, 86] \\ & \text{Larran 2008} & 1 & 1003 & 5 & 1003 & 0.250 [0, 0.7, 16, 86] \\ & \text{Converts} & 2 & 6 \\ & \text{-intercognometry Chiffer ELSE, dim 1 [p^2 = 0.255; p^{22} = 0.26 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 355 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 355 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 355 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 355 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 355 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 2, 200 $p^2 = 0.16 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 84 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 84 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 84 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 84 \\ & \text{Control over 18 off with $\mathcal{L}$ = 1, 84 \\ & \text{Control $\mathbb{C}$ = 1, 84 \\ & \text$	ika Pratwi 2009		-692	0	45			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Shavane 2012				68		Not wait mable	
Automatic (95% CT)         28C3         281 # 9060,9%         6.34 [8.07, 10.44]           Cold dwords         2         6         6           Artistogenolity: Ch F* E.S.B, df* 1 [F* 0.25); F* 0.26; Control oversilling         6         6           Setting conversille of Fill C.S.28 (beam-biday         7         7         7           Call Developmentary: Ch F* E.S.8, df* 1 [F* 0.25); F* 0.26; Control oversille of Fill C.S.28 (beam-biday         7         7           Call Developmentary: Ch F* E.S.8, df* 1 [F* 0.25); F* 0.26; Control 0.1618         3         1.40         3         1.58         5.4%         0.011[0.10, 4.45]; Control 0.1010, 1.12, 1.12]           Call Developmentary: Ch F* 1.58, 0.29 (beam-biday         1.10         1.13         1.53         0.67 [0.37, 1.12]; Control 0.46, 0.390]         1.10           Automatic field Control 0.11         1.13         1.52         1.84, 0.057 [0.33, 1.00]         1.10           Automatic field Control 0.18         3.8         0.000, 0.000         0.000 [0.46, 0.390]         1.000           Statistor oversite of the field off of 0.18         3.8         1.84, 0.057 [0.33, 1.00]         1.10           Automatic 1.18         3.126         0.176         0.057 [0.32, 1.00]         1.10           Automatic 1.18         3.126         0.185         0.057 [0.32, 1.00]         1.10							1.02[0.07, 15.85]	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		1		2			0.34 [0.07, 1.64]	
$\begin{array}{c} \text{Control over all offset C, $Z=1,36,9^{2}=0,100 \\ \text{A.S. Demandion of HMC, $Z=1,36,9^{2}=0,100 \\ \text{Control of HMC, $Z=1,30,9^{2}=0,100 \\ \text{Control of HMC, $Z=1,20,9^{2}=0,100 \\ \text{Control of HMC, $Z=2,20,9^{2}=0,100 \\ Control of HMC, $Z=$	otal events	2						
A 6 Denution of NMC 5.20 insumiting informed 1669 3 1.40 3 126 5.4% 0.01 [0.10, 4.45] in apoke 1967 11 250 19 243 1.2186 0.57 [0.37, 1.12] in an 1984 11 121 13 153 21.6% 0.990 [0.46, 0.968] inter 1984 11 121 13 153 21.6% 0.990 [0.46, 0.968] inter 2000 16 0692 682 682 900.0% 6.07 [0.46, 0.968] inter 2000 16 0692 682 900.0% 6.07 [0.46, 0.968] inter 2000 16 0692 7 10 0692 7 10 06 inter 2000 1 0 06 inter 2000	interageneity: ChiP-	8.08, df=	1   P  = 0	0.25); P* =	(P%)			
$ \begin{aligned} & \text{attraction 1668} & 3 & 1.40 & 3 & 156 & 5.4% & 0.01 [0.10, 4.45] \\ & \text{an appoint 1677} & 11 & 250 & 16 & 243 & 3.248 & 0.57 [0.37, 1.17] \\ & \text{an an 1934} & 11 & 131 & 13 & 153 & 21.8\% & 0.590 [0.45, 2.13] \\ & \text{an an 1934} & 11 & 131 & 13 & 153 & 21.8\% & 0.590 [0.45, 2.13] \\ & \text{an an 1934} & 11 & 131 & 13 & 153 & 21.8\% & 0.590 [0.45, 2.13] \\ & \text{attraction 1955} & 14 & 652 & 24 & 61 & 41.1\% & 0.57 [0.33, 1.00] \\ & \text{attraction 1967} & 53 & 59 \\ & \text{attraction 1968} & 518 & 518 & 518 & 519 & 500 \\ & \text{attraction 1981} & 3 & 148 & 3 & 158 & 518 & 559 \\ & \text{attraction 1981} & 3 & 148 & 3 & 138 & 518 & 519 & 509 [0.13, 4.45] \\ & \text{attraction 1981} & 3 & 148 & 3 & 138 & 518 & 559 & 0.57 [0.17, 1.17] \\ & \text{attraction 1985} & 1 & 444 & 1 & 45 & 1.8\% & 0.57 [0.17, 1.17] \\ & \text{attraction 1985} & 1 & 444 & 1 & 45 & 1.8\% & 0.57 [0.13, 1.00] \\ & \text{attraction 1985} & 1 & 444 & 1 & 45 & 1.8\% & 0.57 [0.13, 1.00] \\ & \text{attraction 1985} & 1 & 444 & 1 & 45 & 1.8\% & 0.57 [0.13, 1.00] \\ & \text{attraction 1985} & 1 & 444 & 1 & 45 & 1.8\% & 0.57 [0.13, 1.00] \\ & \text{attraction 2185} & 1 & 46 & 2 & 24 & 61 & 8.1\% & 0.57 [0.13, 1.00] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.57 [0.13, 1.00] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.57 [0.13, 1.00] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.55 [0.37, 0.85] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.55 [0.37, 0.85] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.55 [0.37, 0.85] \\ & \text{attraction 2186} & 138 & 62 & 24 & 61 & 8.1\% & 0.55 [0.37, 0.85] \\ & \text{attraction 2186} & 138 & 62 & 62 & 62 & 62 & 62 & 62 & 62 & 6$	on their oriental to the life	2 = 1.95 (	F = 1.11	0				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$								
Isami 1984         11         121         13         152         21.81%         0.980 [0.46], 21.5]           Verto 2.005         14         62         24         61         41.36         0.677 [0.33, 1.00]           verto 3.005         0.682         662         9682         960,0%         6.007 [0.44, 0.968]           verto 3.005         3.0         9.0         960,0%         6.007 [0.44, 0.968]         ●           verto 3.005         3.0         9.0         960,0%         6.007 [0.44, 0.968]         ●           verto 3.005         3.0         9.0         9.0         9.0         ●         ●           verto 3.007         0.0710 days at initiation of HOMC         •         •         •         ●           verto 3.005         1.42         3.138         5.1%         0.5710.27, 1.17]         ●           verto 3.005         1.43         3.43         3.45%         0.6710.27, 1.17]         ●           verto 3.005         1.44         1.45         1.9%         1.02(10.7, 1.58]         ●           verto 3.016         1.03         5.10         8.5%         0.5710.32, 1.00]         ●         ●           verto 3.016         1.03         5.10         8.5%	attence 1668	3	1.49					
Noise 2016         14         62         24         61         1.1.3%         0.657 [0.33, 1.00]           Unitated 66% CD         0682         0682         060.0%         0.657 [0.33, 1.00]         •           Obliceworks         38         59         59         500.0%         0.657 [0.34, 6.0.88]         •           Microsoversity         38         59         59         500.0%         0.657 [0.34, 6.0.88]         •           A.2* Inflaet age: _s10 dags aft initiation of HMC         31.26         0.57 [0.37, 1.17]         •         •           A.2* Inflaet 396         31.46         0.45         Note with work in mable         •         •           A.2* Inflaet 396         31.46         0.45         Note with work in mable         •         •           A.2* Inflaet 306         1.44         1.45         1.85%         0.67 [0.37, 1.17]         •           A.2* Inflaet 3005         8         0.45         Note with work in mable         •         •           work 2108         1.44         1.45         1.95%         0.20 [0.0.2, 1.66]         •           work 2108         1.62         2.4         61         8.5%         0.57 [0.33, 1.06]         •           work 2108         1.62								
ubersted (95% CD) 0692 0692 0692 000.0% 0.07 (0.44, 0.986)								
Intercopervolu: C NP = 1.61, df = 3 NP = 0.660; P = 0.96         eartific overall effect Z = 2.00; OP = 0.16;         A.7 Infect app = 210 days at initiations of HMMC         withere 1888       3 149       3 126       0.81 [0.19, 4.45]         Warren 1888       3 149       3 126       0.85 [0.27, 1.17]         A.7 Infect app = 210 days at initiations of HMMC       Not Postorial 2009       0.45       Not Postorial 2017, 1.17]         A Product 2009       0.46       0.45       Not Postorial 2018, 1.858       0.57 [0.27, 1.17]         waren 2185       1.44       1.45       1.856       0.20 [0.12, 1.68]         waren 2183       1.03       5.103       8.56       0.20 [0.12, 1.68]         waren 2183       1.03       5.103       8.56       0.20 [0.12, 1.68]         waren 2183       1.03       5.103       8.56       0.20 [0.12, 1.68]         waren 2183       1.03       5.103       8.55       0.57 [0.37, 0.05]         waren 2184       1.03       5.103       8.57       0.30 [0.12, 1.68]         waren 2185       1.8       62       2.4       61       8.57 [0.37, 0.053]         Waren 2007       3.13       6.26       62       62       62       62         Waren 2007       0.31 <td></td> <td>1.4</td> <td></td> <td>1.4</td> <td></td> <td></td> <td>0.07 [0.46, 0.98]</td> <td></td>		1.4		1.4			0.07 [0.46, 0.98]	
initial oper stimilation of HMC         4.7 Initiant age stimilation of HMC         tarped 1938         1 440         1 450         1 460         1 460         1 460         1 460         1 470         1 480         1 480         1 480         1 480         1 480         1 480         1 480         1 480         1 480         1 480         1 480	tel events							-
4.7 Inflant age _≤10 days at initiation of HMC riterwar 1998 3 148 3 158 5.8% 0.91 [3.19, 4.45] Isayok 1997 11 360 19 343 3.8.5% 0.57 [3.27, 1.17] a Pratio 2006 8 db 0 45 Note at initiation at Pratio 2006 8 db 0 45 Note at initiation at an at 1955 1 44 1 45 1.5% 1.02 [3.87, 15.85] where 2008 1 40 5 103 8.5% 0.200 [0.8, 1.58] where 2008 14 62 24 61 8.6% 0.200 [0.8, 1.58] where 3005 14 62 24 61 8.6% 0.55 [0.37, 0.05] the devents 30 66 [0.37, 0.05]	rterageneity ChP-	1.60.df=	3 P = 0	).665; P =	0%			
efferwar 1998         3         1.46         3         1.36         6.8%         0.91 [0.12, 4.45]           is speak 1997         11         9.90         19         9.43         3.8.5%         0.57 [0.27, 1.17]           is Product 2009         8         .62         0         45         historic invalue           offer 20185         1         44         1         45         historic invalue           orient 20185         1         44         1         45         0.057 [0.37, 1.17]           orient 20185         1         44         1         45         1.02 [0.87, 15.28]           orient 20185         1         44         1         45         0.5% [0.32, 1.00]           orient 20185         1.4         6.2         2.4         61         8.6%         0.200 [0.2, 1.66]           orient 20185         1.4         6.2         2.4         61         8.1%         0.5% [0.37, 0.05]         0.4           orient 20185         1.8         6.2         61         8.1%         0.5% [0.37, 0.05]         0.4           orient 20185         1.8         6.2         62         62         62         62           orientorientinc 10         1.8         62	en far overall effect	2 = 2.09 ()	P = 1.15	0				
Isapaci (1907)         II         350         19         343         34.5.5%         0.67 [0.27, 1.17]           or Product 2006)         0         0         0         45         hold rectinuable           other 2005         1         44         1         45         hold rectinuable           other 2005         1         44         1         45         1.5%         1.02 [0.07, 15.25]           order 2005         1         100         5         1.03         5.5%         0.20 [0.02, 1.66]           order 2005         1         1.00         5         1.00         8.5%         0.20 [0.02, 1.66]           order 2005         18         62         24         61         8.5%         0.25 [0.37, 0.050]           other devents         30         62         62         62         64           other devents         30         62         62         64         64	4.7 Infertage ≤10	days at in	listion	of HMC				
ba Prodeki 2009 8 de 0 45 Not estimate isolare 2009 8 de 1 44 1 45 1.9% 1.02(10.7,15.05) unais 2008 1 103 5 100 8.5% 0.20(0.82,1.66) intria 2008 11 62 24 61 8.1% 0.57(0.23,1.00) → definitial (5% CD) 1756 723 990.0% 6.56 (0.37,0.85) Obliceration (5% CD) 19 62 interagemently CD = 1.45, dt = 4 (F = 0.64); F = 036	witerway 1999	3	1-49	3				
indexe 2005 1 44 1 45 1.9% 1.02(0.07, 0.85) where 2005 1 03 5 10 8.5% 0.20(0.02, 1.66) where 2005 1 4 62 24 61 8.1% 0.57(0.33, 1.60) where 2005 0 1 756 733 906.0% 0.55 (0.37, 0.95) Obliceworks 30 62 intercoperative C1 F = 1.45, dF = 4 (F = 0.54); F = 0.35	8 a (p-ak: 1997		360	19	343	38.6%	0.67 [0.27, 1.17]	
umas 2008 1 103 5 108 8.5% 0.20(0.02,1.68) where 2005 1 8 62 24 81 8 6.1% 0.25(0.03, 1.00) kabintat (25% C) 1 856 723 99600% 6.56 (0.37, 0.05) Othicsevents 0 0 62 detension with Ch F = 1.8, dr = 4 (F = 0.64); F = 036						1.00		
(artis: 13185         14         62         24         61         14.1%         0.57 [0.33, 1.00]            (artis: 1375, C)         735         550,0%         6.256 [0.37, 0.053]             (bit side (\$57, C))         735         550,0%         6.256 [0.37, 0.053]             (bit side (\$57, C))         735         550,0%         6.256 [0.37, 0.053]             (bit side (\$51, C))         735         550,0%         6.256 [0.37, 0.053]             (bit side (\$51, C))         735         550,0%         6.256 [0.37, 0.053]	induces 7.5 P.C						0.2010.02.1.660	
otal events 30 62 staragenetic ChF= 1.45, dF= 4 (F= 0.94); F= 0%	edere 3695 amer 2699		6.2		671	10.116	0.67 [0.33, 1.00]	
risespensity: $C \in \mathbb{P} = 1.45$ , $df = 4$ ( $\mathbb{P} = 0.64$ ); $f^2 = 0.76$ .	amaa 2009 arka 2005		756		733	1000,015	0.56 [0.37, 0.85]	•
$a = 10^{\circ} \text{ over all of the } \mathcal{L} = 2.70 \text{ (frequencies)}$	uman 2006 Index 2006 Abhatial (55% CC)			62				
	luman 21193 Varias 21195 Jubilatai (55% CI) Iotai events		4 12 - 1	10142-09-	CPGL -			
1	lumen 2006 Verka 2005 Jubiatal (35% CI) Iotal events Interageneity: C t F =	1.45, df=	4 (P = 0 F = 1, 1)	2.94% P* = 102	9%			
8.3% 0.07 (0.08, 15.16) histerit robbe 8.0% 1.64 (0.18, 17.05) 4.6% 0.99 (0.48, 2.12) 2.2% 1.02 (0.15, 8.90) 80.0% 1.02 (0.53, 2.00) 1 1 13 2 63 27 153 28 346 5.8% 74.8% 13.3% 900.0% 17 90% P - 0% Testilor over all effective 1.4.5 Lossimidile-inc Boo 2007 Catarase 1668 Chapaki 1827 Dia Protesi 2012 Nadeni 2185 Siano 1994 Suma 2889 Suma 2899 0.07 [1.16, 15.16] 0.91 [0.19, 4.45] 0.57 [0.27, 1.17] Not ext involve Fact ext involve 1.02 [1.17, 15.85] 0.96 [0.46, 2.12] 0.20 [0.42, 1.46] 0.57 [0.33, 1.00] 0.66 [0.45, 0.93] 63 128 343 45 88 45 163 100 87 1016 1.5% 4.6% 2.8.3% 120011354 1.5% 18.4% 7.6% 38.8% 100.0% ÷4 Prioritical 20105 Statements of 45625 (CD) 2 55 >= 0.81;; P = 0% 1.62; Total events 42 Historogeneity: C k P = 1.97, df = 6 Teat for overall effect Z = 2.97 (P atitios 3 22 2 35 68 
 1.4.100 High ancome countries

 Regin 2013
 3
 32
 1
 22

 Protocov 1818
 2
 35
 2
 33

 Statestol (6% CO)
 68
 68
 68

 Total events
 4
 2
 2

 Helikologovský C 5P = 0.08, dTe 1 8° = 0.100; P = 0.35
 Test for overali effect Z = 0.29 dP = 1.77
 35
 1 27 3.5.8% 2 38 5.4.2% 63 1000.0% 1.64 (0.16, 17.06) 1.05 (0.15, 8.90) 1.26 (0.29, 5.42) 
 1.4.11 Infant entered into that boltere state

 Warks 2005
 1.4

 Statestal (SSCQ)
 62

 Total events
 1.4

 Hartessperalty National Call
 1.4

 Hartessperalty National Call
 1.4
 4024000 24 61 133.0% 61 50600% 0.57 (0.33, 1.00) 0.57 (0.33, 1.00) 24

0 45 Nof-ost matte 0 48 2.3% 1.02(0.87, 15.85) 1 45 2.3% 1.02(0.87, 15.85) 1 27 2.6% 1.64(0.18, 17.08) 2 15 17.1% 0.99(0.80, 2.12) 5 150 11.7% 0.20(0.82, 1.68) 2 36 4.4% 1.03(0.15, 6.90)			55	1	6.3	2.2%	0.97 [1.88, 15.16]
0         45         Not ossi matrie           0         68         Not ossi matrie           1         45         2.7%         1.02 (0.87, 15.85)           1         27         2.5%         1.64 (0.1%, 17.06)           12         15.2         3.7.1%         0.98 (0.63, 2.12)           5         103         1.7.3%         0.98 (0.15, 6.50)           2         36         4.4%         1.0310.1%, 6.50)	Catanes 1668		149	3	138	7.1%	0.91 (0.19, 4.45)
D         D6         National matching           1         45         2.3%         1.02 (0.87, 19.85)           1         27         2.6%         1.64 (0.18, 17.06)           12         2.6%         1.64 (0.18, 17.06)           12         153         3.7.1%         0.96 (0.46, 2.12)           15         100         1.1.3%         0.20 (0.16, 2.12)           2         36         4.4%         1.09 (0.16, 6.90)	Of a tptak: 1997		250	-19	243	43.2%	0.57 [0.27, 1.17]
1         45         2.2%         1.02(10.7, 15.05)           1         27         2.6%         1.64(11.16, 17.06)           12         153         3.7.1%         D.98(D.46, 3.12)           5         103         11.3%         D.29(0.12, 1.52)           2         36         4.4%         1.03(0.15, 6.90)	Bia Profivi 2009		-498	0	45		P-lot croti what lie
1 27 2.5% 1.64 (0.18, 17.06) 12 153 37.1% 0.992(0.6, 3.12) 5 100 11.3% 0.20(0.02, 1.66) 2 36 4.4% 1.03(0.15, 6.60)	Stavate 2012		66	0	66		hipt estimable
12 153 37.1% 0.992[0.00, 3.12] 5 103 11.3% 0.20[0.02, 1.65] 2 36 4.4% 1.03[0.15, 6.90]	Gedere 2005		-64		45	2.2%	1.02 (1.07, 15.85)
5 103 11.3% 0.20 0.82, 1.88 2 36 4.4% 1.03 0.15, 6.90	Report 2000	2	-33	1	27	2.6%	1.64 [1.18, 17.09
2 36 4.4% 1.03(0.15, 6.90	alisten 1994.		1.21	12	153	37.1%	0.99 [0.06, 3.12]
	Sumer 2003		103	5	103	1.1.2%	0.20 0.82, 1.68
1018 100.05 0.73 (0.47.1.13)	Whitelaw 1553	2	-35	2	36	4.436	1.03(0.15, 6.90
	Aubitorital (95% CI)	-	100216		1018	10000-015	0.73 [0.47, 1.13]
45	notel events	32		4.55			
	Total avants Heterogeneity: ChiP= 3		P=0		0%		



Figure 5. Forest plot of comparison: 1 Kangaroo mother care versus conventional neonatal care, outcome: 1.2 Severe infection/sepsis at latest follow up - stabilized infants.

incetion sep		ince			чp	Stubilizeu	in anos
	KMC		Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.5.1 Intermittent							
Ali 2009	3	58	10	56	12.4%	0.29 [0.08, 1.00]	
Boo 2007	2	56	1	62	1.2%	2.21 [0.21, 23.76]	
Eka Pratiwi 2009	1	48	3	45	3.8%	0.31 [0.03, 2.90]	
Kadam 2005	6	44	8	45	9.6%	0.77 [0.29, 2.03]	
Rojas 2003	5	33	8	27	10.7%	0.51 [0.19, 1.38]	+
Suman 2008	4	103	15	103	18.3%	0.27 [0.09, 0.78]	
Subtotal (95% CI)		342		338	<b>55.9</b> %	0.45 [0.28, 0.73]	◆
Total events	21		45				
Heterogeneity: Chi <sup>2</sup> =	4.46, df=	5 (P =	0.48); l² =	= 0%			
Test for overall effect:	Z = 3.22 (	(P = 0.0	001)				
1.5.2 Continuous							
Charpak 1997	26	343	35	320			
Subtotal (95% CI)		343		320	44.1%	0.69 [0.43, 1.12]	•
Total events	26		35				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z=1.48	(P = 0.1	4)				
Total (95% CI)		685		658	100.0%	0.56 [0.40, 0.78]	•
Total events	47		80			• / •	
Heterogeneity: Chi <sup>2</sup> =		6 (P =		= 0%			
Test for overall effect:		`		•			
Test for subaroup diff				1 (P =	0.21) P=	35.3%	Favours KMC Favours control
							oo mother care
versus conve	-			-		0	
1.10 weight g	gain a	it la	test i	0110	w up	(g/aay) - st	abilized infants.

	KMC		Com	tral			Maan Difference	Maan Difference	
Study or Subgroup Mea	KMC n SD	Total	Com Mean		otal W	eiaht	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl	
1.18.1 Intermittent							,		
	.3 3.8			4.8	56 1		8.90 [7.31, 10.49]	+	
,	6667446			5		9.5%	1.00 [-2.06, 4.06]		
	.7 11.6 2 1.44		27.5 18.61 1	9 28		8.3% 2.8%	1.20 [-2.57, 4.97] 3.31 [2.78, 3.84]	+	
Ghavane 2012 20.				8.2		9.8%	2.60 [-0.28, 5.48]		
Ramanathan 2001 15.				4.5		9.0%	5.30 [1.97, 8.63]		
	06			6		7.5%	0.00 [-4.30, 4.30]		
	.4 3.8 19 9.84		14 15.58 8			1.5% 9.8%	1.40 [-0.37, 3.17] 8.41 [5.52, 11.30]		
Subtotal (95% CI)	0.04	411	10.00 0			0.1%	3.75 [1.75, 5.74]	•	
Heterogeneity: Tau <sup>2</sup> = 7.36; Test for overall effect: Z = 3.6			°= 8 (P < 0	.00001	l); l² = 8	8%			
1.18.2 Continuous									
	.3 11.8		17.7 1			9.9%	3.60 [0.78, 6.42]		
Subtotal (95% CI)	10	149			136	9.9%	3.60 [0.78, 6.42]	-	
Heterogeneity: Not applicab Test for overall effect: Z = 2.9		0.01)							
					<b>F</b> 40 (1)			•	
Total (95% CI) Heterogeneity: Tau² = 6.65;	Chiz- C	<b>560</b> 9 61 df	-0/0-0		512 10 N IZ - 01		3.74 [1.92, 5.56]		
Test for overall effect: Z = 4.0			- 3 (F > 0	.00001	1), 1 – 0	/ 70		-10 -5 Ó 5 10	
Test for subaroup difference	es: Chi²∶	= 0.01.	df = 1 (P =	0.93).	I <sup>2</sup> = 0%			Favours control Favours KMC	
Authors' concl									
			-					the use of KMC	
in LBW infants									
mainly in reso	urce	-lim	ited s	sett	tings	5. F	urther info	rmation is	
required conce	rnin	g e	ffecti	iver	ness	and	l safety of e	early onset	
continuous KN	IC i	n ur	ıstabi	ilize	ed o	r re	elatively sta	abilized LBW	
infants, long te							•		
care.					•			,	
	; <sup>,</sup> C	0	NCI	U	SI	0 1	NS Implica	tions for practice	
Although curren								-	
U					•			vidence that use of	
							00		
	-					_	0	income countries.	
								and intermittent	
								Since the control	
group in studies	eva	luat	ing co	onti	nuoi	ıs l	KMC was in	n incubators or	
radiant warmers	s, the	e po	tentia	l be	enefi	cia	l effects of l	KMC on morbidity	
and mortality of	· ·							•	
•							1	vailable. <b>To date</b> ,	
early onset con									
stabilized LBW								•	
evidence provid									
Abstract	at U	J			u (11		•		3.a Parental
	hen	aron	ital av	ner	iono	<b>A</b> C -	of providing	g skin-to-skin care	experiences of
	-			-	ICIIC	65 (	or browning	z skill-to-skill care	-
(SSC) to their n					1	• •	. 1 1	. 1. 1	providing skin-to-
-								en reported to have	skin
	-		-	-	-	-		the infants and	care to their
their parents. No	o sys	stem	natic r	evi	ew 1	ega	rding parer	ntal experiences has	newborn infant
been identified.	-					-			*Part 1: A
	first	par	t of a	me	ta-st	udv	the findin	gs of a systematic	qualitative
literature review		-				-			systematic
		•		-				1	review
								out year or language	
minimums, up t	mm	Dec	embe	er 2	013.	. IVI	anual search	hes were performed	

analysis <b>Results</b> original from 40 provisio draining <i>A. Anderzen</i>	articles were e s. The systemati qualitative pap 1 mothers and on of SSC emer g experience. <i>n-Carlsson et al.</i>	er a quality-a extracted and ic and manua pers from nin 94 fathers. T ged: a restor	analysed I searche e countrie 'wo theme	topic. process, data from using qualitative s led to the inclu es, reporting express that characteri ience and an ene	e content sion of 29 eriences zed the	Anderzen-Carlsson A, CaravalhoLampy Z, & Eriksson M. Int J Qualitative Stud Health Well-being <b>2014</b> , 9: 24906 REVIEW ARTICLE
	erview of themes, sub-themes					
Themes		torative experience		An energy-draining		-
Sub-themes	Feeling good	Doing good	Becoming us	Feeling exposed	Hurting others	-
Categories	A heart-warming experience Relieving emotional suffering A rewarding experience A natural instinct A learning experience Finding a role Improved self-esteem Feeling of control A supportive environment	A way of knowing and understanding Important for the infant	A bonding experience Intimate togethemess	Environment as an obstacle A physical and emotional burden Incongruence between wishes and demands Uncertainty about the purpose of and own skill in providing SSC	Fear of hurting Feeling insufficient towards the family	
It const on phys	titutes a valuat siological and j	ble complem psychosocial	ent to pr l outcome	providing SSC. es is recommendevious metaana es on mothers a	lyses nd	
It const on phys infants, meta-a systema	titutes a valuat siological and y , and it offers a nalyses on the atic review show	ble complem psychosocial a more detai topic. From ws that mothe	ent to pr l outcome iled pictu an evider ers and fa	thers who provide the provide	<b>lyses</b> nd vious ctive, this le SSC	
It const on phys infants, meta-a systema	titutes a valuat siological and y , and it offers a nalyses on the atic review show	ble complem psychosocial a more detai topic. From ws that mothe	ent to pr l outcome iled pictu an evider ers and fa	tes is recommend revious metaana es on mothers a re than the prev nce-based perspe	<b>lyses</b> nd vious ctive, this le SSC	
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor	titutes a valuat siological and j , and it offers a nalyses on the attic review show perience the SSC of synthesize and g on parental ex- n infants.	ble complem psychosocial a more detain topic. From ws that mothe C as restoration and interpret que xperiences of	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s	there who provid the second perspective of the second perspective of t	lyses nd vious ctive, this le SSC ning.	3.b Parental experiences of providing skin-to- skin
It const on physi infants, meta-a systema can exp Abstrac Aim: T focusing newbor Backgr	titutes a valuat siological and j , and it offers a nalyses on the attic review show perience the SSO of o synthesize an g on parental ex- n infants. round: SSC ind	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b	<b>ent to pr</b> l <b>outcome</b> <b>iled pictu</b> an evider ers and fa ve, as we ualitative f skin-to-s	there who provid research finding skin care (SSC) f	lyses nd vious ctive, this le SSC ning.	experiences of providing skin-to- skin care to their
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor Backgr their pa physiolo parental Designs describ	titutes a valuat siological and j , and it offers a nalyses on the attic review show berience the SSC or synthesize and g on parental ex- n infants. round: SSC indu- rents. Three me ogical outcomes l experiences of the present me ed by Paterson	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b eta-analyses I s, but no pre f SSC has be neta-synthesis and co-work	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s benefits fo have beer vious qua en identif s was guid ers.	es is recommend revious metaana es on mothers a re than the prev nee-based perspe thers who provid 11 as energy-drain research findings skin care (SSC) f or newborn infant a conducted on litative meta-syn ied. ded by the metho	lyses nd vious ctive, this le SSC ning. s for s and thesis on dology	experiences of providing skin-to- skin
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor Backgr their pa physiolo parental Designs describ	titutes a valuat siological and j , and it offers a nalyses on the attic review show berience the SSC or synthesize and g on parental ex- n infants. round: SSC indu- rents. Three me ogical outcomes l experiences of the present me ed by Paterson	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b eta-analyses I s, but no pre f SSC has be neta-synthesis and co-work	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s benefits fo have beer vious qua en identif s was guid ers.	these is recommender revious metaana es on mothers a re than the previous nece-based perspect thers who provident ll as energy-drain research finding skin care (SSC) for newborn infant a conducted on litative meta-syn ied.	lyses nd vious ctive, this le SSC ning. s for s and thesis on dology	experiences of providing skin-to- skin care to their newborn infant *Part 2: A qualitative systematic
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor Backgr their pa physiolo parenta Design describ Data so	titutes a valuat siological and j , and it offers a nalyses on the utic review show perience the SSC or synthesize and g on parental ex- n infants. round: SSC indu- trents. Three me ogical outcome l experiences of the present me ed by Paterson ources: Four da ons, up until De	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b eta-analyses I s, but no pre f SSC has be neta-synthesis and co-work atabases were ecember 2013	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s penefits fo have beer vious qua en identif s was guid ers. e searched 3. Manual	the s is recommender revious metaana es on mothers a re than the prevence-based perspe- thers who provid 11 as energy-drain research findings skin care (SSC) for r newborn infant a conducted on litative meta-syn ied. ded by the metho l, without year on searches were a	lyses nd vious ctive, this le SSC ning. s for s and thesis on dology language lso	experiences of providing skin-to- skin care to their newborn infant *Part 2: A qualitative systematic review Anderzen-Carlsson
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor Backgr their pa physiolo parental Designs describ Data so limitatio	titutes a valuat siological and j , and it offers a nalyses on the utic review show erience the SSC or synthesize an g on parental ex- n infants. round: SSC indu- rents. Three me ogical outcomes l experiences or the present me ed by Paterson ources: Four da ons, up until De- ned. The search	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b eta-analyses I s, but no pre f SSC has be neta-synthesis and co-work atabases were ecember 2013 es and subset	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s benefits fo have beer vious qua en identif s was guid ers. e searched 3. Manual quent qua	es is recommend revious metaana es on mothers a re than the prev- nce-based perspe- thers who provid 11 as energy-drain research findings skin care (SSC) f or newborn infant a conducted on litative meta-syn ied. ded by the metho l, without year on searches were a lity appraisal res	lyses nd vious ctive, this le SSC ning. s for s and thesis on dology : language lso ulted in	experiences of providing skin-to- skin care to their newborn infant *Part 2: A qualitative systematic review Anderzen-Carlsson A,
It const on physi infants, meta-a systema can exp Abstract Aim: T focusing newbor Backgr their pa physiolo parental Designs describ Data so limitation perform the incl	titutes a valuat siological and j , and it offers a nalyses on the tic review show erience the SSO to synthesize an g on parental ex- n infants. round: SSC indu- rents. Three me ogical outcomes l experiences of the present me ed by Paterson ources: Four da ons, up until De- ned. The search usion of 29 orig	ble complem psychosocial a more detai topic. From ws that mothe C as restorati ad interpret que prevent of the second luces many be eta-analyses la s, but no pre f SSC has be neta-synthesis and co-work atabases were ecember 2013 es and subsec ginal qualitat	ent to pr l outcome iled pictu an eviden ers and fa ve, as we ualitative f skin-to-s penefits fo have beer vious qua en identif s was guid ers. e searched 3. Manual quent qua ive paper	es is recommend revious metaana es on mothers a re than the prev nee-based perspe thers who provid 11 as energy-drain research findings skin care (SSC) f or newborn infant n conducted on litative meta-syn ied. ded by the metho searches were a lity appraisal res s from 9 countrie	lyses nd vious ctive, this le SSC ning. s for s and thesis on dology : language lso ulted in	experiences of providing skin-to- skin care to their newborn infant *Part 2: A qualitative systematic review Anderzen-Carlsson A, CaravalhoLampy
It const on physi infants, meta-a systema can exp Abstrac Aim: T focusing newbor Backgr their pa physiolo parenta Designs describ Data so limitatio perform the incl reportir	titutes a valual siological and y and it offers a nalyses on the tric review show perience the SSO to synthesize an g on parental ex- n infants. round: SSC indu- rents. Three me ogical outcomes l experiences of the present me ed by Paterson ources: Four da ons, up until De- ned. The search usion of 29 origing experiences of	ble complem psychosocial a more detai topic. From ws that mothe C as restorati and interpret que xperiences of luces many b eta-analyses l s, but no pre f SSC has be neta-synthesis and co-work atabases were ecember 2011 es and subsec ginal qualitat from 401 mot	ent to pr l outcome iled pictu an evider ers and fa ve, as we ualitative f skin-to-s benefits fo have beer vious qua en identif s was guid ers. e searched 3. Manual quent qua ive paper thers and	es is recommend revious metaana es on mothers a re than the prev nee-based perspe thers who provid 11 as energy-drain research findings skin care (SSC) f or newborn infant n conducted on litative meta-syn ied. ded by the metho searches were a lity appraisal res s from 9 countrie	lyses nd vious ctive, this le SSC bing. s or s and thesis on dology language lso ulted in es,	experiences of providing skin-to- skin care to their newborn infant *Part 2: A qualitative systematic review Anderzen-Carlsson A,

	-								-	ses, a stanc									ing	,
										as ar			-				-		. A	
										des						-				
			-							obsta									to	
									0	y-dr		0	-							
			-				-	-		e, it t				-	-		-			
								-		s rea	-						-		-	
										e the								0	ties	,
					sub-theme				ueu	artic	ies	is p	1011	uec	1 111	Ta		1.		4
_					Feding good	۸	motorative	esperieso	•	Doing (	pad	Becom	ing us		Feel	An energy-d	mining experie	ion Hurt	ingothers	Anderze
															The		Uncerta about t purpose	he of		in-Carl
A	heart-	Releving emotional suffering	A rewarding experience	A	A learning experience		Improved self-	Feeling of	A supportive	A way of knowing and	Important for the	A honding	Istimate togethemess	Environmen as an obstacle	physical t and emotions burden	Incongru betwee d wishes o deman	ence and ov m skill i and providi	-	Feding insufficient toward the family	SSON et
eqp	x	x	expensive	x	x	x	x	x	x	underst straing X	mant	x	ogen në monos	ODEACE	barara	dena	as sac. X	nurang	Tiendy	
	x				x	x	x	x		x	x	x	x		x	x		x		
									x		x	x	x			x			x	
							x		x					x	x	x			x	
						x			x	x	x			x	x				x	
		x			x				x	x	x	x		x	x	x		x	x	
	x			x				x			x	x		x		x		x		
		x		x					x		x		x			x			x	
	x	x	x		x	x	x	x	x		x	x		-					x	
	x		x					x			x	x	x	x	x			x	x	
					x	x	x			x	x	x	x	x			x	x	x	
	x		x	x		x	x				x	x	x			x				
	x	x			x	x	x	x	x	x	x	x	x	x	x	x			x	
tiqued	0						Arestone	ive experi	1501							An	energy-drainin	g experience		
					Feeling good					De	ing good		kcom-ing us			Feeling	exposed	Uncertainty	Harti	ing oth
																The physical	Incongruence	about the purpose of and own		For
A h ware	nart- ning fence	Relieving emotional suffering	A rewarding experience		A learning experience	Finding a role	Improve self este em	d Feein of contro	8 Asuppor i environm		nd for t					and motional burden	hetween wishes and demands	skill in providing SSC	Fear of hurting	itsuff towar fan
,	¢					x			x				x		x		x			
3	¢				x	x	x	x			x	x			x		x		x	
3	¢					x	x			x	x	x 	x			×	x	x	x	x
3	c				x	x	x		x	x	x	x	x		x	x	x	x	x	x
					x		x		x		x					x	x	x	x	3
,	¢	x	x			x	x	x			x	x			x	x	x	x		
		x					x			x	x	x	x			x			x	
3				x		x	x		x x	x	x x	x x	x		x x	x x	x x	x	x x	
3	c c				x	x	x	x	x	x	x x x	x x x			x	x x x	x		x	
					x	~		x	x	*	x	x	~		x	x	x	*	x	x
r	lu	sior	n: ]	[]he	e re	sul	ts s	sho	w t	hat S	SSC	ca C	n be	e in	ter	pre	ted	not	on	v

external factors in three different levels; family and friends, community, and society at large. The descriptions of providing SSC are similar to what has previously been described as the **2014**;9: 24906

REVIEW ARTICLE

	1
natural process of becoming a mother or a father.	
<b>ABSTRACT</b> : The birth of a premature infant can have adverse effects	4. Effects of
on the mood of mothers and on the interaction patterns between	Kangaroo Mother
parents and	Care on maternal
their preterm babies. The aim of the present systematic review was to	mood and
examine whether the Kangaroo Mother Care (KMC) intervention can	interaction
attenuate these adverse psychological effects of a premature birth by	patterns between
ameliorating negative maternal mood and/or promoting more positive	parents and their
interactions between preterm infants and their parents. The results	preterm, low birth
showed that although findings of studies were inconclusive, there	weight infants: A
is some evidence to suggest that KMC can make a positive	Systemic review
difference on these areas. Specifically, it was found that KMC can	
improve negative maternal mood (e.g., anxiety or depression) and	Athanasopoulou E.,
promote more positive parent-child interactions. Limitations and	Fox JRE
directions for future research are discussed.	
KANGAROO MOTHER CARE	Infant Mental
KMC was introduced in 1978 in Bogota, Colombia by the pediatrician	Health Journal,
Edgar Rey (Ruiz-Pel'aez, Charpak, & Cuervo, 2004) as a way to solve	Vol.35(3), 2014
the problem of insufficient resources in hospitals where there was a	
demand for incubators (Doyle, 1997). It was first used to maintain the	
infant's temperature within normal range, through contact with the	
caregiver's body.	
KMC is currently used widely in Western as well as developing	
countries for parent-low birth weight infant dyads, and the models of	
application include continuous and intermittent KMC (Nyqvist et al.,	
2010). <u>Continuous KMC</u> is commonly used in developing	
countries, but is also applied in some high-tech NICU (Blomqvist &	
Nyqvist, 2010; Nyqvist et al., 2010). It involves continuous skin-to-	
skin contact between mother and baby, from birth until (at least)	
the 40th week, ideally accompanied by breastfeeding, discharge	
when the infant is medically stable, and careful follow-up	
(Cattaneo, Davanzo, Uxa, & Tamburlini, 1998; Nyqvist et al., 2010).	
<u>Intermittent KMC</u> is commonly used in Western countries to	
facilitate bonding between caregivers and infants and is applied	
for shorter periods daily for a numbers of days (Nyqvist et al.,	
2010). <u>During KMC</u> , the infant is placed in skin-to-skin contact	
with the mother's, father's, or caregiver's chest in a frontal	
position with the infant's head turned sideways; the airway is	
secured so that obstruction to breathing is prevented (Nyqvist et	
al., 2010). To maintain appropriate body temperature, the infant may	
wear a hat, socks, or diaper and is usually placed under the caregiver's	
clothes or covered with a blanket (Cattaneo et al., 1998; Nyqvist et al.,	
2010). Elastic cloth bands also can be used to maintain the infant's	
position (Nyqvist et al., 2010). At the same time, it is recognized	
that caregivers who provide KMC should be provided with	
adequate support and information while education and training	
needs to be offered to healthcare staff (Cattaneo et al., 1998;	
Nyqvist et al., 2010). Finally, consistent protocols and guidelines for	
KMC need to be in place in healthcare facilities (Cattaneo et al., 1998;	
Nyqvist et al., 2010).	
1.194106.06 m., 2010).	

Many researchers have reported positive outcomes of KMC on the infant's physiological state. The benefits include better cognitive development, reduction of infections and positive outcomes on sleep and crying, temperature, weight gain, heart and respiratory rates, energy expenditure and oxygenation (Dodd, 2005; Hall, & Kirsten, 2008; Ludington-Hoe, 2011; Tessier, Cristo, Nadeau, & Schneider, 2011). Moreover, positive psychological effects have been identified for infants and their families, such as positive outcomes on mother–infant interaction, maternal mood, and sense of coping (Charpak et al., 2005; Tallandini & Scalembra, 2006; Tessier et al., 2011).

**Aim:** This systematic review is the first to synthesize and evaluate research findings from randomized and nonrandomized controlled trials on the effects of KMC on parent-preterm infant interaction patterns and/or maternal mood. Participants. Eligible studies included preterm and low birth weight infants (healthy or otherwise) and their caregivers (mothers and fathers)-biological parents or otherwise. Infants' gestational age had to be <37 weeks, as infants born within this age range are considered preterm (McCarton, Wallace, Divon, & Vaughan, 1996). There was no specific cutoff point for birth weight, but eligible studies had to describe their sample as low birth weight. Study design. Primary randomized and other controlled clinical trials that utilize a quasi-experimental design (e.g., non-equivalent groups design) were included in the review. A total of 13 randomized and nonrandomized controlled trials examining the effects of KMC on maternal mood and/or parent-preterm infant interaction were identified and retrieved.

## Summary.

#### KMC and Parental Mood

Nine studies have examined the effects of KMC on the mood of mothers of preterm, low birth weight babies. Five of those have found significant differences between the mood of mothers in the KMC group and those in the control group (De Macedo, Cruvinel, Lukasova,&D'Antino, 2007; Feldman et al., 2002; Lai et al., 2006; Tallandini & Scalembra, 2006; Tessier et al., 1998) while four did not (Ahn, Lee, & Shin, 2010; Miles, Cowan, Glover, Stevenson, & Modi, 2006; Roberts, Paynter, & McEwan, 2000; Whitelaw, Heisterkamp, Sleath, Acolet, & Richards, 1988).

Specifically, Tessier et al. (1998) reported that mothers in the KMC group felt more competent in looking after their babies and were less stressed when separated from them, as compared to mothers in the control group. At the same time, however, they reported that they felt less supported during their babies' stay at the NICU and more socially isolated. In a similar vein, two more studies have found that mothers who performed KMC alone (Tallandini & Scalembra, 2006) or combined KMC with relaxing music (Lai et al., 2006) reported lower stress. Moreover, Feldman et al. (2002) found that mothers in the KMC group were less depressed, as compared to mothers in the control group, and perceived their infants as more normal. However, the infants' level

## of medical risk was

found to be a significant factor in both groups, as mothers of infants in high risk had higher depression scores, and this was not ameliorated by KMC. Finally, De Macedo et al. (2007) **reported that mothers in the KMC group felt calmer, stronger, more energetic, contented and tranquil, better coordinated, more clear-headed and quickwitted, more relaxed, attentive, proficient, friendly, and happier. Furthermore, the lack of information on the exact amount of KMC that was performed by caregivers makes it difficult to draw conclusions on the amount of KMC that is required for the intervention to be effective.** 

## KMC and Parent–Preterm Infant Interaction Patterns

Researchers in nine studies investigated the effects of KMC on parent–preterm infant interaction patterns. Researchers in seven of those studies detected significant improvements in the KMC groups, as compared to control groups (Ahn et al., 2010; Feldman et al., 2002; Feldman et al., 2003; Gathwala, Singh, & Balhara, 2008; Neu & Robinson, 2010; Tallandini & Scalembra, 2006; Tessier et al., 1998), while in two studies they did not (Chiu & Anderson, 2009; Miles et al., 2006).

Follow-up measurements at 41 weeks and 3 and 6 months showed that some of the improvements were still apparent.

Specifically, Ahn et al. (2010) found that mothers in the KMC group demonstrated stronger attachment to their babies than did mothers in the control group. Specifically, mothers tended to be more sensitive toward their infants when they had spent more time in the NICU. **At 3 months**, Gathwala et al. (2008) reported that mothers in the KMC group picked up their babies more often, slept with them in their bed, were thinking of their babies more frequently, and did not go out without them. They also were more involved in their infant's care and gained more pleasure from interactions with them. Moreover, Feldman et al. (2003) found that both parents in the KMC group created a more sensitive and stimulating home environment through their interactions with their children and with each other. **At 6 months**, it also was found that mothers in the KMC groups had maintained their sensitivity and positive interactions with their infants (Feldman et al., 2002; Feldman et al., 2003).

**Positive effects** were observed in some of the infants who received KMC. Some infants in the KMC groups showed less negative emotions during play (Feldman et al., 2003) and more positive behaviors during reunion with their mother (Neu & Robinson, 2010). They also were better at expressing their needs and more responsive to their mothers (Tallandini & Scalembra, 2006), as compared to infants who received routine care.

**Conversely, researchers** in two studies did not detect a significant difference in mother–infant interaction patterns between KMC and control groups (Chiu & Anderson, 2009; Miles et al., 2006). Interaction patterns were found to be similar between KMC and control groups at 4, 6, 12, and 18 months. Moreover, in the study by Chiu and Anderson (2009), infants in the control group were more

responsive to their mothers than were the infants in the KMC group at	
6 months of age, but this difference was no longer apparent by 12 and	
18 months of age.	
In summary, the findings of the reviewed studies have suggested	
that KMC can have positive effects on maternal mood and parent-	
infant interaction patterns.	
A B S T R A C T	5. Early skin-to-
Background Mother-infant separation postbirth is common in	skin contact for
Western culture. Early skin-to-skin contact (SSC) begins ideally at	mothers and their
birth and involves placing the naked baby, head covered with a dry cap	healthy newborn
and a warm blanket across the back, prone on the mother's bare chest.	infants
According to mammalian neuroscience, the intimate contact inherent	
in this place (habitat) evokes neurobehaviors ensuring fulfillment of	Moore ER,
basic biological needs. This time may represent a	Anderson GC,
psychophysiologically 'sensitive period' for programming future	Bergman N,
physiology and behavior.	Dowswell T
<b>Objectives</b> To assess the effects of early SSC on breastfeeding,	
physiological adaptation, and behavior in healthy mother-newborn	The Cochrane
dyads.	Database Syst
Search methods We searched the Cochrane Pregnancy and Childbirth	Review 2012
Group's Trials egister (30 November 2011), made personal contact	
with trialists, and consulted the bibliography on kangaroo mother care	
(KMC) maintained by Dr. Susan Ludington.	
Selection criteria Randomized controlled trials comparing early SSC	
with usual hospital care.	
Data collection and analysis We independently assessed trial quality	
and extracted data. Study authors were contacted for additional	
information.	
Main results Thirty-four randomized controlled trials were included	
involving 2177 participants (mother-infant dyads). Data from more	
than two trials were available for only eight outcome measures. For	
primary outcomes, we found a statistically significant positive effect	
of early SSC on reastfeeding at one to four months postbirth (13 trials;	
702 participants) (risk ratio (RR) 1.27, 95% confidence interval (CI)	
1.06 to 1.53, and SSC increased breastfeeding duration (seven trials;	
324 participants) (mean difference (MD) 42.55 days, 95% CI - 1.69 to	
86.79) but the results did not quite reach statistical significance ( $P = 0.06$ ).	
0.06). Late preterm infants had better cardio-respiratory stability with	
early SSC (one trial; 31 participants) (MD 2.88, 95% CI 0.53 to 5.23).	
Blood glucose 75 to 90 minutes following the birth was significantly	
higher in SSC infants (two trials, 94 infants) (MD 10.56 mg/dL, 95%	
CI 8.40 to 12.72). The overall methodological quality of trials was	
mixed, and there was high heterogeneity for some outcomes.	
<b>Types of participants</b> Mothers and their healthy full term or late	
preterm newborn infants (34 to less than 37 completed weeks'	
gestation) having early SSC starting less than 24 hours after birth, and	
controls undergoing standard patterns of care. Four studies (Anderson 2003: Bargman 2004: Chuo 1990: Sufratt 1996) wara done with	
2003; Bergman 2004; Chwo 1999; Syfrett 1996) were done with	
healthy late preterm infants who were assigned to the normal newborn pursery Three studies (Gouchen 2010; McClellen 1980; Nolen 2000)	
nursery. Three studies (Gouchon 2010; McClellan 1980; Nolan 2009)	

were conducted with mothers scheduled for repeat cesarean birth using regional anesthesia. One study (Huang 2006) was conducted with hypothermic, but otherwise healthy, newborns post-cesarean birth with spinal anesthesia. One paper reported results for studies carried out in three different sites and we have treated these as three different studies in the data and analysis (Sosa 1976a; Sosa 1976b; Sosa 1976c).

## Types of interventions

### <u>Early SSC for term or late preterm infants can be divided into</u> <u>several subcategories.</u>

(a) In 'birth SSC', the infant is placed prone skin-to-skin on the mother's abdomen or chest during the first minute postbirth. The infant is suctioned while on the mother's abdomen or chest, if medically indicated, thoroughly dried and covered across the back with a prewarmed blanket. To prevent heat loss, the infant's head may be covered with a dry cap that is replaced when it becomes damp. Ideally, all other interventions are delayed until at least the end of the first hour postbirth or the first successful breastfeeding.

(b) In 'very early SSC', beginning approximately 30 to 40 minutes postbirth, the naked infant, with or without a cap, is placed prone on the mother's bare chest. A blanket is placed across the infant's back.

(c) 'Early SSC' can begin anytime between one and 24 hours postbirth. The baby is naked (with or without a diaper and cap) and is placed prone on the mother's bare chest between the breasts.

The mother may wear a blouse or shirt that opens in front, or a hospital gown worn backwards, and the baby is placed inside the gown so that only the head is exposed. What the mother wears and how the baby is kept warm and what is placed across the baby's back may vary. What is most important is that the mother and baby are in direct ventral-to-ventral SSC and the infant is kept dry and warm. In the future these groups may be analyzed separately. However, at present, not enough studies are available for subgroup analysis. Standard contact includes a number of diverse conditions, infants held swaddled or dressed in their mothers arms, or infants placed in open cribs or under radiant warmers in the mother's room or elsewhere with no holding allowed.

## AUTHORS'CONCLUSIONS Implications for practice

**Breastfeeding outcomes:** this review does provide evidence to support current practices as recommended by the UNICEF endorsed Baby Friendly Hospital Initiative, <u>in which SSC is encouraged for the first</u> hour after birth. There is, however, inadequate evidence with respect to details such as timing of initiation, dose of skin-toskin contact (SSC) and technique. This review does not address subsequent ongoing SSC as an intervention to support breastfeeding. It is, however, noteworthy that an intervention practiced for a short time at birth should have measurable breastfeeding effects one to four months postbirth.

Infant outcomes: the significant increase in blood glucose, and

maintenance of infant temperature in the neutral thermal range are both clinically important, and lend support to current American Academy of Pediatrics recommendations for the use of SSC in the first hour after birth (American Academy of Pediatrics 2005). Clearly there is a relationship between improved breastfeeding and higher blood glucose. In terms of evolutionary biology, and mammalian studies, this higher value may in fact be the norm, and a loweringmay reflect the autonomic nervous system evoking a separation distress response, consuming excess calories (Christensson 1995). This is further supported by the significantly increased crying seen in separation versus SSC (three studies). The decreased crying is in itself clinically important for other reasons as described in the background (Ludington-Hoe 2002). Late-preterm infants

are at increased risk for hypoglycemia and hypothermia which can worsen any symptoms of respiratory distress (Raju 2006). The SCRIP score attempts to provide a composite measure of cardiorespiratory stability. Only one study reported this, with significant benefit in favor of SSC, providing further support for the use of early SSC. While differences in particular cardiorespiratory outcomes are evident, these are open to different interpretations, and mean little without a sense of trend and direction in terms of stabilization and physiological selfregulation.

Although a number of the infant physiological outcomes, (except SCRIP scores, blood glucose, infant crying, and maintenance of physiological parameters), demonstrated little or no clinically significant differences with or without SSC, no negative short- or long-term effects were found. <u>Based on the available evidence, SSC</u> appears to have some clinical benefit, especially for temperature and cardio-respiratory stability in late preterm infants.

Attachment outcomes: despite the variability in dose and timing of the intervention, there is at least a small effect on several dimensions of maternal neurobehavior in relation to her infant. This is consistent with evolutionary biology theory, in which infant survival depended on an immediate care-giving imperative. There is no benefit shown in any study from infants being separated.

<u>The main results of the meta-analysis, and</u> from the single studies, indicate that SSC appears to have a positive effect on breastfeeding one to four months postbirth, blood glucose, infant crying and on infant temperature stability. <u>The timing of the intervention may be</u> <u>important, because most infants are very alert in the first two hours</u> <u>postbirth and, if undisturbed and unmedicated, will self-attach to the</u> <u>nipple, and do so correctly, at approximately 55 minutes postbirth.</u> However,Widstrom 2011 noted that it may take some infants up to 45 minutes to latch after they reach the mother's nipple. The temperature of a healthy newly delivered infant will remain in a safe range, provided ventral-to-ventral SSC is uninterrupted; the infant is thoroughly dried and covered across the back with a prewarmed blanket; and the head is covered with a dry cap that is replaced if it becomes damp. These practices need to be incorporated into hospital routines along with the stipulation that mothers and newborn infants

should not be left alone and unattended by medical personnel in the	
delivery or recovery room during this transitional period (Dageville	
2008).	
P L A I N L A N G U A G E S U M M A R Y	
Early skin-to-skin contact for mothers and their healthy newborn	
infants Skin-to-skin contact between a mother and her baby at birth	
reduces crying, and helps the mother to breastfeed successfully. In	
many cultures, babies are generally cradled naked on their mother's	
bare chest at birth. Historically, this was necessary for the baby's	
survival. In recent times, in some societies such as in industrialized	
countries more babies are born in hospital, and as part of usual hospital	
care babies are often separated and swaddled or dressed before being	
given to their mothers. It has been suggested that hospital routines	
may significantly disrupt early mother and baby interactions and	
have harmful effects. This review was done to see if there was any	
impact of early skin-to-skin contact between the mother and her	
newborn baby on infant health, behavior, and breastfeeding.	
The review included 34 randomized studies involving 2177 mothers	
and their babies. It showed that babies exposed to skin-to-skin contact	
interacted more with their mothers and cried less than babies receiving	
usual hospital care. Mothers were more likely to breastfeed in the first	
one to four months, and tended to breastfeed longer, if they had early	
skin-to-skin contact with their babies. Babies were possibly more	
likely to have a good early relationship with their mothers but this was	
difficult to measure. The overall methodological quality of trials was	
mixed. There was variation in how the intervention was implemented,	
including the time of skin-to-skin contact started after the birth and	
how long it lasted, the outcomes looked at and how they were	
measured. No clear negative outcomes were reported in association	
with skin-to-skin contact.	
Abstract Background: Skin-to-skin care has been adopted all over	6. Meta-analysis
the world, although physiological changes during or after it have not	of physiological
been evaluated very well. The purpose of the present study was	effects of skin-to-
therefore to investigate whether skin-to-skin contact for newborn	skin contact for
	newborns and
babies and their mothers affects body temperature, heart rate and	
oxygen saturation of the babies.	mothers
Methods: Studies investigating body temperature, heart rate and	
oxygen saturation of babies during and/or after skin-to-skin contact	Mori R,Khanna R,
were systematically searched and reviewed. Meta-analyses to examine	Debbie P,
the effects and metaregression analyses to investigate correlations	Nakayama T
between the effects and birthweight, duration of the care,	_
environmental	Pediatrics
temperature, and resources of the setting, were conducted.	International,
<b>Results</b> : A total of 23 studies were included. Meta-analyses showed	<b>2010</b> ; 52;161–170
evidence of an increase in body temperature (weighted mean	doi: 10.1111
difference [WMD] $0.22^{\circ}$ C, P < 0.001) and a decrease in saturation of	
babies (WMD -0.60%; $P = 0.01$ ) during skin-to-skin care, compared	
with those before skin-to-skin care. Increase in body temperature was	
more evident	
in middle–low-income settings (WMD, 0.61°C, P < 0.001) than high-	

		0.001). Both the positive effect of fect of fect of fect on saturation were more	n
• 1	Id environments than w		
	was higher (WMD 0.18	$^{\circ}$ C, P < 0.001; WMD -0.82%, P =	=
0.02).		ן בא איז	
	ion trate trate trate	t rate t rate t rate t rate	
et ers	hear hear hear hear hear	hear hear hear hear threat threat threat	
ments Para met ers	It e/sa a ture a ture a ture a ture a ture a ture a ture a ture a ture	ature ature ature ature ature ature ature ature ature ature ature ature	
P	Heart rate/saturation Temperature/heart rate Temperature Temperature Temperature Temperature saturation saturation Temperature saturation Temperature Temperature Temperature saturation	remperature Temperature Temperature Temperature saturation Temperature saturation Temperature Temperature Temperature saturation saturation saturation Temperature saturation Temperature saturation Temperature saturation Temperature saturation Temperature saturation Temperature saturation	
meas	H H H H H H H H H H H H H H H H H H H		
Outcome measurements ng Param	fter fter fter	er and ther	
Outc	Before/during/after Before/during/after Before/during/after Before/during/after Before/during Before/during/after Before/during/after Before/during/after	Before/during/after Before/during/after Before/during/after Before/during/after Before/during/after Before/during/after After/during/after After/during/after	
Ou Timing	Before/during/ Before	Before/during/ Before/during/ Before/during/ Before/during/ Before/during/ Before/during/a After/during/a After/during/a	
	Befor Befor	After After	
=			
Duration of SSC (min)s	10 15 15 15 15 15 15 15 15 15 15 15 15 15	6 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	
D D D	6 -	0	
oral otks)			
Gestational age (weeks)	28 29 29 29 29 29 29 29 29 29 29 29 29 29	28 33 33 33 33 33 33 33 33 33 33 33 33 33	
ge Ge			
ght			
Birthweight (g)	1060 1200 1200 1200 1061 3374 33574 3355 3355 3355 3155 779 779 N/R	N/R 3100 1225 1225 1225 2130 2130 12130 12130 12130 1315 1315 1315 1315 1315 1315 1315 1	
Bird			
3.5	F 9 F 9		
Preterm/ Term	Preterm Preterm Preterm Term Term Preterm Preterm	Preterm Preterm Preterm Preterm Preterm Preterm Preterm	k. <sup>16</sup>
		- 252 2 2222 22 2	at wor
Income	High High High High High High High High	High High High High High High High High	ž
Inc	High High High High High High High High	High High High High Middl High High High High	tolog
z	22 14 87 17 17 17 17 17 17 17 17 17 17 17 17 17	39 33 33 11 12 13 13 13 13 13 13 13 13 13 13 13 13 13	Climatology Net work. <sup>16</sup>
			<u> </u>

Table 1 Description of included studies	cluded studies	
Study	Place of study	Temperature
Author, published year	City, country	or the aty'
Acolet et al. 198928	London, UK	10.4
Bauer et al. 1997	Berlin, Germany	6.8
Bustrows of al. 1995	San Francisco, USA St Datarshura Pussia	14.1
Chin et al. $2005^{30}$		90
Christensson et al. 1992 <sup>31</sup>	Madrid, Spain	14.2
Christensson et al. 199533	Madrid, Spain	14.2
Clifford & Barnsteiner 2001 <sup>34</sup>	Philadelphia, USA	12.2
Durand et al. 1997 <sup>36</sup> Fohe et al. 2000 <sup>25</sup>	El Paso, USA Maodeburo, Germany	17.5 8.6
	100000 1000000000000000000000000000000	2
Gardner 1979 <sup>38</sup> Huang et al. 2002 <sup>39</sup>	Chi cago, USA Taipei, Taiwan	11 21.9
Ibe et al. 2004 <sup>27</sup>	Lagos, Nigeria	265
Karlsson 1996 <sup>28</sup> Legault & Goulet 1995 <sup>26</sup>	Goteborg, Sweden Montreal. Canada	6.7 6.3
1.0018 and 10018	A DIT and and the I	166
1661 <i>et al</i> . 1661	Los Angacs, USA	100
	Cali, Colombia	23.7
Ludington et al. 1999	Call, Colombia Richland, USA	12.1
	Richland, USA	12.1
Messmer et al. 199722	Miami Beach, USA	23.5
Closa et al. 1998 <sup>35</sup>	Tarragona, Spain	162
Wieland et al. 1995 <sup>19</sup>	Berlin, Germany	8.9
$^{\dagger}\text{Annual average temperature obtained}$ NR, not reported.	ture obtained from the G	from the Global Historical

itudy r sub-category	п	During Mean (SD)	п	Before Mean (SD)			) (fixed) % Cl	Weight %	WMD (fixed) 95% Cl	Year
1 High income countries										
Bauer 1997	22	35.60(1.00)	22	35.00(0.70)			+	0.69	0.60 [0.09, 1.11]	1997
Bosque 1995	8	36.50(0.64)	8	36.80(0.27)		-	+	0.77	-0.30 [-0.78, 0.18]	1995
Chiu 2005	39	36.80(0.20)	39	36.70(0.30)			÷	13.98	0.10 [-0.01, 0.21]	2005
Christensson 1992	25	37.10(0.37)	25	36.60(0.47)			+	3.26	0.50 [0.27, 0.73]	1992
Christensson 1995	14	36.90(0.40)	14	36.00(0.50)			+	1.59	0.90 [0.56, 1.24]	1995
Clifford 2001	7	36.76(0.34)	7	36.76(0.33)			÷	1.45	0.00 [-0.35, 0.35]	2001
Durand 1997	25	37.20(0.29)	25	36.90(0.40)			+	4.77	0.30 [0.11, 0.49]	1997
Fohe 2000	53	37.30(0.30)	53	37.00(0.30)				13.72	0.30 [0.19, 0.41]	2000
Gardner 1979	10	36.72(0.16)	10	37.33(0.11)				12.36	-0.61 [-0.73, -0.49]	1979
Karlsson 1996	9	34.70(0.40)	9	34.10(0.40)			+	1.31	0.60 [0.23, 0.97]	1996
Legault 1995	61	37.30(0.30)	61	36.60(0.30)				15.79	0.70 [0.59, 0.81]	1995
Ludington 1991	12	36.89(0.44)	12	36.05(0.61)			+	0.99	0.84 [0.41, 1.27]	1991
Ludington 2000	16	36.90(0.31)	16	36.69(0.38)			+	3.10	0.21 [-0.03, 0.45]	2000
Ludington 2004	11	36.99(0.36)	11	36.33(0.95)			+	0.50	0.66 [0.06, 1.26]	2004
Monasterolo 1998	38	36.80(0.30)	38	36.80(0.30)			÷	9.84	0.00 [-0.13, 0.13]	1998
Wieland 1995	39	37.25(0.33)	39	37.02(0.28)			+	9.70	0.23 [0.09, 0.37]	1995
lubtotal (95% CI)	389		389				1	93.83	0.20 [0.15, 0.24]	
est for heterogeneity: Ch? est for overall effect: Z = 8.	36 (P < 0.0000		.3%							
2 Middle-low income counts										
Bystrova 2003	44	36.20(1.51)	44	34.50(1.21)				0.55	1.70 [1.13, 2.27]	2003
Huang 2002	24	37.30(0.40)	24	37.00(0.40)			+	3.50	0.30 [0.07, 0.53]	2002
be 2004	13	37.60(0.50)	13	37.10(0.80)			-	0.68	0.50 [-0.01, 1.01]	2004
Ludignton 1999	6	37.30(0.40)	6	36.30(0.78)				0.36	1.00 [0.30, 1.70]	1999
Ludington 1992	11	37.45(0.30)	11	36.43(0.62)			+	1.08	1.02 [0.61, 1.43]	1992
lubiotal (95% CI) est for heterogeneity: Ch? : est for overall effect: Z = 7.1			98				•	6.17	0.61 [0.44, 0.78]	
otal (95% CI) est for heterogeneity: Chi <sup>2</sup>			487 .6%				1	100.00	0.22 [0.18, 0.27]	
est for overall effect: Z = 10	.34 (P < 0.000	01)								
					4	2	0 2	4		
						Decrease	Increase			

		Effects during skin-to-skin care, compared with before skin-to-skin care	I with before skin-	to-skin care	
Body temperature (°C)		Heart rate (beats/min)		Saturation (%)	
21		12		10	
0.22 [0.18-0.27]	P < 0.001	2.04 (-0.04  to  4.12)	$C_{0.0} = 4$	(CI.0-01 CO.1-) 00.0-	P = 0.01
I2 = 94.6%	P < 0.001	12 = 27.8%	P = 0.17	12 = 12.7%	P = 0.33
Correlation coefficient	Ρ	Correlation coefficient	Ь	Correlation coefficient	Ч
21		12		10	
-0.05	0.06	0.64	0.17	0.07	0.51
0.82	0.007	-14.47	0.04	-0.59	0.70
0.04	0.85	N/A		NA	
0.002	0.25	0.14	0.55	-0.001	0.88
	Effects after s	kin-to-skin care, compared	with before skin-	o-skin care	
Body temperature (°C)		Heart rate (beats/min)		Saturation (%)	
		10		0	
71	10000	01	100	0 10 10 10 10 10	2000
0.14 (0.09 - 0.18)	P < 0.001	-0.07 (-2.27 10 2.15)	$C_{0} = 4$	-0.48 (-0.97 to 0.02)	P = 0.00
12 = 55.2%	V = 0.01	12 = 0.%	F = 0.80	12 = 0.%	F = 0.81
Correlation coefficient	Ь	Correlation coefficient	Ρ	Correlation coefficient	Ρ
12		10		×	
-0.03	0.004	0.37	0.20	0.11	0.02
0.34	0.25	N/A		NA	
0.34 -0.64	0.25 0.38	N/A N/A		NA	
	0.82 0.04 0.02 Body temperature (°C) 12 0.14 (0.09–0.18) 12 = 53.2% Correlation coefficient 12 -0.03				0.000 $-14 + 7$ 0.04           0.85         N/A         0.55           0.25         0.14         0.55           8         0.14         0.55           Fffects after skin-to-skin care, compared with before skin-to-skin can         Satt           10         P<0.001

tcome: 02 Heart rat		s (During SSC - Pre SSC)	kin-to-skin ca						
idy sub-category	,	During Mean (SD)	n	Before Mean (SD)	WMD (fixed) 95% Cl	Weight %	WMD (fixed) 95% Cl	Year	
High income countries colet 1989		158.70(9.20)	9	152.20(8.50)		<del></del>	6.50 [-1.68, 14.68]	1989	
auer 1997 osque 1995	22 8	151.00(10.00) 161.00(12.40)	22	151.00(9.00) 160.00(11.20)	·	13.65	0.00 [-5.62, 5.62] 1.00 [-10.58, 12.58]	1997 1995	
lifford 2001 ohe 2000	7 53 61	163.63(11.25) 149.00(16.00)	7 53 61	162.78(11.10) 144.00(14.00)	·	3.15	0.85 [-10.86, 12.56] 5.00 [-0.72, 10.72]	2001 2000 1995	
egault 1995 udington 1991 udington 2004	12	148.50(19.60) 154.77(15.23) 152.17(10.84)	12	151.10(16.70) 145.38(6.83) 144.04(9.61)		4.84	-2.60 [-9.06, 3.86] 9.39 [-0.05, 18.83] 8.13 [-0.43, 16.69]	1995 1991 2004	
lessmer 1997 Ionasterolo 1998	20	160.54(11.60) 152.40(16.10)	20 38	160.34(11.00) 150.10(18.80)		- 8.79 6.96	0.20 [-6.81, 7.21] 2.30 [-5.57, 10.17]	1997	
/ieland 1995 btotal (95% CI)	39 280	158.00(12.00)	39 280	154.00(12.00)	-	15.20 91.61	4.00 [-1.33, 9.33] 2.82 [0.65, 4.99]	1995	
st for heterogeneity: Chi <sup>2</sup> = st for overall effect: Z = 2.5		) (P = 0.51), P = 0%							
Middle-low income countri luang 2002	24	135.10(13.40)	24	141.60(11.90)	<b></b>	8.39	-6.50 [-13.67, 0.67]	2002	
btotal (95% Cl) st for heterogeneity: not ap st for overall effect: Z = 1.7	24 plicable 8 /D - 0.08\		24			8.39	-6.50 [-13.67, 0.67]		
tal (95% CI)	304		304		•	100.00	2.04 [-0.04, 4.12]		
st for heterogeneity: Chi <sup>2</sup> = st for overall effect: Z = 1.9		11 (P = 0.17), P = 27.8%			-10 -5 0 5	10			
					-10 -5 0 5 Decrease Increase	10			
					ompared with that before ghted mean difference.	skin-to-skin	care, stratified by resou	rce of the	
-					pared with that before sk	in-to-skin ca	re. CI, confidence inter-	al; SSC,	
in-to-skin care; W	MD, w	eighted mean dif	fference.						
mparison: 01 Physiolog	ical changes	newborn babies during ski (During SSC - Pre SSC)	in-to-skin car	0					
tcome: 03 Saturation dy sub-category		During Mean (SD)		Before Mean (SD)	WMD (fixed) 95% Cl	Weight %	WMD (fixed) 95% Cl	Your	
colet 1989	n 9	Mean (SU) 94.10(3.20)	n 9	Mean (SD)		3.11	95% CI	Year 1989	
ifford 2001 she 2000	7	96.11(2.35) 93.00(3.10)	7 53	95.92(2.70) 92.60(3.20)		- 2.93 14.32	0.19 [-2.46, 2.84] 0.40 [-0.80, 1.60]	2001 2000	
uang 2002 Igault 1995	24	96.80(1.80) 92.80(3.30)	24	97.20(2.20) 94.80(2.80)		15.94 17.47	-0.40 [-1.54, 0.74] -2.00 [-3.09, -0.91]	2002 1995	
dington 1991 dington 2004	12 11	95.16(1.79) 94.30(2.55)	12 11	95.79(2.02) 95.30(1.83)		8.84	-0.63 [-2.16, 0.90] -1.00 [-2.85, 0.85]	1991 2004	
essmer 1997 onasterolo 1998	20 38	94.85(2.60) 96.40(3.30)	20 38	94.85(3.40) 96.80(2.70)		5.86	0.00 [-1.88, 1.88] -0.40 [-1.76, 0.96]	1997 1998	
eland 1995	39	93.50(2.60)	39	94.10(2.80)		14.33	-0.60 [-1.80, 0.60]	1995	
al (95% CI) it for heterogeneity: Chi <sup>2</sup> =	274 1031 df = 9	(P=0.33) P=12.7%	274		•	100.00	-0.60 [-1.05, -0.15]		
					I				
st for overall effect: Z = 2.5					4 -2 0 2	4			
					-4 -2 0 2 Decrease Increase	4			
st for overall effect: Z = 2.59	e (P = 0.010)	on saturation duri	ing skin	to-skin care, con		4 kin-to-skin ca	re. CI, confidence inter	val; SSC,	
t for overall effect: Z = 2.05 g. 5 Forest plot: in-to-skin care; W	effect o	on saturation dur eighted mean dif	fference.		Decrease Increase	4 kin-to-skin ca	re. CI, confidence inter	val; SSC,	
st for overall effect: Z = 2.55 g. 5 Forest plot: in-to-skin care; W <b>pplicatio</b>	e (P = 0.010) : effect of VMD, w on fo	on saturation dur eighted mean dif or clinico	fference. al pr	actice	Decrease Increase				
g, 5 Forest plot: in-to-skin care; W mplicatio onsiderir	effect of VMD, w on fo ng th	on saturation duri eighted mean dif or clinica ne overal	fference. al pr 1 eff	<i>actice</i> fects of F	Deresse Increase npared with that before st Cangaroo Mc	other C	are and/or s	kin-	
g, 5 Forest plot: in-to-skin care; W mplicatio onsiderir	effect of VMD, w on fo ng th	on saturation duri eighted mean dif or clinica ne overal	fference. al pr 1 eff	<i>actice</i> fects of F	Decrease Increase	other C	are and/or s	kin-	
g,5 Forest plot in-to-skin care; W <i>nplicatio</i> onsiderir -skin car	effect of /MD, w/ on fo ng three in	on saturation duri eighted mean dif or <i>clinicc</i> ne overal low—mi	fference. al pr  1 eff ddle	<i>actice</i> fects of H -income	Deresse Increase npared with that before st Cangaroo Mc	other C nis type	are and/or s e of care car	kin-	
g, 5 Forest plot in-to-skin care; W <i>nplicatio</i> considerir -skin car comoted	effect of VMD, wo on fo ng th re in in th	on saturation duri eighted mean dif or <i>clinicc</i> ne overal low—mi- nese setti	fference. al pr ll eff ddle ngs	<i>actice</i> fects of F -income for stabl	Deresse Increase npared with that before st Kangaroo Mc countries, th e low- and n	other C iis type ormal	are and/or s e of care car birthweight	kin- 1 be	
g, 5 Forest plot: in-to-skin care; W <i>mplicatio</i> onsiderir -skin can romoted f fants. Th	effect of VMD, w on fo ng th ce in in th is d	n saturation dur eighted mean dif or clinicco ne overal low—min ese setti oes not i	fference. al pr ll eff ddle ngs impl	<i>actice</i> fects of F -income for stabl y any ch	Decress Increase npared with that before sh Cangaroo Mc countries, the e low- and n hanges for cur	other C nis type ormal rrent co	are and/or s e of care car birthweight onfiguration	kin- 1 be s. In	
g,5 Forest plot in-to-skin care; W <i>nplicatio</i> onsiderir -skin car comoted fants. Th articular,	effect of VMD, wo on fo ng th ce in in th is d bab	n saturation dur eighted mean dif or clinica ne overal low—mi- ese setti oes not i ies at ris	fference. al pr ll eff ddle ngs impl sk of	actice ects of F -income for stabl y any ch apnea o	Decress Increase npared with that before sh Kangaroo Mc countries, th e low- and n anges for cut f prematurity	other C nis type ormal rrent co shoul	are and/or s of care car birthweight onfiguration d not given	kin- 1 be s. In skin-	
g,5 Forest plot in-to-skin care; W <i>nplicatio</i> onsiderir -skin can fants. Th articular, -skin can	effect of /MD, w on fo ng th ce in in th is d bab	n saturation duri eighted mean dif or clinica e overal low—mi- ese setti oes setti ies at ris ithout ad	ference. al pr ll eff ddle ngs impl sk of lequ	actice Fects of Fects of Fects of Fects of Fects for stable y any check apnea o ate moni	Decress Increase npared with that before sh Cangaroo Mcc countries, th e low- and n hanges for cur f prematurity toring of satu	other C nis type ormal rrent co shoul uration	are and/or s e of care car birthweight onfiguration d not given and respira	kin- 1 be s. In skin- 1tory	
g,5 Forest plot in-to-skin care; W <i>nplicatio</i> considerir -skin car fomoted f fants. The urticular, -skin car atus. The	effect of VMD, we on fo ng th the in th is d bab the with	n saturation dur eighted mean dif or clinica ne overal low—min ese setti oes not i ies at ris ithout ad vironmen	ference. al pr ll eff ddle ngs impl sk of lequ nt se	actice ects of F -income for stabl y any ch apnea o ate moni ems also	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n hanges for cur f prematurity toring of satur to play an in	other C nis type ormal rrent co shoul uration mporta	are and/or s of care car birthweight onfiguration d not given and respira nt role in th	kin- 1 be s. In skin- 1tory	
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin can comoted f fants. The articular, -skin can atus. The arte. Atten	effect of VMD, w on fo ng th ce in this d bab ce w ce envition	n saturation dur eighted mean dif or clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmen should	ference. al pr ll eff ddle ngs impl sk of lequ nt se be p	actice ects of H -income for stabl y any ch apnea o ate moni ems also paid to er	Decress Increase npared with that before sh Cangaroo Mcc countries, th e low- and n hanges for cur f prematurity toring of satu	other C nis type ormal rrent co shoul uration mporta	are and/or s of care car birthweight onfiguration d not given and respira nt role in th	kin- 1 be s. In skin- 1tory	
g,5 Forest plot in-to-skin care; W <i>mplicatio</i> considerir -skin car romoted fants. Th articular, -skin car atus. The	effect of VMD, w on fo ng th ce in this d bab ce w ce envition	n saturation dur eighted mean dif or clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmen should	ference. al pr ll eff ddle ngs impl sk of lequ nt se be p	actice ects of H -income for stabl y any ch apnea o ate moni ems also paid to er	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n hanges for cur f prematurity toring of satur to play an in	other C nis type ormal rrent co shoul uration mporta	are and/or s of care car birthweight onfiguration d not given and respira nt role in th	kin- 1 be s. In skin- 1tory	
g,5 Forest plot in-to-skin care; W <i>mplicatio</i> onsiderir -skin car fants. The articular, -skin car atus. The atus. The are. Atten wironme	effect of /MD, w on fo ng th re in this d bab bab re w tion nt th	n saturation duri eighted mean dif or clinica ne overal low-mid ese setti oes not i ies at ris ithout ad vironmen should nroughthe	ference. al pr ll eff ddle ngs impl sk of lequ nt se be p e ca	actice Fects of Fects	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n hanges for cur f prematurity toring of satur to play an in	other C is type ormal rrent cu shoul uration mporta riate an	are and/or s e of care car birthweight onfiguration d not given and respirant nt role in the	kin- ı be s. In skin- ttory is	
g,5 Forest plot in-to-skin care; W <i>mplicatio</i> onsiderir -skin car formoted fants. The articular, -skin car atus. The atus. The are. Atten wironme <b>onclusio</b>	effect of YMD, w on fo ng th re in this d bab re w e envition nt th n SI	n saturation dur eighted mean dif or clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmen should proughthe kin-to-sk	ference. al pr ll eff ddle ngs impl sk of lequ nt se be p e ca in c	actice Fects of Fects	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n hanges for cur f prematurity toring of saturation to play an in insure approp effective wa	other C is type ormal rrent co shoul uration mporta riate an	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies,	kin- a be s. In skin- ttory is	
g,5 Forest plot in-to-skin care; W <i>mplicatio</i> onsiderir -skin car fants. The articular, -skin car atus. The artis. The artis. The artis. Attem wironme onclusion pecially	effect of /MD, w on fo mg th re in this d bab re w tion nt th n SI whe	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmen should nroughtha kin-to-sk ere resou	al pr al pr ll eff ddle ngs impl k of lequ nt se be p e ca in c rces	actice Fects of H -income for stabl y any ch apnea o ate moni eems also paid to er ure. are is an are limi	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n anges for cur f prematurity toring of satu to play an is nsure approp- effective wa ted and when	other C is type ormal rrent co rrent co shoul uration mporta riate an ay to w re the e	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment	kin- ı be s. In skin- ttory is	
g,5 Forest plot in-to-skin care; W mplicatio onsiderir -skin car romoted f fants. The articular, -skin car atus. The arts. Atten wironme onclusion pecially latively	effect of /MD, w on fo ong the re in the is d bab bab bab bab ce w tion nt th n SI whee cold	n saturation dur eighted mean dif or clinica e overal low-mi ese setti oes not i ies at ris ithout ad vironmen should nroughthe kin-to-sk ere resou l. Monita	al pr ll eff ddle ngs impl k of lequ ht se be p e cz in c rces pring	actice Fects of Fects	Decress Increase npared with that before sh Kangaroo Mcc countries, th e low- and n hanges for cur f prematurity toring of satur to to play an in usure approp effective wa ted and when yer, of the satur	other C nis type ormal rrent co shoul uration mporta riate an ay to w to the e turation	are and/or s of care car birthweight onfiguration d not given and respira nt role in th adequate arm babies, environment and respir	kin- a be s. In skin- atory is is	
g,5 Forest plot in-to-skin care; W mplicatio onsiderir -skin car formoted fants. The articular, -skin car atus. The ure. Attem onclusion pecially latively atus of th	effect of mon for mon for m	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita	ference. al pr ll eff ddle ngs impl kk of lequ ht se be p e ca in c scrces pring ough	actice Fects of F for stabl y any ch apnea o ate moni ems also paid to en are is an are limi g, howev out the	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n anges for cur f prematurity toring of satt to play an i nsure approp effective wa ted and when ver, of the satt care, where n	other C is type ormal rrent co shoul uration mporta riate an ay to w re the e turation resource	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir	kin- be s. In skin- ttory is is atory vely	
g,5 Forest plot in-to-skin care; W mplicatio onsiderir -skin car formoted fants. The articular, -skin car atus. The ure. Attem onclusion pecially latively atus of th	effect of mon for mon for m	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita	ference. al pr ll eff ddle ngs impl kk of lequ ht se be p e ca in c crces oring ough	actice Fects of F for stabl y any ch apnea o ate moni ems also paid to en are is an are limi g, howev out the	Decress Increase npared with that before sh Kangaroo Mcc countries, th e low- and n hanges for cur f prematurity toring of satur to to play an in usure approp effective wa ted and when yer, of the satur	other C is type ormal rrent co shoul uration mporta riate an ay to w re the e turation resource	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir	kin- be s. In skin- ttory is is atory vely	
g,5 Forest plot in-to-skin care; W mplicatio onsiderir -skin car formoted fants. The articular, -skin car atus. The ure. Attem onclusion pecially latively atus of th	effect of mon for mon for m	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita	ference. al pr ll eff ddle ngs impl kk of lequ ht se be p e ca in c crces oring ough	actice Fects of F for stabl y any ch apnea o ate moni ems also paid to en are is an are limi g, howev out the	Decress Increase npared with that before sh Kangaroo Mo countries, th e low- and n anges for cur f prematurity toring of satt to play an i nsure approp effective wa ted and when ver, of the satt care, where n	other C is type ormal rrent co shoul uration mporta riate an ay to w re the e turation resource	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir	kin- be s. In skin- ttory is is atory vely	
g, 5 Forest plot in-to-skin care; W mplication onsiderir -skin care fants. The articular, -skin car atus. The articular, -skin car atus. The articular, -skin car atus. The pecially latively atus of th fluent, sl ccount.	effect of /MD, w on fo ang th re in in th is d bab re w tion nt th m SI whe color an bab	n saturation dur eighted mean dif or clinica are overal low-mi ese setti oes not i ies at ris ithout ad vironmen should nroughthe kin-to-sk ere resou d. Monita abies thre d be con	ference. al pr 11 eff ddle ngs impl k of lequ be p e cz in c sirces pring ough sside	actice Fects of F for stabl y any ch apnea o ate moni eems also vaid to er are is an are limi g, howev out the rred, taki	Decess Increase npared with that before sh Kangaroo Mcc countries, th e low- and n anges for cur f prematurity toring of satur to to play an in- usure approp effective wa ted and when ver, of the satur care, where to ng the costs	other C is type ormal rrent co shoul uration mporta riate an ay to w re the e turation resourc of mon	are and/or s of care car birthweight onfiguration d not given and respira nt role in th adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is is atory vely	7. 'Kangaroo
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin care formoted f fants. The articular, -skin car atus. The atus. The ure. Attem onclusion pecially latively atus of th fluent, sl ccount.	effect of mon for mon for m	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita abies three d be con Kangara	ference. <i>al pr</i> Il eff ddle ngs impl k of lequ t se be p e ca in c side corring ough side	actice Fects of F for stabl y any ch apnea o ate moni ems also baid to er are is an are limi g, howev bout the ored, taki	Decesse Increase Inpared with that before shared countries, the e low- and me anges for cur f prematurity toring of satur to to play an it issure appropri- effective way ted and when ver, of the satur care, where the ng the costs re' (KMC) in	other C is type ormal rrent co y shoul- uration mporta riate an ay to w re the e turation resource of mon	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is is atory vely	7. 'Kangaroo mother care' to
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin car comoted f fants. The articular, -skin car atus. The atus. The atus. The pecially latively atus of the fluent, sl ccount. ackgrout rough co	effect of /MD, we on for mg the re in the bab bab bab re w: e enve tion nt the se when color nd ontin	n saturation dur eighted mean dif or clinica ne overal low-mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou d. Monita abies thro d be con Kangara	ference. al pr 11 eff ddle ngs impl ik of lequ nt see be p e ca in c rcces point side ough side ough is do m in c in	actice Fects of F -income for stabl y any ch apnea o ate moni ems also baid to en are is an are limi g, howev out the ored, taki	Decesse Increase Inpared with that before sh Kangaroo Moc countries, th e low- and n ianges for cur f prematurity toring of satur to play an it issure approp effective wa ted and when ver, of the satur care, where the ng the costs re' (KMC) in ntact, support	other C is type ormal rrent cu shoul uration mporta riate an ay to w re the e turation resource of mon	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is is atory vely	mother care' to
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin care fants. The articular, -skin car atus. The articular, -skin car atus. The articular, -skin car atus. The articular, skin car atus. The articular, shin car atus. The articular, shin car atus. The articular, shin car atus. The articular, shin car atus of th fluent, shi arcugh co atus atter arough co	effect of VMD, we on for any f	n saturation dur eighted mean dif or clinica he overal low—mi ese setti oes not i ies at ris ithout ad vironmen should nroughthe kin-to-sk ere resou d. Monita abies thre d be con Kangarc uous ski or other	ference. al pr 11 eff ddlee ngs impl ik of lequ t se be p e ca in c side crcess oring ough side on m in-to appn	actice Fects of F for stabl y any ch apnea o ate moni eems also vaid to er are is an are limi g, howev out the red, taki	Decesse Increase Inpared with that before shared countries, the e low- and me anges for cur f prematurity toring of satur to to play an it issure appropri- effective way ted and when ver, of the satur care, where the ng the costs re' (KMC) in	other C is type ormal rrent cu shoul uration mporta riate an ay to w re the e turation resource of mon	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is is atory vely	mother care' to prevent neonatal
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin care formoted f fants. The articular, -skin care atus. The atus. The internet onclusion pecially latively atus of the fluent, sl count. ackgroun rough core reastfeed cognition	effect of MD, we on for any the end of the e	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita abies three d be con Kangarc uous ski or other is	ference. <i>al pr</i> Il eff ddle ngs impl k of lequ t se be p e ca in c side crces pring ough iside print on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p ngs impl k of lequ t se be p ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on n n n to on n n n n n n n n n n n n n	actice Fects of F -income for stabl y any ch apnea o ate moni ems also paid to er are is an are limi g, howev out the red, taki	Decess Increase npared with that before sh Kangaroo Mo countries, th e low- and n anges for cur f prematurity toring of satu to play an it nsure approp effective wa ted and when ver, of the satu care, where the ng the costs re' (KMC) in ntact, support	other C is type ormal rrent co y shoul uration mporta riate an ay to w re the e turation resourc of mon ncludes t for e early	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is atory vely re	mother care' to prevent neonatal deaths due to
g,5 Forest plot in-to-skin care; W mplication onsiderir -skin care formoted f fants. The articular, -skin care atus. The atus. The internet onclusion pecially latively atus of the fluent, sl count. ackgroun rough core reastfeed cognition	effect of MD, we on for any the end of the e	n saturation dur eighted mean dif pr clinica ne overal low—mi- ese setti oes not i ies at ris ithout ad vironmer should nroughtha kin-to-sk ere resou l. Monita abies three d be con Kangarc uous ski or other is	ference. <i>al pr</i> Il eff ddle ngs impl k of lequ t se be p e ca in c side crces pring ough iside print on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p on ngs impl k of lequ t se be p ngs impl k of lequ t se be p ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on ngs in c side on n n n to on n n n n n n n n n n n n n	actice Fects of F -income for stabl y any ch apnea o ate moni ems also paid to er are is an are limi g, howev out the red, taki	Decesse Increase Inpared with that before sh Kangaroo Moc countries, th e low- and n ianges for cur f prematurity toring of satur to play an it issure approp effective wa ted and when ver, of the satur care, where the ng the costs re' (KMC) in ntact, support	other C is type ormal rrent co y shoul uration mporta riate an ay to w re the e turation resourc of mon ncludes t for e early	are and/or s of care car birthweight onfiguration d not given and respira nt role in th ad adequate arm babies, environment and respir ces are relati itoring into	kin- be s. In skin- ttory is is atory vely re	mother care' to prevent neonatal

benefit, and did not report neonatal-specific data. **Objectives** The objectives of this study were to review the evidence, Lawn JL, Mwansaand estimate the effect of KMC on neonatal mortality due to Kambafwile J, complications Bernardo LH, of preterm birth. Fernando CB, Methods We conducted systematic reviews. Standardized abstraction Cousens S tables were used and study quality assessed by adapted GRADE methodology. Meta-analyses were undertaken. International Results We identified 15 studies reporting mortality and/or morbidity Journal of outcomes including nine randomized controlled trials (RCTs) and six Epidemiology **2010**;39:i144–i154 observational studies all from low- or middle-income settings. Except one, all were hospital-based and included only babies of birth-weight doi:10.1093/ije/dyq <2000 g (assumed preterm). The one community based trial had 031 missing birthweight data, as well as other limitations and was excluded. Neonatal-specific data were supplied by two authors. Metaanalysis of three RCTs commencing KMC in the first week of life showed a significant reduction in neonatal mortality [relative risk (RR) 0.49, 95% confidence interval (CI) 0.29-0.82] compared with standard care. A meta-analysis of three observational studies also suggested significant mortality benefit (RR 0.68, 95% CI 0.58-0.79). Five RCTs suggested significant reductions in serious morbidity for babies <2000 g (RR 0.34, 95% CI 0.17–0.65). week of life and >75% of deaths in very low birth weight babies occur i-outcome assess not blinded RCT-outcome assess not blinded RCT-outcome assess not blinded tCT-outcome assess not blinded CT-poor description of R and luster RCT, more erratic implementation of KMC. Birthwe lata missing for 65%. Poss indercounting of deaths Design/ limitations follow up provided neonatal specific data provided neonatal specific data Aortality at 12 months but Aortality at 9 months but receiving standard care Pre-discharge mortality Mortality at 6 months conatal mortality conatal mortality Outcome commenced after the first compare mortality outcomes in babies receiving KMC to those day of commencing fedian d 12.4 days 3.7 days 10 days KMC davs -9 -neonates (n=4165)<2000g=166 and nalysis restricted to Neomates 1000-1999 g Case definition (n Allo Neonates < 2000 g emates < 2000 g Veonates <2000 L emates < 2000 g bers in trial) (NMC) n = 300n = 2851=123 X indicates not included in this analysis beause intervention during this time. See text for r details and sensitivity analysis Ethiopia (facility) Mexico, Indonesia, thiopia (facility) Cuador (facility) in Cochrane 2003, (conde-Acudelo A et al.<sup>11</sup> olombia (facility) ndia (facility) Country hich Cattaneo et al.,<sup>18</sup> 1998<sub>b</sub> Table 1 RCTs identified wh 66 uman et al.,<sup>15</sup> 2008 Sloan et al.,<sup>17</sup> 1994<sup>a</sup> Vorku et al.,<sup>16</sup> 2005 Sloan et al.,<sup>14</sup> 2008 Charpak et al.<sup>°</sup> References <sup>a</sup>Included i Study

 $\times$ 

 $\times$ 

3

 $\sim$ 

[Type text]



at-scale in most low-income countries.	
Abstract	8. The effects of
<b>Objective.</b> Early mother–infant relationships in preterm populations	preterm birth on
were evaluated in the context of a systematic review of the literature.	mother_infant
<b>Design and setting.</b> A systematic search of three electronic databases	interaction
(PsychINFO, PubMed and Cochrane Library) was undertaken. Three	and attachment
studies of maternal attachment, 18 studies of mother-preterm infant	during the
interaction and eight studies of infant attachment were included.	infant's first two
Studies of preterm infant attachment were also evaluated using a	years
metaanalysis.	
<b>Results.</b> Studies of mother–preterm infant interactions showed that the	<b>Review</b> article
differences in maternal interaction behavior between mothers of	
preterm infants and mothers of full-term infants seem to be most	Korja R, Latva R &
evident during the first six months of life. Differences in the preterm	Lehtonen L.
infant's interaction behavior seem also to continue for six months after	
birth. However, five of 18 studies showed an equal or even higher	Acta Obstetricia et
quality of mother-infant interaction in groups of preterm compared to	Gynecologica
groups of full-term infants. Studies of maternal and infant attachment	Scandinavica,
indicated that preterm infants and their mothers are not at higher risk	<b>2012;</b> 91;164-173
of insecure attachment than full-term infants and their mothers.	
Maternal attachment is defined as a mother's emotional bond with	
the infant, including behavioral and emotional levels. The quality	
of maternal attachment is strongly related to the mother-infant	
relationship (4,5). Good-quality mother-infant interaction behavior	
facilitates the infant's later socio-emotional, behavioral and	
cognitive development and is even related to the physical health of	
the child. The infant needs to experience reciprocal affective	
interaction with the parent to become interested in social interactions	
and to develop secure attachment relationships at a later age. <b>Based on</b>	
the quality of parent-infant interaction, the child forms an	
attachment style during the first year of life. The infant's	
attachment style directs the child's behavior in future social relations	
There are plenty of studies providing important insights into the	
development of the mother-infant relationship following a preterm	
birth. However, the data are inconsistent.	
Some of the inconsistency can be explained by the relatively recent	
development of family-centered neonatal care, where the parents are	
encouraged to be present and to be actively involved in the care of the	
infant. For instance, 'Kangaroo Care' is a technique applied with	
increasing duration at present, and infant mental health	
professionals are more often an integral part of the care team. In	
addition, background factors may contribute to inconsistencies among	
the studies, as several studies have revealed differences in	
socioeconomic, cultural and family backgrounds between preterm	
infants and their controls. Furthermore, more immature preterm infants	
surviving today exhibit specific interaction characteristics that may	
affect the results of new studies on the mother-preterm infant	
relationship. Because of these inconsistencies in studies of the mother-	
preterm infant relationship, this issue should be evaluated by a	
systematic review.	

In the present review, 29 studies covering three crucial areas of the mother–preterminfant relationship were evaluated: 1)maternal attachment, 2) mother–infant interaction and 3)infant's attachment. *Inclusion criteria for the studies* 

Studies of maternal attachment representations in preterm infants that met the following criteria were selected:

• Maternal attachment representations were assessed using validated semi-structured interviews based on parental

• Maternal attachment representations were assessed within two years of the infant's birth.

Studies of mother-preterminfant interaction that met the following criteria were selected:

• Mother–infant interaction was assessed using validated, objective observation methods, either from videorecordings or in observations.

• Mother-infant interaction was studied within two years of the infant's birth.

• The study design included a control group of full-term infants.

Studies of preterm infant attachment that met the following criteria were selected:

• Infant attachment was analyzed using a Strange Situation Test (12).

• Infant attachment was studied within 10–18 months of the infant's corrected age.

The studies of preterm infant attachment were evaluated further using meta-analysis. This was possible because the Strange Situation Test (12) was used in all studies and the infant's attachment was assessed within a narrow timeframe. Pooled proportion estimates and 95% confidence intervals of attachment patterns were calculated within a random effect

model framework using the metaprop function of Rmeta package (Version 0.9–19; by Guido Schwarzer) from R statistical software (R Development Core Team, <u>www.Rproject</u>. org).

## Results

## Maternal attachment representations

Three studies of maternal attachment in preterm infants were included (Korja et al 2009, Borghini et al 2006, Cox et al 2000). In all, maternal representations were analyzed using the Working Model of Child Interview coding system. In this well validated method, maternal

attachment representations are divided into three groups:balanced, disengaged and distorted. Two of the studies included a control group consisting of full-term infants.

The prevalence of balancedmaternal attachment representations in preterminfants varied from30 to 68% among participants in the studies (13–15). Korja et al. (13) and Cox et al. (15) related no differences in the ratio of balanced attachment representations between mothers of preterm and full-term infants. Borghini et al. (14) reported a higher ratio of insecure (disengaged or distorted) attachment representations among the mothers of preterminfants than those of full-term infants. However, in the study by Borghini et al. (14), where the level of balanced representation was lowest, the socioeconomic status of the preterminothers was lower than in the two other studies, which

reported a higher proportion of balanced representations (13,14). Interestingly, Borghini et al. (14) and

Korja et al. (13) indicated qualitative differences in the maternal representations between both the preterm and full-term populations. Both studies showed that themothers of preterm infants had less coherence and acceptance and more unrealistic fears for the infant's safety in their representations than did the mothers of full-term infants. Furthermore, the study by Borghini et al. (14) showed that themothers of preterminfants

had a lower level of sensitivity and involvement in their maternal representations than did the mothers of full-term infants.

## Mother-infant interaction

Eighteen studies of mother-preterm infant interaction were included (17–34; Table 2). <u>Most showed that interactional behavior and affect</u> appeared to be different in preterm infant-mother dyads than in those between full-terminfants and their mothers. However, in five of the studies, researchers

reported no differences or an even better quality of interaction in the group of preterm infants than the full-term infants and their mothers. These inconsistent results could be caused by differences in ages and assessment methods used to evaluate different elements of interaction. Furthermore, socioeconomic backgrounds varied significantly among the

study samples. In addition, the inclusion criteria for preterm delivery varied among the studies. Overall, the studies of mother-preterm infant interaction indicated some specific interactional models that characterize

mother-preterm infant relationships.

One main finding was that mothers of preterm infants seem to have a more direct, active and controlling interaction style than mothers of full-terminfants. Schmücker et al. (20) and Minde et al. (30) showed that mothers of preterm infants talked to and looked at their infants more than mothers of full-term infants, but they touched and smiled less than mothers of full-term infants during the first three months. Furthermore, preterm infants and their mothers have been shown to be less facially responsive and to have less eye contact during interactions than mothers and full-term infants (17,20,26). It has been suggested that a more vocal and active interaction style in the preterm group may compensate for the less-responsive facial interactions during the first months after the infant's birth (30).

Studies by Crnic et al. (32) and Muller-Nix et al. (21) <u>indicated that</u> mothers of preterm infants were less sensitive, more controlling and more active than mothers of full-term infants during dyadic play when the infants were four and six months of age. In addition, a study by Landry et al. (27) showed that mothers of preterm infants used fewer questions to direct the infant's attention and were more straight forward in their attention-directing strategies in mother-infant interacting with their babies than mothers of full-term infants when they were at the corrected age of 12 months. Furthermore, the mothers of preterm infants have been shown to use significantly less emotional mirroring and imitation of emotions

than mothers of full-term infants (26). Malatesta et al. (26) noted that this may be due to a negative affect in preterm infants, suggesting that it is not adaptive to imitate an infant's angry and sad emotions, especially if this precipitates even greater stress.

The other main finding in the studies of mother–preterm infant interactionwas that preterm infants are generally more passive and less alert during interactions than full-term infants. Minde et al. (30), Muller-Nix et al. (21) and Korja et al. (18) demonstrated that preterm infants were more passive, exhibited greater compulsivecompliance behaviors, sober and withdrawnmoods and a lower quality of attention, play and motor skills than full-term infants during the first three months (30) and at the corrected age of 12 (18) and 18 (20) months. These results are in line with Crnic et al. (32), Crawford (33) and Lester et al. (28). In the study by Crawford (33), preterm infants demonstrated less vocalizing and playing and were more fretful during free play mother–infant interactions than full-term infants at the corrected

age of 8, 10 and 12 months. Lester et al. (28) showed that full-term infants led the interactions more often at the corrected age of three and five months than preterm infants. <u>Crnic et al. (32) also reported that preterm infants were more passive and less responsive in interactions at the corrected age of 4, 8 and 12 months of age.</u> The preterm infants' passive and sober interaction behavior and affect seem to continue after

the corrected age of six months, despite the finding that the mothers' direct and controlling behavior seems to decrease after the infant reaches the corrected age of six months (20).

In contrast to the studies described earlier (19,20,24,26,30,32), <u>Monterossi et al. (17), Korja et al. (18), Schermann-Eizirik et al. (23),</u> <u>and Greenberg & Crnic (25) found no differences in the quality of</u> <u>amother's interaction with preterm and full-term infants- during the</u> <u>first six months of the infant's corrected age.</u> The studies by Crawford (33) and Greene et al. (31) demonstrated surprisingly that mothers of preterm infants exhibited more positive maternal interaction, including more responsiveness, caretaking and affectionate holding than mothers of full-term infants.

This is in line with the findings of Korja et al. (18) who reported a longer duration of affectionate holding among mothers of preterm babies compared to mothers of full-term infants.

## Infant attachment

<u>Eight studies of preterm infant attachment were included</u> (35–42; Table 3). Four reported only very low birthweight infants (<1500g), and in the other studies, the selection criteria was birthweight <2500g. Infant attachment was assessed in all studies using the Strange Situation Test (12) and this assessment was carried out with infants with a correct age of

between 11 and 14 months. <u>The Strange Situation Test (12) assesses</u> infant attachment patterns and classifies them into three main <u>categories: 1) secure, 2) insecure avoidant, and 3) insecure resistant</u> (43). Assessment should take place at around one year of age, when the infant has reached his or her preferred attachment style. Seven of the eight studies indicated that preterm infants were comparable in their attachment classifications to full term infants in the middle-class populations (35,36,38–42).

The study by Wille (37) included only families of low socioeconomic status and indicated more insecure attachment classifications in preterm infants (56%) than in full-term infants (17%). The distribution of attachment patterns in the eight preterm populations was evaluated further using metaanalysis, which indicated that the pooled proportion of secure attachment classification was 64% (95% confidence intervall 0.58–0.71), insecure avoidant classification 20% (0.16–0.25), and insecure resistant classification 15% (0.10–0.22). These proportions are comparable to those displayed by full-term infants (secure attachment in 62%, insecure-avoidant attachment in 15%, insecure-resistant attachment in 9%, and disorganized attachment in 15%) in a metaanalysis by Van Ijzendoorn et al. (44) in a normative low-risk sample (n=2104).

Two studies of preterm infant attachment indicated specific risk factors affecting a preterm infant's attachment patterns. Brisch et al. (35) showed that a preterm infant's significant neurological impairment was related to insecure attachment. Plunkett et al. (40) indicated that those infants who had breathing problems or spent a longer period in the Neonatal Intensive Care Unit more often demonstrated an insecure resistant attachment style than did preterm infants without breathing problems or with shorter hospitalization periods.

**Results.** Studies of mother–preterm infant interactions showed that the differences in maternal interaction behavior between mothers of preterm infants and mothers of full-term infants seem to be most evident during the first six months of life. Differences in the preterm infant's interaction behavior seem also to continue for six months after birth. However, five of 18 studies showed an equal or even higher quality of mother–infant interaction in groups of preterm compared to groups of full-term infants. Studies of maternal and infant attachment indicated that preterm infants and their mothers are not at higher risk of insecure attachment than full-term infants and their mothers.

The interaction differences among mothers with preterm and fullterm infants may be caused by maternal stress, separation and an interrupted bonding process, leading to higher intrusiveness and lower sensitivity. The differences in maternal interaction behaviors can also be seen as an adaptive response to the preterm infant's immaturity and deficits in responsiveness. Some researchers have suggested that the average mother of a preterm infant tries to provide compensatory care for her infant, including verbalization, looking in the face, and instrumental

touch, but she does so with less affect, including less frequent smiling

and non-instrumental touching (34)	
<u>Conclusions.</u> The mother–preterm infant relationship is complex,	
and some relational patterns forecast greater psychological risk	
than others. It is important to decrease maternal stress and early	
separation in every possible way during hospitalization as well as	
after discharge.	
ABSTRACT	9. Safety and
Skin-to-skin contact (SSC) is a cornerstone of neurodevel-	Effectiveness of
opmentally supportive and family-oriented care for very	skin-to-skin
low-birth-weight preterm infants (VPIs). However, per-	Contact in the
forming SSC with unstable and/or ventilated VPIs remains	NICU to Support
	Neuro-
challenging for caregiving teams and/or controversial in	development in
the literature. We first aimed to assess the safety and effectiveness of SSC with vulnerable VPIs in a neonatal	Vulnerable
	Preterm Infants.
intensive care unit over 12 months. Our second aim was to	
evaluate the impact of the respiratory support (intubation	Carabasse A,
or not) and of the infant's weight (above or below 1000 g)	Kracher S, Hausser
on the effects of SSC. Vital signs, body temperature, and	M, Lnaglet C,
oxygen requirement data were prospectively recorded by	Escande B, Donato
each infant's nurse before (baseline), during (3 time points),	L, Astruc D, Kuhn
and after their first or first 2 SSC episodes. We compared	P.
the variations of each parameter from baseline (analysis	Γ.
of variance for repeated measures with post hoc analysis	JPerinatol Neonat
when appropriate). We studied 141 SSCs in 96 VPIs of	Nurs, <b>2013</b> ; 27;3,
28 (24-33) weeks' gestational age, at 12 (0-55) days of	Nuis, <b>2013</b> , 27,3, 255-262
postnatal age, and at a postmenstrual age of 30.5 ( $\pm$ 1.5)	233-202
weeks. During SSC, there were statistically significant	
increases in oxygen saturation (Sao <sub>2</sub> ) ( $P < .001$ ) with	
decreases in oxygen requirement ( $P = .043$ ), a decrease in	
heart rate toward stability ( $P < .01$ ) but a transient and mod-	
erate decrease in mean axillary temperature following the	
transfer from bed to mother ( $P < .05$ ). Apneas/bradycardias	
requiring minor intervention occurred in 19 (13%) SSCs,	
without need for SSC termination. These variations were	
similar for intubated newborns (18%) as compared with	
newborns on nasal continuous positive airway pressure	
(52%) or breathing room air (30%). However, ventilated	
infants exhibited a significant increase in transcutaneous	
partial pressure of carbon dioxide (TcPco <sub>2</sub> ) ( $P = .01$ ),	
although remaining in a clinically acceptable range, and	
a greater decrease in oxygen requirements during SSC	
(P < .001) than nonventilated infants. Skin-to-skin contact	
in the neonatal intensive care unit seems safe and effective	
even in ventilated VPIs. Recording physiologic data of	
infants before, during, and after SCC provides data needed	
to secure changes of practice in SCC.	

## RESULTS

## Study population

During the whole study period, 96 newborn infants (55 boys and 41 girls) were included, with a median (range) gestational age of 28 (24-33) weeks. The median birthweight of the study population was 1070 g (510-1972 g) and postnatal age ranged from 0 to 55 days (median, 12 days). Of the 96 infants studied, 92 had a central venous catheter in situ. This was an indwelling percutaneously inserted central venous catheter in 82 infants (85%) and an umbilical venous catheter in 10 infants (11%). Only 4 VPIs (4%) had no central venous access. A total of 17 infants (18%) were intubated and 49 infants (52%) were receiving nasal CPAP whereas 30 infants (30%) were breathing room air.

A total of 141 episodes of SSC were collected, being the first SSC for 51 VPIs and the 2 first for the remaining 45 VPIs. The mean  $(\pm SD)$  postmenstrual age at the time of SSC was 30.5 ( $\pm 1.6$ ) weeks. The mean ( $\pm$  SD) weight at the time of SSC was 1069 g ( $\pm$ 285). Among all SSCs, 69 SSCs were performed in VPIs weighing less than 1000 g, and 72 SSCs were performed in VPIs with a weight of 1000 g or more at the time of SSC. Moreover, 25 SSCs were experienced by intubated infants, whereas 116 were performed in nonintubated ones (75 on nCPAP and 41 breathing room air). The mean duration ( $\pm$ SD) of the 141 SSCs was 71.39 ( $\pm$  34.36) minutes. On the basis of calculations in the 45 infants from whom we recorded 2 SSC episodes, we observed that this mean duration  $(\pm SD)$  significantly increased between the first and second SSCs: 60.5 (±31.4) minutes vs 89.7 ( $\pm$  38.0) minutes; P < .001 (Student *t* test). TcPco2 was only measured in 93 SSCs.

Parameters	Variation (ANOVA)	P (post hoc)	Average maximum variation (95% CI)	
Axillary temperature (°C)	↓ <i>P</i> < .001	$P < .001 (TP_2^a)$ $P = .024 (TP_3^a)$ $P = .020 (TP_5^a)$	-0.2 (95% Cl, -0.25 to -0.15) -0.07 (95% Cl, -0.13 to -0.01) -0.08 (95% Cl, -0.15 to -0.01)	
HR (beat/min)	↓ <i>P</i> = .001	P < .001 (TP <sub>2</sub> *)	- 3.5 (95% Cl, - 5.3 to - 1.8)	
RR (breath/min)	NS (P = .13)	•••		
Sao <sub>2</sub> (%)	↑ <i>P</i> = .005	$P = .025 (TP_5^{a})$	+1.46 (95% Cl, -0.1 to + 3.01)	
TcPco <sub>2</sub> (mm Hg)	NS (P = .46)	• • •		
Fio <sub>2</sub> (%)	↓ <i>P</i> = .043	$P = .020 (TP_5^a)$	-0.9% (95% Cl, -0.1 to -1.8)	
dicate statistical significance (ANOV)		alvia contact (CCC) concets T	D 20 to 60 minutes after CCC exects and TD 5 minutes	
(P2, TP3, and TP5 indicate the time p ter SSC termination) in which a signi	eriods (TP <sub>2</sub> , 5 minutes after skin-to lficant variation of the parameter w	as found in post hoc analys	${\rm P_g}$ , 30 to 60 minutes after SSC onset; and ${\rm TP_g}$ , 5 minutes is (Newman-Keuls test) as compared with baseline.	10. State of the ar
$P_2$ , $P_3$ , and $P_5$ indicate the time p er SSC termination) in which a signi <b>BSTRACT</b>	eriods (TP <sub>2</sub> , 5 minutes after skin-to lficant variation of the parameter w	as found in post hoc analys	P <sub>3</sub> , 30 to 60 minutes after SSC onset; and TP <sub>8</sub> , 5 minutes s (Newman-Keuls test) as compared with baseline.	10. State of the ar and
P2, P2, and P2 indicate the time p ter SSC termination) in which a signi BSTRACT ince Kangaroo N	eriods (TP2, 5 minutes after skin-to ificant variation of the parameter w Mother Care (K	MC) was de	s (Newman-Keuls test) as compared with baseline.	_

infant skin-to-skin contact; early discharge with the infant in the kangaroo position; (ideally) exclusive breastfeeding; and, adequate follow-up. In affluent settings, intermittent KMC with sessions of one or a few hours skin-to-skin contact for a limited period is common. As a result of the increasing evidence of the benefits of KMC for both infants and families in all intensive care settings, KMC in a high-tech environment was chosen as the topic for the first European Conference on KMC, and the clinical implementation of the KMC model in all types of settings was discussed at the 7th International Workshop on KMC. Kangaroo Mother Care protocols in high-tech Neonatal Intensive Care Units (NICU) should specify criteria for initiation, kangaroo position, transfer to/ from KMC, transport in kangaroo position, kangaroo nutrition, parents' role, modification of the NICU environment, performance of care in KMC, and KMC in case of infant instability.

**Conclusion:** Implementation of the original KMC method, with continuous skin-to-skin contact whenever possible, is recommended for application in high-tech environments, although scientific evaluation should continue.

In low income settings, the original method with ideally 24 h/day of mother–infant skin-to-skin care (SSC) in the kangaroo position (KP) is implemented: this method is termed continuous KMC (C-KMC). In affluent settings, the method is implemented as limited sessions with mother–infant SSC in KP, such as one or a few hours, not necessarily every day, occurring over a limited period.

In affluent settings, the first component of KMC is mainly considered, i.e. skin-to-skin contact. It is not a standard policy to offer KMC, and the extent of parent–infant exposure to KMC varies widely; sessions lasting 1 h/day are a common pattern (Boo et al, 2007).

In one randomized controlled trial (RCT) (Ramanathan et al 2001), the intervention group were subjected to KMC at least 4 h/day in not more than three sittings. A mean of 13.5 h/day has been reported (Suman et al, 2010). But even periods of KMC as short as 20 min were used in one intervention study (Miles et al 2006). However, some intervention studies do not present exact data on duration or frequency of KMC sessions.

## <u>Research supporting application of C-KMC in a high-tech</u> <u>environment</u>

A wide range of outcomes is addressed in studies on the effects of KMC. Most outcome variables can be considered universal, as they apply equally to all levels of care in both low income and affluent settings.

In high-tech NICUs, common outcome measures in SSC studies (Bauer et al 1998, Bergman et al 2004, Ludington-Hoe et al 2003, Tornhage et al 1998) which showed improved or maintained stability, even in very preterm infants, are; infant physiological response, such as heart rate; respiration; oxygen saturation; and temperature.

A Cochrane review (McCall et al 2008) concludes SSC is superior to routine measures for preventing hypothermia; however, only one study on skin-to-skin contact (Bergman et al 2004) was included in the

### in a high-tech environment

Nyqvist KH, an Expert Group of the International Network on Kangaroo Mother Care: Anderson GC, Bergman N, Cattaneo A. Charpak N. Davanzo R, Ewald U, Ludington-Hoe S. Mendoza S. Pallás-Allonso C, Peláez JG, Sizun J, Widström A-M COMMITTEE REPORT

Acta Pædiatrica **2010** 99, pp. 812– 819 review. Lower infant cortisol during KMC is noted (Tornhage et al 1998). During transport between hospitals, physiological parameters are stable in infants transported in KP by parents, if available, or otherwise by hospital staff with parental consent (Sontheimer et al 2004). Furthermore, KMC is efficacious in decreasing pain response in preterm and very preterm infants during painful procedures, experiences to which these infants are frequently exposed during their hospital stay (Johntson et al 2008, Johntson et al 2009, Konstandy 2008). Positive effects on infants' sleep patterns and effects that can be interpreted as improved brain maturation (Ludington-Hoe et al 2006, Scher et al 2009) and benefits for neurobehavioral and psychomotor development are observed (Tessier et al 2009, Feldman et al 2003).

Other common outcome variables include <u>psychosocial aspects of</u> <u>parent-infant KMC</u>, such as healing from parental crisis reactions after the birth of a preterm infant (Affonso et al 1993), and <u>improved</u> <u>parent-infant interaction (Feldman et al 2003)</u>. <u>Recovery from</u> <u>postpartum depression in mothers of preterm infants after early</u> <u>introduction of KMC is observed</u> (de Alencar et al 2009) and <u>mothers</u> <u>who practiced 1-h KMC sessions for at least 2 weeks are less stressed</u> <u>and perceived their preterm infants as less difficult than mothers of</u> <u>infants with conventional neonatal care (care without KMC) do</u> (Tallandini et al 2006). <u>Salivary cortisol decreases in mothers</u> of infants born at a gestational age (GA) of <u>25–33 weeks</u> and who <u>practise KMC</u> (Morelius et al 2005). Oxytocin release is suggested as one mediator for these effects of SSC, with short- and long-term consequences <u>on maternal chest temperature and infant temperature</u>, <u>lactation and</u>

breastfeeding, maternal levels of anxiety and social competence, and mother-infant interaction (Uvnas-Moberg 2003).

In addition, a more optimal home environment is created when both mothers and fathers are involved in continuous and prolonged KMC than in the home environment of parents whose infants received conventional neonatal care (Feldman et al 2003). Even short periods of KMC are associated with a higher breastfeeding rate, longer duration, and higher proportions of exclusive breastfeeding in hospital and during follow-up (Hurst et al 1997, Anderson et al 2003, Hake-Brooks et al 2008, Davanzo et al 2009, Renfrew et al 2009). Early breastfeeding competence has been observed even in very preterm infants, with capacity for nutritive sucking from 29 post-menstrual weeks, and attainment of full breastfeeding several weeks before the due date of delivery and as early as at a postmenstrual age of 32 weeks (Nyqvist 2008). These findings support the initiation of KMC and breastfeeding without unwarranted delays: a policy that facilitates early discharge from hospital. **GUIDING PRINCIPLES AND RECOMMENDATIONS FOR** KMC IN A

HIGH-TECH ENVIRONMENT BY THE 7TH INTERNATIONAL WORKSHOP ON KMC AND AN INK EXPERT GROUP

Guiding p	principles
After the u	uterus, maternal / parental-infant SSC is the expected
evolutiona	ry environment for development. All intrapartum and
	• • •
-	care should adhere to a paradigm of non-separation of infants
and their p	parents. Kangaroo Mother Care should be used for
warming.	comfort, physiological and psychological benefits,
0,	evelopment, and the psychosocial needs of the family,
-	
and to pro	omote lactation, breastfeeding initiation and longer
breastfee	<b>ding duration.</b> Prenatally and on arrival at the unit, parents
should be	provided with adequate oral and written information (Table
1).	
Table 1 Parent informa	
Parent information	Contents: Benefits for infant and parents, practical aspects of performance, timing of initiation, substitute KMC provider
Initiation of KMC	Timing: Ideally before delivery, both parents present; continued throughout hospitalization Continuous KMC from birth; exceptions – infant medical condition or parents/substitute unavailable.
GA≥32 weeks	Initial infant assessment on mother's chest in delivery room if possible.
01102 110010	Mild problems in adaptation after birth: Immediately after initial stabilization, as permitted by infant's condition and care
	Infant with CPAP: After stabilization, transport to mother for KMC with monitoring and observation (CPAP/ventilator treatment does not constitute an obstade to KMC).
GA 28-31 weeks	Immediately after initial assessment/stabilization, as permitted by infant's medical condition and care
GA <27 weeks C-section	During first week of life: based on individual medical assessment (weight loss, sensitivity, S-sodium) Short period on mother's chest immediately in the operating room, if possible continued during post-op observation. Afterwards the
C-section	Short period on moviner's chest immediately in the operating from, it possible commuted during post-op observation. Attendances the mother is assisted with transportation to the NICU for as much KMC as possible without unjustified restrictions: father/substitute act as primary KMC provider.
	When mother is unable to visit NICU after delivery, infant can be transported to her in kangaroo position (KP) by father (accompanied by NICU staff when required to monitor the infant), or in transport incubator by NICU staff, who remain to observe and care for the infant and assist the mother in providing KP, if this is possible.
Maternal criteria	Mother unable to visit the NICU because of her own condition and care: infant transported in kangaroo position by father or in transport
Design for the	incubator by staff to the mother's unit for as much KMC as possible. Father acts as primary KMC provider.
Duration of session	Give infants KMC sessions that last at least 1 h.
et endered and	KMC = Kangaroo mother care; KP = Kangaroo position.
	and substitute designated as kangaroo mother care provider by the family.

taking into consideration the physiological and behavioral state of the infant and parent; it is possible that KMC may contribute to the infant's stabilization. Removal from this place of care should be for specific reasons only. For infants born at a gestational age of 27 weeks or less, decisions about the initiation and timing of KMC sessions during the first week of life should be based on individual medical assessment (Agren et al 1998,2006, Chiou 2004). Mothers / parents should be offered adequate support for physical, social and mental wellbeing. Kangaroo Mother Care should be used for transfer of the infant to the neonatal unit after birth (when appropriate), within the hospital, and between hospitals: this should be carried out with portable equipment for cardio-respiratory monitoring, assisted ventilation and other required medical technical support (Table 2) Visiting regulations should accommodate 247 KMC, in that there should be no restrictions for parents' presence or for persons designated as KMC surrogates by the parents (Table 3). If economic restrictions and social policies create obstacles for allowing parents to stay as much as they wish with their infants, interventions should be implemented for optimal changes, including advocacy for maternity leave policies allowing parents to provide KMC. The physical environment should be adapted as far as possible for parents' and infants' maximum relaxation and comfort (depending on available economic resources). Parents should be involved in the infant's care soon after birth, and coached to take over the infant's care before the infant is discharged from hospital (Nyqvist et al 2009). During KMC, monitoring, nursing and medical care is

provided according to curr as the only difference (Tal KMC sessions are based of instability occurs during K should be taken with the in be discontinued when thes improvement: adjusting th ascertaining maximum infundertake and evaluate. Put the maintenance of the con maximum KMC for effect used during terminal care Parker et al 2002).	ble 4). For unst on ongoing phy MC, relevant infant remaining e measures do e infant's kang ant-parent KN rimary respons rrect kangaroo iveness. Kanga	able infants, de siological asse nursing and me g in KP, and K not produce th aroo position a IC is a primary ibilities include position for sa uroo Mother Ca	ecisions about ssment. If edical measures P should only be expected and v activity to e monitoring fety and the are may be	
ABSTRACT Aim: To determine if clim maintain their temperature for other negative effects. Methods: Continuous mea parameters 2 h before, dur gestational age at birth wa was 8 days, postmenstrual actual weight 702 g. Mean 98 min. 16 infants were sk father and one with an old Results: There were no si temperature, heart rate, res during, and after skin-to-si range, the mean skin temp contact with the mother an contact with the father (p	e during skin-to asurement of 2 ing, and 2 h af as 25 weeks and age was 26 we duration of sk in-to-skin with er sister. gnificant differ spiration rate, o kin contact. We erature increase ad decreased 0.	2 stable infants ter skin-to-skir 1 4 days, mean eeks and 6 day in-to-skin-cont of the mother, fir rences in mean or oxygen satur hile staying wir 3 °C during ski	and to screen s' physical p-contact. Mean post-natal age s, and mean tact was ve with the skin ration before, ithin normal ng skin-to-skin in-to-skin	<ul> <li>11. Extremely preterm infants tolerate skin-to- skin contact during the first weeks of life</li> <li>Maastrup R., Greisen G</li> <li>Acta Paediatrica</li> <li>2010;99;1145-1149</li> </ul>
Table 1         Study group (n = 2)	2)	Mean (ran		
Gestational age, weeks + da Postmenstrual age at test, we Birth weight (g) Weight at test (g) Postnatal age at test (days) Duration of skin-to-skin conta Incubator temperature at pre Incubator humidity at pre-test	eeks + days act (min) -test, (°C)	25 + 4 ( 26 + 5 ( 735 ( 702 ( 8 ( 98 ( 34.1 (	23 + 6-27 + 0) 25 + 1-27 + 6) 460-1050) 435-900) 1-27) 51-387) 29.3-37.5) 30-84)	
Table 2 Physical parameters		-		
	Pretest me an (±SD)	Test mean (±SD)	Posttest mean (±SD)	
Mean skin temperature (°C) Heart rate (bpm) Respiration rate (per min)	37.1 (±0.33) 160 (±11) 47 (±7) 95 (±3)	37 (±0.40) 160 (±12) 47 (±6) 96 (±2)	37.1 (±0.28) 161 (±14) 48 (±8) 95 (±3)	

### Abstract **OBJECTIVE:** To investigate the impact of early skin-to-skin contact (SSC) provided for first 24 h on incidence of hypothermia in stable newborns weighing 1800 g or more during first 48 h of life. STUDY DESIGN: Stable newborns (term and late preterm: Mean gestational age 37.7 (1.35) weeks, range 34-40 weeks) having birth weight 1800 g or more (Mean weight 2605.6 (419.8) grams) were enrolled after approval from Institutional Human Research Ethics Committee (CTRI/2013/06/003790) and randomized into early SSC (intervention group) and conventional care (control group). Initial care in the delivery room for few minutes immediately after birth in both the groups was given under radiant warmer. In the intervention group, newborns were provided SSC by their mother started between 30 min and 1 h after birth for first 24 h with minimal interruption and were provided conventional care other than SSC for next 24 h of life. In the control group, newborns were kept with their mother and received conventional care other than SSC for first 48 h. Temperature and heart rate of newborns were recorded at 30 min, 1, 2, 3, 4, 5, 6, 12, 24 and at 48 h of life in both the groups. Independent Samples t-Test and relative risk were used to analyze the data.

**RESULT:** Both groups had 50 neonates each with similar baseline characteristics. Heart rates were in normal range in both the groups. The intervention group provided an average (s.d.) of 16.98 (0.28) h of SSC over the first 24 h period. The mean temperature was significantly high in the SSC group at all time intervals starting from 1 to 48 h (Po0.05 for all). In the SSC group only two newborns (4%) had mild hypothermia (cold stress), and, of these two newborns, one had two episodes of hypothermia. All these three episodes of hypothermia (32%) developed hypothermia (temperature 36.5 o C) during first 48 h of life. Of them, 11 newborns had single episode, 4 newborns had two episodes and one

newborn had three episodes of hypothermia. Of these 22 hypothermic episodes, 20 occurred in the first 6 h of life and 2 episodes occurred at 48 h of life. Moderate hypothermia was seen in two newborns, whereas rest had mild hypothermia. The relative risk of developing hypothermia in the control group as compared with the SSC group was 8.00 (95% CI 1.94–32.99). There was no seasonal variation in incidence of hypothermia in both the groups.



12. Effect of early skin-to-skin contact following normal delivery on incidence of hypothermia in neonates more than 1800 g: randomized control trial

SM Nimbalkar, VK Patel, DV Patel, AS Nimbalkar, A Sethi and A Phatak

Journal of Perinatology, **2014;** 34;364–368

or 24 h fter birth decreases incidence of hyp ife. Early SSC needs to be aggressive preterm newborns to reduce incidence	ly promoted in	b. Early SSC nitial 48 h of a term and late	
<b>ABSTRACT</b> <b>BACKGROUND.</b> Sleep is important to trategies to promote sleep among prem Behaviorally based measures of sleep ha leep (QS) and decreased active sleep (A SSC) with the mother, but these results bejective electroencephalographic/polys leep organization. Important difference lectroencephalographic/polysomnograp <b>Subjects</b> Seventyone premature infants have been analyzed to date, with 14 in S group. before PMA of 32 weeks, the infinitraventricular hemorrhage of more that ucencies on cranial ultrasound scans, se	ature infants ha ave shown increases AS) during skin have not been comnographic m s exist between whic definitions were recruited, SC group and 1 ant had no ence n grade II, white eizures, meningi	we been tested. eased quiet -to-skin contact confirmed with neasures of behavioral and of sleep state. data for 28 4 in the control ephalopathy, te matter itis, or	13. Neurophysiologic Assessment of Neonatal Sleep Organization: Preliminary Results of a Randomized, Controlled Trial of Skin Contact With Preterm Infants Susan M.
ongenital brain malformations. Subject cores were >6, whose gestational age v esting weight was >1000 g were includ cor 3 hours through bolus gavage or or procedures or sedative medication within	vas ≥28 weeks, ed. Each infant ally and experie	and whose was fed every enced no painful	Ludington-Hoe, , Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS
cores were >6, whose gestational age westing weight was >1000 g were includ cor 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjection	vas $\geq 28$ weeks, ed. Each infant ally and experie n 12 hours befor cts ( $N = 28$ )	and whose was fed every enced no painful ore testing.	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS
cores were >6, whose gestational age westing weight was >1000 g were includ or 3 hours through bolus gavage or or procedures or sedative medication within	vas ≥28 weeks, ed. Each infant ally and experie n 12 hours befo	and whose was fed every enced no painful	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson
cores were >6, whose gestational age w esting weight was >1000 g were includ c or 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable	vas ≥28 weeks, ed. Each infant ally and experie n 12 hours befor cts ( $N = 28$ ) SSC Group ( $n = 14$ )	and whose was fed every enced no painful ore testing. Control Group (n = 14)	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age v esting weight was >1000 g were includ to r 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib	vas ≥28 weeks, ed. Each infant ally and experie n 12 hours befor cts ( $N = 28$ ) SSC Group ( $n = 14$ ) 7 7	and whose was fed every enced no painful ore testing. Control Group (n = 14) 7 7	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age v esting weight was >1000 g were includ to r 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib Feeding schedule, no. 2-h 3-h Gender, no. Feemale Male	vas $\geq 28$ weeks, ed. Each infant ally and experie n 12 hours befor cts (N = 28) SSC Group (n = 14) 7 7 10 4 7	and whose was fed every enced no painful ore testing. Control Group ( $n = 14$ ) 7 7 11 3 4	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age v esting weight was >1000 g were includ cor 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib Feeding schedule, no. 2-h 3-h Gender, no. Fermale Male History of apnea/bradycardia, no. No Yes	vas $\geq 28$ weeks, ed. Each infant ally and experie n 12 hours befor cts (N = 28) SSC Group (n = 14) 7 7 10 4 7 7	and whose was fed every enced no painful ore testing. Control Group ( $n = 14$ ) 7 7 11 3 4 10 8	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age w esting weight was >1000 g were includ cor 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib Feeding schedule, no. 2-h 3-h Gender, no. Fernale Male History of apnea/bradycardia, no. No Yes Caffeine on day of study, no. No Yes Gestational age, mean ± SD, wk	vas $\geq 28$ weeks, ed. Each infant ally and experie n 12 hours befor cts (N = 28) SSC Group (n = 14) 7 7 10 4 7 7 10 4 7 7 10 4 30.8 ± 1.4	and whose was fed every enced no painful ore testing. Control Group (n = 14) 7 7 11 3 4 10 8 6 7 7 9 5 30.8 ± 1.1	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age v esting weight was >1000 g were includ c or 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib Feeding schedule, no. 2-h 3-h Gender, no. Fermale Male History of apnea/bradycardia, no. No Yes Caffeine on day of study, no. No Yes Gestational age, mean ± SD, wk Birth weight, mean ± SD, g PMA at time of study, mean ± SD, d Neurobiologic Risk Scale score, mean ± SD Score of 0, no.	vas ≥28 weeks, ed. Each infant ally and experie n 12 hours befor cts ( $N = 28$ ) SSC Group ( $n = 14$ ) 7 7 7 10 4 7 7 10 4 30.8 ± 1.4 1457 ± 325 32.4 ± 0.9 1487 ± 175 11.6 ± 5.1 0.29 ± 0.47 10	and whose was fed every enced no painful ore testing. Control Group (n = 14) 7 7 11 3 4 10 8 6 7 7 7 9 5 30.8 ± 1.1 1532 ± 241 32.5 ± 0.9 1573 ± 175 12.0 ± 12.0 0.36 ± 0.50 9	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,
cores were >6, whose gestational age v esting weight was >1000 g were includ to r 3 hours through bolus gavage or or procedures or sedative medication within TABLE 2 Characteristics of the Subjective Variable Room, no. NICU Step-down Bed, no. Incubator Open-air crib Feeding schedule, no. 2-h 3-h Gender, no. Female Male History of apnea/bradycardia, no. No Yes Caffeine on day of study, no. No Yes Caffeine on day of study, no. No Yes Caffeine of study, mean ± SD, wk Birth weight, mean ± SD, g PMA at time of study, mean ± SD, d Neurobiologic Risk Scale score, mean ± SD	vas $\geq 28$ weeks, ed. Each infant ally and experie n 12 hours befor cts (N = 28) SSC Group (n = 14) 7 7 10 4 7 7 10 4 7 7 10 4 30.8 ± 1.4 1457 ± 325 32.4 ± 0.9 1487 ± 175 11.6 ± 5.1 0.29 ± 0.47 10 4	and whose was fed every enced no painful ore testing. Control Group (n = 14) 7 7 11 3 4 10 8 6 7 7 9 5 30.8 ± 1.1 1532 ± 241 32.5 ± 0.9 1573 ± 175 12.0 ± 12.0 0.36 ± 0.50 9 5	Mark WJ, Morgan K, Lewis T, Gutman J, Wilson Mark SS PEDIATRICS 117,

positioned prone, inclined, and nested in an incubator during the 2- to 3-hour pretest period, were fed, and then went into he test period of SSC or incubator care. Infants were left largely undisturbed throughout testing. A mixed-model regression analysis compared the test-pretest differences in outcome measures within and between groups.

<b>RESULTS.</b> Results showed that arousals were significantly lower	
in the SSC group, compared with the control group, for the entire	
study period and for test-pretest matched segments of quiet sleep and	
active sleep. Rapid eye movement was significantly lower for the	
SSC group for the study period and active sleep segments.	
Indeterminate sleep was significantly lower for the SSC group when	
confounding environmental variables were included in the regression	
analysis. When 4 subjects who experienced excessive ambient light	
levels during SSC were removed from analysis, quiet increased during	
SSC.	
CONCLUSIONS. The patterns demonstrated by the SSC group	
are analogous to moremature sleep organization. SSC may be used	
as an intervention to improve sleep organization. Size may be used	
of preterm infants.	
ABSTRACT	14. NIDCAP: A
<b>BACKGROUND,OBJECTIVE:</b> The "synactive" theory of	Systematic Deview and Mate
neurobehavioral development forms the basis of the Neuropern Individualized	Review and Meta-
development forms the basis of the Newborn Individualized	analyses of
Developmental	Randomized
Care and Assessment Program (NIDCAP). Our objective was to assess	<b>Controlled Trials</b>
the effectiveness of NIDCAP in improving outcomes in preterm	
infants.	Ohlsson A, Jacobs
METHODS: Medline, CINAHL, Embase, PsychInfo, The Cochrane	SE
Library,	
Pediatric Academic Societies' Abstracts and Web of Science were	PEDIATRICS Vol
searched in July 2010 and February 2012. The studies selected were	131;3; <b>2013</b>
randomized controlled trials testing the effectiveness of NIDCAP on	
medical and neurodevelopmental outcomes. The authors abstracted	
baseline characteristics of infants and outcomes. The risk of bias was	
assessed by using Cochrane criteria. RevMan 5.1 was used to	
synthesize data by the use of relative risk and risk difference for	
dichotomous outcomes and mean or standardized mean difference for	
continuous outcomes.	
<b>RESULTS: Eleven primary and 7 secondary (follow-up) studies</b>	
enrolling 627 neonates were included, with 2 of high quality. The	
composite primary outcomes of death or major sensorineural	
disability at 18 months corrected age or later in childhood (3 trials,	
•	
302 children; relative risk 0.89 [95% confidence interval 0.61 to 1.29])	
and survival free of disability at 18 months corrected age or later	
in childhood (2 trials, 192 infants; relative risk 0.97 [95% confidence	
interval 0.69 to 1.35]), were not significantly different between the	
NIDCAP and control groups. With the sensitivity analysis that	
excluded the 2 statistically heterogeneous outlying studies, there	
were no significant differences between groups for short-term	
medical outcomes.	

	No. of Studies	•	Source		No. of Infants Reported on		n Statistic	Results (95% CI)[I <sup>2</sup> ]	
Primary outcomes									
Death or major sensorineura disability	3	Pete Wes	uire 2009 ers 2009 <sup>30</sup> trup 2000 trup 2004	25	302		Relative risk	0.89 (0.61 to 1.29) [79%]	
Survival free of any disability	2	Wes	uire 2009 trup 2000 trup 2004	25		192		Relative risk	0.97 (0.69 to 1.35) [0%]
Secondary outcomes									
Visual impairment	2	Wes	ers 2009 <sup>30</sup> trup 2000 trup 2004	25		127		Relative risk	4.0 (0.18 to 89.95) (heterogeneity not applicable, because there were no cases in either group in the study by Peters 2009)
Sensorineural hearing loss	3	McA Pete Wes	1994 <sup>19</sup> multy 2010 ens 2009 <sup>30</sup> thup 2000	25		149		Relative risk	0.61 (0.14 to 2.65) [0%]
Cerebral palsy	3	Als McA Pete Wes	trup 2004 1994 <sup>19</sup> nulty 2011 ers 2009 <sup>30</sup> trup 2000 trup 2004	0 <sup>33</sup>		149		Relative risk	0.22 (0.04 to 1.21 [0%]
	N	IDCAP		Con	rol		Std. M	Mean Difference	Std. Mean Difference
Study or Su		SD 1	Fotal Me	ean	SD Tota	l Wei	ght	IV, Fixed, 95% Cl	IV, Fixed, 95% CI
1.70.1 MDI	at 9 months								
Als 2004	109.55	7.23	11 94.	.85 9	.22 1	35	.0%	1.69 [0.74 to 2.65]	
Als 2011	102.83	10.99	12 90.	.06 11	.33 13	87	.4%	1.11 [0.32 to 1.90]	
Als 2012	99.25	9	12 92					0,65 [-0,11 to 1,41]	
McAnulty 2 Subtotal (9	009 116.24		51 96. 86			2 24	.5%	0.99 [0.56 to 1.42] 1.03 [0.71 to 1.35]	<b>T</b>
	ity: Chi <sup>2</sup> = 2.87, <i>df</i> rall effect: Z = 6.2			0%					
1.70.2 MDI	at 12 months								
Fleisher 19		18.6	13 8	9.4	15 10	n 6	.6% (	).39 [-0.45 to 1.22]	
									1
Maguire 20			69 10 11 7					0.00 [-0.32 to 0.32]	
		= 2 (P =	93 .04); I <sup>2</sup> =	2.9 1 70%	9			1,35 [0,35 to 2,35] .16 [-0,13 to 0,45]	•
Total (95%	CI)		179		18	7 100	.0%	0.55 [0.33 to 0.76]	•
Heterogene Test for ove	ity: Chi <sup>2</sup> = 25.12, d rall effect: Z = 5.0	2 (P < .00	001)		6			· -	-4 -2 0 2 4 Favors control Favors NIDCAP
Test for sub	group differences:	Chi <sup>2</sup> = 15	5.56, df =	1 (P <	.0001), l <sup>i</sup>	= 93.	5%		ravors control - ravors hiddAr
FIGURE 3 Bayley scales of infant deve	lonmont montal	doualas	montin	day ci	0 on 10	month		ated and a	

	NID	1 0 0		ontrol			Std. Mean Differend	e Std. Mean Difference	
Study or Su		.AP SD Total				Weight	IV, Fixed, 95%		
1.71.1 PDI a		SD TOTA	Mean	30	Total	weight	IV, FIXEG, 55/6	Ci iv, rixeu, 35% Ci	
Als 2004	107	28 11	89.23	14.88	3 13	5.4%	1.36 [0.45 to 2	.261	
Ais 2011	92.25 2		82.48			8.1%	0.46 [-0.28 to 1		
Als 2012	96.5 1	.47 12	90.82	15.32	17	7.9%	0.40 [-0.35 to 1	,	
McAnulty 20			84.29	19.24		24.5%	0.81 [0.39 to 1		
Subtotal (95	,	86			90	45.9%	0.74 [0.43 to	1.05]	
	y: Chi <sup>2</sup> = 3.23, <i>df</i> = all effect: <i>Z</i> = 4.69								
1.71.2 PDI a	t 12 months								
Fleisher 199	5 81.7	1.7 13	86.5	19.4	10	6.5%	-0.22 [-1.05 to (	,60]	
Maguire 200				16.3		42.2%	0.08 [-0.24 to (		
Westrup 200				20.4		5.5%	0.48 [-0.42 to ]		
Subtotal (95		93			97	54.1%	0.09 [-0.20 to (	.37] 🕈	
	y: Chi <sup>2</sup> = 1.27, <i>df</i> = all effect: <i>Z</i> = 0.60		);  * = 0%	)					
Total (95% 6	CI)	179			187	100.0%	0.39 [0.18 to (	0,60]	
	y: Chi <sup>2</sup> = 13.74, <i>df</i>			6%				-4 -2 0 -2	
Test for over	all effect: Z = 3.62	P = .0003)						-4 -2 0 2 Favors control Favors NIDCA	AP
Test for sub	group differences: C	ni <sup>2</sup> = 9.25,	df = 1 (	P = .00	)2),   <sup>2</sup> =	89.2%			
FIGURE 4									
Bayley scales of infant devel	onment nevenom	ntor deve	lonmen	t inde	y at Q r	r 19 mo	nths corrected ad	ie.	
buyicy source of infant ucver				t mut	in di U (				
	NIDCAP Events Total	Cont Events		I W	eiaht		k Ratio Fixed. 95% Cl	Risk Ratio M-H, Fixed, 95% CI	
Study or Subaroup					1.5%		3 [0.96–3.11]		
Study or Subgroup Maguire 2009	23 78	14						<b>—</b> 1	
Maguire 2009 Peters 2009	9 55	20	55		6.1%		5 [0.23-0.90]		
Maguire 2009			55		6.1% 2.5%		5 [0.23–0.90] 1 [0.28–1.31]	-	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI)	9 55 5 13 <b>146</b>	20	55 19	) 2		0.6		• •	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events	9 55 5 13 146 37	20 12 46	55 19 156	) 2	2.5%	0.6	1 [0.28–1.31]		
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9.	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = .	20 12 46 008); I <sup>2</sup> :	55 19 156	) 2	2.5%	0.6	1 [0.28–1.31] 9 <b>[0.61–1.29]</b>	0.01 0.1 1 10	100
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = .	20 12 46 008); I <sup>2</sup> :	55 19 156	) 2	2.5%	0.6	1 [0.28–1.31] 9 <b>[0.61–1.29]</b>	0.01 0.1 1 10 avors NIDCAP Favors col	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = . = 0.63 ( <i>P</i> = .53	20 12 46 008); I <sup>2</sup> =	55 19 <b>156</b> = 79%	) 2 ; 10	2.5% <b>0.0%</b>	0.6 0.89	1 [0.28–1.31] 9 [0.61–1.29] 	avors NIDCAP Favors co	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = . = 0.63 ( <i>P</i> = .53	20 12 46 008); I <sup>2</sup> =	55 19 <b>156</b> = 79%	) 2 ; 10	2.5% <b>0.0%</b>	0.6 0.89	1 [0.28–1.31] 9 [0.61–1.29] 	avors NIDCAP Favors co	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = . = 0.63 ( <i>P</i> = .53) t 18 months	20 12 46 008); I <sup>2</sup> =	55 19 <b>156</b> = 79%	) 2 10	2.5% <b>0.0%</b>	0.6 0.89	1 [0.28–1.31] 9 [0.61–1.29] 	avors NIDCAP Favors co	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2	9 55 5 13 <b>146</b> 37 55, <i>df</i> = 2 ( <i>P</i> = . = 0.63 ( <i>P</i> = .53) t 18 months	20 12 46 008); I <sup>2</sup> =	55 19 <b>156</b> = 79% ater i 3 Years (	9 2 5 10 in cl	2.5% <b>0.0%</b>	0.6 <b>0.8</b> 9 Dod. M	1 [0.28–1.31] 9 [0.61–1.29] 	avors NIDCAP Favors co	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a' TABLE 2. Neurodevelopmental (	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months Dutcomes From 4 M	20 12 46 008); I <sup>2</sup> = 0 CA or I onths to 8	55 19 <b>156</b> = 79% ater i 3 Years (	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh	0.6 0.89 000. M	1 [0.28–1.31] 9 <b>[0.61–1.29]</b> - - -H, Mantel-H	avors NIDCAP Favors co aenszel.	
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months Dutcomes From 4 M	20 12 46 008); I <sup>2</sup> = 0 CA or I onths to 8 Sou	55 19 156 = 79% ater i 3 Years ( rce	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh(	0.6 0.89 000. M	1 [0.28–1.31] 9 <b>[0.61–1.29]</b> - - -H, Mantel-H	avors NIDCAP Favors co aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heteroge	ontrol
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2 Neurodevelopmental ( Outcome	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months Dutcomes From 4 N No. of Studies	20 12 46 008); I <sup>2</sup> = 0 CA or I onths to 8 Sou Fleisher Ariagno <sup>3</sup>	55 19 156 = 79% ater i 3 Years ( rce 1995 <sup>24</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa ieported 22	0.6 0.89 000. M	1 [0.28–1.31] • [0.61–1.29] 	aenszel. Results (95% CI)(1 <sup>2</sup> )	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 008); I <sup>2</sup> = 0 CA or I onths to 8 Sou Fleisher Ariagno <sup>2</sup> Fleisher Ariagno <sup>2</sup>	55 19 156 156 1956 4 8 Years ( 1995 <sup>24</sup> 1995 <sup>24</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic Iean difference Iean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months Dutcomes From 4 N No. of Studies	20 12 46 008); I <sup>2</sup> = 0 CA or I onths to 8 Sou Fleisher Ariagno Als 2004	55 19 156 156 19 195 19 1995 <sup>24</sup> 1995 <sup>24</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa ieported 22	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic lean difference tean difference tandardized mean	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heteroge not applicable] 3.80 (-11.06 to 18.66) [heterogene	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 008); P = CA or I onths to & Sou Fleisher Ariagno Als 2012 Als 2012	55 19 156 156 156 195 2 199% 2 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic Iean difference Iean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 466 0008); I <sup>2</sup> = 00008); I <sup>2</sup> = 00008 0008 0008 0008 0008 0008 0008 0	55 19 156 156 156 195 4 Years ( 9 Years ( 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 27 31 32 27	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic lean difference tean difference tandardized mean	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chl <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 008); P = CA or I onths to & Sou Fleisher Ariagno Als 2012 Als 2012	555 19 1566 = 79% atter i 9 Years ( 1995 <sup>24</sup> 1995 <sup>24</sup> 22 9 2009 <sup>28</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic lean difference tean difference tandardized mean	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chl <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 008); I <sup>2</sup> = 0008; I <sup>2</sup>	55 19 156 = 79% ater i 3 Years ( 7 rce 1995 <sup>24</sup> 1995 <sup>24</sup> y 2009 <sup>38</sup> 1995 <sup>24</sup> 2009 <sup>38</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic lean difference tean difference tandardized mean	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2 Neurodevelopmental ( Outcome	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 0008); I <sup>2</sup> := : 0 0008); I <sup>2</sup> := : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	555 19 1566 = 79% atter 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>38</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.89 DOOL. M	1 [0.28–1.31] • [0.61–1.29] -H, Mantel-H Statistic lean difference tean difference tandardized mean	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chl <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months butcomes From 4 N No. of Studies	20 12 46 0008); I <sup>2</sup> := - - - - - - - - - - - - - - - - - - -	55 19 156 = 79% ater 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>28</sup> 2009 <sup>28</sup> 2009 <sup>28</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 	0.6 0.85 000d. M	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (-14.69 to 10.89) [heterogenent not applicable] 3.80 (-11.06 to 18.66) [heterogenent not applicable]	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chl <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> = 46 008); I <sup>2</sup> = 46 008; I <sup>2</sup> = 47 008; I <sup>2</sup>	55 19 156 = 79% ater i 8 Years ( rce 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>35</sup> 2009 <sup>55</sup>	) 2 ; 10 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M	1 [0.28–1.31] 9 [0.61–1.29] -H, Mantel-H Statistic tean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> = - - - - - - - - - - - - - - - - - - -	555 19 156 3 (Years ( 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 2000 <sup>25</sup> 5 77 31 2000 <sup>25</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chl <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> := 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	55 19 156 = 79% ater 195 <sup>24</sup> 195 <sup>24</sup> 195 <sup>24</sup> 2009 <sup>20</sup> 2009 <sup>20</sup> 2009 <sup>20</sup> 2009 <sup>20</sup> 2009 <sup>20</sup> 2009 <sup>20</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> = - - - - - - - - - - - - - - - - - - -	55 19 156 = 79% ater 8 Years ( 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 2009 <sup>30</sup> 2009 <sup>31</sup> 2000 <sup>25</sup> 52 27 31 22 2009 <sup>31</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> = 008; I <sup>2</sup> = 0008; I <sup>2</sup> = 0008; I <sup>2</sup> = 0008; I <sup>2</sup> = 0008; I <sup>2</sup> = 0009; I <sup>2</sup>	555 19 156 3 (Years ( rec 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 2009 <sup>30</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA PDI at 9 or 12 mo CA	9 55 5 13 146 37 55, df = 2 (P = , = 0.63 (P = ,53 t 18 months No. of Studies 1 1 7	20 12 46 008); I <sup>2</sup> = 0008); I <sup>2</sup> = 0008; I <sup></sup>	555 19 1566 3 Years ( rce 1995 <sup>24</sup> 4 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>38</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa 22 2 366	0.6 0.85 000d. M nts N N S S	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic tean difference tean difference tandardized mean difference tandardized mean difference	aenszel.         Results (95% CI)[I <sup>2</sup> ]           -1.90 (- 14.69 to 10.89) [heteroge not applicable]         3.80 (- 11.06 to 18.66) [heterogen not applicable]           0.55 (0.33 to 0.76) [76%]*         0.39 (0.18 to 0.60) [56%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA PDI at 9 or 12 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months No. of Studies 1 1 7 7	20 12 46 008); I <sup>2</sup> := - 47 008); I <sup>2</sup> := - 47 46 008); I <sup>2</sup> := - 47 47 47 47 47 47 47 47 47 47	555 19 1566 = 79% ater i 8 Years ( 7 rce 1935 <sup>24</sup> 1935 <sup>24</sup> 2009 <sup>38</sup> 2009 <sup>38</sup> 2009 <sup>35</sup> 1935 <sup>24</sup> 2009 <sup>35</sup> 2009 <sup>35</sup> 1935 <sup>24</sup> 2009 <sup>35</sup> 1935 <sup>24</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa eported 22 2 366 366	0.6 0.85 000d. M nts N N S S	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference	avors NIDCAP Favors col aenszel. Results (95% CI)[[ <sup>2</sup> ] -1.90 (- 14.69 to 10.89) [heterogenot applicable] 3.80 (- 11.06 to 18.66) [heterogenot applicable] 0.55 (0.33 to 0.76) [76%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability at TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months No. of Studies 1 1 7 7	20 12 46 008);   <sup>2</sup> = CA or I onths to 6 Sou Fleisher Ariagno <sup>3</sup> Ais 2012 McAnult Fleisher Maguire Westrup Kleberg <sup>2</sup> Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Ais 2012 McAnult Fleisher Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Ais 2012 McAnult Fleisher Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Ais 2012 McAnult Fleisher Ariagno <sup>3</sup> Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Maguire Maguire Maguire Westrup Kleberg <sup>2</sup> Fleisher Ariagno <sup>3</sup> Maguire M	555 156 156 3 (156 3 (156) 3 (	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa eported 22 2 366 366	0.6 0.85 000d. M nts N N S S	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference tandardized mean	aenszel.         Results (95% CI)[I <sup>2</sup> ]           -1.90 (- 14.69 to 10.89) [heteroge not applicable]         3.80 (- 11.06 to 18.66) [heterogen not applicable]           0.55 (0.33 to 0.76) [76%]*         0.39 (0.18 to 0.60) [56%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2. Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA PDI at 9 or 12 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months No. of Studies 1 1 7 7	20 12 46 008); I <sup>2</sup> := 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	555 19 1956 8 Years ( ree 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 1995 <sup>24</sup> 2009 <sup>30</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 0. of Infa eported 22 2 366 366	0.6 0.85 000d. M nts nts N N S S S	1 [0.28–1.31] • [0.61–1.29] - H, Mantel-H Statistic lean difference tean difference tandardized mean difference tandardized mean	aenszel.         Results (95% CI)[I <sup>2</sup> ]           -1.90 (- 14.69 to 10.89) [heteroge not applicable]         3.80 (- 11.06 to 18.66) [heterogen not applicable]           0.55 (0.33 to 0.76) [76%]*         0.39 (0.18 to 0.60) [56%]*	eneity
Maguire 2009 Peters 2009 Westrup 2000 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 9. Test for overall effect: Z FIGURE 2 Death or disability a TABLE 2 Neurodevelopmental ( Outcome MDI at 4 mo CA PDI at 4 mo CA PDI at 9 or 12 mo CA	9 55 5 13 146 37 55, df = 2 (P = . = 0.63 (P = .53 t 18 months No. of Studies 1 1 7 7 7	20 12 46 008); I <sup>2</sup> = 6 008); I <sup>2</sup> = 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	555 159 1566 = 79% ater i 8 Years ( 700 1995 <sup>24</sup> 1995 <sup>24</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 2009 <sup>30</sup> 2009 <sup>30</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 1995 <sup>24</sup> 2009 <sup>30</sup> 1995 <sup>24</sup>	) 2 ; 10 ; 10 ; 10	2.5% 0.0% hildh( 22 2 366 366	0.6 0.85 000d. M nts nts N N S S S	1 [0.28–1.31] 9 [0.61–1.29] -H, Mantel-H Statistic tean difference tean difference tandardized mean difference tandardized mean difference	acros NIDCAP         Favors col           aenszel.         Results (95% CI)[1 <sup>2</sup> ]           -1.90 (-14.69 to 10.89) [heterogenot applicable]         3.80 (-11.06 to 18.66) [heterogenet not applicable]           3.80 (-11.06 to 18.66) [noterogenet not applicable]         0.55 (0.33 to 0.76) [76%] <sup>a</sup> 0.39 (0.18 to 0.60) [56%] <sup>a</sup> 0.39 (0.18 to 0.60) [56%] <sup>a</sup>	eneity

		Maguire 2	200038		
Full-scale IQ at 5.5 (WPPSI-R)	or	2 Westrup 2		Standardized mean	0.21 (-0.37 to 0.78) [0%]
8 (WISC-R) y CA	01	Westrup <sup>3</sup>		difference	0.21 ( 0.01 (0.010) [0.0]
		Als 199418	9		
		McAnulty <sup>3</sup>	53		
Verbal IQ at 5.5 (WPPSI-R) or		2 Westrup 2		Standardized mean	-0.06 (-0.63 to 0.51) [0%]
8 (WISC-R) y CA		Westrup <sup>33</sup>		difference	
		Als 1994 <sup>15</sup>	3 5.3		
Denformer et IO E E (NIDDOLD	1.07	McAnulty <sup>3</sup> 2 Westrup 2	2000 <sup>25</sup> 40	Oton double of moon	0.57 ( 0.00 to 1.11) [09/]
Performance IQ 5.5 (WPPSI-R	) Or	2 Westrup 2 Westrup <sup>31</sup>	2000 <sup>25</sup> 48	Standardized mean difference	0.53 (-0.06 to 1.11) [0%]
8 (WISC-R) y CA		Als 1994 <sup>16</sup>	9	unierence	
		McAnulty <sup>3</sup>	53		
a Indicates statistically significar	nt finding				
TABLE 3 Short-term Med					
Outcome	No. of Studie:	s Source	No. of Infants Enrolled or N	o. of Statistic	Results (95% CI) [I <sup>2</sup> ]
			Infants for Which the		
			Outcome Is Reported		
Mortality (in hospital)	4	Fleisher 1995 <sup>24</sup>	354	Risk ratio	1.58 (0.79 to 3.16) [0%]
		Maguire 2009 <sup>29</sup> Peters 2009 <sup>30</sup>			
		Westrup 2000 <sup>25</sup>			
CLD at 36 wk PMA	4	Fleisher 1995 <sup>24</sup>	329	Risk ratio	0.81 (0.57 to 1.16) [79%]
		Maguire 2009 <sup>29</sup>			
		Peters 2009 <sup>30</sup> Westrup 2000 <sup>25</sup>			
IVH: all grades	10	Als 2004 <sup>27</sup>	581	Risk ratio	0.83 (0.64 to 1.07) [16%]
		Als 2011 <sup>31</sup>	001	in orthogo	
		Als CHB 2003 <sup>26</sup>			
		Als CHO 2003 <sup>26</sup>			
		Buehler 1995 <sup>23</sup> Fleisher 1995 <sup>24</sup>			
		Maguire 2009 <sup>29</sup>			
		McAnulty 2009 <sup>28</sup>			
		Peters 2009 <sup>30</sup>			
Net and William	10	Westrup 2000 <sup>25</sup>	50.1	Dist	
IVH grade III/IV	10	Als 2004 <sup>27</sup> Als 2011 <sup>31</sup>	581	Risk ratio	0.90 (0.55 to 1.47) [0%]
		Als CHB 2003 <sup>26</sup>			
		Als CHO 2003 <sup>26</sup>			
		Buehler 1995 <sup>23</sup>			
		Fleisher 1995 <sup>24</sup>			
		Maguire 2009 <sup>29</sup> McAnulty 2009 <sup>28</sup>			
		Peters 2009			
		Westrup 2000 <sup>25</sup>			
Sepsis	4	Fleisher 1995 <sup>24</sup>	335	Risk ratio	0.89 (0.72 to 1.09) [0%]
		Maguire 2009 <sup>29</sup>			
		Peters 2009 <sup>30</sup>			
DOD all atorian	7	Westrup 2000 <sup>25</sup> Als 2004 <sup>27</sup>	400	Risk ratio	0.89 (0.71 to 1.10) [0%]
ROP all stages	1	Als 2004 Als 2011 <sup>31</sup>	400	RISK Fallo	0.69 (0.71 [0 1.10) [0%]
		Als CHB 200326			
		Als CHO 2003 <sup>28</sup>			
		Fleisher 1995 <sup>24</sup>			
		Maguire 2009 <sup>29</sup>			
		McAnulty 200928			
$ROP \ge stage III$	8	Als 2004 <sup>27</sup>	502	Risk ratio	0.73 (0.46 to 1.14) [0%]
		Als CHB 2003 <sup>26</sup>			
		Als CHO 2003 <sup>28</sup>			
		Fleisher 1995 <sup>24</sup> Maguire 2009 <sup>29</sup>			
		McAnulty 2009 <sup>28</sup>			
		Peters 2009 <sup>30</sup>			
		Westrup 2000 <sup>25</sup>			
NEC	6	Als BWH 200328	315	Risk ratio	0.46 (0.18 to 1.16) [0%]
		Als CHB 2003 <sup>26</sup>			
		Als CHO 200326			
		Buehler 1995 <sup>23</sup>			
		Fleisher 1995 <sup>24</sup>			
Quantamental curitor d	7	Maguire 2009 <sup>29</sup>	507	Maan difference	-0.77 (-4.70 to 4.00) [750/]
Supplemental oxygen, d	7	Als 2004 <sup>27</sup> Als 2011 <sup>31</sup>	503	Mean difference	-0.37 (-4.76 to 4.02) [35%]
		Als CHB 2003 <sup>26</sup>			
		Als CH0 2003 <sup>26</sup>			
		Maguire 2009 <sup>29</sup>			
		McAnulty 200928			
		Peters 2009 <sup>30</sup>			


Outcome	No. of Studies	Source	No. of Infants Reported on	Statistic	Results (95% CI) [l <sup>2</sup> ]	
Head circumference at term or 2 wk CA (cm)	6	Als 2004 <sup>27</sup> Als 2011 <sup>31</sup> Als CHB 2003 <sup>26</sup> Als CHO 2003 <sup>26</sup> Maguire 2009 <sup>29</sup>	371	Weighted mean difference	0.08 (-0.24 to 0.40) [44%]	
Head circumference at 9 mo CA (cm)	2	McAnulty 2009 <sup>28</sup> Als 2004 <sup>27</sup> Als 2011 <sup>31</sup>	60	Weighted mean difference	0.09 (-0.61 to 0.79) [55%]	
Head circumference at 1 y CA (cm)	1	Maguire 2009 <sup>38</sup>	148	Mean difference	—0.40 (— 1.00 to 0.20) (heterogeneity not applicable)	
Head circumference at 2 y CA (cm)	1	Maguire 2009 <sup>38</sup>	143	Mean difference	<ul> <li>-0.30 (-0.87 to 0.27) (heterogeneity not applicable)</li> </ul>	
Daily weight gain (g/d)	6	Als 2004 <sup>27</sup> Als 2011 <sup>31</sup> Als CHB 2003 <sup>26</sup> Als CHO 2003 <sup>26</sup> Maguire 2009 <sup>29</sup>	374	Weighted mean difference	1.46 (0.30 to 2.63) [33%]*	
Weight at term or 2 wk CA (g)	6	McAnulty 2009 <sup>28</sup> Als 2004 <sup>27</sup> Als 2011 <sup>31</sup> Als CHB 2003 <sup>28</sup> Als CHO 2003 <sup>28</sup> Maguire 2009 <sup>28</sup> McAnulty 2009 <sup>28</sup>	374	Weighted mean difference	89.23 (30.26 to 208.72) [33%]	
Weight at 9 mo CA (g)	2	Als 2004 <sup>27</sup> Als 2011 <sup>31</sup>	60	Weighted mean difference	-247.31 (-841.72 to 347.11) [0%]	
Weight at 1 y CA (g)	1	Maguire 2009 <sup>38</sup>	148	Mean difference	-0.18 (-0.60 to 0.24) (heterogeneity not applicable)	
Weight at 2 y CA (g)	1	Maguire 2009 <sup>38</sup>	141	Mean difference	-0.30 (-0.87 to 0.27) (heterogeneity not applicable)	
neurodevelopme Abstract Background the	risks fo	or long-te	erm adv	erse neurode	velopmental	15. Randomized controlled trial of
and behavioral of	utcomes	remain	unaccep	otably high. 7	These include	Family Nurture
attention deficits	[Johnso	on et al 2	011], ez	xecutive dysf	unction [Peterson	Intervention in
et al 2000, Baron			L .	<b>1</b>		the NICU:
[Nosarti et al 201 2011].	[2], and	autism s	pectrun	n disorder [Pi	into-Martin et al	assessments of length
Accordingly, the	re have	been inc	reasing	calls for nov	el evidence-	of stay, feasibility
based interventio			-			and safety
developmental m					-	
2012,Sizun et al			-	• •		Welch MG, Hofer
controlled trials ( In addition to sev	(RCTs)	to valida	te the re	esults [Symin	gton et al 2006].	MA, Stark RI, Andrews HF,
there have been r		-				Austin J, Glickstein
the infant through	-			-	C	SB, Ludwig RJ
enrichment of the	e infant'	s NICU	enviror	ment, includ	ing increased	Myers MM and the
parent involveme	ent in in	fant care	[Brett	et al 2011]. T	The best studied	FIN trial Group
of these latter app	-			-		
		,	-		et al 2012], skin-	<b>BMC</b> Pediatrics
to-skin care [Felo				U		<b>2013,</b> 13:148
0 10	-				ckers et al 2004].	
				•	therefore seeks to	
positively effect	-		-	•	-	
infant and mother			•	-		
communication a						
so in the very ear	• •					
the incubator by	-			nge, sustained	d touch, vocal	
soothing and eye					• • •	
stages, when the						
incubator, FNI fa	cilitates	s wrappe	d or ski	n-to-skin hol	ding and as much	

engagement of mothers in daily infant care as possible. Throughout the	
hospitalization,	
FNI facilitates family-based support for mother-infant	
interactions.	
Abstract	
Background: While survival rates for preterm infants have increased,	
the risk for adverse long-term neurodevelopmental and behavioral	
outcomes remains very high. In response to the need for novel,	
evidence-based interventions that prevent such outcomes, we have	
assessed Family Nurture Intervention (FNI), a novel dual mother-	
infant intervention	
implemented while the infant is in the Neonatal Intensive Care Unit	
(NICU). Here, we report the first trial results, including the primary	
outcome measure, length of stay in the NICU and, the feasibility and	
safety of its implementation in a high acuity level IV NICU.	
Methods: The FNI trial is a single center, parallel-group, randomized	
controlled trial at Morgan Stanley Children's Hospital for mothers and	
their singleton or twin infants of 26–34 weeks gestation. Families were	
randomized to standard care (SC) or (FNI). FNI was implemented by	
nurture specialists trained to facilitate affective communication	
between mother and infant during specified calming interactions.	
These interactions included scent cloth exchange, sustained touch,	
vocal soothing and eye contact, wrapped or skin-to-skin holding, plus	
family-based support interactions.	
<b>Results:</b> A total of 826 infants born between 26 and 34 weeks during	
the 3.5 year study period were admitted to the NICU. After infant and	
mother screening plus exclusion due to circumstances that prevented	
the family from participating, 373 infants were eligible for the study.	
Of these, we were unable to schedule a consent meeting with 56, and	
consent was withheld by 165. Consent was obtained for 150 infants	
from 115 families. The infants were block randomized to groups of N	
= 78, FNI and N = 72, SC. Sixteen $(9.6\%)$ of the randomized infants	
did not complete the	
study to home discharge, 7% of those randomized to SC and 12% of	
FNI infants. Mothers in the intervention group engaged in 3 to 4	
facilitated one- to two-hour sessions/week. Intent to treat analyses	
revealed no significant difference between groups in medical	
complications. The mean length of stay was not significantly affected	
by the intervention.	
Safety of the intervention was determined by examining specific	
clinical characteristics of infants during hospitalization and at	
discharge (Table 1).	
Table 1 Clinical characteristics of infants during hospitalization and at	
discharge: $N = 134$ infants who completed the study	
• •	

#### [Type text]

	SC	FNI		
	N = 67	N = 67		
	n (%)	n (%)	x <sup>2</sup>	р
During NICU stay				
Antibiotics to rule out sepsis	40 (59.7)	43 (64.2)	.285	.594
Treated for presumed sepsis	7 (10.4)	9 (13.4)	.284	.594
Confirmed sepsis	11 (16.4)	7 (10.4)	1.027	.311
Medical treatment for NEC	4 (6.0)	7 (10.4)	.891	.345
Surgical treatment for NEC	2 (3.0)	0 (0.0)	*	.496
Caffeine	9 (13.4)	7 (10.4)	.284	.594
Intra-ventricular hemorrhage	17 (25.4)	14 (20.9)	.378	.539
Hydrocephalus	2 (3.0)	0 (0.0)	*	.496
Seizures diagnosed	1 (1.5)	0 (0.0)	*	1.00
Treatment for seizures	1 (1.5)	0 (0.0)	*	1.00
Cardiology †	7 (10.4)	7 (10.4)	0.000	1.00
Retinopathy of prematurity: diagnosis	6 (9.0)	7 (10.4)	.085	.770
Retinopathy of prematurity: surgery	1 (1.5)	0 (0.0)	*	1.00
Feeding problems	15 (22.4)	7 (10.4)	3.481	.062
At discharge				
Nasal oxygen	2 (3.0)	0 (0)	*	.496
Other medications	16 (23.9)	12 (17.9)	.722	.395
	$mean \pm SD$	$mean \pm SD$	t	P
Weight (grams)	2596 (748)	2521 (565)	.655	.513

*\*Fisher's exact test.* † 4 Atrial septal defects; 2 ventricular septal defects; 5 patent foramen ovale; 1 ventricular dilatation; 1 dysplastic pulmonary valve; 1 biventricular dilatation. Abbreviations: NEC Necrotizing enterocolitis.

# Table 2 Demographic characteristics of 115 families randomized for study

mily characteristics	sc	FNI
	N = 56	N = 59
	Mean ± SD	Mean ± SD
Mothers' age (years)	32.8 (5.69)	34.1 (6.11)
Fathers' age (years)	34.9 (6.49)	37.3 (8.09)
	n (%)	n (%)
Married	39 (69.6)	41 (69.5)
Mothers' ethnicity		
Black	13 (23.2)	13 (22.0)
Hispanic	14 (25.0)	17 (28.8)
White	24 (42.9)	24 (40.7)
Other	5 (8.9)	5 (8.5)
Fathers' ethnicity		
Black	15 (26.8)	12 (20.3)
Hispanic	12 (21.4)	15 (25.4)
White	21 (37.5)	28 (47.5)
Other	8 (14.3)	4 (6.8)
Mothers' education		
ligh school or lower	6 (10.7)	7 (11.9)
Some college	15 (26.8)	12 (20.3)
Graduate or higher	35 (62.5)	40 (67.8)
Fathers' education		
High school or lower	14 (25.0)	13 (22.0)
Some college	11 (19.6)	12 (20.3
Graduate or higher	31 (55.4)	34 (57.6
Family income		
< \$40,000	13 (23.2)	10 (16.9
\$40,000 - \$70,000	3 (5.4)	13 (22.1
> \$70,000	34 (60.7)	31 (52.5
Did not report	6 (10.7)	5 (8.5)

of N = 150 infants Baseline characteristics		SC	FNI	
		N = 56	N = 59	
Maternal		n (%)	n (%)	
Preeclampsia		17 (30.4)	23 (39.0)	
HELLP syndrome		3 (5.4)	4 (6.8)	
Hypertension		10 (17.9)	9 (15.3)	
Diabetes		9 (16.1)	13 (22.0)	
Steroids Tocolytic drugs		52 (92.9) 47 (83.9)	55 (93.2) 47 (79.7)	
Cesarean delivery		35 (62.5)	47 (79.7)	
		SC	FNI	
		N = 72	N = 78	
Infant		mean $\pm$ SD	mean ± SD	
Gestational age (wk)		30.7 (2.6)	30.8 (2.1)	
Birth weight (g)		1474 (439)	1426 (396)	
Length at birth (cm)		39.6 (4.2)	39.7 (3.4)	
Head circumference a	at birth (cm)	28.1 (3.0)	28.2 (3.0)	
Mala		n (%)	n (%)	
Male		36 (50.0)	41 (52.6)	
Singleton Cesarean delivery		40 (55.6) 48 (66.7)	39 (50.0) 62 (79.5)	
Resuscitated at birth		18 (26.5)	21 (29.2)	
Placed on CPAP at de	livery	67 (94.4)	67 (90.5)	
Placed on CPAP at o		67 (94.4)	67 (90.5)	
Apgar scores 2	≥7 at 1 minute	57 (79.2)	54 (69.2)	
2	≥4 at 1 minute	66 (91.7)	69 (88.5)	
	≥7 at 5 minutes	68 (94.4)	72 (92.3)	
2	=/ at J minutes			
	≥4 at 5 minutes	71 (98.6)	74 (94.9)	
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was ntervention amount on	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary sho	71 (98.6) ay pressure, HELLP et count. fect demonstra ort-term outco	74 (94.9) syndrome ted with this me, length of	
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was ntervention amount on tay. FNI can be safely a	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary sho	71 (98.6) ay pressure, HELLP et count. fect demonstra ort-term outco	74 (94.9) syndrome ted with this me, length of	
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was ntervention amount on tay. FNI can be safely a NICU.	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary sho and feasibly imp	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou lemented within	74 (94.9) syndrome ted with this me, length of in a level IV	16. Family
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was Intervention amount on tay. FNI can be safely a NICU. Background: Preterm in	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high	71 (98.6) ay pressure, <i>HELLP</i> et count. ifect demonstra ort-term outcou lemented within	74 (94.9) syndrome ted with this me, length of in a level IV	•
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and	24 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou lemented with risk for adverse mes. Family Nu	74 (94.9) syndrome ted with this me, length of in a level IV	Nurture
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was ntervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and ntervention (FNI) in the	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou lemented within risk for adverse mes. Family Nu ve Care Unit (N	74 (94.9) syndrome ted with this me, length of in a level IV arture IICU) is	Nurture Intervention in
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad	24 at 5 minutes nuous positive airwa enzymes, low platel no significant eff the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou lemented with risk for adverse mes. Family Nu ve Care Unit (No separation of mo	74 (94.9) syndrome ted with this me, length of in a level IV arture IICU) is	Nurture Intervention in the Neonatal
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant eff the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate eff	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou lemented with risk for adverse mes. Family Nu ve Care Unit (No separation of mo	74 (94.9) syndrome ted with this me, length of in a level IV arture IICU) is	Nurture Intervention in the Neonatal Intensive
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her eurobehavioral outcome	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate ef s.	71 (98.6) ay pressure, HELLP et count. ifect demonstration ort-term outcom lemented within risk for adverse mes. Family Nu ve Care Unit (No separation of mo ifects of FNI on	74 (94.9) syndrome ted with this me, length of in a level IV arture (IICU) is others and	Nurture Intervention in the Neonatal Intensive Care Unit
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ac heir preterm infants. Here eurobehavioral outcome Methods: Data were coll	≥4 at 5 minutes nuous positive ainwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate ef s. lected at 18 mont	71 (98.6) ay pressure, HELLP et count. ifect demonstration ort-term outcom lemented within risk for adverse mes. Family Nu- ve Care Unit (No separation of mo- ffects of FNI on the corrected age	74 (94.9) syndrome ted with this me, length of in a level IV arture (IICU) is others and	Nurture Intervention in the Neonatal Intensive Care Unit improves social-
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her eurobehavioral outcome Methods: Data were coll	≥4 at 5 minutes nuous positive ainwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate ef s. lected at 18 mont	71 (98.6) ay pressure, HELLP et count. ifect demonstration ort-term outcom lemented within risk for adverse mes. Family Nu- ve Care Unit (No separation of mo- ffects of FNI on the corrected age	74 (94.9) syndrome ted with this me, length of in a level IV arture (IICU) is others and	Nurture Intervention in the Neonatal Intensive Care Unit
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her eurobehavioral outcome Methods: Data were coll preterm infants. Infants w	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate ef s. lected at 18 month vere assigned at b	71 (98.6) ay pressure, HELLP et count. <b>Efect demonstra</b> ort-term outcou- lemented within risk for adverse mes. Family Nu- ve Care Unit (No- separation of mo- ffects of FNI on the corrected age out th to FNI or s	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care	Nurture Intervention in the Neonatal Intensive Care Unit improves social-
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her eurobehavioral outcome Methods: Data were collo reterm infants. Infants w SC). Bayley Scales of In	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate ef s. lected at 18 month vere assigned at b fant Developmen	71 (98.6) ay pressure, HELLP et count. ifect demonstra ort-term outcou- lemented within risk for adverse mes. Family Nu- ve Care Unit (No- separation of mo- flects of FNI on the corrected age out to FNI or s at III (Bayley-II	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the esigned to counteract ad neir preterm infants. Here eurobehavioral outcome Methods: Data were coll reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (S	≥4 at 5 minutes nuous positive ainvas enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensis liverse effects of s re, we evaluate effects te, we evaluate effects liverse affects of s re, we evaluate effects te, we evaluate effects for a signed at b fant Development of an the primary she res.	71 (98.6) ay pressure, HELLP et count. <b>Ffect demonstra</b> <b>ort-term outcom</b> <b>lemented with</b> risk for adverse mes. Family Nuve Care Unit (No separation of mo ffects of FNI on the corrected age of the to FNI or s at III (Bayley-III n = 45); the Chil	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the esigned to counteract ad neir preterm infants. Her eurobehavioral outcome Methods: Data were colli reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (S Checklist (CBCL) for 57	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant eff the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv lverse effects of s re, we evaluate eff s. lected at 18 month vere assigned at b fant Developmen SC, n = 31; FNI, n infants (SC, n =	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Efect demonstra</b> ort-term outcom lemented within risk for adverse mes. Family Nu ve Care Unit (No separation of mo effects of FNI on the corrected age out to FNI or s at III (Bayley-III n = 45); the Chill 31; FNI, $n = 26$	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior ); and the	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her eurobehavioral outcome Methods: Data were collo reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (S Checklist (CBCL) for 57 Modified Checklist for A	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv liverse effects of s re, we evaluate effects of s re, me	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Efect demonstra</b> ort-term outcom lemented within risk for adverse mes. Family Nu ve Care Unit (No separation of mo effects of FNI on the corrected age out to FNI or s at III (Bayley-III n = 45); the Chill 31; FNI, $n = 26$	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior ); and the	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the esigned to counteract ad neir preterm infants. Here eurobehavioral outcome Methods: Data were colli reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (SC checklist (CBCL) for 57 Modified Checklist for A por 59 infants (SC, n = 33	≥4 at 5 minutes nuous positive ainvas enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensis liverse effects of s re, we evaluate effects te, we evaluate effects of s re, we eva	71 (98.6) ay pressure, HELLP et count. <b>Ffect demonstra</b> <b>ort-term outcom</b> <b>lemented with</b> risk for adverse mes. Family Nuve Care Unit (No separation of mo effects of FNI on the corrected age of the to FNI or s int III (Bayley-III n = 45); the Chil 31; FNI, $n = 26$ rs (M-CHAT) w	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior ); and the as obtained	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized
Abbreviations: CPAP Continent Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a AICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the esigned to counteract ad heir preterm infants. Her eurobehavioral outcome Aethods: Data were colli- reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (SC) hecklist (CBCL) for 57 Aodified Checklist for A br 59 infants (SC, n = 32 Results: Family Nurture	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant eff the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv liverse effects of s re, we evaluate eff s. lected at 18 month vere assigned at b fant Developmen SC, n = 31; FNI, n infants (SC, n = autism in Toddler 3; FNI, n = 26). Intervention sign	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Efect demonstra</b> ort-term outcom lemented within risk for adverse mes. Family Nu ve Care Unit (No separation of mo fiects of FNI on the corrected age out to FNI or s at III (Bayley-II n = 45); the Chill 31; FNI, $n = 26$ rs (M-CHAT) w	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior ); and the as obtained wed Bayley-	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the esigned to counteract ad neir preterm infants. Here eurobehavioral outcome Methods: Data were colli reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (S Checklist (CBCL) for 57 Modified Checklist for A for 59 infants (SC, n = 33 Results: Family Nurture II cognitive (p = .039) an	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant eff the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv liverse effects of s re, we evaluate eff s. lected at 18 month vere assigned at b fant Developmen SC, n = 31; FNI, n infants (SC, n = autism in Toddler 3; FNI, n = 26). Intervention sign	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Efect demonstra</b> ort-term outcom lemented within risk for adverse mes. Family Nu ve Care Unit (No separation of mo fiects of FNI on the corrected age out to FNI or s at III (Bayley-II n = 45); the Chill 31; FNI, $n = 26$ rs (M-CHAT) w	74 (94.9) syndrome ted with this me, length of in a level IV arture (ICU) is others and e from tandard care I) were d Behavior ); and the as obtained wed Bayley-	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized
Abbreviations: CPAP Conti Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in eurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Here eurobehavioral outcome Methods: Data were collo reterm infants. Infants w SC). Bayley Scales of In ssessed for 76 infants (S Checklist (CBCL) for 57 Modified Checklist for A for 59 infants (SC, n = 33 Results: Family Nurture II cognitive (p = .039) an whose	≥4 at 5 minutes nuous positive ainvas enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensis liverse effects of s re, we evaluate effects of s re, w	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Fect demonstra</b> <b>ort-term outcom</b> <b>lemented with</b> risk for adverse mes. Family Nu- ve Care Unit (No separation of mo ffects of FNI on the corrected age of FNI or s at III (Bayley-II n = 45); the Chil 31; FNI, $n = 26$ rs (M-CHAT) w ifficantly impro- .008) scores for	74 (94.9) syndrome ted with this me, length of in a level IV a level IV	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized controlled trial Welch MG,
Abbreviations: CPAP Continuent Hemolysis, elevated liver Conclusion: There was intervention amount on atay. FNI can be safely a NICU. Background: Preterm in neurodevelopmental and intervention (FNI) in the designed to counteract ad heir preterm infants. Her neurobehavioral outcome Methods: Data were colloreterm infants. Infants w SC). Bayley Scales of In assessed for 76 infants (S Checklist (CBCL) for 57 Modified Checklist for A for 59 infants (SC, n = 33 Results: Family Nurture II cognitive (p = .039) an whose cores were greater than 5 on the CBCL (p < .02). F	≥4 at 5 minutes nuous positive airwa enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensiv liverse effects of s re, we evaluate ef s. lected at 18 month vere assigned at b fant Developmen SC, n = 31; FNI, n infants (SC, n = .utism in Toddler 3; FNI, n = 26). Intervention sign nd language (p = 85. FNI infants h FNI improved tota	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Effect demonstra</b> <b>ort-term outcom</b> <b>lemented with</b> risk for adverse mes. Family Nu- ve Care Unit (No separation of mo flects of FNI on the corrected age out the to FNI or s at III (Bayley-II n = 45); the Chill 31; FNI, $n = 26$ rs (M-CHAT) we difficantly improv- .008) scores for ad fewer attention of M-CHAT score	74 (94.9) syndrome ted with this me, length of in a level IV a level IV b level is others and a level i a level i a level IV a level i a	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized controlled trial Welch MG, Morgan RF, Austin J, Hane AA, Stark
Abbreviations: CPAP Continuent Hemolysis, elevated liver Conclusion: There was intervention amount on tay. FNI can be safely a NICU. Background: Preterm in neurodevelopmental and intervention (FNI) in the lesigned to counteract ad heir preterm infants. Her neurobehavioral outcome Methods: Data were colli- preterm infants. Infants w SC). Bayley Scales of In assessed for 76 infants (S Checklist (CBCL) for 57 Modified Checklist for A for 59 infants (SC, n = 33 Results: Family Nurture II cognitive (p = .039) an whose cores were greater than 3	≥4 at 5 minutes nuous positive ainvas enzymes, low platel no significant ef the primary she and feasibly imp fants are at high behavioral outco Neonatal Intensis dverse effects of s re, we evaluate effects re, we evaluate effects the effects of s re, we evaluate effects of s re, we	71 (98.6) ay pressure, <i>HELLP</i> et count. <b>Fiect demonstra</b> <b>ort-term outcom</b> <b>lemented with</b> risk for adverse mes. Family Nu- ve Care Unit (No separation of mo fiects of FNI on the corrected age of FNI or s of FNI or s of III (Bayley-II n = 45); the Chil 31; FNI, $n = 26$ rs (M-CHAT) w ifficantly impro- .008) scores for ad fewer attention of M-CHAT scores t least one of the	74 (94.9) syndrome ted with this me, length of in a level IV a level IV	Nurture Intervention in the Neonatal Intensive Care Unit improves social- relatedness, attention, and neurodevelopment of preterm infants at 18 months in a randomized controlled trial Welch MG, Morgan RF, Austin

relatedness M-CHAT item ( $p < .001$ ). Conclusions: Family Nurture Intervention is the first NICU intervention to show significant improvements in preterm infants across multiple domains of neurodevelopment, social-relatedness, and attention problems. These gains suggest that an intervention	Brunelli SA Ludwig RJ, Myers MM Journal of Child
that facilitates emotional interactions between mothers and	Psychology and
infants in the NICU may be key to altering developmental	Psychiatry 2015
trajectories of preterm infants.	Mar 11. doi:
	10.1111/
	jcpp.12405
abstract	17. Single-Family
<b>OBJECTIVE:</b> To determine whether a single-family room (SFR) NICU,	Room Care and Neurobehavioral
including factors associated with the change to a SFR NICU, is	and
associated with improved medical and neurobehavioral outcomes.	Medical
<b>METHODS:</b> Longitudinal, prospective, quasi-experimental cohort	Outcomes in
study	Preterm Infants
conducted between 2008 and 2012 comparing medical and	- i v vini inunto
neurobehavioral outcomes at discharge in infants born ,1500 g.	Lester MB, Hawes
Participants included 151 infants in an open-bay NICU and 252	К,
infants after transition to a SFR NICU. Structural equation modeling	Abar B, Sullivan
was used to determine the role of mediators of relations between	М,
type of NICU and medical and neurobehavioral outcomes.	Miller R, Bigsby R,
<b>RESULTS:</b> Statistically significant results (all Ps #.05) showed that	Laptook A,
infants in the SFR NICU weighed more at discharge, had a greater rate	Salisbury A, Taub
of weight gain, required fewer medical procedures, had a lower	М,
gestational age at full enteral feed and less sepsis, showed better	Lagasse LL, F.
attention, less physiologic stress, less hypertonicity, less lethargy, and	Padbury JF.
less pain. NICU differences in weight at discharge, and rate of weight	Pediatrics
gain were mediated by increased developmental support; differences in	<b>2014;</b> 134:754–760
number of medical procedures were mediated by increased maternal involvement. NICU differences in attention were mediated by	
increased	
developmental support. Differences in stress and pain were mediated	
by maternal involvement. Nurses reported a more positive work	
environment and attitudes in the SFR NICU.	
CONCLUSIONS: The Single-Family Room is associated with	
improved neurobehavioral and medical outcomes. These	
improvements are related to increased developmental support and	
maternal involvement.	
A B S T R A C T	18. Skin-to-skin
Background Skin-to-skin care (SSC), otherwise known as Kangaroo	care for
Care (KC) due to its similarity with marsupial behaviour of ventral	procedural pain in
maternal-infant contact, is one non-pharmacological intervention for	neonates (Review)
pain control in infants.	
Objectives	Johnston C,
The primary objectives were to determine the effect of SSC alone on	Campbell-Yeo M,
pain from medical or nursing procedures in neonates undergoing	Fernandes A, Inglis
painful procedures compared to no intervention, sucrose or other	D, Streiner D, Zee
analgesics, or additions to simple SSC such as rocking; and the effects	R

of the amount of SSC (duration in minutes) and the method of administration (who provided the SSC, positioning of caregiver and neonate pair). The secondary objectives were to determine the incidence of untoward effects of SSC and to compare the SSC effect in different postmenstrual age subgroups of infants. Search methods The standard methods of the CochraneNeonatal Collaborative Review (Torup were used). Database searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> ); Evidence-Based Medicine Reviews; MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); Searches were conducted throughout September 2012. Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks PMA) receiving SSC for painful procedures, conducted by doctors, nurses, or other healthcare professionals. Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (Cl) using a fixed-effect model was reported for continuous outcome measures. We included variation on type of tissue-damaging procedure, provider of care, and duration of SSC. Main results Nineten studies (n = 1594 infants) were included. Fifteen studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate at ming painful procedures, data from only four studies (n = 1294 infant) were i		1
<ul> <li>neonate pair).</li> <li>Database Syst</li> <li>The secondary objectives were to determine the incidence of untoward effects of SSC and to compare the SSC effect in different postmenstrual age subgroups of infants.</li> <li>Search methods The standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i>); Evidence-Based Medicine Reviews;</li> <li>MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); CONAMEL (1982 onwards); CONAMEL (1982 onwards); EMEASE (1974 onwards); CINAHL (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); Bissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012.</li> <li>Selection criteria Studies with randomisation or quasi-randomisation, double or single-bilnded, involving term infants (&gt; 37 completed Weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.</li> <li>Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC.</li> <li>Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were not included in meta-analyses also reported no difference in trate after the painful procedure. Two studies reported heart rate variability outcomes and found</li></ul>		
The secondary objectives were to determine the incidence of untoward effects of SSC and to compare the SSC effect in different postmenstrual age subgroups of infants.Review, 2014Search methodsThe standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane</i> (1980 onwards); Evidence-Based Medicine Reviews; MEDLINE (1950 onwards); CINEHAL (1982 onwards); SCIELOdatabase (1982 onwards); CINAHL (1982 onwards); SCIELOdatabase (1982 onwards); CINAHL (1982 onwards); SCIELOdatabase (1982 onwards); CINAHL (1982 onwards); Scarches were conducted throughout September 2012.Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.Data collection and analysisThe main outcome measures were physiological or behavioural pain indiations on type of tissue-damaging procedure, provider of care, and duration of SSC.Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 142) weed heal tance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 143) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). T		
untoward effects of SSC and to compare the SSC effect in different postmenstrual age subgroups of infants. Search methods The standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> ); Evidence-Based Medicine Reviews; MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); Web of Science (1980 onwards); ElxCIS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intranuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference. Mio 35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not	neonate pair).	Database Syst
postmenstrual age subgroups of infants. Search methods The standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> ): Evidence-Based Medicine Reviews: MEDLINE (1950 onwards): PubMed (1975 onwards): EMBASE (1974 onwards): CINAHL (1982 onwards): Web of Science (1980 onwards): LILACS database (1982 onwards): SCIELOdatabase (1982 onwards): Psychrfo (1980 onwards): AMED(1985 onwards): Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (Cl) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses	The secondary objectives were to determine the incidence of	Review, 2014
<ul> <li>Search methods The standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Comrolled Trials (CENTRAL) in <i>The Cochrane Chitral</i> Register of Controlled Trials (CENTRAL) (1974 onwards); EUNAHL (1982 onwards); SCIELOdatabase (1982 onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012.</li> <li>Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (&gt; 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.</li> <li>Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC.</li> <li>Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 500, two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measure heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference. Five studies used the Premature Infant Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 163) (MD -1.3.2, 1.95% CI -3.03 to -0.68), and 90 seconds (n = 163</li></ul>	untoward effects of SSC and to compare the SSC effect in different	
<ul> <li>Search methods The standard methods of the CochraneNeonatal Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Comrolled Trials (CENTRAL) in <i>The Cochrane Chitral</i> Register of Controlled Trials (CENTRAL) (1974 onwards); EUNAHL (1982 onwards); SCIELOdatabase (1982 onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012.</li> <li>Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (&gt; 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.</li> <li>Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC.</li> <li>Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 500, two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measure heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference. Five studies used the Premature Infant Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 163) (MD -1.3.2, 1.95% CI -3.03 to -0.68), and 90 seconds (n = 163</li></ul>	postmenstrual age subgroups of infants.	
Collaborative Review Group were used. Databases searched in August 2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> ); Evidence-Based Medicine Reviews; MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); Web of Science (1980 onwards); ILACS database (1982 onwards); SCIELOdatabase (1982 onwards); Dissertation-Abstracts International (1980 onwards); Searches were conducted throughout September 2012. <b>Selection criteria</b> Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (C1) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepureture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference.		
<ul> <li>2011: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i>); Evidence-Based Medicine Reviews;</li> <li>MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); SCIELOdatabase (1982 onwards); LLACS database (1982 onwards); SCIELOdatabase (1982 onwards); EJLACS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Completed throughout September 2012.</li> <li>Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (&gt; 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (&lt; 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.</li> <li>Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variation on SSC.</li> <li>Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedure, and fifterence (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were no included in meta-analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - 3.21, 95%</li></ul>		
<i>The Cochrane Library</i> ); Evidence-Based Medicine Reviews; MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); Web of Science (1980 onwards); LLACS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. <b>Selection criteria</b> Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedure, data from only four studies (n = 121) could be combined to give a mean difference. (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a pr	1 0	
MEDLINE (1950 onwards); PubMed (1975 onwards); EMBASE (1974 onwards); CINAHL (1982 onwards); Web of Science (1980 onwards); EJLACS database (1982 onwards); SCIELOdatabase (1982 onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. <b>Selection criteria</b> Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nincteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference in heart rate are rability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - 3.21, 95% CI - 3.03 to -0.68), and 90 seconds (n = 163) (MD - 1.34, 95% CI - 3.03 to -0.68), and 90 seconds (n = 163) (MD - 1.34, 95% CI - 3.03 to -0.68), and 90 seconds (n = 163) (MD - 1.34, 95% CI - 3.03 to -0.68), and 90 second	e ,	
<ul> <li>(1974 onwards); CINAHL (1982 onwards); Web of Science (1980 onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); SCIELOdatabase (1982 onwards); Dissertation Abstracts International (1980 onwards). Searches were conducted throughout September 2012.</li> <li>Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (&gt; 37 completed weeks pMA and preterm infants (&lt; 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals.</li> <li>Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (Cl) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC.</li> <li>Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta-analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - 3.21, 95% CI - 3.94 to -2.48), 60 seconds (n = 164) (MD - 1.85, 95% CI - 3.04 to -2.48), 60 seconds (n = 164) (MD - 1.85, 95% CI - 3.04 to -2.48), do seconds (n = 163) (MD - 1.25, 6to -0.13),</li></ul>		
onwards); LILACS database (1982 onwards); SCIELOdatabase (1982 onwards); Psychfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. <b>Selection criteria</b> Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.03 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.		
onwards); PsycInfo (1980 onwards); AMED(1985 onwards); Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No st		
Dissertation-Abstracts International (1980 onwards). Searches were conducted throughout September 2012. <b>Selection criteria</b> Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.04 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to ba		
conducted throughout September 2012. Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. Data collection and analysis The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. Main results Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol		
Selection criteria Studies with randomisation or quasi-randomisation, double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.04 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be com		
double or single-blinded, involving term infants (> 37 completed weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention	C I	
weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA and preterm infants (< 37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	1	
and preterm infants (<37 completed weeks PMA) receiving SSC for painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	double or single-blinded, involving term infants (> 37 completed	
painful procedures conducted by doctors, nurses, or other healthcare professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta-analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - 3.21, 95% CI - 3.94 to -2.48), 60 seconds (n = 164) (MD - 1.85, 95% CI - 3.03 to -0.68), and 90 seconds (n = 163) (MD - 1.34, 95% CI - 2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	weeks postmenstrual age (PMA)) to a maximum of 44 weeks PMA	
professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (Cl) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no differences in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 167) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	and preterm infants (< 37 completed weeks PMA) receiving SSC for	
professionals. <b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (Cl) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no differences in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 167) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	painful procedures conducted by doctors, nurses, or other healthcare	
<b>Data collection and analysis</b> The main outcome measures were physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of cryi	· · ·	
physiological or behavioural pain indicators and composite pain scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies ( $n = 1594$ infants) were included. Fifteen studies ( $n = 744$ ) used heel lance as the painful procedure, one study combined venepuncture and heel stick ( $n = 50$ ), two used intramuscular injection, and one used 'vaccination' ( $n = 80$ ). The studies that were included were generally strong and free from bias. Eleven studies ( $n = 1363$ ) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies ( $n = 121$ ) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds ( $n = 268$ ) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds ( $n = 164$ ) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds ( $n = 163$ ) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	1	
scores. A weighted mean difference (WMD) with 95% confidence interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies ( $n = 1594$ infants) were included. Fifteen studies ( $n = 744$ ) used heel lance as the painful procedure, one study combined venepuncture and heel stick ( $n = 50$ ), two used intramuscular injection, and one used 'vaccination' ( $n = 80$ ). The studies that were included were generally strong and free from bias. Eleven studies ( $n = 1363$ ) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies ( $n = 121$ ) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds ( $n = 268$ ) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds ( $n = 164$ ) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds ( $n = 163$ ) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	•	
interval (CI) using a fixed-effect model was reported for continuous outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
outcome measures. We included variations on type of tissue-damaging procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
procedure, provider of care, and duration of SSC. <b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
<b>Main results</b> Nineteen studies (n = 1594 infants) were included. Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
Fifteen studies (n = 744) used heel lance as the painful procedure, one study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta-analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - 3.21, 95% CI - 3.94 to -2.48), 60 seconds (n = 164) (MD - 1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD - 1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	· ·	
study combined venepuncture and heel stick (n = 50), two used intramuscular injection, and one used 'vaccination' (n = 80). The studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
intramuscular injection, and one used 'vaccination' ( $n = 80$ ). The studies that were included were generally strong and free from bias. Eleven studies ( $n = 1363$ ) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies ( $n = 121$ ) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta-analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds ( $n = 268$ ) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds ( $n = 164$ ) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds ( $n = 163$ ) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
studies that were included were generally strong and free from bias. Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	•	
Eleven studies (n = 1363) compared SSC alone to a no-treatment control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD - $3.21$ , 95% CI - $3.94$ to - $2.48$ ), 60 seconds (n = 164) (MD - $1.85$ , 95% CI - $3.03$ to - $0.68$ ), and 90 seconds (n = 163) (MD - $1.34$ , 95% CI - $2.56$ to - $0.13$ ), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
control. Although 11 studies measured heart rate during painful procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
procedures, data from only four studies (n = 121) could be combined to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
to give a mean difference (MD) of 0.35 beats per minute (95% CI - 6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	•	
6.01 to 6.71). Three other studies that were not included in meta- analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
analyses also reported no difference in heart rate after the painful procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds ( $n = 268$ ) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds ( $n = 164$ ) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds ( $n = 163$ ) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
procedure. Two studies reported heart rate variability outcomes and found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	,	
found no significant differences. Five studies used the Premature Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC at 30 seconds ( $n = 268$ ) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds ( $n = 164$ ) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds ( $n = 163$ ) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
at 30 seconds (n = 268) (MD -3.21, 95% CI -3.94 to -2.48), 60 seconds (n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds (n = 163) (MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds (n = 157) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	found no significant differences. Five studies used the Premature	
(n = 164) (MD - 1.85, 95% CI - 3.03 to -0.68), and 90 seconds $(n = 163) (MD - 1.34, 95% CI - 2.56 to -0.13)$ , but at 120 seconds $(n = 157)$ there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	Infant Pain Profile (PIPP) as a primary outcome, which favoured SCC	
(MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	at 30 seconds (n = 268) (MD - 3.21, 95% CI - 3.94 to -2.48), 60 seconds	
was no difference. No studies provided findings on return of heart rate to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	(n = 164) (MD -1.85, 95% CI -3.03 to -0.68), and 90 seconds $(n = 163)$	
to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment	(MD -1.34, 95% CI -2.56 to -0.13), but at 120 seconds ( $n = 157$ ) there	
to baseline level, oxygen saturation, cortisol levels, duration of crying, and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
and facial actions that could be combined for analysis. Eight studies compared SSC to another intervention with or without a no-treatment		
compared SSC to another intervention with or without a no-treatment		
	control. Two cross-over studies $(n = 80)$ compared mother versus other	

	,
provider on PIPP scores at 30, 60, 90, and 120 seconds with no	
significant difference. When SSC was compared to other	
interventions, there were not enough similar studies to pool results in	
an analysis. One study compared SSC with and without dextrose and	
found that the combination was most effective and that SSC alone was	
more effective than dextrose alone. Similarly,	
in another study SSC was more effective than oral glucose for heart	
rate but not oxygen saturation. SSC either in combination with	
breastfeeding or alone was favoured over a no-treatment control, but	
was not different to breastfeeding. There were not enough participants	
with similar outcomes and painful procedures to compare age groups	
or duration of SSC. No adverse events were reported in any of the	
studies.	
Authors' conclusions SSC appears to be effective, as measured by	
composite pain indicators and including both physiological and	
behavioural indicators, and safe for a single painful procedure such as	
a heel lance. Purely behavioural indicators tended to favour SSC but	
there remains questionable bias regarding behavioural indicators.	
Physiological indicators were typically not different between	
conditions. Only two studies compared mother providers to others,	
with non-significant results. There was more heterogeneity in the	
studies with behavioural or composite outcomes. There is a need for	
replication studies that use similar, clearly defined outcomes. New	
-	
studies examining optimal duration of SSC, gestational age groups,	
repeated use, and long-term effects of SSC are needed. A B S T R A C T	19. Sucrose for
<b>Background</b> Administration of oral sucrose with and without non-	analgesia in
nutritive sucking is themost frequently studied non-pharmacological	newborn infants
intervention for procedural pain relief in neonates.	undergoing
<b>Objectives</b> To determine the efficacy, effect of dose and safety of oral	painful
sucrose for relieving procedural pain in neonates.	procedures
Search methods We used the standard methods of the Cochrane	Charles D. Marrielle
Neonatal Review Group. Electronic and manual searches were	Stevens B, Yamada
performed in November 2011 for published randomised controlled	J, Lee GY, Ohlsson
trials (RCTs) inMEDLINE (1950 to November 2011), EMBASE	А
(1980 to 2011), CINAHL (1982 toNovember 2011) and the Cochrane	
Central Register of Controlled Trials ( <i>The Cochrane Library</i> ). We did	The Cochrane
not impose language restrictions.	Database Syst
Selection criteria RCTs in which term, preterm, or both term and	Review, 2013
preterm neonates (postnatal age maximum of 28 days after reaching 40	
weeks' postmenstrual age) received sucrose for procedural pain.	
Control conditions included no treatment, water, pacifier,	
-	
positioning/containing or breastfeeding.	
positioning/containing or breastfeeding. Data collection and analysis Main outcome measures were	
positioning/containing or breastfeeding. <b>Data collection and analysis</b> Main outcome measures were physiological, behavioural, or both pain indicators with or without	
positioning/containing or breastfeeding. <b>Data collection and analysis</b> Main outcome measures were physiological, behavioural, or both pain indicators with or without composite pain scores. A mean difference (MD) with 95% confidence	
positioning/containing or breastfeeding. <b>Data collection and analysis</b> Main outcome measures were physiological, behavioural, or both pain indicators with or without composite pain scores. A mean difference (MD) with 95% confidence intervals (CI) using the fixed-effect model was reported for continuous	
positioning/containing or breastfeeding. <b>Data collection and analysis</b> Main outcome measures were physiological, behavioural, or both pain indicators with or without composite pain scores. A mean difference (MD) with 95% confidence intervals (CI) using the fixed-effect model was reported for continuous outcome measures. Trial quality was assessed as per The Cochrane	
positioning/containing or breastfeeding. <b>Data collection and analysis</b> Main outcome measures were physiological, behavioural, or both pain indicators with or without composite pain scores. A mean difference (MD) with 95% confidence intervals (CI) using the fixed-effect model was reported for continuous	

Collaboration. Published by JohnWiley & Sons, Ltd. <b>Main results</b> Fifty-seven studies enrolling 4730 infants were included. Results from only a few studies could be combined in meta-analyses. When Premature Infant Pain Profile (PIPP) scores were pooled, sucrose groups had significantly lower scores at 30 seconds (weighted mean difference (WMD) -1.76; 95% CI -2.54 to -0.97; 4 trials; 264 neonates] and 60 seconds (WMD-2.05; 95% CI -3.08 to -1.02; 3 trials' 195 neonates) post-heel lance. For retinopathy of prematurity (ROP) examinations, sucrose did not significantly reduce PIPP scores (WMD -0.65; 95% CI -1.88 to 0.59; 3 trials; 82 neonates). There were no differences in adverse effects between sucrose and control groups. Sucrose significantly reduced duration of total crying time (WMD -39 seconds; 95% CI -44 to -34; 2 trials; 88 neonates), but did not reduce duration of first cry during heel lance (WMD -9 seconds; 95% CI -20 to 2; 3 trials; 192 neonates). Oxygen saturation (%) was significantly lower in infants given sucrose during ROP examination compared to controls (WMD -2.6; 95% CI - 4.9 to -0.2; 2 trials; 62 neonates). Results of individual trials that could not be incorporated in meta-analyses supported these findings. The effects of sucrose on long-term neurodevelopmental outcomes are unknown. <b>Authors' conclusions</b> Sucrose is safe and effective for reducing procedural pain fromsingle events. An optimal dose could not be identified due to inconsistency in effective sucrose dosage among studies. Further investigation on repeated administration of sucrose in neonates and the use of sucrose in combination with other non- pharmacological and pharmacological interventions is needed. Sucrose use in extremely preterm, unstable, ventilated (or a combination of these) neonates needs to be addressed. Additional research is needed to determine the minimally effective dose of sucrose during a single painful procedure and the effect of repeated sucrose administration on immediate (pain in	
outcomes. Sweet taste is believed to trigger the release of endogenous opioids. The analgesic efficacy of a solution may be dependent on its degree of sweetness, with the order from highest to lowest degree of sweetness being sucrose, fructose, glucose and lactose. Manufactured sucrose may not always be readily available or institutions may not be equipped with pharmacies to prepare sucrose solutions; therefore, the efficacy of alternative sweet solutions, such as glucose, as analgesic strategies for painful procedures in neonates needs to be determined. <b>Abstract</b> <b>Background:</b> Sucrose has been demonstrated to provide analgesia for minor painful procedures in infants. However, results of trials investigating other sweet solutions for neonatal pain relief have not yet been synthesized. <b>Objective:</b> To establish the efficacy of nonsucrose sweet-tasting	20. A systematic review and meta- analyses of nonsucrose sweet solutions for pain relief in neonates. M Bueno, J Yamada, D Harrison, S Khan, A Ohlsson, T Adams-Webber, J Beyene, B Stevens
solutions for pain relief during painful procedures in term and preterm neonates (from birth to one month of age).	Pain Res Manag 2013;18(3):153-

Method: The present article is a systematic review and meta-analyses	161.
of the literature. Standard methods of the Coshrane Nacrotal	
the literature. Standard methods of the Cochrane Neonatal Collaborative	
Review Group were used. Literature searches were reviewed for randomized controlled trials investigating the use of sweet solutions,	
except sucrose, for procedural pain management in neonates.	
Outcomes assessed included validated pain management in neonates.	
and	
physiological indicators.	
<b>Results:</b> Thirty-eight studies (3785 neonates) were included.	
Glucose was investigated in 35 trials, with doses ranging from 0.2 mL	
to 2 mL of 5% to 50% solutions. Other solutions studied were artificial	
sweeteners, fructose, glycine, honey and maltitol.	
<u>Solutions were administered</u> to the anterior portion of the tongue	
using a syringe in the majority of the trials. Akcam and Ormeci	
compared the use of spray and syringe to administer 30% glucose to	
infants. Non-nutritive sucking was offered in combination with the	
sweet solution in five trials (22-26). In four studies, neonates were	
stimulated to suck the syringe during the administration of the	
solutions (27-30). Gradin et al (31) described the use of a pacifier or a	
finger for providing sucking after offering the solution as optional.	
Finally, Kass and Holman (32), Sajedi et al (33) and Gharehbaghi and	
Ali (34) did not provide sufficient information regarding the methods	
used to administer sweet solutions before the procedure.	
Control and/or comparison groups received water (with or without	
sucking), pacifier, swaddling, skin to skin contact, sensorial saturation,	
facilitated tucking, sucrose solution (with or without sucking),	
breastfeeding, expressed breast milk, 2.5% lidocaine/2.5% prilocaine	
cream (EMLA; AstraZeneca, United Kingdom), dorsal penile nerve	
block,	
acetaminophen, oxycodone or inhaled sevoflurane. No intervention	
groups were included in eight trials and water groups were included in	
19 trials. In six trials, both no intervention and water groups were	
evaluated (Table 1). Reinful procedures investigated were heal lance (10 studies)	
<u>Painful procedures investigated</u> were heel lance (19 studies), venipuncture	
(10 studies), intramuscular injection (three studies), subcutaneous	
injection (one study), peripherally inserted central catheter (PICC)	
placement (one study), eve examination for retinopathy of prematurity	
(one study) and circumcision (one study). Two studies analyzed pain	
during different procedures: heel lance and venipuncture (one study),	
and heel lance and pharyngeal suctioning (one study).	
Heel lancing was performed in 21/38 studies and venipuncture in	
11/38 studies. A 3.6-point reduction in Premature Infant Pain Profile	
scores during heel lances was observed in studies comparing 20% to	
30% (1ml to 2ml) glucose with no intervention (two studies, 124	
neonates, Eriksson term infants, Freire preterm infants; mean	
difference -3.6 [95% CI -4.6 to -2.6]; P<0.001; I2=54%).	
	·]

	Expe	rimen	tai	С	ontrol			Mean Difference		Mean Di	fference	
Study or Subgroup	Mean	\$D	Total	Mean	8D	Total	Weight	IV, Fixed, 86% (	CII	IV, Flore	1, 96% CI	
Eriksson 1999	3.9	2.6	30	8.4	3.4	30	40.6%	-4.50 [-6.03, -2.97]	1			
Freire 2008	7.93	2.69	31	10.93	2.46	33	59.4%	-3.00 [-4.27, -1.73	1			
Total (86% CI)			81			63	100.0%	-3.81 [-4.68, -2.63]	1	•		
Heterogeneity: ChP = 2	2.19, df -	- 1 (P	0.14)	² = 54	96				<u> </u>	-		
Test for overall effect:	Z = 7.25	(P < 0	00001	)					-10 Favours		Favours o	s 10 control

Figure 2) Mean Premature Infant Pain Profile scores after heel lancing for infants receiving 20% to 30% glucose (1 mL to 2 mL) compared with no intervention

Two trials used the NIPS and the PIPP to assess the same heel lance (47,51). Bonetto et al (47) reported no differences in PIPP scores, while NIPS scores significantly favoured 25% glucose (1 mL) versus 2.5% lidocaine/2.5% prilocaine cream, acetaminophen or water. Axelin et al (51) reported significantly lower PIPP scores for neonates receiving 24% glucose (0.2 mL) versus water (0.2 mL) but reported no differences in NIPS scores.

In the one trial that compared 20% glucose and sucrose (2 mL) solutions (36), differences in NFCS scores were not significant. **These results suggest similar effectiveness of both glucose and sucrose.** A significant reduction in the incidence of cry after venipuncture for infants receiving 25% to 30% glucose versus water or no intervention was observed (three studies, 130 infants; risk difference -0.18 [95% CI -0.31 to -0.05]; P=0.008, number needed to treat = 6 [95% CI 3 to 20]; I2=63%).

	Experime	ental	Contr	lor		Rick Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 86% Cl	M-H, Fixed, 95% Cl
Bauer 2004	9	18	18	20	29.2%	-0.40 [-0.67, -0.13]	=
Deshmukh 2002	18	20	19	20	30.8%	-0.05 [-0.21, 0.11]	•
Ling 2005	18	26	21	26	40.0%	-0.12 [-0.35, 0.12]	•
Total (86% CI)		64		88	100.0%	-0.18 [-0.31, -0.06]	•
Total events	45		58				
Heterogeneity: Chi <sup>2</sup> =	5.35, df = 2	(P = 0.)	07); I <sup>z</sup> = 6	3%			-4 -2 0 2 4
Test for overall effect:	Z = 2.66 (P	- 0.000	B)			Fav	-4 -2 U 2 4 ours experimental Favours control

Figure 3) Incidence of crying after venipuncture for infants receiving 25%	
to 30% glucose (1 mL to 2 mL) compared with water	
Conclusions: The present systematic review and meta-analyses	
demonstrate that glucose reduces pain scores and crying during single	
heel lances and venipunctures. Results indicate that 20% to 30%	
glucose solutions have analgesic effects and can be recommended as	
an alternative to sucrose for procedural pain reduction in healthy term	
and preterm neonates.	
Abstract	21. Breastfeeding
<b>BACKGROUND:</b> Physiological changes brought about by pain may	or breast milk for
<b>DACIGROUID.</b> Thysiological changes brought about by pain may	or breast milk for
contribute to the development of morbidity in neonates. Clinical	procedural pain in
contribute to the development of morbidity in neonates. Clinical	procedural pain in
contribute to the development of morbidity in neonates. Clinical studies have shown reduction in changes in physiological parameters	procedural pain in
contribute to the development of morbidity in neonates. Clinical studies have shown reduction in changes in physiological parameters and pain score measurements following pre-emptive analgesic	procedural pain in neonates.
contribute to the development of morbidity in neonates. Clinical studies have shown reduction in changes in physiological parameters and pain score measurements following pre-emptive analgesic administration in situations where the neonate is experiencing pain or	procedural pain in neonates. Shah PS, Herbozo
contribute to the development of morbidity in neonates. Clinical studies have shown reduction in changes in physiological parameters and pain score measurements following pre-emptive analgesic administration in situations where the neonate is experiencing pain or stress. Non-pharmacological measures (such as holding, swaddling	procedural pain in neonates. Shah PS, Herbozo C, Aliwalas LL,

effectiveness of breastfeeding or supplemental breast milk in reducing 12:12:CD004950. procedural pain in neonates. The secondary objective was to conduct doi: subgroup analyses based on the type of control intervention, 10.1002/14651858. gestational age and the amount of supplemental breast milk given. CD004950.pub3. SEARCH METHODS: We performed a literature search using the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 10), MEDLINE (1966 to February 2011), EMBASE (1980 to February 2011), CINAHL (1982 to February 2011), abstracts from the annual meetings of the Society for Pediatric Research (1994 to 2011), and major paediatric pain conference proceedings. We did not apply any language restrictions. SELECTION CRITERIA: Randomised controlled trials (RCTs) or quasi-RCTs of breastfeeding or supplemental breast milk versus no treatment/other measures in neonates were eligible for inclusion in this review. The study must have reported on either physiologic markers of pain or validated pain scores. DATA COLLECTION AND ANALYSIS: We assessed the methodological quality of the trials using the information provided in the studies and by personal communication with the authors. We extracted data on relevant outcomes, estimated the effect size and reported this as a risk ratio (RR), risk difference (RD) and weighted mean difference (MD) as appropriate. MAIN RESULTS: Of twenty eligible studies, ten evaluated breastfeeding and ten evaluated supplemental breast milk. Sixteen studies analysed used heel lance and four used venepuncture as procedure. We noted marked heterogeneity in control intervention and pain assessment measures among the studies. Neonates in the breastfeeding group had statistically a significantly lower increase in heart rate, reduced proportion of crying time and reduced duration of first cry and total crying time compared to positioning (swaddled and placed in a crib), holding by mother, placebo, pacifier use, no intervention or oral sucrose group, or both. Premature Infant Pain Profile (PIPP) scores were significantly lower in the breastfeeding group compared to positioning, placebo or oral sucrose group, or both. However, there was no statistically significant difference in PIPP scores when compared to no intervention. Douleur Aigue Nouveau-ne scores (DAN) were significantly lower in the breastfeeding group compared to the placebo group and the group held in mother's arms, but not when compared to the glucose group. Neonatal Infant Pain Scale (NIPS) was significantly lower in the breastfeeding group compared to the no intervention group, but there was no difference when compared to the oral sucrose group. The Neonatal Facial Coding System (NFCS) was significantly lower in the breastfeeding group when compared to oral glucose, pacifier use, holding by mother and no intervention, but no difference was found when compared to formula feeding. Supplemental breast milk yielded variable results. Neonates in the supplemental breast milk group had a significantly lower increase in heart rate, a reduction in duration of crying and a lower NFCS compared to the placebo group. Neonates in the supplemental breast milk group had a significantly higher increase

	· · · · · · · · · · · · · · · · · · ·
in heart rate changes when compared to the sucrose group. Sucrose (in	
any concentration, i.e. 12.5%, 20%, 25%) was found to reduce the	
duration of cry when compared to breast milk, as did glycine, pacifier	
use, rocking, or no intervention. Breast milk was found not to be	
effective in reducing validated and non-validated pain scores such as	
NIPS, NFCS, and DAN; only being significantly better when	
compared to placebo (water) or massage. We did not identify any	
study that has evaluated safety/effectiveness of repeated administration	
of breastfeeding or supplemental breast milk for pain relief.	
AUTHORS' CONCLUSIONS: If available, breastfeeding or	
breast milk should be used to alleviate procedural pain in neonates	
undergoing a single painful procedure rather than placebo,	
positioning or no intervention. Administration of glucose/sucrose	
had similar effectiveness as breastfeeding for reducing pain. The	
effectiveness of breast milk for painful procedure should be	
studied in the preterm population, as there are currently a limited	
number of studies in the literature that have assessed it's	
effectiveness in this population.	
<b>Background:</b> Acute pain and distress during medical procedures are	22.
commonplace for young children.	22. Nonpharmacologi
1 0	•
<b>Objective:</b> To assess the efficacy of nonpharmacological interventions	cal management
for acute procedural pain in children up to three years of age,	of procedural pain
excluding breastmilk, sucrose, and music.	in infants and
<b>Methods:</b> Study inclusion criteria were: participants <3 years of age,	young children:
involved in a randomized controlled or crossover trial, and use of a	An abridged
'notreatment' control group (51 studies; n=3396). Additional studies	Cochrane review
meeting all criteria except for study design (eg, use of active control	
group) were qualitatively described (n=20). Preterm born: infants	Riddell RP, Racine
born at 36 weeks gestation or less. Neonate full-term: infants born at	N, Turcotte K,
37 weeks until one month of age. Older infant/young child: infants	Uman LS, Horton
older than one month to 36 months of age. Pain reactivity: measured	R, Osmun LD,
within the first 30 s after the painful stimulus was discontinued.	Kohut SA, Stuart
Immediate pain-related regulation: measured after the first 30 s post	JH, Stevens B, Lisi
acutely painful stimulus. If multiple measurements were taken after the	D.
first 30 s elapsed, the measurement closest to the 30s-time point was	
used.	Pain Res Manage
<b>Results:</b> Fifty-one studies, with 3396 participants, were analyzed. The	2011;16(5):321-
following painful procedures (determined by respective study authors	330
rather than review authors) were included in this review: 29 studies	550
examined treatments for heelstick, 10 studies examined needle-	
injection procedures, six studies assessed venipuncture, two examined	
NICU diaper changes, two studies investigated endotracheal	
suctioning and two studied a neonatal intensive care unit (NICU)	
weighing procedure.	
For every intervention, data were analyzed separately according to age	
group (preterm-born, term-born neonate and older infant/young child)	
and type of pain response (pain reactivity, immediate pain-related	
regulation). The largest SMD for treatment improvement over control	
conditions on pain reactivity were:: sucking-related interventions	
(preterm: $-0.42$ [95% CI $-0.68$ to $-0.15$ ]; neonate $-1.45$ [CI $-2.34$ to	

-0.57]), kangaroo care (preterm -1.12 [95% CI -2.04 to -0.21]), and swaddling/facilitated tucking (preterm -0.97 [95% CI -1.63 to -0.31]). For immediate painrelated regulation, the largest SMDs were: sucking-related interventions (preterm -0.38 [95% CI -0.59 to -0.17]; neonate -0.90 [CI -1.54 to -0.25]), kangaroo care 0.77 (95% CI -1.50to -0.03]), swaddling/facilitated tucking (preterm -0.75 [95% CI -1.14 to -0.36]), and rocking/holding (neonate -0.75 [95% CI -1.20to -0.30]). The presence of significant heterogeneity limited confidence in nonsignificant findings for certain other analyses. Table 3 presents the primary meta-analytic results from this review (SMD, 95% CI and I2) and, when applicable, the secondary statistics

re-run with studies removed due to heterogeneity and/or study quality. <u>Table 3:</u>

Summary of meta-analyses

Treatment	Age group	Pain type	Total, n	Effect size (95% CI)	Heterogeneity analysis (95% CI)	Risk of bias analysis (95% Cl)
Kangaroo care	Preterm	Reactivity	177	-1.12 (-2.04 to -0.21)	-0.38 (-0.65 to -0.12)	_
-		-		l <sup>2</sup> = 89%	l <sup>2</sup> = 0%	
Kangaroo care	Preterm	Immediate regulation	163	-0.77 (-1.50 to -0.03)	-0.45 (-0.69 to -0.20)	-
-		5		l <sup>2</sup> = 82%	l <sup>2</sup> = 0%	
Kangaroo care	Neonate	Reactivity	420	-0.89 (-2.89 to 1.10)	-	-
		,		l <sup>2</sup> = 98%		
Kangaroo care	Neonate	Immediate regulation	343	-0.66 (-1.73 to 0.42)	-	_
				l <sup>2</sup> = 82%		
Swaddling/tucking	Preterm	Reactivity	261	-0.97 (-1.63 to -0.31)	-0.90 (-1.22 to -0.59)	_
owaddiing/tdcking	Treterin	Reactivity	201	l <sup>2</sup> = 88%	l <sup>2</sup> = 0%	_
Quaddling/husking	Preterm	Immediate segulation	65	-0.75 (-1.14 to -0.36)	1 076	-0.61 (-1.12 to -0.11)
Swaddling/tucking	Preterm	Immediate regulation	co	-0.75(-1.14(0-0.36)) $l^2 = 0\%$	-	-0.61(-1.12(0-0.11)) $ ^2 = 0\%$
Our dell's altractions	Nesset	Des effective	10			I= = 0%
Swaddling/tucking	Neonate	Reactivity	42	-1.26 (-1.92 to -0.60)	-	-
Non-nutritive sucking	Preterm	Reactivity	305	-0.42 (-0.68 to -0.15)	-0.32 (-0.05 to -0.15)	-
				l <sup>2</sup> = 48%	$I^2 = 0\%$	
Non-nutritive sucking	Preterm	Immediate regulation	226	-0.38 (-0.59 to -0.17)	-	-0.36 (-0.59 to -0.13)
				$l^2 = 0\%$		$I^2 = 0\%$
Non-nutritive sucking	Neonate	Reactivity	220	-1.45 (-2.34 to -0.57)	-1.88 (-2.25 to -1.50)	-
				$l^2 = 88\%$	$I^2 = 0\%$	
Non-nutritive sucking	Neonate	Immediate regulation	325	-0.90 (-1.54 to -0.25)	-	-0.51 (-0.91 to -0.29)
				l <sup>2</sup> = 84%		l <sup>2</sup> = 11%
Non-nutritive sucking	Older infants	Immediate regulation	41	-0.89 (-1.53 to -0.25)	-	-
Swallowing water	Preterm	Reactivity	36	-0.24 (-0.71 to 0.23)	-	-
Swallowing water	Preterm	Immediate regulation	36	-0.23 (-0.70 to 0.24)	-	-
Swallowing water	Neonate	Reactivity	50	0.10 (-0.45 to 0.66)	-	-
Swallowing water	Neonate	Immediate regulation	34	i.	-	-
Swallowing water	Older infants	Immediate regulation	30			-
Rocking/holding	Neonate	Reactivity	131	,	39) -	-
D 1. A 1.	<b>.</b> .			l <sup>2</sup> = 73%	20)	
Rocking/holding	Neonate	Immediate regulation	81	−0.75 (−1.20 to −0   <sup>2</sup> = 0%	.30) -	-
Rocking/holding	Older infants	Reactivity	106			
Simulated rocking + water	Preterm	Reactivity	44			_
Touch or massage	Preterm	Immediate regulation	34			-
g-			-	l <sup>2</sup> = 86%	/	
Touch or massage	Neonate	Reactivity	40	-0.30 (-0.92 to 0.3	32) -	-
Touch or massage	Neonate	Immediate regulation	66			-
Touch or massage	Older infants	Reactivity	20	) -0.21 (-0.84 to 0.4	41) –	-
Environment modification	Preterm	Reactivity	64		.26) –	-
				$l^2 = 97\%$		
Environment modification	Preterm	Immediate regulation	45	i.		-
Toy distraction	Older infants	Reactivity	259	· ·	14) -	-
				l <sup>2</sup> = 0%		
Toy distraction	Older infants	Immediate regulation	133		33) -	-
	ou : r ·	D (11)	~	I <sup>2</sup> = 0%		
Video distraction	Older infants	Reactivity	90	· ·		-
Video distraction Structured parent	Older infants Older infants	Immediate regulation	126 209	· ·	,	-
involvement	Order Infants	Reactivity	20:	-0.26 (-0.70 to 0.1	17) -0.49 (-0.83 to -0	
				$l^2 = 60\%$	$I^2 = 0\%$	
Structured parent	Older infants	Immediate regulation	288			-
involvement				(		
Mother's voice	Preterm	Reactivity	19	· ·		-
Parent present	Older infants	Immediate regulation	27	B 0.00 (-0.24 to 0.1)	23) –	-

The summary interpretation of the primary meta-analytic findings, contextualized by secondary heterogeneity and quality/treatment integrity analyses, are presented in Table 4. Based on these results, treatments were assigned a number from 1 to 4, for each age and pain response type. As will be discussed below, the ratings reflect whether, as the literature currently stands, evidence supported the specific treatment for pain management (efficacy) or did not support the specific

treatment for pain management (inefficacy). Each treatment's efficacy or inefficacy was further qualified by the level of support (sufficient versus limited). Treatment efficacy was denoted by either a 1 (sufficient evidence, ie, two or more quality trials supporting efficacy) or 2 (limited evidence, ie, either due to quality, quantity or heterogeneity of trials,

supporting efficacy). Treatment inefficacy was denoted by either a 3 (limited evidence [ie, either due to quality, quantity or trial heterogeneity]) or a 4 (sufficient evidence [ie, two or more quality trials supporting inefficacy]). Blank cells indicate no applicable research for

that combination of treatment, age and pain response. TABLE 4  $% \left( {{{\rm{TABLE}}} 4} \right)$ 

Summary conclusions

	Pre	eterm infants		Neonates		lder infants
Treatment arm	Reactivity	Immediate regulation	Reactivity	Immediate regulation	Reactivity	Immediate regulation
Kangaroo care	1	1	3	3	-	-
Non-nutritive sucking-related	1	1	1	1	-	2
Swaddling/tucking-related	1	1	2	-	-	-
Touch or massage-related	-	3	3	3	3	-
Environment modification	3	2	-	-	-	-
Simulated rocking and water	3	-	-	-	-	-
Simulated mother's voice	3	-	-	-	-	-
Swallowing water	3	3	3	3	-	3
Rocking or holding	-	-	3	1	3	-
Toy distraction	-	-	-	-	4	3
Video distraction	-	-	-	-	2	2
Parent present	-	-	-	-	-	3
Structured parent involvement	-	-	-	-	3	3

1 Sufficient evidence supports efficacy for reducing pain-related behaviours (support of two or more trials); 2 Limited evidence suggests efficacy for reducing painrelated behaviours (eg, support of one trial or heterogeneity among trials); 3 Limited evidence suggests inefficacy for reducing pain-related behaviours (eg, support of one trial or heterogeneity among trials); 4 Sufficient evidence supports inefficacy for reducing pain-related behaviours (support of one trial or heterogeneity among trials); 4 Sufficient evidence supports inefficacy for reducing pain-related behaviours (support of one or more trials). Dash indicates no research performed for that treatment, age and pain response combination

**Kangaroo care (also known as skin-to-skin contact)** An infant is placed on their caregiver's bare chest before, during and after a painful procedure. **Preterm infants: Sufficient evidence suggests kangaroo care is efficacious in reducing pain reactivity and improving immediate painrelated regulation.** While there was substantial heterogeneity, secondary analyses confirmed this finding. Four studies that were excluded from the statistical analyses (73-76) also indirectly support kangaroo care as efficacious in improving pain reactivity and immediate pain-related regulation in preterm infants.

<u>Swaddling/facilitated tucking</u> A swaddled infant is securely wrapped in a blanket to prevent excessive movement. Facilitated tucking is a hand-swaddling technique that holds the infant's extremities flexed and contained. Preterm infants: There was sufficient evidence to support the use of swaddling/tucking as an efficacious intervention for reducing painrelated distress reactivity and immediate painrelated regulation in preterm infants. Two studies (74,77), that were not included in the analysis due to use of an active control group, suggested that swaddling was as efficacious as containment but not as efficacious as kangaroo care.

<u>Non-nutritive sucking-related strategies</u> An object (eg, pacifier, nonlactating nipple) is placed into an infant's mouth to stimulate orotactile or sucking behaviours during a painful event. Preterm infants: There is sufficient evidence that sucking is efficacious in reducing pain-related distress reactivity and improving immediate pain-related regulation. Pain relief may be maximized if sucking begins at least 3 min before the painful stimuli. Two studies that were not included in the analyses due to the use of an active control group (85,89) also suggest that sucking helps diminish pain reactivity.

<u>Swallowing water</u> Water is administered for ingestion without inciting extensive sucking (eg, water administered by a dropper). Preterm infants: There was limited evidence that water is an inefficacious

intervention for pain reactivity or immediate pain-related regulation for preterm infants.

**<u>Rocking and/or holding</u>** An infant is held and/or gently moved up and down or side-to-side by a caregiver. – **no preterm** 

<u>Artificial rocking and water</u> An infant is placed in a bassinet-type machine that provides a swaying motion. Water is administered via a dropper. **Preterm infants: Limited evidence indicates that** 

simulated rocking and water is not an efficacious intervention for reducing pain-related distress pain reactivity for preterm infants. <u>Touch/massage/therapeutic touch</u> An infant's body (i.e. touch,

massage) or energy field (therapeutic touch) is 'stroked' or rubbed to provide some type of counter-stimulation to the nociceptive input. **Preterm infants: Current evidence does not support** 

touch/massagerelated interventions as efficacious in improving the immediate painrelated regulation but caution is warranted given the presence of substantial heterogeneity. One study not included in the analysis due to exclusion criteria (79) demonstrated that massage was more efficacious at reducing preterm infant's heart rate than light pressure or no massage therapy.

**Environmental modification** Interventions involved modifying the environment in which an infant experiences painful procedures (ie, low noise and lighting, clustering procedures to avoid over handling, soothing smells). **Preterm infants: While the pooled result from two studies suggest that environmental modification was not efficacious for pain reactivity, this must be interpreted with caution due to substantial heterogeneity. However, there is limited evidence to suggest that environmental modification is efficacious for immediate pain-related regulation.** 

<u>Simulated maternal voice</u> An infant is exposed to a reproduction of the mother's voice to help simulate the fetal environment. Preterm infants: Results from one study indicated that mother's

voice was not more efficacious than a no-treatment control for reducing pain-related distress reactivity for preterm infants. <u>Conclusions:</u> Although a number of nonpharmacological

treatments have sufficient evidence supporting their efficacy with preterm infants and healthy neonates, no treatments had sufficient	
evidence to support efficacy with healthy older infants/young children.	
-We examined 13 different types of commonly investigated	
nonpharmacological treatments (excluding breastmilk, sucrose,	
and music) to determine their efficacy for pain reactions after an	
acutely painful procedure (right after the needle ('pain reactivity')	
and less immediate pain reactions ('immediate pain-related	
regulation').	
-For preterm infants, there was sufficient evidence to recommend	
kangaroo care, sucking-related interventions, and swaddling	
<u>/facilitated tucking interventions for both pain reactivity and</u>	
immediate pain-related regulation.	
Abstract	23. Effects of
<b>Background:</b> Pain and stress agitate preterm infants, interrupting their	combined use of
sleep. Frequent high arousal states may affect infants' brain	non-nutritive
development and illness recovery. Preserving infants' sleep and	sucking, oral
relieving their pain during painful procedures are both important for	sucrose, and
their health.	facilitated tucking
<b>Objectives:</b> To compare the effectiveness of different combinations of	on infant
<b>5</b>	behavioural states
non-nutritive sucking (sucking), oral sucrose, and facilitated tucking	across heel-stick
(tucking) with routine care on infants' sleep–wake states before,	
during, and after heel-stick procedures.	procedures: A
<b>Design:</b> Prospective, randomised controlled trial.	prospective,
Setting: Level III Neonatal Intensive Care Unit in Taipei.	randomised
Method: A convenience sample of 110 infants (gestational age 26.4–	controlled trial
37 weeks) needing heel sticks were randomly assigned to five	T' TT X7 T
combinations of non-pharmacological treatments: sucking-oral	Liaw JJ, Yang L,
sucrose-tucking; sucking-oral sucrose; oral sucrose-tucking; sucking-	Lee CM, Fan HC,
tucking; and routine care. Infant states, measured by a state-coding	Chang YC, Cheng
scheme, included quiet sleep, active sleep, transition, quiet awake,	LP
active awake, and fussing or	<b>T 1</b>
crying. All states were recorded at 1-min intervals during four phases:	International
baseline, intervention, heel-stick procedures, and recovery.	Journal of Nursing
<b>Results:</b> Infants receiving sucking–oral sucrose–tucking or sucking–	Studies 50 (2013)
oral sucrose experienced 52.8% ( $p = 0.023$ ) and 42.6% ( $p = 0.063$ )	883–894
more quiet-sleep occurrences than those receiving routine care after	
adjusting for phase, baseline states, non-treatment sucking during	
baseline and recovery, positioning, and infants' characteristics. Infants	
receiving	
oral sucrose-tucking, sucking-oral sucrose, sucking-oral sucrose-	
tucking, and sucking–tucking experienced 77.3% (p < $0.001$ ), 72.1%	
(p = 0.008), 51.5% $(p = 0.017)$ , and 33.0% $(p = 0.105)$ fewer	
occurrences of fussing or crying, respectively, than those receiving	
routine care after adjusting for related factors.	
Conclusions: The four treatment combinations differentially	
reduced infants' high arousal across heel-stick procedures. The	
combined use of oral sucrose-tucking, sucking-oral sucrose, and	
sucking-oral sucrose-tucking more effectively reduced	
occurrences of infant fussing or crying than routine care.	

Treatment combinations of sucking-oral sucrose-tucking and	
sucking—oral sucrose also better facilitated infants' sleep than	
routine care. To preserve infants' sleep, clinicians should use	
combinations of non-nutritive sucking, oral sucrose, and	
facilitated tucking to reduce agitation during painful procedures.	
Abstract	24. Development
<b>Background:</b> Preterm infants manifest pain and stress by behavioural	of atraumatic
agitation and state change. Few studies have explored the effects of	heel-stick
combining nonpharmacological interventions, i.e. non-nutritive	procedures by combined
sucking, oral sucrose, and facilitated tucking, on infants' behaviours	
across painful procedures.	treatment with
<b>Objectives:</b> To explore the effects of combined use of three	non-nutritive
nonpharmacological interventions (non-nutritive sucking, oral sucrose,	sucking, oral
and facilitated tucking) on infants' pain- and stress-related behaviours	sucrose, and
during four assessment phases: baseline, intervention, heel stick, and	facilitated
recovery. <b>Design:</b> Prospective, randomised controlled trial.	tucking: A
Setting: Level III neonatal intensive care unit in Taipei.	randomised,
Method: A convenience sample of 110 infants (gestational age 27–37	controlled trial
weeks) needing heel sticks was randomly assigned to five	
combinations of nonpharmacological treatments: (1) routine care, (2)	Yin T, Yang L,
non-nutritive sucking + facilitated tucking, (3) oral sucrose +	Lee TY, Li CC,
facilitated tucking, (4) non-nutritive sucking + oral sucrose, and (5)	Hua YM, Liaw JJ
non-nutritive sucking + oral sucrose + facilitated tucking. Outcomes	
were infants' withdrawal or stress (grimace, limb and trunk extension	International
or squirming) and approach or self-soothing (sucking, sucking search,	Journal of Nursing
or mouthing; hand holding or grasping; and hand to mouth, face)	Studies 52 (2015)
behaviours.	1288–1299
<b>Results:</b> The frequency of infants' withdrawal behaviours decreased	
significantly when they received combinations of nonpharmacological	
interventions before heel stick. Specifically, grimace frequency	
decreased by 32.2%, 30.6%, 19.7%, and 13.8% in infants receiving	
oral sucrose + non-nutritive sucking + facilitated tucking, non-nutritive	
suck-ing + oral sucrose, oral sucrose + facilitated tucking, and non-	
nutritive sucking + facilitated tucking, respectively, compared to those	
receiving routine care across assessment phases. Furthermore, infants'	
frequency of limb and trunk extension or squirming decreased by	
24.0% when they received non-nutritive sucking + oral sucrose +	
facilitated tucking compared to those receiving routine care. Infants'	
frequency of approach behaviours did not change significantly across	
all phases when they received non-nutritive sucking + oral sucrose +	
facilitated tucking, non-nutritive sucking + oral sucrose, and oral	
sucrose + facilitated tucking compared to those receiving routine care.	
Conclusions: The combined use of nonpharmacological	
interventions (non-nutritive sucking + oral sucrose + facilitated	
tucking) effectively reduced the frequencies of infants' withdrawal	
behaviours, i.e. grimace and limb and trunk extension or	
squirming. Our results provide evidence supporting clinicians'	
incorporation of the combined use of facilitated tucking, oral	
sucrose, and non-nutritive sucking into clinical practice during	
painful procedures. Heel-stick procedures can be atraumatic when	

conducted while infants are stable and quiet, appropriately	
positioned, and stabilised and by offering facilitated tucking, oral	
sucrose, and non-nutritive sucking before gently sticking the heel	
and squeezing blood.	
Abstract	25. Oral sucrose
<b>OBJECTIVES:</b> To test the comparative effectiveness of 2	and "facilitated
nonpharmacologic pain-relieving interventions administered alone or	tucking" for
in combination across time for repeated heel sticks in preterm infants.	repeated
<b>METHODS:</b> A multicenter randomized controlled trial in 3 NICUs in	pain relief in
Switzerland compared the effectiveness of oral sucrose, facilitated	preterms: a
tucking (FT), and a combination of both interventions in preterm	randomized
infants	controlled trial.
between 24 and 32 weeks of gestation. Data were collected during	contronce thun
the first 14 days of their NICU stay. Three phases (baseline, heel stick,	Cignacco EL,
recovery) of 5 heel stick procedures were videotaped for each infant.	Sellam G, Stoffel
Four independent experienced nurses blinded to the heel stick phase	L, Gerull R, Nelle
rated 1055 video sequences presented in random order by using the	M, Anand
Bernese Pain Scale for Neonates, a validated pain tool.	KJ, Engberg S
<b>RESULTS:</b> Seventy-one infants were included in the study. Interrater	, <u>6</u> <u>6</u>
reliability was high for the total Bernese Pain Scale for Neonates score	Pediatrics
(Cronbach's a: 0.90–0.95). FT alone was significantly less effective	<b>2012</b> ;129:299-308.
in	,
relieving repeated procedural pain (P, .002) than sucrose (0.2	
mL/kg). FT in combination with sucrose seemed to have added	
value in the recovery phase with lower pain scores $(P = .003)$	
compared with both the single-treatment groups. There were no	
significant differences in pain responses across gestational ages.	
CONCLUSIONS: Sucrose with and without FT had pain-relieving	
effects even in preterm infants of <32 weeks of gestation having	
repeated pain exposures. These interventions remained effective	
during repeated heel sticks across time. FT was not as effective	
and cannot be recommended as a nonpharmacologic pain relief	
intervention for repeated pain exposure.	

#### Otsing **History** <u>Download historyClear history</u>

Search	Add to builder	Query	Items found	Time
<u>#25</u>	<u>Add</u>	Search ((((((nCPAP) OR (((nasal continuous positive airway pressure) OR CPAP) OR continuous positive airway pressure)) OR skin-to-skin contact) OR "Kangaroo-Mother Care Method"[Mesh]) OR Kangaroo care)) AND ((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR	<u>207</u>	03:57:30

ecent qu				
Search	Add to builder	Query	Items found	Time
		"premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))) Filters: Guideline; Practice Guideline; Systematic Reviews; Randomized Controlled Trial; published in the last 10 years; English		
<u>#19</u>	Add	Search ((((((nCPAP) OR (((nasal continuous positive airway pressure) OR CPAP) OR continuous positive airway pressure)) OR skin-to-skin contact) OR "Kangaroo-Mother Care Method"[Mesh]) OR Kangaroo care)) AND (((((((((((((() "premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm newborn") OR "preterm newborns") OR ("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh])))))	<u>1526</u>	03:57:30
<u>#18</u>	<u>Add</u>	Search ((((nCPAP) OR (((nasal continuous positive airway pressure) OR CPAP) OR continuous positive airway pressure)) OR skin-to-skin contact) OR "Kangaroo-Mother Care Method"[Mesh]) OR Kangaroo care	<u>11218</u>	03:46:25
<u>#17</u>	Add	Search "Kangaroo-Mother Care Method"[Mesh]	<u>101</u>	03:43:04
<u>#15</u>	Add	Search Kangaroo care	<u>574</u>	03:41:34
<u>#2</u>	Add	Search skin-to-skin contact	<u>449</u>	03:39:30
<u>#13</u>	<u>Add</u>	Search ((nasal continuous positive airway pressure) OR CPAP) OR continuous positive airway pressure	<u>10226</u>	03:34:54
<u>#12</u>	Add	Search nasal continuous positive airway pressure	<u>8913</u>	03:33:57
<u>#9</u>	Add	Search CPAP	<u>5773</u>	03:32:27
<u>#8</u>	Add	Search continuous positive airway pressure	<u>8913</u>	03:31:05
<u>#3</u>	Add	Search nCPAP	<u>840</u>	03:25:08
<u>#1</u>	<u>Add</u>	Search ((((((((((((()'premature infant'') OR "premature infants") OR "premature newborn") OR	<u>83043</u>	03:13:03

Search	Add to builder	Query	Items found	Time
		"premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))		

#### History

## Download historyClear history

Search	Add to builder	Query	Items found	Time
<u>#36</u>	Add	Search (NIDCAP) AND (((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))) Filters: Guideline; Practice Guideline; Systematic Reviews; Randomized Controlled Trial; published in the last 10 years; English	<u>16</u>	04:11:03
<u>#28</u>	<u>Add</u>	Search (NIDCAP) AND (((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates") OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh])))))	<u>76</u>	04:11:03
<u>#27</u>	Add	Search NIDCAP	<u>99</u>	04:08:32
<u>#1</u>	<u>Add</u>	Search ((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate")	<u>83043</u>	03:13:03

Search	Add to builder	Query	Items found	Time
		OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))		

## History

#### Download historyClear history

Search	Add to builder	Query	Items found	Time
<u>#39</u>	Add	Search (family centered care) AND (((((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh])))))	<u>88</u>	04:26:50
<u>#45</u>	Add	Search (family centered care) AND ((((((((((((((((((''premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR ((''Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh])))) Filters: Guideline; Systematic Reviews; Practice Guideline; Randomized Controlled Trial; published in the last 10 years; English	<u>8</u>	04:26:49
<u>#38</u>	Add	Search family centered care	<u>4761</u>	04:22:13
<u>#1</u>	<u>Add</u>	Search ((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR	<u>83043</u>	03:13:03

Search	Add to builder	Query	Items found	Time
		"preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))		

# History

#### Download historyClear history

Search	Add to builder	Query	Items found	Time
<u>#69</u>	Add	Search ((((((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))) AND (((((facilitated tucking) OR oral sucrose) OR non-nutritive sucking) OR heel stick) OR painful procedures) Filters: Randomized Controlled Trial; Systematic Reviews; Practice Guideline; Guideline; published in the last 10 years; English	<u>144</u>	04:48:55
<u>#61</u>	<u>Add</u>	Search ((((((((((((((((''premature infant'') OR "premature infants'') OR "premature newborn'') OR "premature newborns'') OR "premature neonate'') OR "premature neonates'') OR "preterm infant'') OR "preterm infants'') OR "preterm newborn'') OR "preterm newborns'') OR "preterm neonate'') OR "preterm neonates'')) OR ((''Infant, Premature''[Mesh]) OR ''Infant, Low Birth Weight''[Mesh]))))) AND (((((facilitated tucking) OR oral sucrose) OR non-nutritive sucking) OR heel stick) OR painful procedures)	820	04:48:55
<u>#60</u>	<u>Add</u>	Search ((((facilitated tucking) OR oral sucrose) OR non-nutritive sucking) OR heel stick) OR painful procedures	<u>268216</u>	04:47:11

ecent queries					
Search	Add to builder	Query	Items found	Time	
<u>#59</u>	Add	Search facilitated tucking	<u>40</u>	04:42:35	
<u>#58</u>	Add	Search oral sucrose	<u>5125</u>	04:42:02	
<u>#57</u>	Add	Search non-nutritive sucking	<u>261</u>	04:41:36	
<u>#48</u>	Add	Search heel stick	<u>156</u>	04:36:31	
<u>#47</u>	Add	Search painful procedures	<u>262969</u>	04:35:22	
<u>#1</u>	Add	Search (((((((((((((((((("premature infant") OR "premature infants") OR "premature newborn") OR "premature newborns") OR "premature neonate") OR "premature neonates") OR "preterm infant") OR "preterm infants") OR "preterm newborn") OR "preterm newborns") OR "preterm neonate") OR "preterm neonates")) OR (("Infant, Premature"[Mesh]) OR "Infant, Low Birth Weight"[Mesh]))))	<u>83043</u>	03:13:03	